Harnessing The Reactivity Of The N-Methyl Diaminobenzoyl Linker To Access C-Terminally Modified And Macrocyclic Peptides by Arbour, Christine
Wayne State University 
Wayne State University Dissertations 
January 2019 
Harnessing The Reactivity Of The N-Methyl Diaminobenzoyl 
Linker To Access C-Terminally Modified And Macrocyclic Peptides 
Christine Arbour 
Wayne State University, christineaarbour@gmail.com 
Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations 
 Part of the Organic Chemistry Commons 
Recommended Citation 
Arbour, Christine, "Harnessing The Reactivity Of The N-Methyl Diaminobenzoyl Linker To Access C-
Terminally Modified And Macrocyclic Peptides" (2019). Wayne State University Dissertations. 2141. 
https://digitalcommons.wayne.edu/oa_dissertations/2141 
This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has 
been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of 
DigitalCommons@WayneState. 
HARNESSING THE REACTIVITY OF THE N-METHYL DIAMINOBENZOYL LINKER 








Submitted to the Graduate School 
 




in partial fulfillment of the requirements 
 
for the degree of 
 





























To my husband and best friend, Eric. 





I want to first thank my advisor, Jenn Stockdill, for her guidance through these 
challenging years of my life. I have learned beyond what I could have ever imagined, first 
by taking her phys. org. course, followed by joining her laboratory. I immensely appreciate 
her ability to empathize during times of hardship. I am tremendously happy that I joined 
the Stockdill lab and am thankful for all of the opportunities it has given me. 
Additionally, my time in the Stockdill lab was filled with many joyful moments 
thanks to the amazing lab mates with whom I spent the past four and a half years. I 
appreciate all of the postdocs that I was able to work alongside. Thank you, Dripta De 
Joarder, Ahmad Ibrahim, Ganesh Samala, and Naresh Venneti. Furthermore, my success 
in the laboratory would not have been possible without the amazing undergraduates who 
have worked beside me. Kayla Belavek, Ramona Stamatin, Teanna Vorlicek, Rooha 
Tariq, and Jeremiah Jean – you rock! I of course have to also thank Shane for his 
enthusiasm for Sequence and always having a positive attitude. Lastly, I was beyond 
lucky to work alongside the best graduate students in the world. Although it has only been 
a few months, I have really enjoyed chatting with the Stockdill lab’s newest member, Larry 
Mendoza.  You will undoubtedly do great things in graduate school. Thilini Kondasinghe 
– you are a very genuine person and I enjoyed working with you. You are very patient, 
and I have always been impressed by your work ethic.  Hansamali Sirinimal – I swear we 
are the same person. I always adored our many conversations, specifically about coffee! 
Alberto Lopez – I cherish the time in graduate school where we were in Kristina’s class 
every morning at 7 am, Monday through Friday. I look forward to joining you on the East 
 iv 
Coast in Massachusetts! Hasina Saraha– you were absolutely right about us being long 
lost sisters. You single handedly got me through many years of my graduate career. I will 
forever be grateful for your love and support during the hardest times of my life. I want to 
thank both you and Zack for always opening your home to me… and bringing me 
toothpaste! I will never forget Noel Night 2017 *wink*. Lastly, I want to acknowledge other 
past and present Stockdill members, Heng Chen, Greg Rosenhauer, Fatima Elchawich, 
Samantha Odeesho, Mahesh Yadab, Jason Zula, and Rana Morsy. 
Thank you to all of the other wonderful people that I have encountered at Wayne 
State University of which there are too many people to list. However, I want to specifically 
thank, Travis Ness for being very supportive and helpful throughout my search for a 
postdoctoral position. Also, I am happy to have found one of my best friends in graduate 
school, Lina Basal. I enjoyed our mid-day walk/drive to Avalon and New Order Coffee to 
get our cappuccinos and cortados. I loved having you as a (brief) roommate. J  
Melissa Rochon, words cannot describe how helpful you have been during my 
Ph.D. Thank you for your guidance and having time to answer any questions I have had 
throughout this program. I also want to thank everyone in the Chemistry Department who 
has been a pleasure to interact with. Thank you, Jackie Baldyga, Bernie Miesik, Diane 
Kudla, Tenecia Smith, Johnna Birbeck, Judy Westrick, and Nestor Ocampo. 
I want to thank all of my teachers, Prof. David Crich, Prof. Jeremy Kodanko, Prof. 
Stanislav Groysman, Prof. Christine Chow, and Prof. Charles Winter, for sharing their 
expertise with me in my first year of graduate school. Additionally, I want to thank Prof. 
Tamara Hendrickson for being available to chat about anything. 
 v 
I want to thank my committee members, Prof. Mary Kay Pflum and Prof. Matt Allen 
for giving insightful advice and writing letters of recommendation on my behalf. 
Additionally, I want to thank my outside committee member and my mentor at Boehringer-
Ingelheim, Dr. Dan Fandrick. You taught me a great deal during such a short time at 
Boehringer-Ingelheim. I have become a better scientist from my experience working on 
your team. I greatly appreciated how much time you took out of your busy day to teach 
me, from synthesis techniques to how the industry world works.  
Going back to before my time as a graduate student, I would not be where I am 
today without my undergraduate advisor, Dr. Ingo Janser. Thank you for inspiring me to 
pursue organic chemistry research and graduate school. 
Going back even further, I want to thank my family for their unconditional support. 
My parents are responsible for shaping who I am today. My cousins (Greg & Rachael, 
Nikole & Nate, Bryan & Amy, and Rob & Molly) have been the closest thing to siblings I 
could have. Thank you, Aunt Debbie for always having kind, supportive words for me. I 
have also been fortunate enough to have a family-in-law, who have been equally 
supportive. Thank you, Lori, Tony, Pawli, Emily, and Marty. 
I also want to thank my second family, The Russos, for their unconditional love 
and support. Thank you, Dan and Lori for always having a bed (pull-out couch) for me 
and including me in your wonderful Labor Day tradition at Wandawood. Megan, Kyle, and 
Mia Russo-Brown, I cannot say enough about how much you all mean to me. Thank you 
for always opening your home and arms to me whenever I am in need. You are my 
 vi 
favorite people on this earth. Thank you for including me on your fun trips throughout my 
Ph.D. I cannot thank you enough for your support outside of graduate school. 
Last but foremost, I want to thank my husband and best friend, Eric. You are my 
number one supporter. I cannot express in words how much your love and support has 
meant to me. I have grown immensely because of your partnership. Thank you for 
consoling me and subsiding my anxiety, both in person and over the phone, on the nights 
before important seminars and postdoctoral interviews. I am beyond excited to move to 
Boston with you and to explore the East Coast. You are the funniest person I know, and 
I look forward to our future adventures. I love you. “L’enfer, c’est les autres” – Jean-Paul 
Sartre, No Exit 
 vii 
PREFACE 
A variety of C-terminal moieties are present in naturally occurring peptides with 
potential therapeutic applications. However, accessing C-terminally modified peptides 
through solid-support synthesis has been an understudied topic within the synthetic 
peptide chemistry community. Traditional solid-support synthesis is performed from the 
C-terminal to N-terminal region, which means that the C-terminus is directly attached to 
the resin. The C-terminal moiety installed onto the peptide is thus dependent on the 
functional group on the resin. Once attached, there is no option for modifying the C-
terminal region on resin. Efforts to synthesize peptides from the N-terminal to C-terminal 
region have proven unsuccessful due to epimerization during amino acid couplings. 
Chapter 1 will begin with a brief overview of biosynthetic approaches to access 
naturally occurring C-terminally modified peptides. Inspired by nature, a few enzymatic 
strategies were developed. The C-terminal moiety has a large impact on the peptides 
activity and secondary structure and will be discussed. Synthetic approaches are 
discussed to orient the reader with strategies developed previous to and concurrent with 
my approach. Chapter 2, the scope of nucleophiles capable of displacing an N-acyl urea, 
both on-resin and in-solution, is investigated. A major concern with C-terminal activation 
is epimerization of the C-terminal amino acid residue and Chapter 3 details the 
advancement of my method to avoid C-terminal cysteine epimerization. In Chapter 4, I 
discuss efforts toward C-terminal elongations using a single amino acid, circumventing 
the repetition of solid-phase peptide synthesis to generate peptides varying at the C-
terminal amino acid. Lastly, Chapter 5 describes an on-resin cysteine-assisted 
 viii 
macrocyclization to access challenging macrocyclic peptides (Chapter 5). This chemistry 
was inspired by the combination of the in-solution, intramolecular macrolactamization and 
the intermolecular elongation of N-acyl urea-bound peptides. 
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CHAPTER 1: RECENT ADVANCES IN THE SYNTHESIS OF C-TERMINALLY 
MODIFIED PEPTIDES 
1.1 Introduction 
As of 2001, the a-amidated C-terminal moiety is present in over half of all biologically 
active peptides.1 These peptide hormones are synthesized as pro-proteins that are later 
cleaved to reveal their biologically active form.1 These cleavages are performed by 
enzymes after translation to give the active form responsible for their biological activity. 
Post-translational modifications (PTM) are often essential for the receptor to recognize 
the peptide.1 Because of their importance, many strategies to synthetically access these 
peptides have been developed. In the past few years, the Stockdill laboratory has been 
interested in developing improved synthetic methods for accessing C-terminally modified 
peptides.  Previous strategies were limited by epimerization and incompatibility with other 
amino acid side-chain protecting groups. Herein, enzymatic and synthetic approaches to 
the C-terminal modification of peptides are discussed. The advantages and limitations of 
these strategies are highlighted, and opportunities for further growth in the field are 
discussed. Strategies published concurrently to the work in this thesis are also included 
in this chapter.  
1.1.1 Biologically Relevant C-Terminally Diverse Peptides 
Representative linear, C-terminally modified peptides are illustrated below (Figure 
1.1.1). CA-074 methyl ester (1.1.A) is a cathepsin B inhibitor. Cathepsin B is a biomarker 
in several cancers and is associated with tumorigenesis.2 CA-074 methyl ester possesses 
a C-terminal proline methyl ester. The carboxylic acid analog, CA-074, was developed 
first and it showed promising potency towards cathepsin B inhibition. Unfortunately, the 
 2 
C-terminal acid reduced the membrane permeability, making it an ineffective drug. The 
methyl ester analog was then developed to facilitate cell penetration.3 Another methyl 
ester peptide, a-factor peptide (1.1.B), is a yeast pheromone from Saccharomyces 
cerevisiae. The C-terminal cysteine thiol is fanesylated and contains a methyl ester 
moiety, which is essential for its activity. In the case of a-factor peptide, alkyl ester 
analogues of this peptide did not drastically impact the biological activity of the peptide 
with the exception of the benzyl ester analogue. In this case, the activity dropped 
considerably. Thus, the authors hypothesized that when the alkyl group exceeds a certain 
volume, the C terminus cannot interact with the binding pocket, rendering the peptide 
inactive.4 Amide modified C-terminal peptide, ABT-510 (1.1.C), mimics endogenous 
protein thrombospondin-1 (TSP-1) and inhibits pro-angiogenic growth factors associated 
with tumor neovaculariazation.5 ABT-510 was briefly in a phase II clinical trial treating 
patients with stage IV melanoma.6 A pyridine-tethered C-terminal amide, Auristatin PYE 
(1.1.D), is an aminoquinoline derivative of dolastatin 10.7 Auristatin PYE is a potent 
antimitotic agent. The modification to the C terminus increased the peptide’s solubility in 
water while still maintaining potency towards certain tumor lines.8  
 





































































































1.1.2 Biological Importance of C-Terminal Functional Groups 
The main impact of C-terminal modifications is the neutralization of the negative 
charge that the carboxylic acid derivative possesses. This neutralization often improves 
the hydrophobicity of peptides and enables better binding to receptors.9,10 Replacing the 
carboxy terminus with the carboxamide increases parathyroid hormone (hPTH) activity 
because the amide is less susceptible to carboxypeptidases. The C-terminal amide 
hydrogen bonds to the receptor that is responsible for its activation. This interaction 
mimics the peptide bond that is in the naturally circulating hormone fragment. For the 
parathyroid hormone, the C-terminal moiety directly dictates its biological activity.11 All 
modifications have a better efficacy than the carboxylic acid version (NHCH3 > CH2OH > 
N(CH3)2 > NH2 > H > OH). The efficacy in this context is defined as adenylyl cyclase (AC) 
stimulation to binding activities. 
Many inflammatory peptides also possess C-terminal carboxamides. It is 
hypothesized that this modification changes intramolecular hydrogen bonding patterns, 
which alters the structure of the a-helix and changes its ability to disrupt the cell 
membrane.12 Bioactive peptides commonly possess an a-helix. Specifically, amphiphilic 
a-helices are found near the C terminus of most hormones that react with type II G-
protein-coupled receptors (GPCRs).12 G-protein-coupled receptors are ideal targets for 
broad-spectrum therapeutics due to their role in my physiological responses to stimulants 
like hormones and neurotransmitters.13 The ability of the C-terminal group to hydrogen 
bond with a suitable group, such as the peptide backbone or amino acid side-chain, is 
integral to the helical stability.11 The potency of proline-rich antimicrobial peptides towards 
 4 
Gram negative bacteria increases with C-terminal modifications in combination with 
multimerization.14  These mechanisms include cell wall disruption,15 inhibition of the 
protein DnaK,16 and inhibition of bacterial ribosomal protein expression.17 
Another post-translational modification that occurs at the C terminus of a peptide 
is the attachment of glycosylphosphatidylinositol (1.1.E, GPI), which is involved in 
membrane anchoring (Figure 1.1.2).9 In this case, the glycan core with the appended 
phospholipid tail is attached to the C terminus of the peptide through a 
phosphoethanolamine linker; this attachment forms an amide bond. The phospholipid tail 
of GPI is responsible for membrane anchoring. This glycosylation has been observed on 
glycoprotein surfaces in eukaryotes.18 A deficiency in this PTM is commonly associated 
with a form of anemia called paroxysmal nocturnal hemoglobinuria (PNH).19  
 
Figure 1.1.2. Membrane anchoring of peptides via C-terminal glycosylphosph- 
atidylinositol attachment.20 
A minor modification of the C terminus from the carboxamide to the acid can 
directly impact the folded structure and ultimately the biological activity. For a-conotoxin 
ImI, the C-terminal moiety has a significant impact on its secondary structure (Figure 
















































acids that is isolated from the venom of conus snails. This peptide and various analogs 
are known to bind to Aplysia and Bulinus acetylcholine binding proteins (AChBP).21 The 
overall structure is primarily influenced by the two disulfides in the sequence. However, 
as illustrated by Figure 1.1.3B, the acid version deviates noticeably from the native 
carboxamide secondary structure. Furthermore, when the reduced, linear form of a-
conotoxin ImI amide and acid are subjected to oxidizing conditions, they form different 
major disulfide isoforms (Figure 1.1.3C). 54% of the ImI amide folds into the globular 
isoform (1.2.G), while 67% of the acid folds into the ribbon structure (1.1.H). The simple 
modification of the C terminal moiety switches the folding preference of the peptide. The 
authors note that when the folding is performed in the presence of a denaturant, the 
formation of the minor bead form (1.2.I) increases, implying that the side-chains of the 
peptide also influence the folding tendencies.22 
 
Figure 1.1.3. A) Primary structure of native a-conotoxin ImI, B) backbone overlay of both 
amide and acid analogs of a-conotoxin ImI determined by Nuclear Magnetic Resonance 
(NMR),23 C) the three isoforms of a-conotoxin ImI. 
Another advantage to the modification of the C-terminal moiety is that it is known 
to influence the peptides’ self-assembly behavior, which has been used to target and kill 




































































X = NH or O
 6 
tetrapeptide’s C-terminal moiety on its ability to self-assemble.25 All modified peptides 
displayed higher self-assembly tendencies over the carboxylic acid parent substrate. This 
simple modification on tripeptides demonstrated comparable IC50 values to cisplatin, a 
widely used chemotherapy drug.26 This modification is beneficial to self-assembly, 
because it only increases the molecular weight by 2%. Before discussing synthetic efforts 
to access these biologically-relevant peptides, it is important to consider how nature 
makes these modifications. 
1.2 Biosynthesis of Naturally Occurring C-Terminally Modified Peptides 
Enzymatic approaches are selective and efficient processes.27 More specifically, 
they are responsible for catalyzing the two biosynthetic pathways that produce C-terminal 
carboxamide and methyl ester peptides. One bifunctional enzyme responsible for the 
removal of the C-terminal amino acid to unmask the C-terminal carboxamide is 
peptidylglycine a-amidating monooxygenase (PAM) (Scheme 1.2.1A). The two subunits 
of PAM are peptidylglycine a-hydroxylating monooxygenase (PHM) and peptidyl-a-
hydroxyglycine-a-amidating lyase (PAL). In this case, the mature form of the peptide, 
which interacts with the enzyme, contains a C-terminal glycine carboxylic acid (1.2.A). 
Upon exposure to the first subunit, PHM, in combination with Cu(II), molecular oxygen, 
and ascorbate (Scheme 1.2.1B), the a-radical that forms on glycine oxidizes to the 
hydroxyacetate 1.2.C.28 Subsequently, PAL in combination with Zn(II) is responsible for 
the cleavage of glycine as 2-oxoacetate (1.2.E) to reveal the C-terminal carboxamide 
1.2.D. Oxytocin and vasopressin are examples of peptides that undergo this oxidative 
cleavage to unmask the bioactive C-terminal carboxamide.29 
 7 
Scheme 1.2.1. A) Two-step biosynthetic amidation of peptidylglycine, B) the Cu(II) and 
 ascorbate-catalytic cycle responsible for the production of hydroxyl radicals.28 
 
 The biosynthetic pathway for a-factor peptide, a C-terminal farnesylated cysteine 
methyl ester, is illustrated in Scheme 1.2.2. The initial biosynthetic intermediate for a-
factor peptide (1.2.F) contains an N-terminal extension, mature fragment, and a C-
terminal CAAX domain.30 The farnesylation of cysteine is mediated by Ram1/Ram2, 
which is a heterodimeric farnesyltranferase, to access peptide 1.2.G. The CAAX portion 
of the peptide is subsequently cleaved from the mature fragment (1.2.H) by either Ste24 
or Rce1 to unmask the C terminus. The C terminus is then esterified by Ste14 to produce 
the methyl ester peptide 1.2.I. The N-terminal fragment of the extension is cleaved by 
Ste24 to generate the penultimate intermediate (1.2.J) followed by the cleavage of the 
next N-terminal extension fragment by Axl1, which is proposed to be a zinc 
metalloprotease, to yield the a-factor peptide 1.1.B. The peptide is then exported out of 



































































extracellular peptide then binds to the Ste3 receptor. The C-terminal amidation and 
esterification, catalyzed by nature, is an inspiration for chemical synthesis. 
Scheme 1.2.2. Biosynthetic pathway for a-factor peptide.30 
 
1.3 Advances in Chemical Synthesis 
The ability to access a diverse library of C-terminally modified peptides from a 
single peptide substrate is a powerful transformation (Scheme 1.3A). Once the Fmoc 
solid-phase peptide synthesis (Fmoc-SPPS) is performed on unfunctionalized resin 
(1.3.A), the linear peptide 1.3.B can be divided into different reaction vessels (1.3.C). 
These individual vials can be treated with different nucleophiles to access a library of C-
terminally modified peptides. This can expedite the synthesis of these different 
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modifications (1.3.D-F) by only requiring one on-resin synthesis, which minimizes solvent 
waste and synthesis time. 
Scheme 1.3A. Potential synthetic access to diverse C-terminal peptides using solid- 
phase peptide synthesis. 
 
A major concern with C terminal modifications, when performed on unprotected 
peptides, is selectivity. Selective activation and functionalization of the C-terminal 
carboxylic acid in the presence of other reactive groups is challenging. To avoid undesired 
reactions, enzymatic approaches are usually used, or the modification is performed on 
protected peptides. 
Modification of the C terminus can be performed on resin during SPPS when the 
synthesis is performed in the N terminal to C terminal direction (N to C).31 However, this 
approach is limited by epimerization via oxazolone formation as illustrated in Scheme 
1.3B.31 The C-terminal amino acid of the linear peptide (1.3.G) is activated (1.3.H) toward 
nucleophilic attack; however, intramolecular attack of the adjacent backbone amide 
carbonyl can lead to oxazolone formation (1.3.I). Once the oxazolone is formed, 
deprotonation of the a-H of the amino acid is driven by the formation of aromatic species 
1.3.J, which planarizes the a-position and destroys the stereointegrity. Non-selective 





























epimerized peptide. The nucleophile then opens the lactone to give the functionalized 
peptide (1.3.L). This is the major limitation of N to C peptide synthesis and many C-
terminal modification approaches. It is important to be aware of this mechanistic pitfall for 
any approach. 
Scheme 1.3B. Mechanism of C-terminal amino acid epimerization via oxazolone 
formation. 
 
1.3.1 C-Terminal Thioesters 
The synthetic peptide community is interested in C-terminal thioesters because of 
their involvement in protein synthesis. However, these building blocks are not within the 
scope of this chapter, therefore they will only be briefly reviewed. A major class of C-
terminally modified peptides are thioesters (Scheme 1.3.1, 1.3.1.A).32 These substrates 
are employed in native chemical ligation (NCL) reactions, making them impactful 
synthetic intermediates to access large polypeptides and proteins. Solid-phase peptide 
synthesis is limited to a certain number of amino acids (~40-50)33 before complications 
from inefficient couplings and aggregation34 occur. To overcome this challenge, Kent and 
co-workers developed NCL to join two peptide fragments together in solution.35 The 
thioester 1.3.1.A can be obtained using many strategies.33,36 This intermediate can be 
readily displaced by a peptide fragment bearing an N-terminal cysteine 1.3.1.B via a 







































































transfer to give the native amide peptide bond (1.3.1.D). This strategy is impactful for the 
selectivity of the nucleophilic attack of the N-terminal cysteine thiol to the C-terminal 
thioester. This preference will further be exploited in other approaches, vide infra. 
Scheme 1.3.1. Native chemical ligation. 
 
1.3.2 Harnessing Enzymes for Synthetic C-Terminal Modifications 
Enzymes are exceptional at catalyzing reactions at high rates under mild 
conditions and for their selectivity.27  However, because of their susceptibility to denature, 
attempts to utilize enzymes for ex vivo approaches have proven challenging.37 
Additionally, the selectivity often limits their application to general processes, since an 
enzyme will often need to be optimized for the specific substrate. For this reason, only 
one C-terminal modification approach will be highlighted. A hybridization of enzymatic 
nucleophilic functionalization followed by a light-mediated deprotection to access C-
terminal carboxamides was demonstrated by Breddam and co-workers in 1992 (Scheme 
1.3.2.A).38 Starting from the C-terminal alanine peptide 1.3.2.B, the enzyme 
carboxypeptidase-Y (CPD-Y) catalyzes the transpeptidation between the C-terminal 
alanine and the photocleavable nucleophile, to give the C-terminal peptide 1.1.F. After 
exposure to light, the auxiliary is oxidized to hemiaminal 1.3.2.C, which is converted to 
the C-terminal carboxamide 1.3.2.D with 1.3.2.E as the by-product, when treated with 




































available, and the reaction only requires minimal amounts. However, this method is 
limited to the C-terminal carboxamide moiety. Because the peptide 1.3.2.A is prepared 
via solid-phase peptide synthesis, implementation of Rink Amide resin would circumvent 
the need for this strategy. 
Scheme 1.3.2. Enzymatic coupling of a photolabile auxiliary to access C-terminal  
carboxamides. 
 
1.3.3 Strategic Selection of Linker 
To functionalize the C terminus of a peptide in C to N solid-phase peptide 
synthesis, a linker can be selected to give the desired moiety upon cleavage.39 For 
example, Wang (1.3.3.A) and Rink Amide (1.3.3.C) resins are used to access C-terminal 
acids (1.3.3.B) or amides (1.3.3.D), respectively (Scheme 1.3.3.1). Analogously, there 
are solid-supports available for the synthesis of N-alkyl, N-aryl, aldehyde, and other 
functionalities.39 However, each resin can generate only one moiety, limiting these 
solutions to situations where a single C-terminal modification is desired.  
Scheme 1.3.3.1. Generation of C-terminal acids/amides from Wang or Rink Amide 
linkers, respectively. 
 
Non-traditional resins have been developed to modify the C terminus through pre-
































































has been used to attach amines through imine formation, followed by reduction using 
sodium triacetoxyborohydride (Scheme 1.3.3.2, 1.3.3.E®1.3.3.F).40 After the reductive 
amination, an amino acid can be coupled to the benzylamine 1.3.3.F on resin (1.3.3.G). 
Liberation of the amino acid 1.3.3.H can be achieved with 95% TFA/H2O. This approach 
is limited to small amines and single amino acid modifications. 
Scheme 1.3.3.2. Utilizing the AHB linker to functionalize amino acids. 
 
1.3.4 Side-Chain Anchoring Strategies 
Attachment of peptide to solid supports through side-chains of select amino acids 
can enable functionalization of C-termini because the carboxylic acid is not attached to 
the resin. Selective deprotection and functionalization of the C-terminal carboxylic acid 
can be achieved on resin. Two strategies can be implemented to access this modification. 
Once the side-chain is attached to the resin and after solid-phase peptide synthesis, the 
protected C-terminal acid can be deprotected and the desired functional group can be 
coupled using traditional activation. However, this strategy allows for the formation of 
oxazolone, so epimerization must be closely monitored.41 The second approach involves 
using a pre-functionalized amino acid, which is directly attached to the resin through a 
side-chain (Scheme 1.3.4.1). One major synthetic challenge in peptide chemistry is 
cysteine modifications without causing epimerization. Specifically, C-terminal cysteines 
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cysteine can be pre-functionalized with different alcohols to give the corresponding esters 
(1.3.4.A).4 This strategy avoids oxazolone formation, a major contributor to epimerization 
in peptide synthesis.42 The free thiol of cysteine is subsequently attached to 2-chlorotrityl 
(CTC) resin via an SN1 reaction (forming 1.3.4.B). The peptide can then be elongated on 
solid-support using Fmoc-SPPS (1.3.4.C). After completion of the synthesis, peptide can 
be cleaved from the resin using a 1:1:3 cocktail of trifluoroethanol (TFE), acetic acid 
(AcOH), and dichloromethane (CH2Cl2) to access the protected peptide 1.3.4.D.43 An 
advantage to this strategy is that functionalization is done prior to attachment/elongation. 
However, repeated or prolonged exposure of CTC-linked cysteine to piperidine causes 
significant epimerization via direct deprotonation because of the increased acidity of the 
a-hydrogen.44 Cysteine is not the only amino acid side-chain that has been attached to a 
solid-support. Aspartic and glutamic acid have been attached to both Wang and Rink 
Amide resins,39 although the Rink Amide linkage would generate either asparagine or 
glutamine as a result. Lysine, serine, threonine, arginine, and tyrosine have also been 
utilized in this manner.39 Additionally, these handles have been used for on-resin 
macrocyclization. Backbone attachment through the amide has also been developed.39 





























Over two decades ago, Bradley and co-workers developed a rearrangement 
strategy used towards accessing C-terminally modified peptides (Scheme 1.3.4.2).45 
Once the Alloc/OAllyl protected peptide 1.3.4.E is synthesized, both the allylic protecting 
groups are removed using Pd(0) conditions. Next, the carboxylic acid is coupled with the 
N-terminus of lysine to access the macrocycle 1.3.4.F on resin. Exposure to 1% TFA in 
CH2Cl2 causes a ring opening at the C-terminal carboxylic acid of the synthesized peptide 
(1.3.4.G). This acid is then coupled to the desired amine, followed by cleavage from the 
resin by neat TFA to give the functionalized peptide 1.3.4.H. However, this approach 
requires many tedious steps to access these modified peptides and the epimerization of 
this strategy was not reported. 
Scheme 1.3.4.2. Rearrangement strategy to unmask C-terminal carboxylic acids on 
resin. Conditions: a) Pd(PPh3)4, dimedone, CH2Cl2/THF (1:1); b) PyBroP, EtiPr2N, DMAP, 
CH2Cl2, 12 h; c) 1% TFA/CH2Cl2; d) PyBroP, RNH2, DMAP, EtiPr2N; e) TFA. 
 
1.3.5 Resin-Cleaving Diversification Methods 
The 4-hydroxymethylbenzoic acid (HMBA) linker was initially developed to allow 
on-resin side-chain deprotection with TFA.46 These ester linkages are acid-stable and can 
undergo transesterification, hydrolysis, or thiolysis to yield C-terminal esters, acids, and 
thioesters, respectively (Table 1.3.5). The HMBA linker (1.3.5.A) can be transesterified 
with alkoxides generated from potassium tert-butoxide and the parent alcohol to access 
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C-terminal amides and thiolates (from a mixture of thiol with KOtBu) to form thioesters. 
The conversion of these reactions ranged from 0-100% depending on the steric bulk of 
both the C-terminal amino acid and the nucleophile. C-terminal isoleucine behaved poorly 
with bulky nucleophiles like iBuNH2. The epimerization of this chemistry was only 
investigated for the thiolysis reaction using propanethiol and KOtBu. As previously 
mentioned, the KOtBu is used to generate the reactive thiolate. However, KOtBu has a 
pKa of ~16, which could readily deprotonate both propanethiol (pKa ~10)48 and the a-
position (pKa 9). It is not surprising that the stereointegrity at that C-terminal amino acid 
is completely lost, giving a 1:1 ratio of both diastereomers. The advantage of this 
approach is that the resin is readily available; however, this approach generates high 
amounts of epimerization due to the use of KOtBu, and the authors state that this 
chemistry is limited to C-terminal glycine.  
Table 1.3.5. Accessing C-terminally modified peptides via a nucleophilic displacement 
of the HMBA linker. 
 
In 2004, Camarero and co-workers developed an aryl hydrazine linker for C-
terminal modifications (Scheme 1.3.5.1).49 The aryl hydrazine is stable to Fmoc-SPPS, 
and after peptide synthesis, the hydrazine linker (1.3.5.C) can be oxidized with N-



















ROH KOtBu 15-120 20-1001
2 RNH2 – 120-480 0-100
3 PrSH KOtBu 360 0-70
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which subsequently forms the diazenyl bound peptide (1.3.5.E). Peptide 1.3.5.E can be 
readily displaced with different nucleophiles to access the C-terminally modified peptides 
(1.3.5.F). This strategy has been utilized to access C-terminal thioesters without 
epimerization ultimately used for native chemical ligation. NBS may be problematic for 
oxidation-sensitive peptides. Residues such as tryptophan, tyrosine, methionine, and 
cysteine were investigated. When peptides containing protected tryptophan and tyrosine 
were subjected to NBS, there was no observable oxidation or bromination. However, 
when the unprotected forms were exposed to NBS, a complicated mixture of oxidized and 
brominated peptide resulted. Even protected methionine and cysteine were completely 
oxidized in the presence of NBS, but they were reduced in the subsequent TFA 
deprotection step if EtSH was added. In the effort to avoid cysteine oxidation, Cys(Npys)50 
was incorporated and no observable oxidation was observed. The limitation with this 
protecting group is that it can only be coupled last, since Npys is labile to Fmoc-
deprotection conditions. The authors recommend insertion of Cys(SStBu) for any internal 
cysteine residues. 
Scheme 1.3.5.1. Aryl hydrazine oxidation to access C-terminal thioesters and amides. 
 
A strategy to activate the C terminus of the peptide using a serine cyclic urethane, 
was developed by Raj and co-workers in 2016 (Scheme 1.3.5.2).51 The approach uses 
































group of serine (1.3.5.I) using TFA, the cyclic urethane (1.3.5.K) is generated using DSC 
and DMAP in DMF. The activated DMAP species (1.3.5.H) readily reacts with the free 
hydroxyl group to first generate the succinimide carbonate intermediate (1.3.5.J), which 
undergoes cyclization with the neighboring amide. Once activated, the nucleophile 
displaces the carbamate to access the C-terminally modified peptide 1.3.5.L. This 
approach was epimerization-free when tested on C-terminal alanine with both water and 
a thiol as nucleophiles. Cysteine epimerization was not investigated, and based on my 
work (see Chapter 3), it is not clear that Cys(Trt) would not be compatible with this 
strategy. A practical drawback to this strategy is that the hydroxyl group is slow to activate, 
requiring overnight agitation. The advantage of using serine as the activatable linker is 
that Fmoc-Ser(Trt)-OH is commercially available, although it is more expensive than the 
traditional Fmoc-Ser(tBu)-OH.52 
Scheme 1.3.5.2. Site-selective cleavage and functionalization of peptides using serine. 
 
A related approach employs the diaminobenzoyl (Dbz) linker, which was 
developed in 2008 to access C-terminal thioesters for native chemical ligation. 
Concurrently with the work described in Chapter 3, Kao and co-workers utilizes this linker 
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which is generated from a nitrite salt reacting with hydrochloric acid, to form the nitrous 
amide 1.3.5.N. Intramolecular attack by the amide nitrogen leads to loss of water and 
forms the reactive benzotriazole leaving group (1.3.5.O). The activated peptide can be 
displaced by various nucleophiles, including peptides and dendrimers, to access C-
terminally modified and elongated peptides (1.3.5.P). The unique take on this approach 
was showing peptide elongation using linear pentapeptides as nucleophiles to access an 
elastin peptide. The Dbz linker has several known pitfalls, and it is less frequently used 
since the development of the improved second-generation linker (MeDbz). The 
development of MeDbz was to minimize branching during SPPS. When Dbz is 
incorporated, it has the aniline amine free during the entire synthesis. The amine is 
susceptible to acylation in the form of branched peptide (1.3.5.Q). Kao and co-workers 
assert that this branching should be tolerated because these undesired peptides will not 
be cleaved from the resin with a nucleophile. However, this by-product leads to significant 
peptide loss since the linker cannot be activated. Even the less reactive MeDbz linker is 
susceptible to acylation with reactive electrophiles like acetic anhydride.54 The 
epimerization was not reported. 





























































1.3.6 Solution-Phase Diversification of Peptide C-Termini 
Solution-phase diversification can sometimes be necessary. Peptide solubility and 
resin incompatibility with specific activation conditions are some reasons why solution-
phase chemistry is necessary. Pentelute and co-workers recently developed a 
stereoretentive Curtius rearrangement strategy, which does not activate the C-terminal 
carbonyl (Scheme 1.3.6.1). This functional group interconversion method uses a C-
terminal peptide hydrazide 1.3.6.A and activates to the azide 1.3.6.B using sodium nitrite. 
The azide then undergoes the Curtius rearrangement, which initially forms nitrene 1.3.6.E 
followed by rearrangement to form the isocyanate (1.3.6.C) in situ. The reactive 
isocyanate can be directly functionalized by a nucleophile to give non-traditional C-
terminally modified peptide (1.3.6.D).55 These modifications, like ureas and carbamates, 
are excellent handles for peptidomimetics.56 This strategy is compatible with unprotected 
peptides, which allows for easier manipulations in terms of solubility. Although traditional 
Curtius rearrangements retain stereointegrity,57 the enantiopurity of the C-terminal amino 
acid was still investigated. As expected, the amino acid retained its stereochemistry. This 
transformation showed excellent reactivity with C-terminal amino acids, valine, isoleucine, 
and tyrosine; however, this reaction was challenging for C-terminal amino acids like 
serine, threonine, and histidine (0-11% conversion). Aspartic acid derived (aspartic acid, 
asparagine, and glutamine) C-terminal hydrazides were not tested. 




























In-solution functionalization has been reported by Chiba and co-workers using a 
soluble C-terminal auxiliary (Scheme 1.3.6.2).58 The soluble tag aldehyde 1.3.6.F 
undergoes a reductive amination with ethylamine to access amine 1.3.6.G. The tag is 
then used as a handle for solution phase peptide synthesis to give the C-terminal tag 
peptide 1.3.6.H. The auxiliary is then removed giving the ethylamide C-terminal peptide 
1.3.6.I using TFA. Previously, this group was used for in-solution peptide synthesis and 
the tag was saponified to unmask the carboxylic acid, followed by amidation; however, 
this led to significant epimerization. The new approach pre-functionalizes the linker with 
the desired amine, then performs SPPS in-solution. 
Scheme 1.3.6.2. Hydrophobic tag for solution phase peptide synthesis. 
 
1.3.7 Single Amino Acid Elongation 
Inspired by native chemical ligation, Aucagne and co-workers developed a single 
amino acid elongation strategy to access C-terminal cysteine peptides (Scheme 1.3.7). 
The work was developed to circumvent C-terminal cysteine epimerization, which was a 
major issue in the synthesis of their desired target, the reduced form of miniprotein 
AhPDF1.1b. Using classical Fmoc-SPPS with cysteine on the C terminus, they observed 
30% epimerization, which significantly lowered their final yield to 7%. To circumvent 
epimerization, the peptide was subsequently synthesized on a pre-functionalized resin 
with a bound N-alkylated cysteine auxiliary (1.3.7.A, Scheme 1.3.7A). The disulfide-
































solid-support with TFA. Once in solution, the disulfide is reduced to the free-thiol 1.3.7.B 
followed by an in-situ N to S acyl transfer which gives the C terminal alkyl thioester 
1.3.7.C. This intermediate then undergoes a transthioesterification with free cysteine to 
give the elongated peptide 1.3.7.D in native chemical ligation buffer. This approach by-
passes the oxazolone mechanistic pathway for epimerization of cysteine. Their optimized 
conditions require heating to 50 ºC at pH 5.8 and 48 h of reaction time. They attribute this 
sluggish reactivity to C terminal proline. A drawback to these conditions is that the long 
reaction time and higher temperatures cause both hydrolysis (1.3.7.E) and aspartimide 
(1.3.7.F) by-products (Scheme 1.3.7B). 
Scheme 1.3.7. A) In solution, single cysteine elongation of miniprotein AhPDF1.1.b 
(PDB file),59 B) undesired by-products observed with this method. 
 
1.4 Conclusions 
In the past four years there has been a resurgence in investigating new ways to 
access these challenging C-terminally modified peptide substrates. The next logical step 
was using linker design to enable access to a specific moiety. However, diversification is 
not feasible via this approach. Side-chain attachment through amino acids like cysteine 
and aspartic acid, can be valuable approaches for C-terminal modifications and on-resin 
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acid and the solid-support to facilitate on-resin nucleophilic displacement, seems to be 
the most powerful technique, due to the functionalization step happening concurrently 
with the cleavage from resin. This strategy will be discussed in more detail in regard to 
my work. Lastly, in-solution modifications can be easier to handle due to the peptide being 
completely deprotected, in some cases avoiding solubility issues, but they can also be 







CHAPTER 2: EXPLOITING THE MEDBZ LINKER TO GENERATE PROTECTED AND 
UNPROTECTED C-TERMINALLY MODIFIED PEPTIDES 
This chapter was adapted with permission from Arbour, C. A.; Saraha, H. Y.; McMillan, 
T. F.; Stockdill, J. L. Chem.–Eur. J. 2017, 23, 12484–12488 (reproduced by permission 
of Wiley and Sons). 
2.1 Introduction 
C-Terminally modified peptides are important for the development and delivery of 
peptide based pharmaceuticals because they improve peptide activity,60 stability,39,61 
hydrophobicity, and membrane permeability.62 Additionally, the vulnerability of C-terminal 
esters to cleavage by endogenous esterases makes them excellent pro-drugs.62 
Meanwhile, C-terminal thioesters63 and hydrazides64 are critical to the synthesis of larger 
peptide targets via native chemical ligation (NCL)35 and non-cysteine NCL.65 Despite the 
demand for C-terminally modified peptides, there remain significant limitations in the 
available strategies to access them by chemical synthesis.66,67 Variations at the C 
terminus traditionally require repetition of the solid-phase peptide synthesis (SPPS) on a 
different linker for each desired C-terminal moiety2c,61a,68 or the use of a C-terminal 
glycine.69 Solution-phase activation of protected C-terminal acids risks epimerization (see 
Chapter 1, Scheme 1.3B).31,70 Side-chain anchoring strategies are limited by the need 
for particular amino acids at the C terminus and by epimerization during the activation of 
the C-terminal carboxylic acid.4,71 Recent efforts to diversify the C terminus from a single 
SPPS effort suffer from epimerization,47 require extended reaction times or heating,51 are 
incompatible with common cysteine protecting groups,49,72 or require pre-functionalization 
of the peptide.55,73 
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For broad utility, the ideal functionalization method should employ a commercially 
available resin/linker, use convenient reagents for activation, undergo reaction with a 
variety of nucleophiles of varying steric and nucleophilic properties, and proceed at 
ambient temperature without epimerization of the C-terminal residue. Furthermore, the 
approach should enable the user to select between the production of protected peptides 
and the solution-phase diversification of unprotected peptides. To date, no report has 
demonstrated the achievement of this set of objectives. Herein, I commandeer the 
commercially available MeDbz linker74 to realize these goals for the first time. 
The strategy presented in this chapter for divergent C-terminal functionalization is 
outlined in Scheme 2.1. MeNbz-linked resin-bound peptides 2.1.B are accessible upon 
activation of the MeDbz linker (2.1.A).74 I envisioned that these peptides could be directly 
cleaved to afford protected C-terminally modified peptides 2.1.C or treated with 
trifluoroacetic acid (TFA) to afford side-chain-deprotected MeNbz peptides 2.1.D. Upon 
exposure to various nucleophiles, unprotected peptides 2.1.D would be diversified at the 
C terminus (2.1.C). The susceptibility of this linker to attack by weaker nucleophiles than 
thiols63 and hydrazine75 remains under-explored.76 Additionally, the direct nucleophilic 




Scheme 2.1 C-Terminal modifications of peptides using MeDbz.  
 
2.2 Evaluation of MeDbz Displacement at Various C-terminal Amino Acid Residues 
2.2.1 C-Terminal Functionalization of Glycine Derivatives 
To establish the reactivity of the resin-bound MeNbz group, MeNbz-linked 
tripeptides (2.2.A) were treated with a variety of nucleophiles (Table 2.2.1). A Gly residue 
was installed at the C terminus (2.2.A) to avoid concerns related to epimerization at this 
stage. The generation of thioesters from MeNbz is well established,74b so I began my 
investigation with nitrogen nucleophiles. As the smallest nucleophile, I expected that 
bubbling with ammonia would readily induce cleavage from the resin.77 Indeed, I observed 
complete removal of the peptide from the resin after bubbling with a balloon of NH3 for 
1.5 h. The corresponding tripeptide carboxamide (2.2.B-NH2) was isolated in 41% yield 
(entry 1). Primary amines of varying nucleophilicity were evaluated by Hasina Saraha and 
Tim McMillan.78 Butylamine (2.2.B-NH(CH2)3CH3) and 3-azidopropylamine79 (2.2.B-
NH(CH2)3N3) proceeded with complete conversion (entries 2 and 3). Propargyl amine 
(2.2.B-NHCH2CCH) and benzyl amine (2.2.B-NHCH2Ph) are slightly less nucleophilic 
than primary alkyl amines, but both are efficient in displacing MeNbz (entries 4 and 5). 



























































alkyne cycloaddition.80 The least nucleophilic amine tested was aniline, which led to 
minimal product formation (2.2.B-NHPh). However, in the presence of 5 equiv Hünig’s 
base, aniline displacement proceeded with 53% conversion, allowing access to peptide 
N-aryl amides via this strategy (entry 6).  
Table 2.2.1 C-Terminal modifications of glycine peptides using amine nucleophiles. 
 
Because of the unique biological properties of C-terminal esters,62 I was interested 
in the ability of oxygen nucleophiles to displace MeNbz. To maximize the amount of RO– 
in solution, alcohols were combined with KOtBu and added to the swelled resin.47 Primary 
alkoxides reacted with complete conversion to afford the corresponding esters. Steric 
hindrance in the nucleophile slows the reaction considerably, with isopropoxide 
proceeding to only 62% conversion. Although benzyl oxide was also less efficient than 
the other primary alkoxides, phenoxide led to complete conversion. Finally, treatment with 
aqueous NaOH resulted in >99% conversion to the corresponding carboxylic acid. 
Overall, a variety of strong, weak, and even branched N- and O-nucleophiles are effective 
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1 NH3 – >99 (41)
a All reactions were conducted on 100 mg of resin at rt (24 ± 1 ºC), b Conversion based on MS 
ratio of MeNbz-Gly and AWG-MeNbz-Gly, c A 0.7 M solution of Nuc-H in DMF (500 µL) was 
used, d N-terminus is Fmoc protected.
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Table 2.2.2 C-Terminal modifications of glycine peptides using water and alcohol  
nucleophiles. 
 
2.2.2 C-Terminal Functionalization of Sterically Hindered Derivatives 
Hindered C-terminal amino acids and bulky protecting groups are tolerated. 
Tripeptide 2.2.C (X=Ile) and 2.2.D (X=Arg(Pbf)) reacted with excellent conversion when 
treated with ammonia, butylamine, or MeOH/KOtBu.81 
Table 2.2.3 C-Terminal modifications of sterically hindered amino acid residues with  
select nucleophiles. 
 
2.3 Divergent Synthesis of Conopressin G and Two Analogs 
I next synthesized conopressin G (2.3.C), a C-terminal carboxamide-containing 
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a All reactions were conducted on 100 mg of resin at rt (24 ± 1 ºC), b Conversion based on MS ratio of 
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1 Ile (2.3.A) NH3 – >99 (68)
2 Ile (2.3.A) – >99
3c Ile (2.3.A) MeOH KOtBu
4 Arg(Pbf) (2.3.B) – >99NH3
5 Arg(Pbf) (2.3.B) – >99




a All reactions were conducted on 100 mg of resin at rt (24 ± 1 ºC), b Conversion based on MS 
ratio of MeNbz-Gly and AWG-MeNbz-Gly, c Incomplete removal of Fmoc was observed.
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(Scheme 2.3) to demonstrate the versatility of this chemistry.82 This neuroactive peptide 
contains a single disulfide bridge and a C-terminal carboxamide. Following SPPS, the 
disulfide bond was accessed via iodine-mediated Trt cleavage/oxidation. The MeDbz 
linker (2.3.A) was activated in the presence of the disulfide linkage. The resin was divided 
into three vessels and treated with ammonia, propargylamine, or MeOH/KOtBu, cleaving 
the peptide from the resin and generating the fully protected conopressins. The remaining 
protecting groups were removed, affording native conopressin (2.3.C) in 29% isolated 
yield, propargyl conopressin (2.3.D) in 7% yield, and conopressin methyl ester (2.3.E) in 
11% isolated yield. Additionally, I synthesized the active portion of glucagon-like peptide-
1, GLP-1(7-36) (2.3.G). GLP-1 receptor agonists are state-of-the-art pharmaceutical 
agents, with 16 different GLP-1 agonists in clinical trials as of 2015.83 GLP-1(7-36)–
MeNbz-Gly-Resin (2.3.F) was treated with ammonia in DMF for 1.5 h to afford native 
GLP-1(7-36) (2.3.G) in >99% conversion and 4% isolated yield after rinsing with (1:1:3) 
TFE/AcOH/CH2Cl2 (27% crude). Acidic cleavage condition rinses, either a mixture of 
TFE/AcOH or TFA, were required to dislodge the fully protected peptide from the 
polystyrene resin.  
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Scheme 2.4.1 A) Synthesis of native Conopressin G and analogs, B) synthesis of  
protected native GLP-1. 
 
2.4 Evaluation of MeDbz Displacement at Non-Glycine C-Terminal Amino Acids 
With the viability of C-terminal MeNbz displacement established, my next focus 
was evaluating the extent of epimerization under these conditions using Fmoc-
AW(Boc)A–MeNbz-Gly-Wang (2.4.A).81 C-terminal alanine was chosen to directly 
compare with previous approaches.49,51 No epimerization was observed upon 
displacement of MeNbz by butylamine (Table 2.4.1). Given the extent of epimerization 
observed by Meldal and co-workers in the presence of KOtBu (50%),47,84 I expected to 
observe epimerization during treatment with KOtBu/MeOH. Indeed, under these 
conditions, 15% epimerization was observed. Dawson reported <2% epimerization during 
the activation of C-terminal Tyr-Dbz in the presence of Hünig’s base.74 Thus, I 
hypothesized that under similar conditions, an epimerization-free ester modification might 
be feasible. Indeed, treatment with 5 equiv Hünig’s base in MeOH led to complete 































(7% yield, 4 steps)
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    DMF, 1.5 h
2) TFE/AcOH/CH2Cl2










water led to the carboxylic acid with no epimerization. Additionally, H-AW(Boc)H(Trt)-
MeNbz-Gly-Wang was prepared and cleaved with ammonia. No epimerization was 
observed.81  
Table 2.4.1 Evaluation of C-Terminal Alanine Epimerization. 
 
2.4.1 Nucleophilic Displacement of MeNbz In Solution 
An advantage of the MeDbz linker is that the activated linker (MeNbz) is stable to 
typical post-SPPS manipulations including resin cleavage, purification,74 and storage.85 
Thus, I imagined that solution-phase modifications of unprotected peptides would be 
feasible. The ability to diversify the C terminus of an unprotected peptide in solution would 
be ideal for situations where the SPPS itself led to multiple close-eluting products. Rather 
than diversification during resin cleavage followed by several challenging purifications, a 
single purification could be performed, followed by solution-phase diversification of the 
pure MeNbz peptide. For simplicity during evaluation of the nucleophile scope, I 
generated the tripeptide H-AWA-MeNbz-Gly-NH2 (2.4.C), which does not have any 
nucleophilic side chains. The crude peptide was dissolved in MeCN then treated with the 
nucleophile. To avoid epimerization, Hünig’s base was employed when a stoichiometric 
base was needed. A variety of primary amines were tolerated, leading to complete 
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2d MeOH >99 15KOtBu
–
4d H2O DIEA 70 N/A
a Unless otherwise noted, reactions were performed on 20 mg of resin containing all L amino acids in 
200 µL of Nuc-H at rt (24 ± 1 ºC), b  Conversion based on MS ratio of MeNbz-Gly and AWG-MeNbz-Gly. 
cTFA/TIPS/H2O (95:2.5:2.5) was used (PGs removed for assay), d Partial removal of Fmoc was 
observed. N/A = Below the limit of detection (PDA/MS).
Boc
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conversion in 30 min (Table 2.4.2). In contrast to the resin-bound approach, complete 
conversion was also observed for less nucleophilic amines such as aniline. Hydrazine 
and hydroxylamine were excellent nucleophiles,86 affording the corresponding hydrazide 
and hydroxamide87 with >99% conversion. The reaction has some sensitivity to steric 
effects, as demonstrated by the low conversion observed with Weinreb amine. Primary 
alkyl, benzyl, and phenyl alcohols were competent nucleophiles in the presence of 
Hünig’s base, whereas i-PrOH was more sluggish (61% conversion, 5 h). In the presence 
of aqueous NaOH, the carboxylic acid was produced. Finally, the b-amino alcohol could 
be generated by NaBH4 addition. 

























a All reactions were performed on 20 mg crude peptide in 200 µL MeCN at rt (24 ± 1 ºC), b 5 equiv, 
unless noted. c Conversion based on MS data, d 10 equiv Nuc-H was first dissolved in 100 µL MeCN 
then added to the peptide mixture, e 5 equiv of the Nuc•HCl salt was used with 10 equiv base, f  10 
equiv of PhOH was added directly to the peptide mixture, g Reaction was conducted in 200 µL THF, 



















































15g >99NaBH4 – 0.5














2.4.2 Synthesis of the Active Portion of Glucagon-Like Peptide-1(7-36) 
To probe the utility of the in-solution chemistry, Fmoc-GLP-1(7-36)–MeDbz-Gly-
Rink was activated (2.3.F) and cleaved from the resin to afford unprotected GLP-1(7-36)–
MeNbz-Gly-NH2 in 45% crude yield (Scheme 2.4.2). Subsequent displacement with 
butylamine in MeCN/H2O led to GLP-1(7-36)-NHBu (2.4.E) with >99% conversion and 
22% isolated yield. 




In summary, I have developed a versatile method for the C-terminal 
functionalization of peptides. This functionalization approach is tolerant of a variety of 
nucleophiles, yielding carboxamides, alkyl and aryl amides and esters, hydrazides, 
hydroxamides, acids, and amino alcohols from a single SPPS effort. Either protected or 
unprotected peptides can be used. When employing a large excess of a strong 
nucleophile, both water and unprotected nucleophilic side chains are tolerated. I have 
demonstrated the utility of this approach via the divergent synthesis of three conopressin 
G derivatives and 2 GLP-1(7-36) derivatives. This convenient method will facilitate the 
synthesis of important bioactive peptides with diverse C-terminal functionalities, enabling 
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2.6 General Experimental Procedures 
2.6.1 Materials and Methods 
Solid-Phase Peptide Synthesis was performed on a Biotage SP Wave Initiator+ 
and all peptides were synthesized on either pre-loaded glycine Wang Resin (Fmoc-Gly-
Wang Resin loading: 0.62 mmol/g from Chem-Impex Int’l. Inc.) or Rink Amide Resin 
(Novabiochem, 100-200 mesh, loading: 0.77 mmol/g). 1H NMR spectra and 13C NMR 
spectra were recorded on a Varian MR-400, Agilent MR-400, Varian V-500 MHz, or an 
Agilent DD2-600 MHz instrument with a multinuclear broadband probe at ambient 
temperature unless otherwise stated. Chemical shifts are reported in parts per million 
relative to residual solvent peaks (as established by Fulmer, et al. in Organometallics 
2010, 29, 2176). All 13C spectra are recorded with complete proton decoupling. All HPLC 
analyses and purifications were performed on a Custom Reverse Phase Shimadzu Liquid 
Chromatograph Mass Spectrometer (LCMS-2020), which can toggle between analytical 
and semi-preparative columns. This instrument has a photodiode array (PDA) detector 
(D2 & W lamp), which collects a range of wavelengths, in place of a traditional single 
channel UV detector. RP-HPLC-MS mobile phases (MeCN and H2O) contained 0.1% 
formic acid. Analytical HPLC was performed on a Phenomenex Kinetex C18 column (5 
µm, 250 x 4.6 mm) and a Thermo Scientific Hypersil Gold C8 column (5 µm, 250 x 4.6 
mm). Semi-Preparative HPLC was conducted using a Thermo Scientific Hypersil Gold C8 
column (5 µm, 150 x 10 mm). Thin layer chromatography was performed using glass-
backed SiliaPlate™ TLC Plates (cat. # TLG-R10011B-323) cut to the desired size then 
visualized with short-wave UV lamps and KMnO4, CAM, PMA, or anisaldehyde stains 
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prepared according to standard recipes.88 All yields refer to chromatographically and 
spectroscopically pure products. Unless otherwise specified, all commercially available 
reagents were used without further purification. Anhydrous Et2O, PhMe, n-hexane, 
MeCN, DMF, DMSO, CH2Cl2 were purchased from Fisher, THF was purchased from 
EMD, PhH was purchased from Sigma-Aldrich and HPLC grade MeCN and H2O were 
purchased from Fisher. These were passed through a commercial solvent purification 
system (2 columns of alumina) and used without further drying. Triethylamine, 
diisopropylamine, pyridine, and Hünig’s base were distilled over CaH2 immediately prior 
to use. All L-amino acids were purchased from EMD Millipore and Chem-Impex Int’l. Inc. 
4-Nitrophenyl chloroformate was purchased from Alfa Aesar. 4-Fluoro-3-nitrobenzoic 
acid, and N-(3-bromopropyl)phthalimide were purchased from Oakwood Chemical. 
Methylamine (33 wt.%) in absolute ethanol was purchased from Sigma-Aldrich. HATU 
was purchased from GenScript and Oakwood Chemical.  
Semi-Automated Microwave Synthesis of Peptides: 
Reactor Vials [Vial size (Volume range allowed)]: 2 mL reactor vial (0.8-1.1 mL), 5 
mL reactor vial (1.6-3.2 mL), and 10 mL reactor vial (3.2-6.4 mL) 
Swell + Heat: DMF was added and vortexed at 1200 RPM for 20 min at 70 ºC. The 
solvent was then removed over 1 min followed by two DMF washes (DMF was added and 
the suspension was vortexed at 600 RPM for 45 s, followed by the removal of solvent 
(over 2 min)).  
Coupling: A solution of Fmoc-aa-OH (5 equiv), HATU (4.9 equiv), and DIEA (10 
equiv) in DMF was made immediately prior to addition to the reaction vial containing the 
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resin. Once the solution was added, the suspension was heated to 75 ºC for 5 min with a 
vortex rate of 1200 RPM. After the reaction, the solution was removed, (over 2 min) and 
the resin was rinsed with DMF 4 times (after addition of DMF, the suspension was agitated 
at a vortex rate of 1200 RPM for 1 min, solvent removal was at a rate of 2 min). Fmoc-
Cys(Trt)-OH was coupled using a modified method established by Dawson, et al. J. Am. 
Chem. Soc. 2015, 137, 7197 to minimize epimerization, using Fmoc-Cys-OH (1.55 
mmol), HATU (1.55 mmol), and DIEA (1.705 mmol) in 4 mL DMF at 75 ºC for 5 min.74c 
Fmoc Removal (Deprotection): The reactor vial was filled with 20% piperidine in 
DMF. The suspension was vortexed at 1200 RPM for 3 min at RT. The solvent was 
removed, followed by addition of 20% piperidine in DMF. The suspension was vortexed 
again at 1200 RPM for 10 min at RT. The solvent was removed, over 2 min, followed by 
4 DMF washes (after addition of DMF, the suspension was agitated at a vortex rate of 
1200 RPM for 1 min, solvent was removed over 2 min). 
Wash: DMF was added to the reaction vial and agitated at a vortex rate of 1200 
RPM for 1 min. The solvent was removed, over 1 min and repeated for a total of 4 times. 
Final Wash: Resin was rinsed with DCM (3 x 1 mL) and MeOH (3 x 1 mL). 
Drying for Storage/Weighing: After the final wash, the resin was placed on the 
lyophilizer for 12 h for drying. 
MeDbz Activation: All activations were completed using a previously established 
protocol.74 p-Nitrophenyl chloroformate (5 equiv) was dissolved in 500 µL CH2Cl2, added 
to the pre-swelled resin, and agitated for 1 h. The solvent was removed, and the resin 
was rinsed with CH2Cl2 (3 x). Then 250 µL of 0.5-1 M DIEA/DMF was added and agitated 
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for 15-30 min. The solvent was removed, and the resin was rinsed with DMF and CH2Cl2 
(2x each). 
Ammonia Cleavage of Peptides on Resin: Peptide on resin (100 mg, dry) was weighed 
into a fritted reaction vial with an attached needle and rubber stopper (suggested selection 
of SPPS vial: 10-40 mg of peptide on resin goes into the 2 mL reaction vial, 40-200 mg in 
the 5 mL reaction vial and ³200 mg goes into the 10 mL reaction vial). The resin was 
swelled in DCM (500 µL – 4 mL) for 0.5-1 h. The MeDbz linker was activated by a 
previously established protocol.165 Next, 500 µL of DMF was added and the reaction vial 
was closed off with a septum (needle and stopper still attached at the bottom). A balloon 
was placed inside a balloon and filled with ammonia. A hypodermic needle was attached 
to the balloon and inserted into the septum and submerged into the DMF solution. The 
25 G 1-1/2” (Blue) gauge needle was placed into the septum to allow for the exiting of 
gas. The ammonia gas was bubbled into DMF for 1.5 h. Then The solvent was removed 
and collected. Additional rinsing was required to completely remove the desired peptide 
from resin. DCM (3 x 1 mL) was used to rinse the resin, followed by MeCN (3 x 1 mL), 
and lastly DCM (3 x 1 mL). The washes were combined with the initial DMF solution and 
reduced in volume with air. The residue was subjected to 1:1 MeCN/H2O, frozen (LN2), 
and lyophilized to yield the crude product. For Amine Cleavages of Peptides on Resin: 
After activation the resin was subjected to neat amine (500 µL) and agitated for 19 h.78 
After this time, the reaction contents were removed and collected. Additional rinsing was 
required to completely remove the desired peptide from resin. DCM (3 x 1 mL) was used 
to rinse the resin, followed by MeCN (3 x 1 mL), and lastly DCM (3 x 1 mL). The washes 
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were combined with the initial amine solution, reduced in volume with air, subjected to 1:1 
MeCN/H2O, frozen (LN2), and lyophilized to yield the crude product, which was analyzed 
by RP-HPLC-MS. For Alcohol Cleavages of Peptides on Resin: After activation the 
resin was subjected to a 0.089 M solution of KOtBu/ROH (500 µL) and agitated for 19 h. 
The reaction mixture was removed and quenched with 1:1 MeCN/H2O (0.05% TFA). 
Additional rinsing was required, using DCM (3 x 1 mL), MeCN (3 x 1 mL), and lastly DCM 
(3 x 1 ml). The washes were combined with the initial solution, reduced in volume with 
air, subjected to 1:1 MeCN/H2O, frozen (LN2), and lyophilized to yield the crude product, 
which was analyzed by RP-HPLC-MS. 
Calculating Conversion of On Resin Reactions. 
Conversion Method A: After the nucleophilic cleavage was conducted, the resin was 
subjected to 95:2.5:2.5 TFA/TIPS/H2O to cleave the remaining MeNbz-Gly and unreacted 
peptide-MeNbz-Gly. The solution was concentrated using a constant stream of air until a 
small amount of residue was left. Then –20 ºC diethyl ether was added to the vial to crash 
out the crude peptide. After centrifugation, the ether was decanted and the solid was 
dissolved in 1:1 MeCN/H2O and lyophilized. The lyophilized solid was then dissolved in 
20% MeCN/H2O and analyzed via RP-HPLC-MS using a gradient of 20-80% MeCN/H2O 
over 15 min. Conversion was calculated based on the ratio of H2N-peptide-MeNbz-Gly-
OH to H2N-MeNbz-Gly-OH. In some cases, Fmoc was still intact and incorporated into 
the % conversion calculation. Conversion Method B: Some nucleophile cleavages using 
neat primary amines caused cleavage from the resin at the ester linkage. In these cases, 
 39 
no residual MeNbz-Gly was observed, and the conversion was based on the ratio of H2N-
peptide-MeNbz-Gly-NHR to product in the crude reaction mixture. 
2.6.2 Experimental Procedures 
 
H-AW(Boc)G-NH2 (2.2.B-NH2). Table 2.2.1, entry 1: The general procedures for 
activation and ammonia cleavage were followed.  Purification was conducted after 3 
cycles of lyophilization (until crude product composition was a fluffy white solid). A silica 
column was used with a mobile phase eluent of 10-30% MeOH/CH2Cl2. The product was 
isolated, concentrated under reduced pressure, and lyophilized to yield a fluffy white solid 
(8.20 mg, 41% yield, >99% conversion). 1H NMR (400 MHz, DMSO-d6) d 8.42 (s, 1H), 
8.37 (t, J = 5.7 Hz, 1H), 8.00 (d, J = 8.0 Hz, 1H), 7.68 (d, J = 7.7 Hz, 1H), 7.50 (s, 1H), 
7.33–7.19 (m, 3H), 7.07 (s, 1H), 4.58 (s, 1H), 3.73–3.54 (m, 1H), 3.48 (q, J = 6.6 Hz, 1H), 
3.15 (dd, J = 14.8, 4.5 Hz, 1H), 2.98 (dd, J = 14.7, 8.9 Hz, 1H), 1.60 (s, 9H), 1.15 (d, J = 
6.9 Hz, 3H). 13C NMR (101 MHz, DMSO) d 173.3, 171.4, 171.1, 149.5, 135.1, 130.8, 
124.7, 124.6, 122.8, 119.9, 116.7, 115.0, 83.9, 52.8, 49.8, 42.4, 40.4, 28.2, 27.6, 19.7. 
 
H-AW(Boc)G-NHBu (2.2.B-NHBu). Table 2.2.1, entry 2: The general procedures were 
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H-AW(Boc)G-NH(CH2)3N3 (2.2.B-NH(CH2)3N3). Table 2.2.1, entry 3: The general 
procedures were followed with the following modifications: The reaction was conducted 
on 50 mg resin-bound peptide. A 0.7 M solution of 3-azidopropylazide in DMF (8.3 equiv, 
500 µL) was added to the activated resin and agitated for 12 h. Purification was conducted 
after crude product was lyophilized. A silica column was used with a mobile phase eluent 
of 0-50% MeOH/CH2Cl2. The product was isolated, concentrated under reduced 
pressure, and lyophilized to yield a fluffy solid (6.45 mg, 30% yield, >99% conversion). 1H 
NMR (400 MHz, DMSO-d6) d 8.42 (t, J = 5.7 Hz, 2H), 8.00 (d, J = 8.2 Hz, 1H), 7.84 (t, J 
= 5.7 Hz, 1H), 7.69 (d, J = 7.7 Hz, 1H), 7.51 (s, 1H), 7.34–7.19 (m, 2H), 4.60 (s, 1H), 
3.74–3.59 (m, 2H), 3.55 (q, J = 7.0 Hz, 1H), 3.33 (t, J = 6.8 Hz, 4H), 3.11 (q, J = 6.7 Hz, 
3H), 2.96 (dd, J = 14.7, 8.8 Hz, 1H), 1.68–1.55 (m, 11H), 1.19 (d, J = 6.9 Hz, 3H). 13C 
NMR (101 MHz, DMSO) d 172.0, 171.4, 168.9, 149.5, 135.0, 130.7, 124.7, 122.9, 119.9, 
116.5, 115.1, 84.0, 52.9, 49.2, 48.7, 42.5, 36.3, 28.8, 28.2, 27.7, 18.9. 
 
H-AW(Boc)G-NHPropargyl (2.2.B-NHPropargyl). Table 2.2.1, entry 4: The general 
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mixture was azeotroped with toluene to remove additional propargylamine. A silica 
column was used with a mobile phase eluent of 10-20% MeOH/CH2Cl2. The product was 
isolated, concentrated under reduced pressure, and lyophilized to yield a fluffy solid. 
Further purification was required. Semi-prep RP-HPLC-MS was conducted to yield the 
fluffy white solid. After 19 h, the reaction went to completion (>99% conversion). 
 
H-AW(Boc)G-NHBn (2.2.B-NHBn). Table 2.2.1, entry 5: The general procedures were 
followed, but the reaction was conducted on 50 mg resin-bound peptide. Purification was 
conducted after 3 cycles of lyophilization. A silica column was used with a mobile phase 
eluent of 0-10% MeOH/CH2Cl2. The product was isolated, concentrated under reduced 
pressure, and lyophilized to yield a fluffy solid. After 19 h, 98% conversion was observed. 
 
Fmoc-AW(Boc)G-NHPh (2.2.B-NHPh). Table 2.2.1, entry 6: The general procedures 
were followed. Purification was conducted after 3 cycles of lyophilization (until crude 
product composition was a fluffy white solid). A silica column was used with a mobile 
phase eluent of 0-10% MeOH/CH2Cl2. The product was isolated, concentrated under 
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of a reaction time of 46 h with no DIEA. Figure A2-011 represents conversion after 19 h 
with 5 equiv DIEA. 
 
H-AWG-OMe (2.2.D-OMe) and Fmoc-AWG-OMe (Fmoc-2.2.D-OMe). Table 2.2.2, 
entry 1: The general procedures were followed except the reaction was agitated for 42 h 
(un-optimized), a mixture of free N-terminal and Fmoc N-terminal peptides were obtained. 
After 42 h, the reaction went to completion. A silica column was used with a mobile phase 
eluent of 20-60% ethyl acetate/hexanes. Once the Fmoc product (Fmoc-2.2.D-OMe) 
eluted, the column was switched to a gradient of 0-20% MeOH/CH2Cl2 to isolate the free 
amine product (2.2.D-OMe). Both spots were isolated, concentrated under reduced 
pressure, and lyophilized to yield fluffy white solids (18% and 23%, respectively). 2.2.D-
OMe: 1H NMR (400 MHz, DMSO-d6) d 8.69 (t, J = 5.8 Hz, 1H), 8.59 (d, J = 8.1 Hz, 1H), 
8.01 (d, J = 8.2 Hz, 1H), 7.74 (d, J = 7.7 Hz, 1H), 7.55 (s, 1H), 7.35–7.21 (m, 3H), 4.64 
(q, J = 8.1 Hz, 1H), 3.86 (dd, J = 17.5, 5.9 Hz, 3H), 3.67 (m, 2H), 3.61 (s, 3H), 3.11 (dd, 
J = 14.6, 4.9 Hz, 1H), 2.95 (dd, J = 14.7, 8.86 Hz, 1H), 2.86 (m, 1H), 1.61 (s, 9H), 1.27 
(d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, DMSO) d 171.6, 170.5, 149.5, 135.1, 130.6, 
124.9, 124.8, 122.9, 119.8, 116.4, 115.1, 84.0, 52.8, 52.2, 48.9, 41.0, 28.2, 27.9, 18.3. 
Fmoc-2.2.D-OMe: 1H NMR (500 MHz, chloroform-d) d 8.12 (s, 1H), 7.77 (d, J = 7.5 Hz, 
2H), 7.59 (dd, J = 19.4, 8.1 Hz, 3H), 7.49 (s, 1H), 7.41 (t, J = 7.4 Hz, 2H), 7.31 (q, J = 7.8, 
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5.0 Hz, 1H), 4.79 (q, J = 7.0 Hz, 1H), 4.36 (d, J = 6.7 Hz, 2H), 4.18 (t, J = 6.8 Hz, 2H), 
4.07–3.83 (m, 3H), 3.67 (s, 3H), 3.23 (d, J = 6.1 Hz, 2H), 1.64 (s, 9H), 1.34 (d, J = 6.2 Hz, 
3H). 13C NMR (126 MHz, chloroform-d) d 172.3, 170.8, 169.7, 156.1, 149.5, 143.8, 143.6, 
141.3, 135.4, 130.2, 127.8, 127.1, 125.0, 125.0, 124.7, 124.5, 122.7, 120.0, 118.9, 115.4, 
115.2, 83.7, 67.2, 53.3, 52.3, 51.0, 47.1, 41.1, 28.2, 27.6, 18.3. 
 
H-AWG-OEt (2.2.D-OEt) and Fmoc-AWG-OEt (Fmoc-2.2.D-OEt). Table 2.2.2, entry 2: 
The general procedures were followed except the reaction was agitated for 40 h (un-
optimized), a mixture of free N-terminal and Fmoc N-terminal peptides were obtained. A 
silica column was used with a mobile phase eluent of 20-60% ethyl acetate/hexanes. 
After 40 h, the reaction went to completion. Once the Fmoc product (Fmoc-2.2.D-OEt) 
eluted, the column was switched to a gradient of 0-5% MeOH/CH2Cl2 to isolate the free 
amine product (2.2.D-OEt). Both spots were isolated, concentrated under reduced 
pressure, and lyophilized to yield fluffy white solids. 
 
Fmoc-AW(Boc)G-OiPr (Fmoc-2.2.D-OiPr). Table 2.2.2, entry 3: The general 
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19 h, 62% conversion was observed. A silica column was used with a mobile phase eluent 
of 1:9 ethyl acetate/hexanes. The product was isolated, concentrated under reduced 
pressure, and lyophilized to yield a fluffy white solid. 
 
Fmoc-AW(Boc)G-OBn (Fmoc-2.2.D-OBn). Table 2.2.2, entry 4: The general 
procedures were followed. Purification was conducted after 1 cycle of lyophilization. After 
19 h, 63% conversion was observed. A silica column was used with a mobile phase eluent 
of 20-70% ethyl acetate/hexanes. The product was isolated, concentrated under reduced 
pressure, and lyophilized to yield a fluffy white solid. 
 
H-AW(Boc)G-OPh (2.2.D-OPh). Table 2.2.2, entry 5: The general procedures were 
followed except the reaction was agitated for 12 h. Purification was conducted after 1 
cycle of lyophilization. After 19 h, 98% conversion was observed. A silica column was 
used with a mobile phase eluent of 0.5-5% MeOH/CH2Cl2. The product was isolated, 
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 H-AW(Boc)G-OH (2.2.D-OH). Table 2.2.2, entry 6: The general procedures were 
followed; however, instead of using KOtBu a 1 M aqueous solution of NaOH (500 µL) was 
used. RP-HPLC-MS was conducted after 1 cycle of lyophilization. After 19 h, the reaction 
went to completion (>99% conversion). The product was isolated and lyophilized to yield 
a fluffy white solid. 
 
H-AW(Boc)I-NH2 (2.3.C-NH2). Table 2.2.3, entry 1: The general procedures were 
followed.  Purification was conducted after 3 cycles of lyophilization (until crude product 
composition was a fluffy white solid). After 1.5 h, the reaction went to completion (>99% 
conversion). A silica column was used with a mobile phase eluent of 10-30% 
MeOH/CH2Cl2. The product was isolated, concentrated under reduced pressure, and 
lyophilized to yield a fluffy white solid (6.8 mg, 68%).1H NMR (500 MHz, DMSO-d6) d 8.28 
(s, 1H), 8.01 (d, J = 9.3 Hz, 2H), 7.68 (d, J = 8.0 Hz, 1H), 7.47 (s, 1H), 7.43 (s, 1H), 7.30 
(t, J = 7.6 Hz, 1H), 7.23 (t, J = 7.5 Hz, 1H), 7.05 (s, 1H), 4.69 (s, 1H), 4.19–4.11 (m, 1H), 
3.43–3.21 (m, 1H), 3.11 (dd, J = 14.9, 4.5 Hz, 1H), 2.95 (dd, J = 14.5, 8.4 Hz, 1H), 1.76–
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(m, 6H).13C NMR (126 MHz, DMSO) d 177.5, 173.1, 171.0, 149.5, 135.1, 130.9, 124.7, 
124.5, 122.9, 120.0, 115.0, 83.9, 57.2, 52.6, 49.8, 37.3, 28.2, 27.6, 26.0, 25.7, 15.9, 11.7. 
 
H-AW(Boc)I-NHBu (2.3.C-NHBu). Table 2.2.3, entry 2: The general procedures were 
followed. After 19 h, the reaction went to completion (>99% conversion). 
 
H-AW(Boc)I-OMe (2.3.C-OMe) and Fmoc-AW(Boc)I-OMe (Fmoc-2.3.C-OMe). Table 
2.2.3, entry 3: The general procedures were followed. After 19 h, 96% conversion was 
observed. 
 
H-AW(Boc)R(Pbf)-NH2 (2.3.D-NH2). Table 2.2.3, entry 4: The general procedures 
were followed. The crude reaction was immediately analyzed via RP-HPLC-MS. After 









    chloroformate 
    then DIPEA/DMF























    chloroformate 
    then DIPEA/DMF
2) (5 equiv KOtBu)


































    chloroformate 
    then DIPEA/DMF






















H-AW(Boc)R(Pbf)-NHBu (2.3.D-NHBu). Table 2.2.3, entry 5: The general procedures 
were followed. The crude reaction was immediately analyzed via RP-HPLC-MS. 
However, I observed streaking of the product on the HPLC-MS. After 19 h, the reaction 
went to completion (>99% conversion). 
 
H-AW(Boc)R(Pbf)-OMe (2.3.D-OMe) and Fmoc-AW(Boc)R(Pbf)-OMe (Fmoc-2.3.D-
OMe). Table 2.2.3, entry 6: The general procedures were followed. The crude reaction 
was immediately analyzed via RP-HPLC-MS. After 19 h, the reaction went to completion 
(>99% conversion). 
 
H2N-AW(Boc)H(Trt)-NH2 (2.6.B). The general procedures were followed. The crude 
reaction was immediately analyzed via RP-HPLC-MS. After 1.5 h, the reaction went to 
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Amine Cleavages of Unactivated Linker: 
 
Unactivated substrate (2.2.A, 30 mg) was weighed and swelled in DCM for 30 min. The 
solvent was then removed, and the resin was subjected to 150 µL of neat propargyl amine 
and agitated for 19 h. After this time, the solvent was removed, and collected. The mixture 
was diluted with 1:1 MeCN/H2O, frozen (LN2), and lyophilized to yield the crude amide 
2.6.C. The mixture was dissolved in 50% MeCN/H2O and analyzed via RP-HPLC-MS. 
 
Unactivated substrate (2.2.A, 30 mg) was weighed and swelled in DCM for 30 min. The 
solvent was then removed, and the resin was subjected to 150 µL of neat benzylamine 
and agitated for 19 h. After this time, the solvent was removed, and collected. The mixture 
was diluted with 1:1 MeCN/H2O, frozen, and lyophilized to yield crude amide 2.6.D. The 



















































































Conopressin G (2.3.C). Fmoc-CFIRNCPKG-MeDbz-G-Wang (100 mg, 34 µmol based 
on final loading) was weighed in a 5 mL peptide reaction vial and swelled in DCM for 30 
min. The resin was subjected to 8 equiv I2 in DCM (500 µL) for 40 m, removed and rinsed 
with a solution of saturated ascorbic acid in (1:1) DMF/phosphine buffer with a pH of 7. 
The resin was activated and cleaved with ammonia (see General Procedure). The crude 
product solution was lyophilized, and the resulting residue was subjected to (95:2.5:2.5) 
TFA/TIPS/H2O and agitated for 3 h. The solution was reduced in volume with a constant 
stream of air, precipitated with –20 ºC diethyl ether, centrifuged, and decanted to yield 
the crude product. RP-HPLC-MS purification was conducted resulting in a 29% yield of 
native Conopressin G (2.3.C). Gradient: 20-30% MeCN/H2O (0.1% formic acid) over 15 
min. 
 
Propargyl Conopressin G (2.3.D). Fmoc-CFIRNCPKG-MeDbz-G-Wang (100 mg, 34 
µmol based on final loading) was weighed in a 5 mL peptide reaction vial and swelled in 
1) Iodine in CH2Cl2
2) 4-nitrophenyl chloroformate
    in CH2Cl2
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DCM for 30 min. The resin was subjected to 8 equiv I2 in DCM (500 µL) for 40 m, removed 
and rinsed with a solution of saturated ascorbic acid in (1:1) DMF/phosphine buffer with 
a pH of 7. The resin was activated and cleaved with propargylamine (see General 
Procedure). The crude product solution was lyophilized, and the resulting residue was 
subjected to (95:2.5:2.5) TFA/TIPS/H2O and agitated for 1 h 30 min. The solution was 
reduced in volume with a constant stream of air, precipitated with –20 ºC diethyl ether, 
centrifuged, and decanted to yield the crude product. RP-HPLC-MS purification was 
conducted resulting in a 7% yield of propargyl Conopressin G (2.3.D). Gradient: isocratic 
30% MeCN/H2O (0.1% formic acid) over 15 min. 
 
Methyl Ester Conopressin G (2.3.E). Fmoc-CFIRNCPKG-MeDbz-G-Wang (100 mg, 34 
µmol based on final loading) was weighed in a 5 mL peptide reaction vial and swelled in 
DCM for 30 min. The resin was subjected to 8 equiv I2 in DCM (500 µL) for 40 m, removed 
and rinsed with a solution of saturated ascorbic acid in (1:1) DMF/phosphine buffer with 
a pH of 7. The resin was activated and cleaved with MeOH and KOtBu (see General 
Procedure). The crude product solution was lyophilized, and the resulting residue was 
subjected to (95:2.5:2.5) TFA/TIPS/H2O and agitated for 2 h. The solution was reduced 
in volume with a constant stream of air, precipitated with –20 ºC diethyl ether, centrifuged, 
1) Iodine in CH2Cl2
2) 4-nitrophenyl chloroformate
    in CH2Cl2





































and decanted to yield the crude product. RP-HPLC-MS purification was conducted 
resulting in a 11% yield of methyl ester Conopressin G (2.3.E). Gradient: isocratic 30% 
MeCN/H2O (0.1% formic acid) over 15 min. 
 
Fmoc-GLP-1(7-36)-MeDbz-Gly-Rink Amide. The SPPS was not optimized. The initial 
loading of MeDbz-Gly-Rink Amide was 0.35 mmol/g and the final loading was 0.16 
mmol/g. All yields were based off the final loading. Fmoc-GLP-1(7-36)-MeDbz-Gly-Rink 
Amide (20 mg, 3.2 µmol based on final loading) was weighed in a 5 mL peptide reaction 
vial and swelled in DCM for 30 min. The peptide was cleaved using (95:2.5:2.5) 
TFA/TIPS/H2O (1 h x 2). The mixtures were combined, reduced in volume with a constant 
stream of air, precipitated using –20 ºC diethyl ether, centrifuged, and decanted to give a 
pale brown pellet. The peptide was then dissolved in MeCN/H2O, frozen in LN2, and 
lyophilized giving a pale brown solid (6.8 mg, 61% crude yield). 
 
Native GLP-1(7-36) (2.3.G). Fmoc-GLP-1(7-36)-MeDbz-Gly-Rink Amide (100 mg, 16 
µmol based on final loading) was weighed in a 5 mL peptide reaction vial and swelled in 
DCM for 30 min. The resin was activated and cleaved with ammonia (see General 
Procedure). The fully protected peptide was adhered to the resin and multiple rinses of 
(95:2.5:2.5) TFA/TIPS/H2O was required to remove it from the resin (1 h x 3). All 
O
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cleavages were combined, reduced in volume with a constant stream of air, precipitated 
with –20 ºC diethyl ether, centrifuged, and decanted to give the crude fully deprotected 
product. RP-HPLC-MS purification was conducted resulting in a 4% yield of native GLP-
1(7-36) (>99% conversion).  
 
H-AWA-NHBu (2.4.B-NHBu). Table 2.4.1, entry 1: Resin 2.4.A (20 mg) was weighed 
into a 2 mL reactor vial and swelled in 1 mL of DCM for 15 min. After this time, the solvent 
was removed, and the resin was subjected to activation conditions. The resin was then 
subjected to 200 µL of butylamine. The resin was agitated for 19 h at ambient 
temperature. The solution was removed, and the resulting residue was dissolved in 3 mL 
of TFA/TIPS/H2O (95:2.5:2.5) and agitated for 30 min. After this time, the solution was 
concentrated under a constant stream of air, diluted with H2O, frozen, and lyophilized to 
yield the crude peptide (>99% conversion). The peptide was dissolved in 20% MeCN/H2O 
(1% TFA) and analyzed via RP-HPLC-MS. Epimerization was not detected.  
 
H-AW(Boc)A-OMe (2.4.B-OMe). Table 2.4.1, entry 2: Resin 2.4.A (20 mg) was weighed 
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was removed, and the resin was subjected to activation conditions. The resin was then 
subjected to 1.5 mL of a premixed solution of MeOH and KOtBu. The resin was agitated 
for 19 h at ambient temperature. The solution was concentrated under reduced pressure 
and the resulting residue was dissolved in H2O, frozen, and lyophilized to yield the crude 
peptide (>99% conversion). The peptide was dissolved in 20% MeCN/H2O (1% TFA) and 
analyzed via RP-HPLC-MS. The D-Ala epimer was observed (15%). 
 
H-AW(Boc)A-OMe (2.4.B-OMe). Table 2.4.1, entry 3: Resin 2.4.A (20 mg) was weighed 
into a 2 mL reactor vial and swelled in1 mL of DCM for 15 min. After this time, the solvent 
was removed, and the resin was subjected to activation conditions. The resin was then 
subjected to 1.5 mL of MeOH and DIEA. The resin was agitated for 19 h at ambient 
temperature. The solution was concentrated under reduced pressure and the resulting 
residue was dissolved in H2O, frozen, and lyophilized to yield the crude peptide (>99% 
conversion). The peptide was dissolved in 20% MeCN/H2O (1% TFA) and analyzed via 
RP-HPLC-MS. Epimerization was not detected. 
 
H-AW(Boc)A-OH (2.4.B-OH). Table 2.4.1, entry 4: Resin 2.4.A (20 mg) was weighed 
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was removed, and the resin was subjected to activation conditions. Then 200 µL of H2O 
was added to the resin followed by 5 equiv DIEA. The resin was agitated for 19 h at 
ambient temperature. The solution was concentrated under reduced pressure and the 
resulting residue was dissolved in H2O, frozen, and lyophilized to yield the crude peptide 
(70% conversion). The peptide was dissolved in 20% MeCN/H2O (1% TFA) and analyzed 
via RP-HPLC-MS. Epimerization was not detected. 
 
H-AWA-MeNbz-G-NH2 (2.4.C). Substrate was made on a 500 mg scale using Rink Amide 
resin (loading: 0.77 mmol/g). Each amino acid was coupled once, apart from Fmoc-
Trp(Boc)-OH, which was double coupled. After the completion of SPPS, the resin was 
subjected to previously established activation conditions,74c followed by cleavage from 
resin using 95:2.5:2.5 TFA/TIPS/H2O for 2 h. After this time, the solvent was removed, 
and collected. The collected solution was then reduced in volume with a continuous flow 
of air until a residue remained. Then the residue was subjected to –20 ºC diethyl ether to 
crash out the crude peptide. After centrifuging, the ether layer was decanted and the 
crude peptide was dissolved in 1:1 MeCN/H2O, frozen in liquid nitrogen, and lyophilized. 
Both the parent and +139 masses are observed by HPLC and represent compound 2.6.E. 
I hypothesized that [M + 139]+ was [M + H + 4-nitrophenol]+, or simply the partially 













































(DIEA) leads to disappearance of 716 m/z and increase of 577 m/z indicating that 716 
m/z is being converted to 577 m/z. In all in-solution reactions, this peak disappears, and 
so it appears that the activation is completed in situ in the next step. 
 
H-AWA-NHBu (2.4.D-NHBu). Table 2.4.2, entry 1: Crude peptide (2.4.C, 20 mg) was 
dissolved in 200 µL of HPLC grade MeCN. Butylamine (200 µL) was added to the peptide 
and allowed to stir at ambient temperature. The reaction was monitored by removing an 
aliquot of the reaction mixture and quenching in 20% MeCN/H2O (1% TFA) and analyzed 
via RP-HPLC-MS. The reaction went to completion after 30 min (>99% conversion). 
 
H-AWA-NH(CH2)3N3 (2.4.D-NH(CH2)3N3). Table 2.4.2, entry 2: Crude peptide (2.4.C, 20 
mg) was dissolved in 200 µL of HPLC grade MeCN. 3-azidopropylamine (10 equiv) was 
dissolved in 100 µL MeCN and added to the peptide and allowed to stir at ambient 
temperature. The reaction was monitored by removing an aliquot of the reaction mixture 
and quenching in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. The 





































































H-AWA-NHpropargyl (2.4.D-NHpropargyl). Table 2.4.2, entry 3: Crude peptide (2.4.C, 
20 mg) was dissolved in 200 µL of HPLC grade MeCN. Propargylamine (200 µL) was 
added to the peptide and allowed to stir at ambient temperature. The reaction was 
monitored by removing an aliquot of the reaction mixture and quenching in 20% 
MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. The reaction went to completion 
after 30 min (>99% conversion). 
 
H-AWA-NHBn (2.4.D-NHBn). Table 2.4.2, entry 4: Crude peptide (2.4.C, 20 mg) was 
dissolved in 200 µL of HPLC grade MeCN. Benzylamine (200 µL) was added to the 
peptide and allowed to stir at ambient temperature. The reaction was monitored by 
removing an aliquot of the reaction mixture and quenching in 20% MeCN/H2O (1% TFA) 






































































H-AWA-NHPh (2.4.D-NHPh). Table 2.4.2, entry 5: Crude peptide (2.4.C, 20 mg) was 
dissolved in 200 µL of HPLC grade MeCN. Aniline (200 µL) was added to the peptide 
followed by 5 equiv DIEA, and the resulting mixture was allowed to stir at ambient 
temperature. The reaction was monitored by removing an aliquot of the reaction mixture 
and quenching in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. The 
reaction went to completion after 6 h (>99% conversion). 
 
H-AWA-NHNH2 (2.4.D-NHNH2). Table 2.4.2, entry 6: Crude peptide (2.4.C, 20 mg) was 
dissolved in 200 µL of HPLC grade MeCN. 200 µL of hydrazine was added to the peptide 
and allowed to stir at ambient temperature. The reaction was monitored by removing an 
aliquot of the reaction mixture and quenching in 20% MeCN/H2O (1% TFA) and analyzed 










































































H-AWA-NHOH (2.4.D-NHOH). Table 2.4.2, entry 7: Crude peptide (2.4.C, 20 mg) was 
dissolved in 200 µL of HPLC grade MeCN and added to 5 equiv of hydroxylamine•HCl. 
Then 5 equiv DIEA was added to the solution and allowed to stir at ambient temperature. 
The reaction was monitored by removing an aliquot of the reaction mixture and quenching 
in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. The reaction went to 
completion after 3 h (>99% conversion). 
 
H-AWA-NMeOMe (2.4.D-NMeOMe). Table 2.4.2, entry 8: Crude peptide (2.4.C, 20 mg) 
was dissolved in 200 µL of HPLC grade MeCN and added to 5 equiv of N,O-
dimethylhydroxylamine•HCl. Then 10 equiv DIEA was added to the solution and allowed 
to stir at ambient temperature. The reaction was monitored by removing an aliquot of the 
reaction mixture and quenching in 20% MeCN/H2O (1% TFA) and analyzed via RP-









































































H-AWA-OMe (2.4.D-OMe). Table 2.4.2, entry 9: 20 mg of crude peptide (2.4.C) was 
dissolved in 200 µL of HPLC grade MeCN. 200 µL of MeOH was added to the peptide 
solution and allowed to stir at ambient temperature. The reaction was monitored by 
removing an aliquot of the reaction mixture and quenching in 20% MeCN/H2O (1% TFA) 
and analyzed via RP-HPLC-MS. The reaction went to completion after 30 min (>99% 
conversion). 
 
H-AWA-OEt (2.4.D-OEt). Table 2.4.2, entry 10: Crude peptide (2.4.C, 20 mg) was 
dissolved in 200 µL of HPLC grade MeCN. Ethanol (200 µL) was added to the peptide 
solution and allowed to stir at ambient temperature. The reaction was monitored by 
removing an aliquot of the reaction mixture and quenching in 20% MeCN/H2O (1% TFA) 




































































H-AWA-OBn (2.4.D-OBn). Table 2.4.2, entry 11: Crude peptide (2.4.C, 20 mg) was 
dissolved in 200 µL of HPLC grade MeCN. Benzyl alcohol (200 µL) was added to the 
peptide solution and allowed to stir at ambient temperature. The reaction was monitored 
by removing an aliquot of the reaction mixture and quenching in 20% MeCN/H2O (1% 
TFA) and analyzed via RP-HPLC-MS. The reaction went to completion after 30 min 
(>99% conversion). 
 
H-AWA-OPh (2.4.D-OPh). Table 2.4.2, entry 12: Crude peptide (2.4.C, 20 mg) was 
dissolved in 200 µL of HPLC grade MeCN and added to 10 equiv of phenol. Then 5 equiv 
of DIEA was added allowed to stir at ambient temperature. The reaction was monitored 
by removing an aliquot of the reaction mixture and quenching in 20% MeCN/H2O (1% 




































































H-AWA-OiPr (2.4.D-OiPr). Table 2.4.2, entry 13: Crude peptide (2.4.C, 20 mg) was 
dissolved in 200 µL of HPLC grade MeCN. i-PrOH (200 µL) was added to the peptide 
mixture, followed by (5 equiv) DIEA and allowed to stir at ambient temperature. The 
reaction was monitored by removing an aliquot of the reaction mixture and quenching in 
20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. After 5 h, the reaction stalled 
at 61% conversion. 
 
H-AWA-OH (2.4.D-OH). Table 2.4.2, entry 14: Crude peptide (2.4.C, 20 mg) was 
dissolved in 200 µL of HPLC grade MeCN. Aqueous NaOH (1 M, 200 µL) was added to 
the peptide solution and allowed to stir at ambient temperature. The reaction was 
monitored by removing an aliquot of the reaction mixture and quenching in 20% 
MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. The reaction went to completion 


































































H-AWA-b-amino alcohol (2.4.D-b-amino alcohol). Table 2.4.2, entry 15: Crude peptide 
(2.4.C, 20 mg) was dissolved in 200 µL of THF. Then 10 equiv of NaBH4 was added 
portion-wise and allowed to stir at ambient temperature. The reaction was monitored by 
removing an aliquot of the reaction mixture and quenching in 20% MeCN/H2O (1% TFA) 
and analyzed via RP-HPLC-MS. The reaction went to completion after 30 min (>99% 
conversion). 
 
Protected native GLP-1(7-36). Fmoc-GLP-1(7-36)-MeDbz-Gly-Rink Amide (20 mg, 3.2 
µmol based on final loading) was weighed in a 5 mL peptide reaction vial and swelled in 
CH2Cl2 for 30 min. The resin was activated and cleaved with ammonia (see General 
Procedure). After removal of DMF, the fully protected peptide was rinsed from the resin 
using 1:1:3 TFE/AcOH/CH2Cl2 until the peptide was fully removed (45 min x 3). All 
cleavages were combined, reduced in volume with a constant stream of air, diluted with 
1:1 MeCN/H2O, frozen in LN2, and lyophilized yielding the crude fully protected product 

































     in CH2Cl2
      then 1 M DIPEA/DMF













Fmoc-GLP-1(7-36)-MeDbz-Gly-Rink Amide (200 mg, 32 µmol based on final loading) was 
weighed in a 5 mL peptide reaction vial and swelled in DCM for 30 min. The resin was 
activated and cleaved with (95:2.5:2.5) TFA/TIPS/H2O and agitated for (1 h x 2). The 
solution was reduced in volume with a constant stream of air, precipitated with –20 ºC 
diethyl ether, centrifuged, and decanted to yield the crude product Fmoc-GLP-1(7-36) in 
45% yield (53.8 mg). 
 
Crude Fmoc-GLP-1(7-36)-MeNbz-Gly-NH2 (26.9 mg, 7.2 µmol) was weighed in a 2 mL 
glass vial and dissolved in 500 µL MeCN and 150 µL H2O. Then 100 µL of BuNH2 was 
added, and the mixture was stirred at ambient temperature until the reaction went to 
completion (30 min, determined by HPLC-MS). The solution was diluted with H2O and 
directly purified by HPLC-MS to yield the pure GLP-1(7-36)-NHBu in 22% yield (5.3 mg, 






    chloroformate
     in CH2Cl2






HAEGT FTSDV SSYLE GQAAK EFIAW LVKGR


















CHAPTER 3: EPIMERIZATION-FREE ACCESS TO C-TERMINAL CYSTEINE 
PEPTIDE ACIDS, CARBOXAMIDES, SECONDARY AMIDES, AND ESTERS VIA 
COMPLIMENTARY STRATEGIES 
Parts of this chapter were adapted with permission from Arbour, C. A.; Kondasinghe, T. 
D.; Saraha, H. Y.; Vorlicek, T. L.; Stockdill, J. L. Chem. Sci. 2018, 9, 350–355. 
Reproduced by permission of The Royal Society of Chemistry. 
3.1 Cysteine: A Vital Yet Problematic Amino Acid in Peptide Synthesis 
C-terminal cysteine peptides, including prenylated and farnesylated peptides,4,89 
disulfide linked peptide toxins,90 and insulinotropic peptides,91,92 comprise an important 
but synthetically challenging class of biologically active peptides. Many of these peptides 
are modified at the C terminus. C-terminal modifications such as esters and amides can 
be critical to maintaining a peptide’s active conformation,93 in vivo activity, and 
pharmacokinetics;94 therefore, the ability to vary the peptide structure in this location is 
crucial to drug development efforts.95 Although several methods have been reported for 
C-terminal functionalization after solid-phase peptide synthesis (SPPS) is complete,39 
these approaches either result in epimerization when applied to C-terminal cysteine 
peptides47 or the applicability of the method to C-terminal cysteine peptides is not 
addressed.49,51,55,67,72a-b While activation of the C-terminal carboxylic acid can induce 
epimerization via oxazolone formation in most amino acids,31 cysteine is also prone to 
epimerization via direct deprotonation during its attachment to the resin96 and upon 
prolonged or repeated exposure to base (i.e., during peptide elongation via Fmoc 
SPPS).96c,97 Therefore, even the preparation of simple carboxylic acids or carboxamides 
of C-terminal cysteine peptides can be fraught with contamination by epimerized 
products,71,89f-g,96a,98 reducing the overall yield and complicating the purification of the 
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target peptides. A method for the epimerization-free synthesis and subsequent C-terminal 
modification of C-terminal cysteine peptides would be highly impactful. 
 In this work, I demonstrate the first mild and convenient method for the 
epimerization-free diversification of peptides bearing a C-terminal cysteine. Carboxylic 
acids, primary and secondary amides, and esters are accessed without epimerization or 
formation of diketopiperazine and piperidinyl-alanine side products.97e,99 I apply this 
strategy to the total synthesis of the nicotinic acetylcholine receptor (nAChR) antagonist 
a-conotoxin ImI.100 Additionally, I include an alternate strategy employing N-deprotected 
cysteine derivatives as nucleophiles, and I demonstrate its utility via the synthesis of the 
insect pheromone a-factor.89  
 In the context of my ongoing efforts toward the synthesis of disulfide-linked a- and 
µ-conotoxins,90b,101,102 I was concerned about possible epimerization of the C-terminal 
cysteine during the SPPS. I recently reported a strategy for C-terminal functionalization 
of non-cysteine peptides involving activation of the methyl-diaminobenzoyl (MeDbz) 
linker74 followed by nucleophilic cleavage of the N-acyl urea (MeNbz) group (3.1.A)76a to 
yield various protected or unprotected peptides (3.1.B, Scheme 3.1A).167 If this approach 
were to prove mild enough to enable preparation of challenging C-terminal cysteine 
peptide derivatives, it would establish the MeNbz group as one of the mildest known 
activated carbonyl intermediates.103 I describe herein the exploitation of this reactivity to 
access C-terminal cysteine peptide acids, primary and secondary amides, and esters 
without epimerization.  
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For epimerization-free functionalization at cysteine, the attachment of the first 
amino acid,74b peptide elongation, linker activation, and nucleophilic attack all must occur 
without epimerization of the unusually acidic96b cysteine a-stereocenter. There are two 
possible mechanisms that epimerization can occur for C-terminal cysteine (Scheme 3.1). 
The activation of the C-terminal carbonyl can induce oxazolone (3.1.C) formation 
(Scheme 3.1B), or the acidic a-hydrogen can be directly deprotonated with a base 
(Scheme 3.1C). Once deprotonated, the enol (3.1.E) can reprotonate to a mixture of 
diastereomers (3.1.F). 
Scheme 3.1. A) Nucleophilic displacement of C-terminal cysteine peptides, B) oxazolone 
formation, C) direct deprotonation of the a-hydrogen of C-terminal cysteine. 
 
 I expected that the parent diaminobenzoyl group would not be sufficiently 
activating to cause epimerization during prolonged piperidine exposure. Thus, I sought to 
establish the stereochemical integrity of the cysteine residue under these conditions 
unequivocally. I selected Cys(Trt) for these experiments because of its extreme tendency 
toward epimerization.97 Thus, Hasina Saraha synthesized tripeptide Boc-Ala-Trp(Boc)-
Cys(Trt)–MeDbzGly–Wang and exposed it to 20% piperidine/DMF over 2, 4, and 24 h. 














































































OH. As expected, no epimerization was detected immediately following SPPS or after 
piperidine exposure at any time point.81 Importantly, this is the first report of a linker for 
which no epimerization is detected at a C-terminal Cys(Trt) residue after treatment with 
20% piperidine for 24 h.  
3.2 Epimerization of C-Terminal Cysteine with Different Thiol Protecting Groups 
 With this result in hand, I was poised to evaluate the ability of the activated MeNbz 
linker to undergo nucleophilic displacement without inducing epimerization of the C-
terminal cysteine. I first evaluated epimerization-prone Cys(Trt)-terminated peptides with 
N and O nucleophiles (3.2.A). I began with displacement by ammonia because of its small 
size and the relatively low pKa of +NH4. I was pleased to observe formation of the target 
peptide (3.2.B, Nuc = NH2) with complete conversion and no detectable epimerization in 
54% isolated yield (Table 3.2, entry 1). I next evaluated benzylamine, which has a similar 
pKa, but found that treatment of the activated linker with neat BnNH2 led to 16% 
epimerization (entry 2). However, using only 5 equiv benzylamine in MeCN, the product 
was formed with no detectable epimerization (entry 3). I next tested neat butylamine, 
which is slightly more basic, and 8% epimerization was observed. Reducing the amount 
of amine and varying the solvent did not improve epimerization in this case (entry 4-6). 
However, when I reduced the amount of butylamine to 1.1 equiv, I retained reactivity while 
eliminating epimerization of C-terminal Cys(Trt) (entry 7).  
Other commercially available cysteine PGs should be less prone to epimerization 
than Trt. Therefore, I used 5 equiv BuNH2 (i.e., entry 6 conditions) for the remaining 
protecting groups. First, I evaluated the Acm group in MeCN (entry 8), finding <1% 
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epimerization in the formation of the C-terminal Cys(Acm) butylamide. Next, I tested Mob, 
Bn, StBu, and tBu with BuNH2 in MeCN. In all cases, no epimerization was detected 
(entries 9-12). Turning my attention to alcohol nucleophiles, I tested MeOH/KOtBu with 
Cys(Trt) as a benchmark47 and found 42% epimerization (entry 13). However, in the 
presence of 5 equiv Hünig’s base (DIEA) in MeOH, no epimerization was observed (entry 
14). Because of the lower conversion in this case, I also investigated the use of a 1:1 
MeOH/phosphate buffer solvent mixture (pH 8). In this case, complete conversion was 
observed while maintaining no detectable epimerization (entry 15). Even carboxylic acid 
derivatives with a C-terminal Cys(Trt) can be difficult to access without epimerization.104 
Therefore, water was investigated as a nucleophile in the presence of Hünig’s base. In 
this case, the reaction was slower, but the product acid was observed with <1% 
epimerization (entry 16).105 Thus, all nucleophiles tested react with the activated C 




Table 3.2. Evaluation of epimerization during nucleophilic cleavage of the MeNbz group 
in C-terminal cysteine peptides. 
 
 Next, I sought to demonstrate the viability of this cleavage strategy in the context 
of more complex peptides. Because of my interest in disulfide-linked neuroactive 
peptides,106 I targeted the C-terminal carboxamide a-conotoxin ImI (3.2.F), a sub-type 
selective nicotinic acetylcholine receptor antagonist100,107 isolated from the venom of 
Conus imperialis marine snails (Scheme 3.2).102a,107a,108 Both the C-terminal 
carboxamide and the correct disulfide bond connectivity are important to the bioactivity of 
a-ImI (3.2.F).108,109 Thus, peptide 3.2.C was activated and cleaved with ammonia to yield 
the fully protected peptide carboxamide. Acidic removal of protecting groups and HPLC 
purification gave the reduced peptide 3.2.D in 25% isolated yield.110 The first disulfide 
was formed in the presence of air in 1% DMSO in phosphate buffer at pH 8 (peptide 
3.2.E). Subsequent iodine treatment removed both Acm groups and induced oxidation to 









Nuc-H (5 equiv or neat) 
base, solvent, 1.5 h Nuc
O
3.2.B.1-6
    Boc
AWCH/Boc
PG
a All reactions were performed on 20 mg of resin containing all L amino acids in 200 µL of solvent at ambient temperature (24 ± 1 ºC), b all 
PGs were removed prior to epimerization assay unless otherwise noted. c Cys(PG) was intact during epimerization assay, d 1.1 equiv of 











4 BuNH2 >99 8Trt
BuNH2 –5 >99 10Trt
8c BuNH2 >99 <1Acm –
PG
1c NH3 – >99 <1Trt
9c BuNH2 – >99 <1Mob
10c BuNH2 – >99 <1Bn
11 BuNH2 <1StBu >99
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3 BnNH2 – >99 <1Trt MeCN
H2O DIEA16 56 <1Trt H2O/MeCN
12c BuNH2 – <1tBu >99MeCN
MeOH –15g >99 <1Trt MeOH/Na2HPO4(aq)





















form the native conotoxin (3.2.F) in 52% isolated yield over both folding steps. Co-
injection of with a commercially available standard confirmed the correct folding.81 
Alternatively, Thilini Kondasinghe demonstrated the on-resin folding with iodine, followed 
by MeDbz activation, cleavage with NH3, and side-chain deprotection to afford conotoxin 
3.2.F in 43% isolated yield; however, this approach gives a mixture of folded products, as 
expected.111  
Scheme 3.2. Synthesis of conotoxin a-ImI (3.2.F). 
  
3.3 Displacement with Pre-Functionalized Cysteine 
 I envisioned that situations might exist wherein it would prove advantageous to 
access the target peptides by using various pre-functionalized cysteine derivatives as 
nucleophiles for cleavage of MeNbz from the resin.104,112 For example, this approach 
would avoid the need to screen epimerization for each new derivative, it would enable 
access to authentic standards for peptides generated using direct C-terminal modification 
approaches, and it would enable incorporation of poor or hindered nucleophiles. Recently, 
C-terminal cysteine peptide acids were synthesized using an N-(2-hydroxy-5-
nitrobenzyl)-cysteine (N-Hnb-Cys) crypto-thioester approach.104 Although this method 
enabled access to a challenging Pro-Cys linkage at the C terminus, elevated 




    1.5 h
3) TFA/TIPS/H2O

















































(25% yield, 3 steps)
1) activation
2) NH3, DMF, 1.5 h
3) TFA/TIPS/H2O
    (95:2.5:2.5)
(43% yield, 4 steps)
 71 
leading to undesired side products. The stability of esters to this approach was not 
determined. I envisioned that application of the cysteine elongation tactic to my MeNbz-
based C-terminal modification would lead to a convenient alternative method to access 
challenging targets at ambient temperature and with short reaction times. However, there 
was no report of an intermolecular168a NCL-like reaction being conducted with the C-
terminally linked peptide still attached to the resin.  
 The elongation approach was tested with Boc-AW(Boc)A-MeNbz-Gly-Rink peptide 
(3.3.A) and H-AWA-MeNbz-Gly-NH2 (3.3.C), which were treated with free cysteine, H-
Cys-OEt, H-Cys-NH2, or H-Cys-NHBu in the presence of Hünig’s base (Table 3.3.1 and 
3.3.2). Protected peptides Boc-AW(Boc)AC-OH (3.3.B.1), Boc-AW(Boc)AC-OEt 
(3.3.B.2), and Boc-AW(Boc)AC-NH2 (3.3.B.3) were formed with complete conversion 
(entries 1-3), while Boc-AW(Boc)AC-NHBu (3.3.B.4) was formed with 38% conversion. 
Table 3.3.1. C-terminal elongation by nucleophilic attack of cysteine on resin-bound 
MeNbz. 
 
The elongation was more efficient in solution,74 and unprotected peptides 3.3.D.1-
4 were accessed with quantitative conversion (Table 3.3.2, entries 1-4). I assumed that 
the mildly basic reaction conditions would result in rapid S to N acyl transfer upon cysteine 













a Unless noted, on-resin reactions were performed on 20 mg resin in 500 µL solvent, solution-
phase reactions were performed on 20 mg crude peptide in 200 µL solvent, 100 µL of H2O 
was added as indicated, rt = 24 ± 1 ºC, b Conversion based on integration of relevant peaks 







































thiol addition either on resin or in solution. In-situ generation of the backbone amide was 
confirmed by independent synthesis of H-AWAC-OH followed by co-injection with 
3.3.D.1.81 The extent of product peptide epimerization was evaluated for the ethyl ester 
(3.3.D.2), which is the most epimerization-prone derivative. Comparison to a co-injection 
of H-AWA(D-Cys)-OEt confirmed that the product peptides are not epimerized to any 
observable extent under the reaction conditions.81 
Table 3.3.2. C-terminal, in-solution elongation by nucleophilic attack of cysteine on 
MeNbz. 
 
3.4 Evaluating Compatibility of Peptides with Varying Peptide Length and Hydrophobicity 
 Teanna Vorlicek and I next performed the cysteine elongation of a series of 
peptides varying in length and hydrophobicity both on the resin and in solution (Table 
3.4). The unprotected peptide H-AKTWA-MeNbz-Gly (3.4.1.B) was functionalized in 
solution to afford H-AKTWAC-OH (3.4.1.C) with complete conversion in 30 min with no 
observed side-chain macrocyclization.167a To enable comparison with the crypto-thioester 
approach,104 C-terminal proline-containing peptide 3.4.2.A was cleaved from resin using 
H-Cys-OH to afford protected H-AKTWPC-OH (3.4.2.C) with 10% conversion over 4 h.113 
Repeating this reaction in solution on unprotected peptide (3.4.2.B) led to complete 














a Unless noted, on-resin reactions were performed on 20 mg resin in 500 µL solvent, solution-phase 
reactions were performed on 20 mg crude peptide in 200 µL solvent, 100 µL of H2O was added as 
indicated, rt = 24 ± 1 ºC, b Conversion based on integration of relevant peaks in HPLC/MS data, 









































conversion after 1 h at ambient temperature. Elongation of Boc-LYRAGLRAY (3.4.3.A) 
proceeded with resin cleavage and complete conversion in the presence of DMF and NCL 
buffer. Hydrophobic peptide 3.4.4, a fragment of amyloid b (Ab(36-42)),114 was elongated 
both on resin (entry 5) and in solution (entry 6). On-resin elongation proved challenging 
for this substrate (10% conversion), while complete conversion was observed in solution. 
Overall, for shorter or non-hydrophobic peptides, this chemistry could be performed on 
resin and in the absence of added thiol. In challenging cases, resin cleavage and then in 
solution native chemical ligation35 afforded the target peptides. 
Table 3.4. Cysteine elongation to generate C-terminal acids, carboxamides, and esters. 
 
3.5 Total Synthesis of a-Factor Peptide 
 To confirm the viability of this approach in the context of a complex natural product, 
I performed the total synthesis of the insect pheromone a-factor (3.5.C, Scheme 3.5), 
which requires both the C-terminal ester and the prenyl moiety for bioactivity.89e-h 
Protected des-farnesyl a-factor was generated by displacement of peptide 3.5.A with 
cysteine methyl ester. The elongation was conducted in NCL buffer in an effort to reduce 










a Unless noted, on-resin reactions were performed on 20 mg peptide/resin in 500 µL solvent, rt = 24 ± 1 ºC, NCL buffer 
at pH 7.2, b Based on integration of relevant peaks in HPLC/MS data, c Used 600 µL solvent, d Performed on 10 mg of 
















5 10OMe 4VGGVVI (3.4.4) (1:1) DMF/NCL buffer
6e >99OMe 0.5VGGVVI (3.4.4) NCL buffer







3d >99OH NCL buffer 1AKTWAP (3.4.2)H
A = protected, X = resin




























cystine-appended a-factor was still observed. Side-chain deprotection, cystine reduction, 
and HPLC purification afforded peptide 3.5.B in 41% yield over 3 steps. Alkylation per the 
reported conditions afforded a-factor in 9% yield (3.5.C).89e 
Scheme 3.5. Synthesis of a-factor by cysteine elongation. 
 
3.6 Summary 
In summary, I have developed two broadly applicable strategies for the 
epimerization-free preparation of C-terminal cysteine peptides. The first approach 
exploits the exceptionally mild activating nature of the N-acyl urea group for the direct 
diversification of the C terminus. Additionally, an alternative strategy wherein cysteine 
derivatives serve as the nucleophile in a resin-cleaving elongation reaction was also 
effective. For both strategies, the target peptides are prepared without observation of 
either diketopiperazine or piperidinylalanine side products. The utility of these methods 
was demonstrated in the preparation of the disulfide-linked conotoxin a-ImI, bearing a C-
terminal cysteine carboxamide and the insect pheromone a-factor, which possesses a C-
terminal cysteine methyl ester. Notably, no previous report has demonstrated successful 
functionalization of C-terminal cysteine peptides to access carboxylic acids, 
carboxamides, and other C-terminal derivatives without detectable epimerization of the 
a-stereocenter. 
3.7 General Experimental Procedures 
3.7.1 Materials and Methods 
1) H-Cys-OMe, DIEA
    NCL buffer/DMF, 4 h
2) TFA/TIPS/H2O 
    (95:2.5:2.5)
3) Bu3P (5 equiv)






















(41% yield, 3 steps) (9% yield)
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See Chapter Section 2.6 Materials and Methods under Section 2.6.1 General 
Experimental Procedures for Solid-Phase Peptide Synthesis, NMR, RP-HPLC-MS, and 
MeDbz Activation procedures. 
3.7.2 Experimental Procedures 
 
H-Cys-NH2 (3.7.B) (R)-2-amino-3-mercaptopropanamide. H-Cys(Trt)-NH2 (1 g, 2.76 
mmol) was weighed into a 100 mL round bottom flask containing a stir bar. The amino 
acid was then dissolved in 10 mL of (49:50:1) CH2Cl2/TFA/TIPS and stirred at ambient 
temperature. After 15 min, TIPS was added dropwise until the solution turned from bright 
red-orange to a pale-yellow solution. The volatile solvent was then removed under 
reduced pressure after 30 min, followed by addition of 40 mL water. A white solid was 
removed by filtration and the filtrate was frozen (LN2) and lyophilized to yield the crude 
cysteine amide in >99% yield (745 mg).1H NMR (499 MHz, Acetonitrile-d3) d 7.16 (s, 1H), 
6.68 (s, 1H), 4.20 (t, J = 5.3 Hz, 1H), 3.06 (qd, J = 14.9, 5.1 Hz, 2H). 13C NMR (126 MHz, 
CD3CN) d 169.8, 55.3, 26.0. 
 
Boc-Cys(Trt)-NHBu (3.7.D) tert-butyl (R)-(1-(butylamino)-1-oxo-3-(tritylthio)propan-
2-yl)carbamate. To a microwave vial was added Boc-Cys(Trt)-OH and HATU (plus stir 




































were fully dissolved. Upon completion of the reagents dissolving, butylamine was added 
(vial felt warm). Then, the vial was placed in the microwave for 5.5 mins at 75 ºC. This 
heating was done two times, and the reaction was monitored by direct MS. Unfortunately, 
the reaction did not go to completion after these two rounds of microwaving. The reaction 
was allowed to stir vigorously for 2 days at ambient temperature. Again, the starting 
material was observed. The reaction was then quenched/diluted with water (white 
precipitate). Then, ethyl acetate was added. A clear line was not achievable between the 
aqueous and organic layer. Therefore, brine was added and the extraction solution 
(aqueous) became clear, and it was obvious where the layers sectioned for extraction. 
The aqueous layer was extracted 5 times with ethyl acetate, and the organic layer was 
dried over sodium sulfate. After filtration, the organic layer was concentrated and purified 
using column chromatography (DCM to 5% MeOH/DCM). 243.2 mg (43% yield). 1H NMR 
(400 MHz, Chloroform-d) d 7.42 (d, J = 7.4 Hz, 6H), 7.28 (t, J = 7.5 Hz, 6H), 7.21 (t, J = 
7.2 Hz, 3H), 6.05 (s, 1H), 4.94-4.84 (bs, 1H), 3.95-3.74 (bs, 1H), 3.17 (q, J = 6.7 Hz, 2H), 
2.69 (dd, J = 12.5, 7.0 Hz, 1H), 2.52 (dd, J = 12.8, 5.4 Hz, 1H), 1.41 (s, 10H), 1.29 (m, 
2H), 0.88 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, CDCl3) d 170.29, 155.37, 144.44, 
129.57, 128.02, 126.83, 80.14, 67.13, 53.62, 39.18, 33.91, 31.43, 28.27, 19.94, 13.71. 
 
H-Cys-NHBu (3.7.E) (R)-2-amino-N-butyl-3-mercaptopropanamide. To a round 
bottom flask containing Boc-Cys(Trt)-NHBu, 40 mL of deprotection cocktail (49:50:1 of 



















out for 30 minutes at room temperature. The solvent was removed, under vacuum, and 
the residue was suspended in 20 mL of water, and then filtered. The filtrate was collected. 
Thereafter, the aqueous layer was rinsed once with hexanes. The hexanes were 
discarded, and the aqueous layer was frozen using liquid nitrogen and lyophilized. 142.3 
mg (>99% yield). 1H NMR (400 MHz, Methanol-d4) d 3.98 – 3.91 (m, 1H), 3.32 – 3.17 (m, 
3H), 3.05 – 2.89 (m, 2H), 1.57 – 1.47 (m, 2H), 1.38 (dd, J = 15.1, 7.3 Hz, 3H), 0.94 (t, J = 
7.3 Hz, 3H). 13C NMR (101 MHz, CD3OD) d 166.75, 54.74, 39.02, 30.92, 24.89, 19.62, 
12.58. [α]	%&' +5.05 (c 1.01, MeOH).  
 
Peptides 3.7.G.1 and 3.7.G.2 were synthesized using a standard Fmoc-SPPS protocol. 
Both D- and L-Cys substrates were made. 
 
H-AWC-MeDbz-Gly-OH (3.7.G). Resin 3.7.F (10 mg) was weighed into 3 different 2 mL 
reactor vials and swelled in CH2Cl2 for 30 min. After this time, the solvent was removed, 
and the resins were subjected to various times of 20% piperidine in DMF (2,4, and 24 h). 
Then The solvent was removed, and the resins were rinsed with DMF (3 x 1 mL) and 



































































The solution was collected after this time and concentrated under a constant stream of 
air. The sample was then precipitated with –20 ºC diethyl ether, centrifuged, and decanted 
to yield the crude peptide. The peptide was dissolved in 50% MeCN/H2O and analyzed 
via RP-HPLC-MS using a gradient of 20% MeCN/H2O over 15 min. 
 
H-AW(Boc)C(Trt)-NH2 (3.2.B.1-NH2). Table 3.2, entry 1: Peptide on dry resin (3.2.A.1, 
100 mg) was weighed into a 5 mL fritted reaction vial with an attached needle and rubber 
stopper. The resin was swelled in CH2Cl2 (500 µL – 4 mL) for 30 min. The MeDbz linker 
was activated by a previously established protocol.74 Next, 500 µL of DMF was added 
and the reaction vial was closed off with a septum (needle and stopper still attached at 
the bottom). A balloon was placed inside another ballon and filled with ammonia. A 
hypodermic needle was attached to the balloon and inserted into the septum and 
submerged into the DMF solution. The 25 G 1-1/2” (Blue) gauge needle was placed into 
the septum to allow for the exiting of gas. The ammonia gas was bubbled into DMF for 
1.5 h. Then The solvent was removed and collected. Additional rinsing was required to 
completely remove the desired peptide from resin. CH2Cl2 (3 x 1 mL) was used to rinse 
the resin, followed by MeCN (3 x 1 mL), and lastly CH2Cl2 (3 x 1 mL). The washes were 
combined with the initial DMF solution, reduced in volume with air, dissolved in 1:1 
MeCN/H2O, frozen (LN2), and lyophilized to yield the crude product. Purification was 






















    chloroformate 
    then DIPEA/DMF




white solid). A silica column was used with a mobile phase eluent of 50-100% MeCN/ethyl 
acetate followed by 0-10% MeOH/CH2Cl2. The product was isolated, concentrated under 
reduced pressure, and lyophilized to yield a fluffy white solid (11.56 mg, 54%). 1H NMR 
(499 MHz, DMSO-d6) d 8.37 (d, J = 8.2 Hz, 1H), 8.16 (s, 1H), 8.01 (d, J = 8.1 Hz, 1H), 
7.64 (d, J = 7.8 Hz, 1H), 7.45 (s, 1H), 7.39 – 7.18 (m, 19H), 7.16 (s, 1H), 4.64 (s, 1H), 
4.32 (q, J = 6.9 Hz, 1H), 3.26 (q, J = 6.9 Hz, 2H), 3.12 (dd, J = 14.7, 4.1 Hz, 1H), 2.98 – 
2.88 (m, 1H), 2.37 (d, J = 6.7 Hz, 2H), 1.60 (s, 9H), 1.02 (d, J = 6.9 Hz, 3H).13C NMR (126 
MHz, DMSO) d 171.8, 171.1, 168.6, 144.7, 144.2, 129.5, 128.5, 127.2, 124.7, 124.5, 
122.9, 122.8, 119.9, 116.7, 108.5, 83.9, 66.2, 52.2, 51.9, 50.6, 34.5, 31.2, 28.2, 27.8, 
21.4. 
 
H-AWC-NHBn (3.2.B.1-NHBn). Table 3.2, entry 2:  Resin (3.2.A.1, 20 mg) was weighed 
into a 2 mL reactor vial and swelled in CH2Cl2 for 15 min. After this time, the solvent was 
removed, and the resin was subjected to activation conditions. Then 200 µL of BnNH2 
was added to the resin and agitated for 1.5 h at ambient temperature. The solution was 
removed, and the resulting residue was dissolved in 3 mL of TFA/TIPS/H2O (95:2.5:2.5) 
and agitated for 30 min. After this time, the solution was reduced in volume with a constant 
stream of air. Then the resulting residue was dissolved in 1:1 MeCN/H2O, frozen (LN2), 
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added to the crude peptide and agitated for 1 h. The solvent was reduced in volume with 
a constant stream of air, and the resulting residue was subjected to –20 ºC diethyl ether 
to precipitate the crude peptide. The resulting slurry of peptide in diethyl ether was 
centrifuged, decanted and the solid was dissolved in 20% MeCN/H2O (1% TFA) and 
analyzed via RP-HPLC-MS. The reaction went to completion after 1.5 h (>99% 
conversion) and 16% of the D-Cys epimer was observed. 
 
H-AWC-NHBn (3.2.B-NHBn). Table 3.2, entry 3:  Resin 3.2.A(Trt) (20 mg) was weighed 
into a 2 mL reactor vial and swelled in CH2Cl2 for 15 min. After this time, the solvent was 
removed, and the resin was subjected to activation conditions. Then 200 µL MeCN was 
added to the resin followed by 5 equiv BnNH2 and agitated for 1.5 h at ambient 
temperature. The solvent was then removed, and the resulting residue was immediately 
dissolved in 0.5 mL of TFA/TIPS/H2O (95:2.5:2.5). After this time, the solution was 
concentrated down, and the resulting residue was dissolved in 1:1 MeCN/H2O, frozen 
(LN2), and lyophilized to yield the crude peptide. Then 2 mL of TFA/TIPS/H2O (95:2.5:2.5) 
was added to the crude peptide and agitated for 1 h. The solution was reduced in volume 
with a constant stream of air, precipitated with –20 ºC diethyl ether, centrifuged, decanted 
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MS. The reaction went to completion after 1.5 h (>99% conversion) with no observable 
epimerization. 
 
H-AWC-NHBu (3.2.B.1-NHBu). Table 3.2, entry 4:  Resin 3.2.A.1 (20 mg) was weighed 
into a 2 mL reactor vial and swelled in CH2Cl2 for 15 min. After this time, the solvent was 
removed, and the resin was subjected to activation conditions. Then 200 µL of BuNH2 
was added to the resin and agitated for 1.5 h at ambient temperature. The solution was 
removed, and the resulting residue was dissolved in 3 mL of TFA/TIPS/H2O (95:2.5:2.5) 
and agitated for 30 min. After this time, the solution was reduced in volume with a constant 
stream of air, and the resulting residue was dissolved in 1:1 MeCN/H2O 1:1 MeCN/H2O, 
frozen (LN2), and lyophilized to yield the crude peptide. Then 2 mL of TFA/TIPS/H2O 
(95:2.5:2.5) was added to the crude peptide and agitated for 1 h. The solvent was reduced 
in volume with a constant stream of air, and the resulting residue was subjected to –20 
ºC diethyl ether to precipitate the crude peptide. The resulting slurry of peptide in diethyl 
ether was centrifuged, decanted and the solid was dissolved in 20% MeCN/H2O (1% TFA) 
and analyzed via RP-HPLC-MS. The reaction went to completion after 1.5 h (>99% 
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H-AWC-NHBu (3.2.B.1-NHBu). Table 3.2, entry 5: Resin 3.2.A.1 (20 mg) was weighed 
into a 2 mL reactor vial and swelled in CH2Cl2 for 15 min. After this time, the solvent was 
removed, and the resin was subjected to activation conditions. Butylamine (10 equiv) in 
200 µL DMF was added to the resin and agitated for 1.5 h at ambient temperature. The 
solution was removed, and the resulting residue was dissolved in 0.5 mL of 
TFA/TIPS/H2O (95:2.5:2.5). After this time, the solution was concentrated down and the 
resulting residue was dissolved in 1:1 MeCN/H2O, frozen (LN2), and lyophilized to yield 
the crude peptide. TFA/TIPS/H2O (95:2.5:2.5, 2 mL) was added to the crude peptide and 
agitated for 1 h. The solvent was reduced in volume with a constant stream of air, and the 
resulting residue was subjected to –20 ºC diethyl ether to precipitate the crude peptide. 
The mixture was centrifuged, decanted and the solid was dissolved in 20% MeCN/H2O 
(1% TFA) and analyzed via RP-HPLC-MS. The reaction went to completion after 1.5 h 
(>99% conversion) and 10% of the D-Cys epimer was observed. 
 
H-AWC-NHBu (3.2.B.1-NHBu). Table 3.2, entry 6: Resin 3.2.A.1 (20 mg) was weighed 
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removed, and the resin was subjected to activation conditions. Then 200 µL of MeCN and 
added to the resin followed by 5 equiv butylamine. The resin was agitated for 1.5 h at 
ambient temperature. The solution was removed, and the resulting residue was dissolved 
in 0.5 mL of TFA/TIPS/H2O (95:2.5:2.5). After this time, the solution was concentrated 
down and the resulting residue was dissolved in 1:1 MeCN/H2O, frozen (LN2), and 
lyophilized to yield the crude peptide. Then 2 mL of TFA/TIPS/H2O (95:2.5:2.5) was added 
to the crude peptide and agitated for 1 h. The solvent was reduced in volume with a 
constant stream of air, and the resulting residue was subjected to –20 ºC diethyl ether to 
precipitate the crude peptide. The resulting slurry of peptide in diethyl ether was 
centrifuged, decanted and the solid was dissolved in 20% MeCN/H2O (1% TFA) and 
analyzed via RP-HPLC-MS. The reaction went to completion after 1.5 h (>99% 
conversion) and 9% of the D-Cys epimer was observed. 
 
H-AWC-NHBu (3.2.B.1-NHBu). Table 3.2, entry 7: Resin 3.2.A.1 (20 mg) was weighed 
into a 2 mL reactor vial and swelled in CH2Cl2 for 15 min. After this time, the solvent was 
removed, and the resin was subjected to activation conditions. Then 200 µL of MeCN and 
added to the resin followed by 1.1 equiv butylamine. The resin was agitated for 1.5 h at 
ambient temperature. The solution was removed, and the resulting residue was dissolved 
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down and the resulting residue was dissolved in 1:1 MeCN/H2O, frozen (LN2), and 
lyophilized to yield the crude peptide. Then 2 mL of TFA/TIPS/H2O (95:2.5:2.5) was added 
to the crude peptide and agitated for 1 h. The solvent was reduced in volume with a 
constant stream of air, and the resulting residue was subjected to –20 ºC diethyl ether to 
precipitate the crude peptide. The resulting slurry of peptide in diethyl ether was 
centrifuged, decanted and the solid was dissolved in 20% MeCN/H2O (1% TFA) and 
analyzed via RP-HPLC-MS. The reaction went to completion after 1.5 h (>99% 
conversion) with no observable epimerization. 
 
H-AWC(Acm)-NHBu (3.2.B.2-NHBu). Table 3.2, entry 8: Resin 3.2.A.2 (20 mg) was 
weighed into a 2 mL reactor vial and swelled in CH2Cl2 for 15 min. After this time, the 
solvent was removed, and the resin was subjected to activation conditions. Then 200 µL 
of MeCN and added to the resin followed by 5 equiv butylamine. The resin was agitated 
for 1.5 h at ambient temperature. The solution was removed, and the resulting residue 
was dissolved in 0.5 mL of TFA/TIPS/H2O (95:2.5:2.5). After this time, the solution was 
concentrated down and the resulting residue was dissolved in 1:1 MeCN/H2O, frozen 
(LN2), and lyophilized to yield the crude peptide. Then 2 mL of TFA/TIPS/H2O (95:2.5:2.5) 
was added to the crude peptide and agitated for 1 h. The solvent was reduced in volume 
with a constant stream of air, and the resulting residue was subjected to –20 ºC diethyl 
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centrifuged, decanted and the solid was dissolved in 20% MeCN/H2O (1% TFA) and 
analyzed via RP-HPLC-MS. The reaction went to completion after 1.5 h (>99% 
conversion) with no observable epimerization. 
 
H-AWC(Mob)-NHBu (3.2.B.3-NHBu).Table 3.2, entry 9: Resin 3.2.A.3 (20 mg) was 
weighed into a 2 mL reactor vial and swelled in CH2Cl2 for 15 min. After this time, the 
solvent was removed, and the resin was subjected to activation conditions. Then 200 µL 
of MeCN and added to the resin followed by 5 equiv butylamine. The resin was agitated 
for 1.5 h at ambient temperature. The solution was removed, and the resulting residue 
was dissolved in 0.5 mL of TFA/TIPS/H2O (95:2.5:2.5). After this time, the solution was 
concentrated down and the resulting residue was dissolved in 1:1 MeCN/H2O, frozen 
(LN2), and lyophilized to yield the crude peptide. Then 2 mL of TFA/TIPS/H2O (95:2.5:2.5) 
was added to the crude peptide and agitated for 1 h. The solvent was reduced in volume 
with a constant stream of air, and the resulting residue was subjected to –20 ºC diethyl 
ether to precipitate the crude peptide. The resulting slurry of peptide in diethyl ether was 
centrifuged, decanted and the solid was dissolved in 20% MeCN/H2O (1% TFA) and 
analyzed via RP-HPLC-MS. The reaction went to completion after 1.5 h (>99% 
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H-AWC(Bzl)-NHBu (3.2.B.4-NHBu). Table 3.2, entry 10: Resin 3.2.A.4 (20 mg) was 
weighed into a 2 mL reactor vial and swelled in CH2Cl2 for 15 min. After this time, the 
solvent was removed, and the resin was subjected to activation conditions. Then 200 µL 
of MeCN and added to the resin followed by 5 equiv butylamine. The resin was agitated 
for 1.5 h at ambient temperature. The solution was removed, and the resulting residue 
was dissolved in 0.5 mL of TFA/TIPS/H2O (95:2.5:2.5). After this time, the solution was 
concentrated down and the resulting residue was dissolved in 1:1 MeCN/H2O, frozen 
(LN2), and lyophilized to yield the crude peptide. TFA/TIPS/H2O (95:2.5:2.5, 2 mL) was 
added to the crude peptide and agitated for 1 h. The solvent was reduced in volume with 
a constant stream of air, and the resulting residue was subjected to –20 ºC diethyl ether 
to precipitate the crude peptide. The mixture was centrifuged, decanted and the solid was 
dissolved in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. The reaction 
went to completion after 1.5 h (>99% conversion) with no observable epimerization. 
 
H-AWC-NHBu (3.2.B.5-NHBu). Table 3.2, entry 11: Resin 3.2.A.5 (20 mg) was weighed 
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removed, and the resin was subjected to activation conditions. Then 200 µL of MeCN was 
added to the resin followed by 5 equiv butylamine. The resin was agitated for 1.5 h at 
ambient temperature. The solution was removed, and the resulting residue was dissolved 
in 0.5 mL of TFA/TIPS/H2O (95:2.5:2.5). After quenching, the solution was concentrated 
down, and the resulting residue was dissolved in 1:1 MeCN/H2O, frozen (LN2), and 
lyophilized to yield the crude peptide. Then 2 mL of TFA/TIPS/H2O (95:2.5:2.5) was added 
to the crude peptide and stirred for 1 h to give the deprotected cystine peptide 
(AWC(StBu)-NHBu). The solvent was reduced in volume with a constant stream of air, 
and the resulting residue was subjected to –20 ºC diethyl ether to precipitate the crude 
peptide. The resulting slurry of peptide in diethyl ether was centrifuged, decanted, and 
the solid was dissolved in 500 µL TFE and stirred at ambient temperature with 5 equiv 
Bu3P for 2 h. After this time, the solution was concentrated under a constant stream of 
air, suspended in H2O, frozen (LN2), and lyophilized to yield the crude peptide. The 
peptide was dissolved in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. The 
reaction went to completion after 1.5 h (>99% conversion) with no observable 
epimerization. 
 
H-AWC(tBu)-NHBu (3.2.B.6-NHBu). Table 3.2, entry 12: Resin 3.2.A.6 (20 mg) was 
weighed into a 2 mL reactor vial and swelled in CH2Cl2 for 15 min. After this time, the 
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of MeCN and added to the resin followed by 5 equiv butylamine. The resin was agitated 
for 1.5 h at ambient temperature. The solution was removed, and the resulting residue 
was dissolved in 0.5 mL of TFA/TIPS/H2O (95:2.5:2.5). After this time, the solution was 
concentrated down and the resulting residue was dissolved in 1:1 MeCN/H2O, frozen 
(LN2), and lyophilized to yield the crude peptide. Then 2 mL of TFA/TIPS/H2O (95:2.5:2.5) 
was added to the crude peptide and agitated for 1 h. The solvent was reduced in volume 
with a constant stream of air, and the resulting residue was subjected to –20 ºC diethyl 
ether to precipitate the crude peptide. The resulting slurry of peptide in diethyl ether was 
centrifuged, decanted and the solid was dissolved in 20% MeCN/H2O (1% TFA) and 
analyzed via RP-HPLC-MS. The reaction went to completion after 1.5 h (>99% 
conversion) with no observable epimerization. 
 
H-AWC-OMe (3.2.B.1-OMe). Table 3.2, entry 13: Resin 3.2.A.1 (20 mg) was weighed 
into a 2 mL reactor vial and swelled in CH2Cl2 for 15 min. After this time, the solvent was 
removed, and the resin was subjected to activation conditions. Then 0.7 equiv KOtBu was 
dissolved in 200 µL of MeOH and added to the resin. The resin was agitated for 1.5 h at 
ambient temperature. The solution was removed, and the resulting residue was dissolved 
in 0.5 mL of TFA/TIPS/H2O (95:2.5:2.5). After this time, the solution was concentrated 
down and the resulting residue was dissolved in 1:1 MeCN/H2O, frozen (LN2), and 
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to the crude peptide and agitated for 1 h. The solvent was reduced in volume with a 
constant stream of air, and the resulting residue was subjected to –20 ºC diethyl ether to 
precipitate the crude peptide. The resulting slurry of peptide in diethyl ether was 
centrifuged, decanted and the solid was dissolved in 20% MeCN/H2O (1% TFA) and 
analyzed via RP-HPLC-MS. The reaction went to completion after 1.5 h (>99% 
conversion) and 42% of the D-Cys epimer was observed. 
 
H-AWC-OMe (3.2.B.1-OMe). Table 3.2, entry 14: Resin 3.2.A.1 (20 mg) was weighed 
into a 2 mL reactor vial and swelled in CH2Cl2 for 15 min. After this time, the solvent was 
removed, and the resin was subjected to activation conditions. Then 200 µL of MeOH 
was added to the resin followed by 5 equiv DIEA. The resin was agitated for 3 h at ambient 
temperature. The solution was removed, and the resulting residue was dissolved in 0.5 
mL of TFA/TIPS/H2O (95:2.5:2.5). After this time, the solution was concentrated down 
and the resulting residue was dissolved in 1:1 MeCN/H2O, frozen (LN2), and lyophilized 
to yield the crude peptide. TFA/TIPS/H2O (95:2.5:2.5, 2 mL) was added to the crude 
peptide and agitated for 1 h. The solvent was reduced in volume with a constant stream 
of air, and the resulting residue was subjected to –20 ºC diethyl ether to precipitate the 
crude peptide. The mixture was centrifuged, decanted and the solid was dissolved in 20% 
MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. The reaction went to completion 
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H-AWC-OMe (3.2.B.1-OMe). Table 3.2, entry 15. Resin 3.2.A.1 (20 mg) was weighed 
into a 2 mL reactor vial and swelled in CH2Cl2 for 15 min. After this time, the solvent was 
removed, and the resin was subjected to activation conditions. Then 200 µL of MeOH 
was added to the resin along with 200 µL of Na2HPO4/NaH2PO4 buffer at pH = 8. The 
resin was agitated for 1.5 h at ambient temperature. The solution was removed, and the 
resulting residue was dissolved in TFA/TIPS/H2O (95:2.5:2.5, 0.5 mL). After this time, the 
solvent wasfrozen (LN2), and lyophilized to yield the crude peptide. TFA/TIPS/H2O 
(95:2.5:2.5, 2 mL) was added to the crude peptide and agitated for 1 h. The solvent was 
reduced in volume with a constant stream of air, and the resulting residue was subjected 
to –20 ºC diethyl ether to precipitate the crude peptide. The mixture was centrifuged, 
decanted and the solid was dissolved in 20% MeCN/H2O (1% TFA) and analyzed via RP-
HPLC-MS. The reaction went to completion after 1.5 h (>99% conversion) with no 
observable epimerization. 
 
H-AWC-OH (3.2.B.1-OH). Table 3.2, entry 16: Resin 3.2.A.1 (20 mg) was weighed into 
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removed, and the resin was subjected to activation conditions. Then 200 µL of (1:1) 
H2O/MeCN was added to the resin followed by 5 equiv DIEA. The resin was agitated for 
1.5 h at ambient temperature. The solution was removed, and the resulting residue was 
dissolved in 0.5 mL of TFA/TIPS/H2O (95:2.5:2.5). After this time, the solvent wasfrozen 
(LN2), and lyophilized to yield the crude peptide. Then 2 mL of TFA/TIPS/H2O (95:2.5:2.5) 
was added to the crude peptide and agitated for 1 h. The solvent was reduced in volume 
with a constant stream of air, and the resulting residue was subjected to –20 ºC diethyl 
ether to precipitate the crude peptide. The resulting slurry of peptide in diethyl ether was 
centrifuged, decanted and the solid was dissolved in 20% MeCN/H2O (1% TFA) and 
analyzed via RP-HPLC-MS. After 1.5 h, the reaction stalled at 56% conversion with no 
observable epimerization. 
 
H-AWC-OH (3.2.B.1-OH). Table 3.2, entry 3.6.2: Resin 3.2.A.1 (20 mg) was weighed 
into a 2 mL reactor vial and swelled in CH2Cl2 for 15 min. After this time, the solvent was 
removed, and the resin was subjected to activation conditions. Then 200 µL of (1:1) 
H2O/MeCN was added to the resin followed by 5 equiv DIEA. The resin was agitated for 
18 h at ambient temperature. The solution was removed, and the resulting residue was 
dissolved in 0.5 mL of TFA/TIPS/H2O (95:2.5:2.5). After this time, the solvent wasfrozen 
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was added to the crude peptide and agitated for 1 h. The solvent was reduced in volume 
with a constant stream of air, and the resulting residue was subjected to –20 ºC diethyl 
ether to precipitate the crude peptide. The resulting slurry of peptide in diethyl ether was 
centrifuged, decanted and the solid was dissolved in 20% MeCN/H2O (1% TFA) and 
analyzed via RP-HPLC-MS. 
 
Peptide 3.2.C (100 mg, 24 µmol) was weighed into a 5 mL fritted peptide vial and swelled 
in CH2Cl2 for 15 min. The solvent was removed, and the peptide was activated (See 
MeDbz activation). Next, 500 µL of DMF was added and the reaction vial was closed off 
with a septum (needle and stopper still attached at the bottom). A balloon was placed 
inside a balloon and filled with ammonia. A hypodermic needle was attached to the 
balloon and inserted into the septum and submerged into the DMF solution. The 25 G 1-
1/2” (Blue) gauge needle was placed into the septum to allow for the exiting of gas. The 
ammonia gas was bubbled into DMF for 1.5 h. Then The solvent was removed and 
collected. Additional rinsing was required to completely remove the desired peptide from 
resin. CH2Cl2 (3 x 1 mL) was used to rinse the resin, followed by MeCN (3 x 1 mL), and 
lastly CH2Cl2 (3 x 1 mL). The washes were combined with the initial DMF solution and 
reduced in volume with air. The residue was subjected to 1:1 MeCN/H2O, frozen (LN2), 
and lyophilized to yield the crude product (70% crude yield, 86% HPLC purity based on 
254 nm). The crude peptide was then fully deprotected using TFA/TIPS/H2O (95:2.5:2.5) 
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centrifuged, and the ether was decanted to yield the crude fully deprotected peptide. The 
solid was dissolved in 1:1 MeCN/H2O, frozen (LN2), and lyophilized. The peptide was 
purified by RP-HPLC-MS to yield the reduced peptide (3.2.D) in 25% yield (8.9 mg). 
 
Peptide 3.2.D (8.6 mg, 5.7 µmol) was dissolved in 6 mL Na2HPO4/NaH2PO4 buffer (that 
was previously adjusted to pH 8 with 5 M NaOH). Then 60 µL of DMSO was added to the 
mixture and allowed to stir overnight at ambient temperature. After complete consumption 
of starting material, which was monitored by RP-HPLC-MS, peptide 3.2.E was further 
oxidized without removal from this reaction mixture. 
 
The solution of peptide 3.2.E, in the previously mentioned buffer, was subjected to 8 equiv 
iodine in a solution of (4:1) MeOH/H2O (the MeOH/H2O mixture was added until the iodine 
was completely dissolved). The removal of Acm and final folding step was monitored by 
RP-HPLC-MS. After complete consumption of starting material, the mixture was 
quenched with ascorbic acid. The solid ascorbic acid was added portion-wise until the red 
solution turned clear. The mixture was then frozen (LN2) and lyophilized to yield the crude 
peptide 3.2.F. The peptide was purified using RP-HPLC-MS to yield the pure peptide in 


















































Peptide 3.2.C (80.0 mg, 19.2 µmol) was swelled in DMF for 30 min. Then 2.0 mL solution 
of I2 (5 equiv, 40.6 mg) in CH2Cl2 was added to the resin and allowed to agitate for 90 min 
at ambient temperature. Next, the reaction mixture was filtered, and the resin was washed 
thoroughly with CH2Cl2 (10 x 1 mL) and DMF (10 x 1 mL). The peptide was activated (See 
MeDbz activation). Then, 500 µL of DMF was added and the reaction vial was closed off 
with a septum (needle and stopper still attached at the bottom). A balloon was placed 
inside a balloon and filled with ammonia. A hypodermic needle was attached to the 
balloon and inserted into the septum and submerged into the DMF solution. The 25 G 1-
1/2” (Blue) gauge needle was placed into the septum to allow for the exiting of gas. The 
ammonia gas was bubbled into DMF for 2.0 h. Then The solvent was removed and 
collected. Additional rinsing was required to completely remove the desired peptide from 
resin. CH2Cl2 (3 x 1 mL) was used to rinse the resin, followed by MeCN (3 x 1 mL), and 
lastly CH2Cl2 (3 x 1 mL). The washes were combined with the initial DMF solution and 
reduced in volume with air. The residue was subjected to 1:1 MeCN/H2O, frozen (LN2), 
and lyophilized. The resulting crude peptide was then fully deprotected using 
TFA/TIPS/H2O (95:2.5:2.5) for 2.0 h. The solvent was reduced in volume, precipitated 
with –20 ºC diethyl ether, centrifuged, and the ether was decanted to yield the crude fully 
deprotected peptide 3.2.F. The solid was dissolved in 1:1 MeCN/H2O, frozen (LN2), and 
lyophilized. The peptide was purified by RP-HPLC-MS to afford a mixture of conotoxins 
foldamers in 43% yield (11.2 mg). 
3.2.C
1) I2, CH2Cl2 
2) activation
3) NH3, DMF
    2 h
4) TFA/TIPS/H2O
















(43% yield, 4 steps)
 95 
 
Boc-AW(Boc)AC-OH (3.3.B.1). Table 3.3.1, entry 1: Resin 3.3.A (20 mg) was weighed 
into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, the 
solvent was removed, and the linker was activated. H-Cys-OH•HCl (10 equiv) was 
dissolved in 500 µL DMF and 100 µL H2O in a separate vial and added to the swelled 
resin. Then freshly distilled DIEA (11 equiv) was added and the reaction vial was agitated 
at ambient temperature for 4 h. The solvent was removed from the vial and the reaction 
was quenched in (1% TFA) 20% MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 
x 1 mL) and combined with the initial solvent. The volatile solvent was removed, and the 
remaining solution was frozen in liquid nitrogen and lyophilized to yield the crude peptide 
3.3.B.1. The reaction went to completion (>99% conversion) after 4 h. 
 
Boc-AW(Boc)AC-OEt (3.3.B.2). Table 3.3.1, entry 2: Resin 3.3.A (20 mg) was weighed 
into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, the 
solvent was removed, and the linker was activated. H-Cys-OEt•HCl (10 equiv) was 
dissolved in 500 µL DMF and added to the swelled resin. Then freshly distilled DIEA (11 
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solvent was removed from the vial and the reaction was quenched in (1% TFA) 20% 
MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 x 1 mL) and combined with the 
initial solvent. The volatile solvent was removed, and the remaining solution was frozen 
in liquid nitrogen and lyophilized to yield the crude peptide 3.3.B.2. The reaction went to 
completion (>99% conversion) after 4 h. 
 
Boc-AW(Boc)AC-NH2 (3.3.B.3). Table 3.3.1, entry 3: Resin 3.3.A (20 mg) was weighed 
into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, the 
solvent was removed, and the linker was activated. 10 equiv of H-Cys-NH2•TFA was 
dissolved in 500 µL DMF and added to the swelled resin. Then freshly distilled DIEA (11 
equiv) was added and the reaction vial was agitated at ambient temperature for 4 h. The 
solvent was removed from the vial and the reaction was quenched in (1% TFA) 20% 
MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 x 1 mL) and combined with the 
initial solvent. The volatile solvent was removed, and the remaining solution was frozen 
in LN2 and lyophilized to yield the crude peptide 3.3.B.3. The reaction went to completion 








    chloroformate 
    then DIPEA/DMF
2) H-Cys-NH2 (10 equiv)
    DIPEA (11 equiv)





















Boc-AW(Boc)AC-NHBu (3.3.B.4). Table 3.3.1, entry 4: Resin 3.3.A (20 mg) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the linker was activated. H-Cys-NHBu (10 equiv) was 
dissolved in 500 µL DMF and added to the swelled resin. Then 11 equiv of DIEA was 
added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was 
removed from the vial and the reaction was quenched in 20% MeCN/H2O (1% TFA). The 
resin was further rinsed with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The 
volatile solvent was removed, and the remaining solution was frozen in liquid nitrogen 
and lyophilized to yield the crude cystine peptide A3.08. After 4 h, the reaction stalled at 
38% conversion. 
 
H-AWAC-OH (3.3.D.1). Table 3.3.2, entry 1: H-Cys-OH•HCl (10 equiv) was weighed into 
a vial containing a stir bar. Crude peptide 3.3.C (20 mg) was dissolved in 200 µL of HPLC 
grade MeCN and 100 µL H2O and added to the amino acid containing vial. Freshly 








    chloroformate 
    then DIPEA/DMF
2) H-Cys-NHBu (10 equiv)
    DIPEA (11 equiv)
































































for 30 min. After 30 min, the reaction was quenched in 20% MeCN/H2O (1% TFA) and 
analyzed via RP-HPLC-MS. The reaction went to completion (>99% conversion) after 30 
min. 
 
H-AWAC-OEt (3.3.D.2). Table 3.3.2, entry 2: H-Cys-OEt (10 equiv) was weighed into a 
vial containing a stir bar. Crude peptide 3.3.C (20 mg) was dissolved in 200 µL of HPLC 
grade MeCN and added to the amino acid containing vial. Freshly distilled DIEA (11 equiv) 
was added to the vial and allowed to stir at ambient temperature for 30 min. After 30 min, 
the reaction was quenched in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-
MS. The reaction went to completion (>99% conversion) after 30 min. 
 
H-AWAC-NH2 (3.3.D.3). Table 3.3.2, entry 3: H-Cys-NH2 (10 equiv) was weighed into a 
vial containing a stir bar. Crude peptide 3.3.C (20 mg) was dissolved in 200 µL of HPLC 
grade MeCN and added to the amino acid containing vial. Freshly distilled DIEA (11 equiv) 
was added to the vial and allowed to stir at ambient temperature for 30 min. After 30 min, 
the reaction was quenched in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-













































H-AWAC-NHBu (3.3.D.4). Table 3.3.2, entry 4: H-Cys-NHBu (10 equiv) was weighed 
into a vial containing a stir bar. Crude peptide 3.3.C (3.8 mg) was dissolved in 500 µL of 
HPLC grade MeCN and 20 µL H2O and added to the amino acid containing vial. Freshly 
distilled DIEA (11 equiv) was added to the vial and allowed to stir at ambient temperature 
for 30 min. After 30 min, the reaction was quenched in 20% MeCN/H2O (1% TFA) and 
analyzed via RP-HPLC-MS. The reaction went to completion (>99% conversion) after 30 
min. 
 
H-AKTWAC-OH (3.4.1.C). Table 3.4, entry 1. Peptide 3.4.1.B (20 mg, 24.8 µmol) was 
dissolved in 600 µL of (5:1) MeCN/H2O. H-Cys-OH•HCl (39 mg, 10 equiv, 0.25 mmol) 
was weighed into a vial containing a stir bar. The solution of peptide was transferred to 
the vial containing the amino acid, followed by addition of 48 µL DIEA (11 equiv, 0.27 
mmol). The mixture was stirred at ambient temperature for 30 min. The reaction was 
quenched with 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. The reaction 


































































































Boc-AK(Boc)T(tBu)W(Boc)APC-OH (3.4.2.C). Table 3.4, entry 2: Peptide 3.4.2.A (20 
mg, 7 µmol) was swelled in CH2Cl2 for 30 min. After swelling, the solvent was removed, 
and the peptide was activated. In a separate vial, 8.5 mg of H-Cys-OH•HCl (10 equiv, 70 
µmol) was dissolved in 500 µL (1:1) DMF/NCL buffer followed by the addition of 13 µL 
DIEA (11 equiv, 77 µmol). The solution of the amino acid was transferred to the resin and 
agitated at ambient temperature for 4 h. The reaction was quenched with 20% MeCN/H2O 
(1% TFA) and analyzed via RP-HPLC-MS.  After 4 h, the reaction stalled at 10% 
conversion. 
 
H-AKTWAPC-OH (3.4.2.C). Table 3.4, entry 3: Peptide 3.4.2.B (10 mg, 11 µmol) was 
dissolved in 250 µL of NCL buffer. H-Cys-OH•HCl (17.5 mg, 10 equiv, 0.11 mmol) was 
weighed into a vial containing a stir bar. The solution of peptide was transferred to the 
vial containing the amino acid, followed by addition of 21 µL DIEA (11 equiv, 0.12 mmol). 






























    chloroformate 
    then DIPEA/DMF
2) H-Cys-OH (10 equiv)
    DIPEA (11 equiv)



































































20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. The reaction went to 
completion (>99% conversion) after 1 h. 
 
Boc-LY(tBu)R(Pbf)AGLR(Pbf)AY(tBu)C-NH2 (3.4.3.C). Table 3.4, entry 4: Peptide 
3.4.3.A (20 mg, 7 µmol) was swelled in CH2Cl2 for 30 min. After swelling, the solvent was 
removed, and the peptide was activated. In a separate vial, 8.4 mg of H-Cys-NH2•TFA 
(10 equiv, 70 µmol) was dissolved in 500 µL (1:1) DMF/NCL buffer followed by the 
addition of 13 µL DIEA (11 equiv, 77 µmol). The solution of the amino acid was transferred 
to the resin and agitated at ambient temperature for 4 h. The reaction was quenched with 
20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. Due to the protected peptide 
adhering to the resin, the resin was rinsed with TFA/TIPS/H2O (95:2.5:2.5), collected, and 
reduced in volume under a constant stream of air. The resulting residue was subjected to 
–20 ºC diethyl ether to precipitate the peptide. The slurry of peptide in diethyl ether was 
centrifuged, and decanted to yield the deprotected peptide which was analyzed via RP-









    chloroformate 
    then DIPEA/DMF
2) H-Cys-NH2 (10 equiv)
    DIPEA (11 equiv)


















































Boc-VGGVVIC-OMe (3.4.4.C). Table 3.4, entry 5: 20 mg of peptide 3.4.4.A (7 µmol) was 
swelled in CH2Cl2 for 30 min. After swelling, the solvent was removed, and the peptide 
was activated. In a separate vial, 12 mg of H-Cys-OMe•HCl (10 equiv, 70 µmol) was 
dissolved in 500 µL (1:1) DMF/NCL buffer followed by the addition of 13 µL DIEA (11 
equiv, 77 µmol). The solution of the amino acid was transferred to the resin and agitated 
at ambient temperature for 4 h. The reaction was quenched with 20% MeCN/H2O (1% 
TFA) and analyzed via RP-HPLC-MS. Due to the protected peptide adhering to the resin, 
the resin was rinsed with TFA/TIPS/H2O (95:2.5:2.5), collected, and reduced in volume 
under a constant stream of air. The resulting residue was subjected to –20 ºC diethyl 
ether to precipitate the peptide. The slurry of peptide in diethyl ether was centrifuged, and 
decanted to yield the deprotected peptide which was analyzed via RP-HPLC-MS. 
However, product was not observed. 
 
H-VGGVVIC-OMe (3.4.4.B). Table 3.4, entry 6. Crude peptide 3.4.4.B (67.3 mg, 87 
µmol) was dissolved in 250 µL of NCL buffer. H-Cys-OMe•HCl (149 mg, 10 equiv, 0.87 
mmol) was weighed into a vial containing a stir bar. The solution of peptide was 
transferred to the vial containing the amino acid, followed by addition of 167 µL DIEA (11 
3.4.4.C
1) 4-nitrophenyl 
    chloroformate 
    then DIPEA/DMF
2) H-Cys-OMe (10 equiv)
    DIPEA (11 equiv)







































































equiv, 0.96 mmol). The mixture was stirred at ambient temperature for 30 min. The 
reaction was quenched with 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. 
The reaction went to completion (>99% conversion) after 30 min. 
 
Peptide 3.5.A (50 mg, 12 µmol) was activated (see MeDbz activation) and suspended in 
a pre-mixed solution of (10 equiv) H-Cys-OMe•HCl and (11 equiv) DIEA in (1:1) DMF/NCL 
buffer (pH 7.2).  The mixture was agitated for 4 h at ambient temperature. The solvent 
was removed and collected. The resin was rinsed with CH2Cl2 (2 x), water (2 x), followed 
by (1:1:3) TFE/AcOH/CH2Cl2 (2 x). The rinses were combined with the initial reaction 
solvent, reduced in volume under a constant stream of air, and the resulting residue was 
diluted with water, frozen (LN2), and lyophilized to yield the fully protected crude peptide. 
Some remaining peptide was adhered to the resin, which was removed using 95:2.5:2.5 
TFA/TIPS/H2O rinses and combined with the following residue. The fully protected 
peptide residue was dissolved in (95:2.5:2.5) TFA/TIPS/H2O and agitated for 1.5 h. The 
solution was concentrated under a constant steam of air, and the peptide was precipitated 
with –20 ºC diethyl ether. The slurry of peptide in diethyl ether was centrifuged, decanted, 
and the solid was dissolved in 1:1 MeCN/H2O, frozen (LN2), and lyophilized. The crude 
deprotected peptide was then dissolved in 10% THF/H2O (800 µL) and sparged with 
argon for 15 min. 5 equiv of Bu3P was added to the solution and stirred at ambient 
temperature for 2 h. The volatile solvent was removed under reduced pressure and the 
1) H-Cys-OMe•HCl
    DIPEA, DMF
    GuHCl, MPAA, TCEP
    Na2HPO4, 5 h
2) TFA/TIPS/H2O 














(41% yield, 3 steps)
 104 
aqueous solution was frozen (LN2) and lyophilized. The solid was purified using RP-
HPLC-MS to yield the non-alkylated a-factor precursor 3.5.B in 41% yield (7.0 mg). 
 
H-YIIKGVFWDPAC-OMe 3.5.B (2 mg, 1.4 µmol) was weighed in a 25 mL round bottom 
flask and dissolved in 0.8 mL DMF/BuOH (2:1). Then 5 equiv of Fr-Br (2.0 mg, 7.0 µmol) 
was added to the solution followed by a solution of 5 equiv Zn(OAc)2 (1.3 mg, 7.0 µmol) 
in 0.4 mL 0.1% TFA (aq). The reaction went to completion after 1 h. The reaction was 
then diluted with H2O, frozen in LN2, and lyophilized to yield the crude peptide. RP-HPLC-
MS purification was conducted resulting in a 9% yield of farnesylated a-factor peptide 











    Zn(OAc)2 (5 equiv)









CHAPTER 4: SEQUENCE DIVERSIFICATION BY DIVERGENT C-TERMINAL 
 ELONGATION OF PEPTIDES 
Parts of this chapter were adapted with permission from Arbour, C. A.;‡ Stamatin R. E.;‡ 
Stockdill, J. L. J. Org. Chem. 2018, 83, 1797–1803. Reproduced by permission of The 
American Chemical Society. All solution-phase and epimerization experiments in Tables 
4.2.1, 4.4, and 4.5.2 were conducted by me. Ramona Stamatin and I contributed 
equally to the results in Tables 4.3, 4.5.1, and 4.5.3. 
4.1 Accessing Peptides with Varying C-Terminal Amino Acid Residues Without Repetition 
of the Solid-Phase Peptide Synthesis 
Methods for the rapid diversification of peptide sequences are important for the 
optimization of peptide lead targets.66f,115 Because of the tendency to epimerize the C-
terminal residue31,96 during the carboxylic acid activation,41,103,116 sequences that vary at 
the C-terminal amino acid72 have not been readily accessible without repetition of the 
SPPS for each desired C-terminal amino acid. During my initial studies, I found that the 
C-terminal residue is not epimerized during the modification reaction, even for sensitive 
residues such as His or Cys.167 Therefore, I viewed this approach as ideal for backbone 
sequence diversification at the C terminus. 
 In my previous work,167a I reported efficient addition of primary amine nucleophiles 
to MeNbz-appended peptides to generate secondary C-terminal amides. I observed 
reduced reactivity for secondary amines and a-branched alcohols during resin-cleaving 
reactions. However, solution-phase functionalization reactions proceeded more quickly. I 
expected that a-branched primary amines (e.g., amino acids) would be significantly less 
reactive than unbranched primary amines. This hypothesis was consistent with Pascal’s 
observation that glycine N-acyl benzimidazole could be substituted by leucine methyl 
ester in solution to form a dipeptide over 20 h.76a  
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4.2 Solution Phase Elongation 
 I began investigations toward developing a general method for C-terminal peptide 
elongation using unprotected amino acids as nucleophiles in solution-phase reactions. 
As shown in Table 4.2.1, a variety of amino acids can be employed as nucleophiles in 
the elongation of MeNbz-appended peptides in solution. For my initial evaluations, H-
AWA-MeNbz-Gly-NH2 (4.2.A) was employed. Upon treatment with 10 equiv amino acid 
and 11 equiv Hünig’s base, complete conversion was observed in all cases to form either 
the corresponding elongated peptide (4.2.B) or a mixture of 4.2.B and hydrolysis product 
4.2.C.81 Water was employed as a co-solvent to improve the solubility of the unprotected 
amino acid nucleophiles relative to acetonitrile alone. In the absence of added water, 
reactivity was poor.117 The non-branched nucleophile glycine reacted to form the 
elongated peptide H-AWAG-OH exclusively (entry 1). However, when alanine was 
employed as a nucleophile, ~1:1 elongation to hydrolysis was observed (entry 2). In my 
previous work, I found that the secondary amine Weinreb amine reacted much more 
slowly than primary amine nucleophiles. Therefore, I was not surprised to find that when 
proline was the nucleophile, only 29% elongated peptide was observed. Surprisingly, the 
a- and b-branched isoleucine reacted analogously to glycine, giving only the C-terminal 
elongation product H-AWAI-OH (entry 4). Unprotected tryptophan required only 30 min 
and led exclusively to elongated peptide H-AWAW-OH, presumably because the 
unprotected nitrogen in the indole increases the amino acid’s solubility (entry 5).118 
Additionally, it is conceivable that a transient p-p interaction with the MeNbz group assists 
in the addition.119  
 107 
Table 4.2.1. Solution phase C-terminal peptide elongation of AWA-MeNbz-Gly. 
 
 
4.3 On-Resin Elongation of AWA to Access Protected Peptide Acids 
Based on these results, it was clear that a useful strategy for C-terminal elongation 
would need to proceed directly from the resin-bound MeNbz peptide, where nucleophilic 
side chain groups would be protected. Thus, MeDbz-linked peptide 4.3.A was activated 
and treated with 10 equiv glycine, 11 equiv DIEA in 500 µL DMF affording exclusively 
desired peptide 4.3.B (Table 4.3). However, the conversion in this case was very low 
(5%, entry 1). To improve the reactivity of the amino acids, water was again employed as 
a co-solvent, improving the conversion to 39%, which was promising, but certainly not 
synthetically viable (entry 2). We next increased the amount of Hünig’s base employed, 
leading to 76% conversion over 4 h and a 91:9 ratio of elongation (4.3.B) to hydrolysis 
(4.3.C, entry 3). The combination of NaSPh and ethyl-3-mercaptopropionate led to 
complete consumption of 4.3.A; however, the alkyl thioester was the sole observed 
product (entry 4).51a Finally, treatment with NaSPh in a 5:1 mixture of DMF/H2O allowed 
complete reactivity of the MeNbz group. A 94:6 ratio of elongated product to MeNbz 
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a All reactions were performed on 20 mg crude peptide in 300 µL solvent, rt = 24 ± 1 ºC, 






hydrolysis (4.3.B/4.3.C) was observed (entry 5). A similar trend in reactivity was observed 
for isoleucine (entries 6-7) and alanine (entries 10-11) with the absence of NaSPh. 
However, addition of NaSPh did not fully displace the MeNbz group which was previously 
observed with glycine. To improve the reactivity, a mixture of NaSPh and 
mercaptophenylacetic acid (MPAA) in a 5:1 mixture of DMF/Na2HPO4 buffer at pH 7.2 
was used to help solubilize the amino acid (entries 9 and 13). Proline displaced MeNbz 
with complete conversion in the absence of any thiol additive (entry 15), presumably 
because it is more nucleophilic than the primary amines. As mentioned earlier, secondary 
amines were not ideal nucleophiles in this chemistry.167a The improved reactivity of proline 
is likely caused by the more exposed nitrogen lone pair in the cyclic amine relative to the 
linear amine.120 For all amino acids tested under the optimized conditions, hydrolysis 
rates were maintained below 15%. 
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Table 4.3. On-resin elongation to access protected peptide acids. 
 
4.4 Epimerization of C-Terminal Alanine 
I had previously established that Hünig’s base is mild enough to avoid 
epimerization during conversion of MeNbz peptides to the corresponding acids, esters, 
and amides.167a However, I hypothesized that the phenyl thioester, which is generated in 
situ, might be more prone to epimerization than the MeNbz peptides. The intermediate 
thioester will be longest-lived in the presence of the slowest nucleophile. Thus, I tested 
the extent of epimerization observed during elongation with isoleucine and proline (entries 
9 and 17 in Table 4.3). Interestingly, 14% epimerization was observed in the presence of 
NaSPh in a modified native chemical ligation (NCL) buffer with isoleucine (see Table 4.4, 



















    chloroformate 
    then DIEA/DMF
2) H-AA-OH (10 equiv)
    additive, base











a All reactions were conducted on 20 mg of resin in 600 µL (5:1) DMF/H2O, rt = 24 ± 1 ºC, b Conversion based on 
integration of remaining peptide on activated linker after nucleophile cleavage in MS data,c Yield based on final 
loading of (50-100 mg) WA-MeDbz-Gly-Rink resin, d Relative ratios at 254 nm, e Reaction was conducted in 500 µL 
DMF, f 100 µL of ethyl-3-mercaptopropionate was used, giving exclusively the alkyl thioester,g A solution of 600 µL 5:1 
DMF/modified NCL buffer (pH 7.2) was used, h Went to 73% conversion on a larger scale, i Went to 97% conversion 




















3 76Gly (G) 91:09–
11
21
5 >99 (39h)Gly (G) 94:06NaSPh21










4f >99Gly (G) n.o.NaSPh/HS(CH2)3CO2Et21
15 >99 (44i)Pro (P) 88:1221 –
11 77Ala (A) 77:1321 –




9g 94 (22)Ile (I) 90:1021 NaSPh/MPAA
13g 94 (29)Ala (A) 86:1421 NaSPh/MPAA
 110 
but the conversion also dropped to 38% (entry 2). However, treatment with NaSPh but no 
Hünig’s base afforded the elongated peptide with no epimerization and 50% conversion 
(entry 3), supporting my hypothesis that the aryl thioester is susceptible to epimerization 
in the presence of excess base. Under the conditions of entry 7, Table 4.3 (using 21 equiv 
Hünig’s base in 5:1 DMF/H2O), the conversion was improved to 72% while maintaining 
no epimerization (entry 4, Table 4.4). To access AWAI with complete conversion, the 
reaction was shaken for 18 h instead of 4, with minimal epimerization (entry 5). The 
epimerization was not reduced by exposing the resin to the conditions twice and 
combining the samples, but complete conversion could be achieved by this approach 
(entry 6). I was interested in the susceptibility to epimerization during proline addition 
because of its increased basicity. Both entries 15 and 17 in Table 4.3 gave complete 
conversion to AWAP, so the epimerization was evaluated under those conditions. In the 
presence of NaSPh in 5:1 DMF/H2O, 3% epimerization was observed. Removing NaSPh 
did not significantly lower the epimerization in this case (entries 7 and 8, Table 4.4). 
Table 4.4. Epimerization of C-terminal alanine. 
 
 








    chloroformate 
    then DIEA/DMF
2) H-AA-OH (10 equiv)
    additive, base




a All reactions were conducted on 10-20 mg of resin in 300-600 µL (5:1) DMF:solvent, rt = 24 ± 1 ºC, b For Ile, protecting groups were 
removed for better assay separation, c Conversion based on integration of remaining peptide on activated linker after nucleophile 
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1e 94Ile (I) 1421 NaSPh/MPAA Na2HPO4 (aq)
4 72Ile (I) <121 – H2O
7 94 321 NaSPhPro (P) H2O
5 >99Ile (I) 221 – H2O












4.5 LYRAGLRAY Elongation to Access Protected Peptide Acids 
Having established conditions for maximizing conversion and minimizing 
epimerization, we next evaluated the elongation in the context of a longer peptide. I 
expected that the reactions would become slower as the peptide length was increased, 
leading to more non-elongated hydrolysis by-products. We tested the optimized reaction 
conditions from Table 4.3 on H-LYRAGLRAY-MeNbz-Gly-Rink (4.5.A). Except for 
glycine, the ratio of elongation to hydrolysis products was worse for this substrate (Table 
4.5.1, entries 1-4). Unfortunately, most of the carboxylic acid containing peptides (4.5.F) 
were challenging to separate from the desired peptides (4.5.B-4.5.E) by RP-HPLC. 
Originally, water was added to aid in solubilizing the amino acid nucleophiles. I envisioned 
that replacing water with an alcohol would lead to the ester by-product (4.5.G), which 
could be readily separated from the elongated acids. Therefore, a few representative 
alcoholic co-solvents were evaluated. I had previously found that i-PrOH reacted more 
slowly than primary alcohols,167a so I reasoned that it would minimize ester by-product 
formation. In the presence of NaSPh, these conditions reduced by-product formation to 
6% of the ester (4.5.G), which was indeed readily separated from the elongated acid 




Table 4.5.1. LYRAGLRAY elongation to access protected peptide acids. 
 
  
Figure 4.5.1. Spectral and chromatographic data of pure LYRAGLRAYP (4.5.E)  
accessed via Table 4.5.1, entry 8. 
Under these conditions, the peptide AWA was 4% epimerized (Table 4.5.2). When 
NaSPh was omitted, no epimerization was observed for AWA.81 However, for 
LYRAGLRAY, undesired hydrolysis by adventitious water to form 4.5.F increased under 
these conditions (entry 6). Because hexafluoroisopropanol (HFIP) can be useful for 
solubilizing peptides, we evaluated it as a co-solvent as well. Treatment with NaSPh and 
Hünig’s base in the presence of DMF and HFIP led to substantial amounts of the HFIP 
ester, presumably because the pKa of HFIP is significantly lower than that of isopropanol 







1) 4-nitrophenyl chloroformate 
    then DIEA/DMF
2) 
          H-AA-O  (10 equiv)
    NaSPh, DIEA






aAll reactions were conducted on 20 mg of resin in 600 µL (5:1) DMF/H2O, rt = 24 ± 1 ºC, bConversion based on integration of remaining peptide on 
activated linker after nucleophile cleavage in MS data, cYield based on initial loading of 100 mg of MeDbz-Gly-Rink resin and represents 3 steps 
(SPPS, activation, and elongation), dRelative ratios at 254 nm, eUsed 500 µL (5:1) DMF/modified NCL buffer containing MPAA, pH = 7.2, f Treated 





4.5.B-E / 4.5.F / 4.5.Gd
4.5.F: Boc-LYRAGLRAY-OH
4.5.G: Boc-LYRAGLRAY-OR
91    :    09    :    n/a
3e >99Ala (A) 79    :    21    :    n/a
2e >99Ile (I) 74    :    26    :    n/a

















5 97Pro (P) 94    :     <1    :    06LYRAGLRAYP (4.5.E)iPrOH
7 >99Pro (P) 81    :    07     :    12LYRAGLRAYP (4.5.E)HFIP
8g >99 (10)Pro (P) 83    :    05     :    12LYRAGLRAYP (4.5.E)HFIP













HFIP ester is prone to hydrolysis upon quenching with MeCN/H2O. Elongation of AWA 
resulted in 4% epimerization under these conditions. Omission of NaSPh prevented 
epimerization in the AWA elongation and did not significantly alter the product ratios for 
LYRAGLRAY elongation (entry 8 and Figure 4.5.1).81  
Table 4.5.2. Evaluation of epimerization with alcohol co-solvents. 
 
 Until this point, we have focused on hydrophobic amino acids as nucleophiles. To 
further probe the scope of the chemistry, side-chain protected polar amino acids were 
evaluated (Table 4.5.3). We expected that the bulky protecting group on Arg(Pbf) would 
be most challenging to the system. Indeed, the HFIP ester was the major product, 
suggesting slow addition of the amino acid (entry 1). Similarly, Lys(Boc) led to 18% 
desired peptide 4.5.I (entry 2). Both Asp(OtBu) and His(Trt) gave complete conversion 
and reasonable ratios of product to ester (81 and 85% desired, entries 3 and 4, 
respectively). These results were consistent with those of proline elongation in HFIP (i.e., 
Table 4.5.1, entry 8). In cases where low ratios of elongation product were observed, 
reasonable quantities of the elongated peptide could be cleanly isolated with no 
contamination from hydrolysis products (i.e., Table 4.5.3, entry 2), making the method 









    chloroformate 
    then DIEA/DMF
2) 
         
        H-AA-OH (10 equiv)
    additive, base
    (5:1) DMF/co-solvent, 4 h
4.3.B-Pro
entrya
a All reactions were conducted on 10 mg of resin in 300 µL (5:1) DMF:solvent, rt = 24 ± 1 ºC, b  Conversion based on 












2 >99 421 NaSPh
co-solvent
1 83 421 NaSPh








representative trace from the addition of aspartic acid t-butyl ester is provided in Figure 
4.5.2. Taken together, a structurally representative set of amino acids permit the 
formation of the desired elongated products. 
Table 4.5.3. Elongation employing side-chain protected amino acids. 
 
 
Figure 4.5.2. Spectral and chromatographic data of pure LYRAGLRAYD (4.5.J)  
accessed via Table 4.5.3, entry 3. 
4.6 Summary 
In summary, we have developed conditions for the divergent elongation of peptides 
at the C terminus by displacement of the MeNbz group by various amino acids. This 
approach is surprisingly tolerant to steric effects, with good conversions observed for 
challenging amino acids such as isoleucine and proline. Tolerable levels of epimerization 
(2-3%) and high conversions are observed upon elongation for extended times or in the 





aAll reactions were conducted on 50 mg of resin in 600 µL (5:1) DMF/HFIP, rt = 24 ± 1 ºC, bConversion based on integration of 
remaining peptide on activated linker after nucleophile cleavage in MS data, cYield based on initial loading of 50 mg of MeDbz-Gly-




4.5.H-K / 4.5.L / 4.5.Md
18    :    06    :    66
3 >99 (7)Asp (D) 81    :    04    :    15
1 67Arg (R) 12    :    11    :    77

















1) 4-nitrophenyl chloroformate 
    then DIEA/DMF
2) 
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    NaSPh, DIEA
























stereointegrity of the C-terminal amino acid of the starting peptide by omitting NaSPh. 
Water serves as a helpful co-solvent, increasing conversion significantly, but leads to 
challenging separation of the elongated acid from the starting peptide acid. Use of 
isopropanol as the co-solvent minimizes this issue. Overall, this approach offers access 
to sequences with point mutations to the C terminus without the need to repeat the SPPS 
for every variation needed. These studies provide a framework of the scope and 
limitations of this approach to rapidly generating a library of C-terminally varied targets. 
Efforts to exploit the mild reactivity of N-acyl ureas for other synthetic challenges are 
ongoing in the Stockdill laboratory. 
4.7 General Experimental Procedures 
4.7.1 Materials and Methods 
See Chapter Section 2.6 Materials and Methods under Section 2.6.1 General 
Experimental Procedures for Solid-Phase Peptide Synthesis, NMR, RP-HPLC-MS, and 
MeDbz Activation procedures. 
Calculating Conversion of On Resin Reactions. After the nucleophilic cleavage was 
conducted, the resin was subjected to 95:2.5:2.5 TFA/TIPS/H2O to cleave the remaining 
MeNbz-Gly and unreacted peptide-MeNbz-Gly. The solution was concentrated using a 
constant stream of air until a small amount of residue was left. Then, –20 ºC diethyl ether 
was added to the vial to precipitate the crude peptide. After centrifugation, the ether was 
decanted off, and the solid was dissolved in 1:1 MeCN/H2O and lyophilized. The 
lyophilized solid was then dissolved in 20% MeCN/H2O and analyzed via RP-HPLC- MS 
 116 
using a gradient of 20−80% MeCN/H2O over 15 min. Conversion was calculated based 
on the ratio of H2N-peptide-MeNbz-Gly-NH2 to H2N-MeNbz-Gly-NH2. 
Sodium Phosphate Buffer (with Guanidine). Na2HPO4 (56.6 mg, 0.4 mmol) was 
dissolved in 1 mL of water. Guanidine·HCl (1.146 g, 12 mmol) was added and dissolved 
and then diluted to 2 mL with water. The pH was brought to 7 with a solution of NaOH (5 
M, 20 μL). MPAA (67 mg, 0.4 mmol) was then added along with 1 mL of water to fully 
dissolve it. The pH was then brought to 7.2 by adding NaOH (5 M, 135 μL).  
Sodium Phosphate Buffer (Guanidine-Free). Na2HPO4 (56.6 mg, 0.4 mmol) was 
dissolved in 1 mL of water. MPAA (67 mg, 0.4 mmol) was added along with 1 mL of water 
to dissolve it. The pH was then brought to 7.2 by adding NaOH (5 M, 125 μL).  
4.7.2 Experimental Procedures 
 
H-AWAG-OH (4.2.B-Gly). Table 4.2.1, entry 1: H-Gly-OH (10 equiv) was weighed into 
a vial containing a stir bar. Crude peptide 4.2.A (20 mg, 35 µmol) was dissolved in 300 
µL of (2:1) MeCN/H2O and added to the amino acid containing vial. Freshly distilled DIEA 
(11 equiv) was added to the vial and allowed to stir at ambient temperature for 30 min. 
After 30 min, the reaction was quenched in 20% MeCN/H2O (1% TFA) and analyzed via 
RP-HPLC-MS. The reaction went to completion (>99% conversion) after 1 h with a ratio 






































H-AWAA-OH (4.2.B-Ala). Table 4.2.1, entry 2: H-Ala-OH (10 equiv) was weighed into a 
vial containing a stir bar. Crude peptide 4.2.A (20 mg, 35 µmol) was dissolved in 300 µL 
of (2:1) MeCN/H2O and added to the amino acid containing vial. Freshly distilled DIEA 
(11 equiv) was added to the vial and allowed to stir at ambient temperature for 30 min. 
After 30 min, the reaction was quenched in 20% MeCN/H2O (1% TFA) and analyzed via 
RP-HPLC-MS. The reaction went to completion (>99% conversion) after 1 h with a ratio 
of 51:48 4.2.B/4.2.C. 
 
H-AWAP-OH (4.2.B-Pro). Table 4.2.1, entry 3: H-Pro-OH (10 equiv) was weighed into 
a vial containing a stir bar. Crude peptide 4.2.A (20 mg, 35 µmol) was dissolved in 300 
µL of (2:1) MeCN/H2O and added to the amino acid containing vial. Freshly distilled DIEA 
(11 equiv) was added to the vial and allowed to stir at ambient temperature for 6 h, after 
6 h the reaction was quenched in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-









































































H-AWAI-OH (4.2.B-Ile). Table 4.2.1, entry 4: H-Ile-OH (10 equiv) was weighed into a 
vial containing a stir bar. Crude peptide 4.A.2 (20 mg, 35 µmol) was dissolved in 300 µL 
of (2:1) MeCN/H2O and added to the amino acid containing vial. Freshly distilled DIEA 
(11 equiv) was added to the vial and allowed to stir at ambient temperature for 30 min. 
After 30 min, the reaction was quenched in 20% MeCN/H2O (1% TFA) and analyzed via 
RP-HPLC-MS. The reaction went to completion (>99% conversion) after 1 h with a ratio 
of >99:<1 4.2.B/4.2.C. 
 
H-AWAW-OH (4.2.B-Trp). Table 4.2.1, entry 5: H-Trp-OH (10 equiv) was weighed into 
a vial containing a stir bar. Crude peptide 4.2.A (20 mg, 35 µmol) was dissolved in 300 
µL of (2:1) MeCN/H2O and added to the amino acid containing vial. Freshly distilled DIEA 
(11 equiv) was added to the vial and allowed to stir at ambient temperature for 30 min. 
After 30 min, the reaction was quenched in 20% MeCN/H2O (1% TFA) and analyzed via 
RP-HPLC-MS. The reaction went to completion (>99% conversion) after 30 min with a 











































































Boc-AW(Boc)AG-OH (4.3.B-Gly). Table 4.3, entry 1: Resin 4.3.A (20 mg, 4 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Gly-
OH (10 equiv) was dissolved in 500 µL DMF in a separate vial and added to the swelled 
resin. Then freshly distilled DIEA (11 equiv) was added and the reaction vial was agitated 
at ambient temperature for 4 h. The solvent was removed from the vial and the reaction 
was quenched in (1% TFA) 20% MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 
x 1 mL) and combined with the initial solvent. The volatile solvent was removed, and the 
remaining solution was frozen (LN2) and lyophilized to yield the crude peptide. After 4 h, 
5% conversion was observed (>99:<1 of 4.3.B/4.3.C). 
 
Boc-AW(Boc)AG-OH (4.3.B-Gly). Table 4.3, entry 2: Resin 4.3.A (20 mg, 4 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Gly-
OH (10 equiv) was dissolved in 500 µL DMF in a separate vial and added to the swelled 
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at ambient temperature for 4 h. The solvent was removed from the vial and the reaction 
was quenched in (1% TFA) 20% MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 
x 1 mL) and combined with the initial solvent. The volatile solvent was removed, and the 
remaining solution was frozen (LN2) and lyophilized to yield the crude peptide. After 4 h, 
39% conversion was observed (94:06 of 4.3.B/4.3.C). 
 
Boc-AW(Boc)AG-OH (4.3.B-Gly). Table 4.3, entry 3: Resin 4.3.A (20 mg, 4 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Gly-
OH (10 equiv) was added directly to the resin followed by 600 µL DMF/H2O (5:1). Then 
21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient 
temperature for 4 h. The solvent was removed from the vial and the reaction was 
quenched in (1% TFA) 20% MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 x 1 
mL) and combined with the initial solvent. The volatile solvent was removed, and the 
remaining solution was frozen (LN2) and lyophilized to yield the crude peptide. After 4 h, 
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Boc-AW(Boc)AG-OH (4.3.B-Gly). Table 4.3, entry 4: Resin 4.3.A (20 mg, 4 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Gly-
OH (10 equiv) and 1 equiv of NaSPh were added directly to the resin followed by 600 µL 
DMF/H2O (5:1) with 100 µL of ethyl-3-mercaptopropionate. Then 21 equiv of freshly 
distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 
h. The solvent was removed from the vial and the reaction was quenched in (1% TFA) 
20% MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 x 1 mL) and combined with 
the initial solvent. The volatile solvent was removed, and the remaining solution was 
frozen (LN2) and lyophilized to yield the crude peptide. Exclusively alkyl thioester was 
observed (>99% conversion). 
 
Boc-AW(Boc)AG-OH (4.3.B-Gly). Table 4.3, entry 5: Resin 4.3.A (20 mg, 4 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Gly-
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DMF/H2O (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial 
was agitated at ambient temperature for 4 h. The solvent was removed from the vial and 
the reaction was quenched in (1% TFA) 20% MeCN/H2O. The resin was further rinsed 
with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The volatile solvent was 
removed, and the remaining solution was frozen (LN2) and lyophilized to yield the crude 
peptide. After 4 h, >99% conversion was observed (94:06 of 4.3.B/4.3.C). 
 
Boc-AW(Boc)AG-OH (4.3.B-Gly). Table 4.3, entry 5 (Large scale): Resin 4.3.A (100 
mg, 16 µmol) was weighed into a 5 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 
min. After swelling, the solvent was removed, and the resin was activated (see General 
Procedure). H-Gly-OH (10 equiv) and 1 equiv of NaSPh were added directly to the resin 
followed by 600 µL DMF/H2O (5:1). Then 21 equiv of freshly distilled DIEA was added 
and the reaction vial was agitated at ambient temperature for 4 h. The solvent was 
removed from the vial and the reaction was quenched in (1% TFA) 20% MeCN/H2O. The 
resin was further rinsed with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The 
volatile solvent was removed, and the remaining solution was frozen (LN2) and lyophilized 
to yield the crude peptide. The crude peptide was purified using RP-HPLC-MS to yield 
the pure peptide 4.3.B-Gly in 39% yield (4.7 mg). 1H NMR (600 MHz, DMSO-d6) d 8.12 
(s, 1H), 7.98 (dd, J = 33.3, 7.4 Hz, 1H), 7.81 (d, J = 7.9 Hz, 1H), 7.67 (d, J = 8.2 Hz, 1H), 
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Hz, 1H), 4.58 (dd, J = 14.0, 5.8 Hz, 1H), 4.36 – 4.25 (m, 1H), 3.91 – 3.84 (m, 1H), 3.79 – 
3.68 (m, 3H), 3.11 (d, J = 11.0 Hz, 1H), 2.93 (dd, J = 14.9, 8.3 Hz, 1H), 1.60 (s, 9H), 1.34 
(s, 8H), 1.21 (d, J = 7.0 Hz, 2H), 1.11 (dq, J = 16.0, 9.0, 8.1 Hz, 4H). 13C NMR (151 MHz, 
DMSO) d 172.6, 172.3, 171.1, 170.5, 155.0, 149.1, 134.7, 130.4, 124.2, 122.4, 119.5, 
116.1, 114.5, 83.4, 78.2, 52.4, 51.9, 50.1, 48.1, 40.8, 28.2, 27.7, 18.3, 18.1. HRMS (ESI+) 
m/z calc’d for C29H41N5O9Na [M + Na]+ 626.2802, found 626.2786. 
 
Boc-AW(Boc)AI-OH (4.3.B-Ile). Table 4.3, entry 6: Resin 4.3.A (20 mg, 4 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Ile-
OH (10 equiv) was dissolved in 500 µL DMF and 100 µL H2O in a separate vial and added 
to the swelled resin. Then freshly distilled DIEA (11 equiv) was added and the reaction 
vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial 
and the reaction was quenched in (1% TFA) 20% MeCN/H2O. The resin was further 
rinsed with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The volatile solvent 
was removed, and the remaining solution was frozen (LN2) and lyophilized to yield the 
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Boc-AW(Boc)AI-OH (4.3.B-Ile). Table 4.3, entry 7: Resin 4.3.A (20 mg, 4 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Ile-
OH (10 equiv) was added directly to the resin followed by 600 µL DMF/H2O (5:1). Then 
21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient 
temperature for 4 h. The solvent was removed from the vial and the reaction was 
quenched in (1% TFA) 20% MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 x 1 
mL) and combined with the initial solvent. The volatile solvent was removed, and the 
remaining solution was frozen (LN2) and lyophilized to yield the crude peptide. After 4 h, 
72% conversion was observed (88:12 of 4.3.B/4.3.C). 
 
Boc-AW(Boc)AI-OH (4.3.B-Ile). Table 4.3, entry 8: Resin 4.3.A (20 mg, 4 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Ile-
OH (10 equiv) and 1 equiv of NaSPh was added directly to the resin followed by 600 µL 
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was agitated at ambient temperature for 4 h. The solvent was removed from the vial and 
the reaction was quenched in (1% TFA) 20% MeCN/H2O. The resin was further rinsed 
with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The volatile solvent was 
removed, and the remaining solution was frozen (LN2) and lyophilized to yield the crude 
peptide. After 4 h, 76% conversion was observed (85:15 of 4.3.B/4.3.C). 
 
Boc-AW(Boc)AI-OH (4.3.B-Ile). Table 4.3, entry 4.7.2: Resin 4.3.A (20 mg, 4 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. A fresh sodium 
phosphate buffer was prepared (see sodium phosphate buffer with guanidine procedure). 
After swelling, the solvent was removed, and the resin was activated (see General 
Procedure). H-Ile-OH (10 equiv) and 1 equiv of NaSPh were added directly to the resin 
followed by 600 µL DMF/ modified NCL buffer (5:1). Then 21 equiv of freshly distilled 
DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. The 
solvent was removed from the vial and the reaction was quenched in (1% TFA) 20% 
MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 x 1 mL) and combined with the 
initial solvent. The volatile solvent was removed, and the remaining solution was frozen 
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Boc-AW(Boc)AI-OH (4.3.B-Ile). Table 4.3, entry 9: Resin 4.3.A (100 mg, 16 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. A fresh sodium 
phosphate buffer was prepared (see Sodium phosphate buffer, guanidine-free). After 
swelling, the solvent was removed, and the resin was activated (see General Procedure). 
H-Ile-OH (10 equiv) and 1 equiv of NaSPh were added directly to the resin followed by 
600 µL DMF/NCL Buffer (5:1). Then 21 equiv of freshly distilled DIEA was added and the 
reaction vial was agitated at ambient temperature for 4 h. The solvent was removed from 
the vial and the reaction was quenched in (1% TFA) 20% MeCN/H2O. The resin was 
further rinsed with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The volatile 
solvent was removed, and the remaining solution was frozen (LN2) and lyophilized to yield 
the crude peptide. The crude peptide was purified using RP-HPLC-MS to give the pure 
peptide in 22% yield (4.4 mg). 1H NMR (499 MHz, DMSO-d6) d 8.21 (d, J = 7.1 Hz, 1H), 
8.01 (d, J = 8.0 Hz, 1H), 7.88 (d, J = 8.2 Hz, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.65 (d, J = 7.6 
Hz, 1H), 7.49 (s, 1H), 7.29 (t, J = 7.7 Hz, 1H), 7.21 (t, J = 7.5 Hz, 1H), 6.92 (d, J = 7.3 Hz, 
1H), 4.66 – 4.53 (m, 1H), 4.37 (q, J = 6.9 Hz, 1H), 4.17 (dd, J = 8.2, 5.8 Hz, 1H), 3.92 – 
3.83 (m, 1H), 3.13 – 3.02 (m, 1H), 2.97 – 2.87 (m, 1H), 1.76 (dq, J = 13.7, 7.7, 7.2 Hz, 
1H), 1.60 (s, 9H), 1.33 (s, 8H), 1.20 (t, J = 6.9 Hz, 3H), 1.10 (d, J = 7.0 Hz, 4H), 0.84 (t, J 
= 7.8 Hz, 6H). 13C NMR (126 MHz, DMSO) d 172.9, 172.6, 172.1, 170.6, 155.0, 149.1, 
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28.2, 27.7, 27.4, 24.7, 18.2, 15.6, 11.4; HRMS (ESI+) m/z calc’d for C33H49N5O9Na [M + 
Na]+ 682.3428, found 682.3428. 
 
Boc-AW(Boc)AA-OH (4.3.B-Ala). Table 4.3, entry 10: Resin 4.3.A (20 mg) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Ala-
OH (10 equiv) was dissolved in 500 µL DMF and 100 µL H2O in a separate vial and added 
to the swelled resin. Then freshly distilled DIEA (11 equiv) was added and the reaction 
vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial 
and the reaction was quenched in (1% TFA) 20% MeCN/H2O. The resin was further 
rinsed with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The volatile solvent 
was removed, and the remaining solution was frozen (LN2) and lyophilized to yield the 
crude peptide. After 4 h, 19% conversion was observed (81:19 of 4.3.B/4.3.C). 
 
 Boc-AW(Boc)AA-OH (4.3.B-Ala). Table 4.3, entry 11: Resin 4.3.A (20 mg, 4 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
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OH (10 equiv) was added directly to the resin followed by 600 µL DMF/H2O (5:1). Then 
21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient 
temperature for 4 h. The solvent was removed from the vial and the reaction was 
quenched in (1% TFA) 20% MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 x 1 
mL) and combined with the initial solvent. The volatile solvent was removed, and the 
remaining solution was frozen (LN2) and lyophilized to yield the crude peptide. After 4 h, 
77% conversion was observed (77:13 of 4.3.B/4.3.C). 
 
Boc-AW(Boc)AA-OH (4.3.B-Ala). Table 4.3, entry 12: Resin 4.3.A (20 mg, 4 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Ala-
OH (10 equiv) and 1 equiv of NaSPh was added directly to the resin followed by 600 µL 
DMF/H2O (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial 
was agitated at ambient temperature for 4 h. The solvent was removed from the vial and 
the reaction was quenched in (1% TFA) 20% MeCN/H2O. The resin was further rinsed 
with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The volatile solvent was 
removed, and the remaining solution was frozen (LN2) and lyophilized to yield the crude 
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Boc-AW(Boc)AA-OH (4.3.B-Ala). Table 4.3, entry 4.7.3: Resin 4.3.A (20 mg, 4 µmol) 
was weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. A fresh 
sodium phosphate buffer was prepared (see Sodium phosphate buffer with guanidine 
procedure). After swelling, the solvent was removed, and the resin was activated (see 
General Procedure). H-Ala-OH (10 equiv) and 1 equiv of NaSPh were added directly to 
the resin followed by 600 µL DMF/modified NCL Buffer (5:1). Then 21 equiv of freshly 
distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 
h. The solvent was removed from the vial and the reaction was quenched in (1% TFA) 
20% MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 x 1 mL) and combined with 
the initial solvent. The volatile solvent was removed, and the remaining solution was 
frozen (LN2) and lyophilized to yield the crude peptide. Mostly guanidine addition was 
observed. 
 
Boc-AW(Boc)AA-OH (4.3.B-Ala). Table 4.3, entry 13: Resin 4.3.A (100 mg, 16 µmol) 
was weighed into a 5 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. A fresh 
sodium phosphate buffer was prepared (see guanidine-free phosphate buffer) 
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General Procedure). H-Ala-OH (10 equiv) and 1 equiv of NaSPh were added directly to 
the resin followed by 600 µL DMF/modified NCL Buffer (5:1). Then 21 equiv of freshly 
distilled DIEA was added and the reaction vial was agitated at ambient temperature for 4 
h. The solvent was removed from the vial and the reaction was quenched in (1% TFA) 
20% MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 x 1 mL) and combined with 
the initial solvent. The volatile solvent was removed, and the remaining solution was 
frozen (LN2) and lyophilized to yield the crude peptide. The crude peptide was purified 
using RP-HPLC-MS to isolate 2.3 mg of pure peptide and 5.2 mg of mixed peptide (61% 
HPLC purity, 254 nm) to give 29% yield. 1H NMR (600 MHz, DMSO-d6) d 8.20 (s, 1H), 
8.01 (d, J = 7.6 Hz, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.67 (s, 1H), 7.48 (s, 1H), 7.30 (t, J = 
7.5 Hz, 1H), 7.26 – 7.18 (m, 1H), 6.94 (d, J = 6.4 Hz, 1H), 4.59 (s, 1H), 4.28 (d, J = 6.6 
Hz, 1H), 4.16 (s, 1H), 3.90 – 3.85 (m, 1H), 3.08 (s, 1H), 2.92 (dd, J = 14.8, 8.3 Hz, 1H), 
1.60 (s, 9H), 1.33 (s, 7H), 1.28 – 1.22 (m, 3H), 1.19 (d, J = 6.9 Hz, 3H), 1.10 (d, J = 7.3 
Hz, 4H). 13C NMR (151 MHz, DMSO) d 174.0, 172.6, 171.6, 170.4, 155.0, 149.1, 134.7, 
130.4, 124.2, 122.4, 119.5, 116.2, 114.6, 83.4, 78.2, 51.9, 50.1, 47.9, 47.6, 28.2, 27.7, 
18.2, 18.08, 17.3. HRMS (ESI+) m/z calc’d for C30H43N5O9Na [M + Na]+ 640.2958, found 
640.2940. 
 
Boc-AW(Boc)AP-OH (4.3.B-Pro). Table 4.3, entry 14: Resin 4.3.A (20 mg, 4 µmol) was 
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the solvent was removed, and the resin was activated (see General Procedure). H-Pro-
OH (10 equiv) was dissolved in 500 µL DMF and 100 µL H2O in a separate vial and added 
to the swelled resin. Then freshly distilled DIEA (11 equiv) was added and the reaction 
vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial 
and the reaction was quenched in (1% TFA) 20% MeCN/H2O. The resin was further 
rinsed with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The volatile solvent 
was removed, and the remaining solution was frozen (LN2) and lyophilized to yield the 
crude peptide. After 4 h, 34% conversion was observed (62:38 of 4.3.B/4.3.C). 
 
Boc-AW(Boc)AP-OH (4.3.B-Pro). Table 4.3, entry 15a: Resin 4.3.A (20 mg, 4 µmol) 
was weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After 
swelling, the solvent was removed, and the resin was activated (see General Procedure). 
H-Pro-OH (10 equiv) was added directly to the resin followed by 600 µL DMF/H2O (5:1). 
Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at 
ambient temperature for 4 h. The solvent was removed from the vial and the reaction was 
quenched in (1% TFA) 20% MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 x 1 
mL) and combined with the initial solvent. The volatile solvent was removed, and the 
remaining solution was frozen (LN2) and lyophilized to yield the crude peptide. After 4 h, 
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Boc-AW(Boc)AP-OH (4.3.B-Pro). Table 4.3, entry 15b: Resin 4.3.A (100 mg, 16 µmol) 
was weighed into a 5 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After 
swelling, the solvent was removed, and the resin was activated (see General Procedure). 
H-Pro-OH (10 equiv) was added directly to the resin followed by 600 µL DMF/H2O (5:1). 
Then 21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at 
ambient temperature for 4 h. The solvent was removed from the vial and the reaction was 
quenched in (1% TFA) 20% MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 x 1 
mL) and combined with the initial solvent. The volatile solvent was removed and the 
remaining solution was frozen (LN2) and lyophilized to yield the crude peptide. The crude 
peptide was purified using RP-HPLC-MS yielding 1 mg of pure peptide (4.3.B-Pro) and 
5.9 mg of mixed peptide (79% HPLC purity, 254 nm) giving 44% yield. 1H NMR (499 MHz, 
DMSO-d6) d 12.43 (s, 1H), 8.23 (d, J = 7.1 Hz, 1H), 8.01 (d, J = 8.1 Hz, 1H), 7.81 (d, J = 
8.0 Hz, 1H), 7.65 (d, J = 7.8 Hz, 1H), 7.48 (s, 1H), 7.30 (t, J = 7.2 Hz, 1H), 7.22 (t, J = 7.5 
Hz, 1H), 6.93 (d, J = 7.4 Hz, 1H), 4.60 (d, J = 5.8 Hz, 1H), 4.53 – 4.43 (m, 1H), 4.23 (dd, 
J = 8.8, 4.1 Hz, 1H), 3.96 – 3.84 (m, 1H), 3.49 (d, J = 6.7 Hz, 2H), 3.11 – 2.98 (m, 1H), 
2.91 (dd, J = 13.9, 7.6 Hz, 1H), 2.18 – 2.04 (m, 1H), 1.94 – 1.77 (m, 3H), 1.61 (s, 9H), 
1.35 (s, 8H), 1.18 (d, J = 6.7 Hz, 3H), 1.11 (d, J = 7.0 Hz, 3H). 13C NMR (151 MHz, DMSO) 
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78.2, 59.7, 58.6, 51.9, 50.0, 49.5, 46.3, 28.6, 28.2, 27.7, 24.5, 18.1, 16.9. HRMS (ESI+) 
m/z calc’d for C32H45N5O9Na [M + Na]+ 666.3115, found 666.3115. 
 
Boc-AW(Boc)AP-OH (4.3.B-Pro). Table 4.3, entry 16: Resin 4.3.A (20 mg, 4 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Pro-
OH (10 equiv) and 1 equiv of NaSPh were added directly to the resin followed by 600 µL 
DMF/H2O (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial 
was agitated at ambient temperature for 4 h. The solvent was removed from the vial and 
the reaction was quenched in (1% TFA) 20% MeCN/H2O. The resin was further rinsed 
with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The volatile solvent was 
removed, and the remaining solution was frozen (LN2), and lyophilized to yield the crude 
peptide 4.3.B-Pro. After 4 h, 94% conversion was observed (83:17 of 4.3.B/4.3.C). 
 
Boc-AW(Boc)AP-OH (4.3.B-Pro). Table 4.3, entry 17: Resin 4.3.A (20 mg, 4 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
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OH (10 equiv) and 1 equiv of NaSPh were added directly to the resin followed by 600 µL 
DMF/H2O (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction vial 
was agitated at ambient temperature for 4 h. The solvent was removed, collected, and 
the resin was subjected to the same reaction conditions for an additional 4 h. After this 
time, the solvent was removed from the vial and the reaction was quenched in (1% TFA) 
20% MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 x 1 mL) and combined with 
the initial solvent. The volatile solvent was removed, and the remaining solution was 
frozen (LN2), and lyophilized to yield the crude peptide 4.3.B-Pro. After 4 h, >99% 
conversion was observed (87:13 of 4.3.B/4.3.C). 
 
Boc-AW(Boc)AI-OH (4.3.B-Ile). Table 4.4, entry 1: Resin 4.3.A (20 mg, 4 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Ile-
OH (10 equiv) and 1 equiv of NaSPh were added directly to the resin followed by (5:1) 
600 µL DMF/modified NCL buffer (without guanidine). Then 21 equiv of freshly distilled 
DIEA was added and the reaction vial was agitated at ambient temperature for 4 h. After 
this time, the solvent was removed from the vial and the reaction was quenched in (1% 
TFA) 20% MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 x 1 mL) and combined 
with the initial solvent. The volatile solvent was removed, and the remaining solution was 
frozen (LN2), and lyophilized to yield the crude peptide 4.3.B-Ile. After 4 h, 94% 
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Boc-AW(Boc)AI-OH (4.3.B-Ile). Table 4.4, entry 2: Resin 4.3.A (10 mg, 2 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Ile-
OH (10 equiv) was added directly to the resin followed by (5:1) 300 µL DMF/modified NCL 
buffer (without guanidine). Then 21 equiv of freshly distilled DIEA was added and the 
reaction vial was agitated at ambient temperature for 4 h. After this time, the solvent was 
removed from the vial and the reaction was quenched in (1% TFA) 20% MeCN/H2O. The 
resin was further rinsed with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The 
volatile solvent was removed, and the remaining solution was frozen (LN2), and 
lyophilized to yield the crude peptide 4.3.B-Ile. After 4 h, 38% conversion and 1% D-Ala 
epimer were observed. 
 
Boc-AW(Boc)AI-OH (4.3.B-Ile). Table 4.4, entry 3: Resin 4.3.A (10 mg, 2 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Ile-
OH (10 equiv) and 1 equiv NaSPh was added directly to the resin followed by (5:1) 300 
µL DMF/modified NCL buffer (without guanidine). The reaction vial was agitated at 
ambient temperature for 4 h. After this time, the solvent was removed from the vial and 
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with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The volatile solvent was 
removed, and the remaining solution was frozen (LN2), and lyophilized to yield the crude 
peptide 4.3.B-Ile. After 4 h, 50% conversion was observed with no detectable 
epimerization. 
 
Boc-AW(Boc)AI-OH (4.3.B-Ile). Table 4.4, entry 4: Resin 4.3.A (24 mg, 5 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed from the resin, and the resin was activated (see General 
Procedure). H-Ile-OH (10 equiv) was added directly to the resin followed by (5:1) 600 µL 
DMF/H2O. Then 21 equiv of freshly distilled DIEA was added and the reaction vial was 
agitated at ambient temperature for 4 h. After this time, the solvent was removed from the 
vial and the reaction was quenched in (1% TFA) 20% MeCN/H2O. The resin was further 
rinsed with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The volatile solvent 
was removed, and the remaining solution was frozen (LN2), and lyophilized to yield the 
crude peptide 4.3.B-Ile. After 4 h, 72% conversion was observed with no detectable 
epimerization. 
 
Boc-AW(Boc)AI-OH (4.3.B-Ile). Table 4.4, entry 5: Resin 4.3.A (10 mg, 2 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed from the resin, and the resin was activated (see General 
1) 4-nitrophenyl 
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Procedure). H-Ile-OH (10 equiv) was added directly to the resin followed by (5:1) 300 µL 
DMF/H2O. Then 21 equiv of freshly distilled DIEA was added and the reaction vial was 
agitated at ambient temperature for 18 h. After this time, the solvent was removed from 
the vial and the reaction was quenched in (1% TFA) 20% MeCN/H2O. The resin was 
further rinsed with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The volatile 
solvent was removed, and the remaining solution was frozen (LN2), and lyophilized to 
yield the crude peptide 4.3.B-Ile. After 18 h, >99% conversion and 2% D-Ala epimer were 
observed. 
 
Boc-AW(Boc)AI-OH (4.3.B-Ile). Table 4.4, entry 6: Resin 4.3.A (10 mg, 2 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Ile-
OH (10 equiv) was added directly to the resin followed by (5:1) 300 µL DMF/H2O. Then 
21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient 
temperature for 4 h. The solvent was removed, collected, and the resin was subjected to 
the same reaction conditions for an additional 4 h. After this time, the solvent was 
removed from the vial and the reaction was quenched in (1% TFA) 20% MeCN/H2O. The 
resin was further rinsed with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The 
volatile solvent was removed, and the remaining solution was frozen (LN2), and 
lyophilized to yield the crude peptide 4.3.B-Ile. After 4 h (2 x), >99% conversion and 2% 
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Boc-AW(Boc)AP-OH (4.3.B-Pro). Table 4.4, entry 7: Resin 4.3.A (20 mg, 4 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Pro-
OH (10 equiv) and 1 equiv NaSPh was added directly to the resin followed by (5:1) 600 
µL DMF/H2O. Then 21 equiv of freshly distilled DIEA was added and the reaction vial was 
agitated at ambient temperature for 4 h. After this time, the solvent was removed from the 
vial and the reaction was quenched in (1% TFA) 20% MeCN/H2O. The resin was further 
rinsed with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The volatile solvent 
was removed, and the remaining solution was frozen (LN2), and lyophilized to yield the 
crude peptide 4.3.B-Pro. After 4 h, 94% conversion and 3% D-Ala epimer were observed. 
 
Boc-AW(Boc)AP-OH (4.3.B-Pro). Table 4.4, entry 8: Resin 4.3.A (10 mg, 2 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Pro-
OH (10 equiv) was added directly to the resin followed by (5:1) 300 µL DMF/H2O. Then 
21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient 
temperature for 4 h. After this time, the solvent was removed from the vial and the reaction 
was quenched in (1% TFA) 20% MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 
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remaining solution was frozen (LN2), and lyophilized to yield the crude peptide 4.3.B-Pro. 
After 4 h, >99% conversion and 2% D-Ala epimer were observed. The ratio of product to 
acid is 87:17 by PDA (190 nm). 
 
Boc-LY(tBu)R(Pbf)AGLR(Pbf)AY(tBu)G-OH (4.5.B). Table 4.5.1, entry 1: Resin 4.5.A 
(20 mg, 7 µmol) was weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 
30 min. After swelling, the solvent was removed, and the resin was activated (see General 
Procedure). H-Gly-OH (10 equiv) and 1 equiv of NaSPh were added directly to the resin 
followed by 600 µL (5:1) DMF/modified NCL Buffer (see guanidine-free NCL buffer). Then 
21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient 
temperature for 4 h. The solvent was removed from the vial and the reaction was 
quenched in (1% TFA) 20% MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 x 1 
mL) and combined with the initial solvent. The volatile solvent was removed, and the 
remaining solution was frozen (LN2), and lyophilized to yield the crude peptide 4.5.B. After 
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Boc-LY(tBu)R(Pbf)AGLR(Pbf)AY(tBu)I-OH (4.5.C). Table 4.5.1, entry 2: Resin 4.5.A 
(20 mg, 7 µmol) was weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 
30 min. After swelling, the solvent was removed, and the resin was activated (see General 
Procedure). H-Ile-OH (10 equiv) and 1 equiv of NaSPh were added directly to the resin 
followed by 600 µL (5:1) DMF/modified NCL Buffer (see guanidine-free NCL buffer). Then 
21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient 
temperature for 4 h. The solvent was removed from the vial and the reaction was 
quenched in (1% TFA) 20% MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 x 1 
mL) and combined with the initial solvent. The volatile solvent was removed, and the 
remaining solution was frozen (LN2), and lyophilized to yield the crude peptide 4.5.C. After 
4 h, >99% conversion was observed (74:26:n/a of 4.5.C/4.5.F/4.5.G). 
 
Boc-LY(tBu)R(Pbf)AGLR(Pbf)AY(tBu)A-OH (4.5.D). Table 4.5.1, entry 3: Resin 4.5.A 
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30 min. After swelling, the solvent was removed, and the resin was activated (see General 
Procedure). H-Ala-OH (10 equiv) and 1 equiv of NaSPh were added directly to the resin 
followed by 600 µL (5:1) DMF/modified NCL buffer (see guanidine-free NCL buffer). Then 
21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient 
temperature for 4 h. The solvent was removed from the vial and the reaction was 
quenched in (1% TFA) 20% MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 x 1 
mL) and combined with the initial solvent. The volatile solvent was removed, and the 
remaining solution was frozen (LN2), and lyophilized to yield the crude peptide 4.5.D. After 
4 h, >99% conversion was observed (79:21:n/a of 4.5.D/4.5.F/4.5.G). 
 
Boc-LY(tBu)R(Pbf)AGLR(Pbf)AY(tBu)P-OH (4.5.E). Table 4.5.1, entry 4: Resin 4.5.A 
(100 mg, 35 µmol) was weighed into a 5 mL reaction vial and swelled in 500 µL CH2Cl2 
for 30 min. After swelling, the solvent was removed, and the resin was activated (see 
General Procedure). H-Pro-OH (10 equiv) and 1 equiv of NaSPh were added directly to 
the resin followed by 600 µL DMF/H2O (5:1). Then 21 equiv of freshly distilled DIEA was 
added and the reaction vial was agitated at ambient temperature for 4 h. This 4 h cleavage 
was repeated on the same resin the following day. The solvent was removed from the 
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rinsed with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The volatile solvent 
was removed, and the remaining solution was frozen (LN2), and lyophilized to yield the 
crude peptide. After 4 h, >99% conversion was observed (70:30:n/a of 4.5.E/4.5.F/4.5.G). 
The crude peptide was purified using RP-HPLC-MS to yield the pure white solid (4.5.E) 
in 9% yield (7.5 mg, 70% HPLC purity, 254 nm).  
 
Boc-LY(tBu)R(Pbf)AGLR(Pbf)AY(tBu)P-OH (4.5.E). Table 4.5.1, entry 5: Resin 4.5.A 
(20 mg, 7 µmol) was weighed into a 5 mL reaction vial and swelled in 500 µL CH2Cl2 for 
30 min. After swelling, the solvent was removed, and the resin was activated (see General 
Procedure). H-Pro-OH (10 equiv) was added directly to the resin along with 1 equiv 
NaSPh followed by 600 µL DMF/iPrOH (5:1). Then 21 equiv of freshly distilled DIEA was 
added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was 
removed from the vial and the reaction was quenched in (1% TFA) 20% MeCN/H2O. The 
resin was further rinsed with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The 
volatile solvent was removed, and the remaining solution was frozen (LN2), and 
lyophilized to yield the crude peptide. The crude peptide was analyzed via RP-HPLC-MS. 
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 Boc-LY(tBu)R(Pbf)AGLR(Pbf)AY(tBu)P-OH (4.5.E). Table 4.5.1, entry 6: Resin 4.5.A 
(100 mg, 35 µmol) was weighed into a 5 mL reaction vial and swelled in 500 µL CH2Cl2 
for 30 min. After swelling, the solvent was removed, and the resin was activated (see 
General Procedure). H-Pro-OH (10 equiv) was added directly to the resin followed by 600 
µL DMF/iPrOH (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction 
vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial 
and the reaction was quenched in (1% TFA) 20% MeCN/H2O. Then H-Pro-OH (10 equiv) 
was added directly to the resin followed by 600 µL DMF/iPrOH (5:1). Then 21 equiv of 
freshly distilled DIEA was added and the reaction vial was agitated at ambient 
temperature for 4 h. The solvent was removed and collected with the initial reaction 
mixture. The resin was further rinsed with CH2Cl2 (3 x 1 mL) and combined with the initial 
solvent. The volatile solvent was removed, and the remaining solution was frozen (LN2), 
and lyophilized to yield the crude peptide. After 4 h, 89% conversion was observed 
(83:09:08 of 4.5.E/4.5.F/4.5.G). The crude peptide was purified using RP-HPLC-MS to 
yield the pure white solid (4.5.E) in 11% yield (4.4 mg, >99% HPLC purity and 3.6 mg, 
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Boc-LY(tBu)R(Pbf)AGLR(Pbf)AY(tBu)P-OH (4.5.E). Table 4.5.1, entry 7: Resin 4.5.A 
(20 mg, 7 µmol) was weighed into a 5 mL reaction vial and swelled in 500 µL CH2Cl2 for 
30 min. After swelling, the solvent was removed, and the resin was activated (see General 
Procedure). H-Pro-OH (10 equiv) was added directly to the resin along with 1 equiv 
NaSPh followed by 600 µL DMF/HFIP (5:1). Then 21 equiv of freshly distilled DIEA was 
added and the reaction vial was agitated at ambient temperature for 4 h. The solvent was 
removed from the vial and the reaction was quenched in (1% TFA) 20% MeCN/H2O. The 
resin was further rinsed with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The 
volatile solvent was removed, and the remaining solution was frozen (LN2), and 
lyophilized to yield the crude peptide. The crude peptide was analyzed via RP-HPLC-MS. 
After 4 h, >99% conversion was observed (81:07:12 of 4.5.E/4.5.F/4.5.G). 
 
Boc-LY(tBu)R(Pbf)AGLR(Pbf)AY(tBu)P-OH (4.5.E). Table 4.5.1, entry 8: Resin 4.5.E 
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for 30 min. After swelling, the solvent was removed, and the resin was activated (see 
General Procedure). H-Pro-OH (10 equiv) was added directly to the resin followed by 600 
µL DMF/HFIP (5:1). Then 21 equiv of freshly distilled DIEA was added and the reaction 
vial was agitated at ambient temperature for 4 h. The solvent was removed from the vial 
and the reaction was quenched in (1% TFA) 20% MeCN/H2O. The resin was further 
rinsed with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The volatile solvent 
was removed, and the remaining solution was frozen (LN2), and lyophilized to yield the 
crude peptide. After 4 h, >99% conversion was observed (83:05:12 of 4.5.E/4.5.F/4.5.G). 
The crude peptide was purified using RP-HPLC-MS to yield the pure white solid in 10% 
yield (7.4 mg, 91% HPLC purity, 254 nm). 
 
Boc-AW(Boc)AP-OH (4.3.B-Pro). Table 4.5.2, entry 1: Resin 4.3.A (9 mg, 2 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Pro-
OH (10 equiv) and 1 equiv NaSPh was added directly to the resin followed by (5:1) 300 
µL DMF/iPrOH. Then 21 equiv of freshly distilled DIEA was added and the reaction vial 
was agitated at ambient temperature for 4 h. After this time, the solvent was removed 
from the vial and the reaction was quenched in (1% TFA) 20% MeCN/H2O. The resin was 
further rinsed with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The volatile 
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yield the crude peptide 4.3.B-Pro. After 4 h, 83% conversion and 4% D-Ala epimer were 
observed. 
 
Boc-AW(Boc)AP-OH (4.3.B-Pro). Table 4.5.2, entry 2: Resin 4.3.A (9 mg, 2 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Pro-
OH (10 equiv) and 1 equiv NaSPh was added directly to the resin followed by (5:1) 300 
µL DMF/HFIP. Then 21 equiv of freshly distilled DIEA was added and the reaction vial 
was agitated at ambient temperature for 4 h. After this time, the solvent was removed 
from the vial and the reaction was quenched in (1% TFA) 20% MeCN/H2O. The resin was 
further rinsed with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The volatile 
solvent was removed, and the remaining solution was frozen (LN2), and lyophilized to 
yield the crude peptide 4.3.B-Pro. After 4 h, >99% conversion and 4% D-Ala epimer were 
observed. 
 
Boc-AW(Boc)AP-OH (4.3.B-Pro). Table 4.5.2, entry 3: Resin 4.3.A (9 mg, 2 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Pro-
OH (10 equiv) was added directly to the resin followed by (5:1) 300 µL DMF/iPrOH. Then 
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temperature for 4 h. After this time, the solvent was removed from the vial and the reaction 
was quenched in (1% TFA) 20% MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 
x 1 mL) and combined with the initial solvent. The volatile solvent was removed, and the 
remaining solution was frozen (LN2), and lyophilized to yield the crude peptide 4.3.B-Pro. 
After 4 h, 74% conversion was observed with no detectable epimerization. The ratio of 
product to acid to ester is 87:5:8 by PDA (190 nm). 
 
Boc-AW(Boc)AP-OH (4.3.B-Pro). Table 4.5.2, entry 4: Resin 4.3.A (9 mg, 2 µmol) was 
weighed into a 2 mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). H-Pro-
OH (10 equiv) was added directly to the resin followed by (5:1) 300 µL DMF/HFIP. Then 
21 equiv of freshly distilled DIEA was added and the reaction vial was agitated at ambient 
temperature for 4 h. After this time, the solvent was removed from the vial and the reaction 
was quenched in (1% TFA) 20% MeCN/H2O. The resin was further rinsed with CH2Cl2 (3 
x 1 mL) and combined with the initial solvent. The volatile solvent was removed, and the 
remaining solution was frozen (LN2), and lyophilized to yield the crude peptide 4.3.B-Pro. 
After 4 h, >99% conversion was observed with no detectable epimerization. The ratio of 








    chloroformate 
    then DIEA/DMF
2) H-Pro-OH (10 equiv)
    DIPEA (21 equiv)







Boc-LY(tBu)R(Pbf)AGLR(Pbf)AY(tBu)R(Pbf)-OH (4.5.H). Table 4.5.3, entry 1: Resin 
4.5.A (50 mg, 18 µmol) was weighed into a 5 mL reaction vial and swelled in 500 µL 
CH2Cl2 for 30 min. After swelling, the solvent was removed, and the resin was activated 
(see General Procedure). H-Arg(Pbf)-OH (10 equiv) was added directly to the resin 
followed by 600 µL DMF/HFIP (5:1). Then 21 equiv of freshly distilled DIEA was added 
and the reaction vial was agitated at ambient temperature for 4 h. The solvent was 
removed from the vial and the reaction was quenched in (1% TFA) 20% MeCN/H2O. The 
resin was further rinsed with CH2Cl2 (3 x 1 mL) and combined with the initial solvent. The 
volatile solvent was removed, and the remaining solution was frozen (LN2), and 
lyophilized to yield the crude peptide 4.5.H. After 4 h, 67% conversion was observed 
(12:11:77 of 4.5.H/4.5.L/4.5.M) 
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4.5.A (50 mg, 18 µmol) was weighed into a 5 mL reaction vial and swelled in 500 µL 
CH2Cl2 for 30 min. After swelling, the solvent was removed, and the resin was activated 
(see General Procedure). H-Lys(Boc)-OH (10 equiv) was added directly to the resin 
followed by 600 µL DMF/HFIP (5:1). Then 21 equiv of freshly distilled DIEA was added 
and the reaction vial was agitated at ambient temperature for 4 h. The solvent was 
removed from the vial and the reaction was quenched in (1% TFA) 20% MeCN/H2O. The 
resin was further rinsed with (1:1:3) TFE/AcOH/CH2Cl2 (3 x 1 mL) and combined with the 
initial solvent. The volatile solvent was removed, and the remaining solution was frozen 
(LN2), and lyophilized to yield the crude peptide 4.5.I. After 4 h, >99% conversion was 
observed (18:06:66 of 4.5.I/4.5.L/4.5.M) The crude peptide was purified using RP-HPLC-
MS to yield the peptide in 5% yield (3.1 mg, 60% HPLC purity, 254 nm). 
 
Boc-LY(tBu)R(Pbf)AGLR(Pbf)AY(tBu)D(OtBu)-OH (4.5.J). Table 4.5.3, entry 3: Resin 
4.5.A (50 mg, 18 µmol) was weighed into a 5 mL reaction vial and swelled in 500 µL 
CH2Cl2 for 30 min. After swelling, the solvent was removed, and the resin was activated 
(see General Procedure). H-Asp(tBu)-OH (10 equiv) was added directly to the resin 
followed by 600 µL DMF/HFIP (5:1). Then 21 equiv of freshly distilled DIEA was added 
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removed from the vial and the reaction was quenched in (1% TFA) 20% MeCN/H2O. The 
resin was further rinsed with (1:1:3) TFE/AcOH/CH2Cl2 (3 x 1 mL) and combined with the 
initial solvent. The volatile solvent was removed, and the remaining solution was frozen 
(LN2), and lyophilized to yield the crude peptide 4.5.J. After 4 h, >99% conversion was 
observed (81:04:15 of 4.5.J/4.5.L/4.5.M). The peptide was purified by RP-HPLC-MS to 
produce the pure peptide 4.5.J in 7% yield (2.7 mg). *note: [M - tBu]+ was observed  
 
Boc-LY(tBu)R(Pbf)AGLR(Pbf)AY(tBu)H(Trt)-OH (4.5.K). Table 4.5.3, entry 4: Resin 
4.5.A (50 mg, 18 µmol) was weighed into a 5 mL reaction vial and swelled in 500 µL 
CH2Cl2 for 30 min. After swelling, the solvent was removed, and the resin was activated 
(see General Procedure). H-His(Trt)-OH (10 equiv) was added directly to the resin 
followed by 600 µL DMF/HFIP (5:1). Then 21 equiv of freshly distilled DIEA was added 
and the reaction vial was agitated at ambient temperature for 4 h. The solvent was 
removed from the vial and the reaction was quenched in (1% TFA) 20% MeCN/H2O. The 
resin was further rinsed with (1:1:3) TFE/AcOH/CH2Cl2 (3 x 1 mL) and combined with the 
initial solvent. The volatile solvent was removed, and the remaining solution was frozen 
(LN2), and lyophilized to yield the crude peptide 4.5.K. After 4 h, >99% conversion was 
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CHAPTER 5: BRINGING MACROLACTAMIZATION FULL CIRLCE: SYNTHESIS OF  
MACROCYCLIC PEPTIDES 
Parts of this chapter were adapted with permission from Arbour, C. A.; Saraha, H. Y.; 
McMillan, T. F.; Stockdill, J. L. Chem.–Eur. J. 2017, 23, 12484–12488 (Reproduced by 
permission of Wiley and Sons), Arbour, C. A.;‡ Stamatin R. E.;‡ Stockdill, J. L. J. Org. 
Chem. 2018, 83, 1797–1803 (Copyright 2018 American Chemical Society), and Arbour, 
C. A.; Belavek, K. J.; Tariq, R.; Mukherjee, S.; Tom, J. K.; Isidro-Llobet, A.; Kopach, M. 
E.; Stockdill, J. L. J. Org. Chem. 2019, 84, 1035–1041 (Copyright 2018 American 
Chemical Society). All solution-phase experiments were performed by me. Kayla Belavek 
and Rooha Tariq synthesized the majority of the peptide substrates for this Chapter. All 
cyclization reactions were performed by me. 
5.1 The Importance of Synthetically Accessing Macrocyclic Peptides  
Macrocyclic peptides have gained prevalence as pharmaceutical leads for 
“undruggable” biological targets because their large surface areas, minimal 
conformational flexibility, and multiple sidechain moieties facilitate selective binding to 
shallow protein surfaces.123 The conformational rigidity conferred upon macrocyclization 
compensates for the loss of conformational entropy upon binding, and enhances the 
target affinity of the macrocyclic peptide over its linear counterpart.124 In addition, peptide 
macrocycles generally maintain the metabolic stability123,125 and oral bioavailability of a 
small molecule target,126 and their membrane permeability can be modulated via chemical 
modification to target intracellular proteins.123,127 Cyclic peptides also benefit from the 
relatively low toxicity enjoyed by biologics.128 Additionally, unlike biologics, cyclic peptides 
tend to not initiate adverse immunogenic responses.129 Because of these exceptional 
properties, efficient methods for the synthesis of macrocyclic peptides are in constant 
demand.130 I present herein a broadly applicable, fully on-resin method for 
macrocyclization of unprotected peptides. This approach harnesses the mild activating 
nature of N-acyl ureas to achieve selectivity for cysteine-mediated macrocyclization in the 
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presence of other nucleophilic side chains. The method is compatible with structurally 
diverse C-terminal amino acids and is effective for challenging substrates131 such as 
tetrapeptides and pentapeptides.132 I showcase this approach via the total syntheses of 
cyclic peptide natural products mahafacyclin B133 and sunflower trypsin inhibitor 1 (SFTI-
1)134 as well as an SFTI-1 analog. 
5.1.1 In-Solution Synthesis of Head-to-Side-Chain Intramolecular Macrocyclic Peptides 
Early on, I investigated the solution-phase C-terminal diversification of MeNbz-
linked peptides because the activated peptide is readily accessible, the mild conditions, 
and the short reaction times. For maximum utility, the functionalization of unprotected 
peptides should be compatible with residues bearing nucleophilic side chains.55,73 Thus, 
I synthesized H-AKTWA-MeNbz-Gly (5.1.A) and subjected it to various nucleophiles for 
30 min in solution (Table 5.1). The reaction was quenched by dilution with 1:1 MeCN/H2O, 
and the product distribution (5.1.B/5.1.C/5.1.D) was analyzed using HPLC. The 
functionalized acyclic peptide (5.1.B) was the desired target. Unreacted peptide 5.1.A 
was hydrolyzed to the corresponding acid (5.1.C) during the quench and apart from entry 
2, this product represents unreacted starting material. Attack of either the N-terminus or 
the side chain of lysine or threonine would afford a cyclic peptide. The sole macrocyclic 
product was assigned as 5.1.D based on the reactivity of the primary amine relative to an 
a-branched amine or alcohol and by independent synthesis of the head-to-tail cyclized 
lactam.81  
In 1:1 MeCN/BuNH2, only the intermolecular amide product was observed. 
Repeating this reaction with 1:1:1 MeCN/H2O/BuNH2 led primarily to the amide with 7% 
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hydrolysis occurring during the reaction. Thus, the modification has reasonable tolerance 
to aqueous conditions when an excess of nucleophile is employed. Propargylamine was 
similarly effective, while the reduced nucleophilicity of aniline resulted in an 8:92 ratio of 
amide to macrolactam. Peptide hydrazides75,135 and hydroxamides87 were generated with 
no macrocycle formation. In contrast, treatment with Weinreb amine led to 89% 
conversion to the macrolactam. Functionalization with MeOH proceeded with complete 
conversion to a 42:58 ratio of methyl ester to lactam. In the presence of a non-nucleophilic 
base, the lactam was formed with 91% conversion. Finally, sodium borohydride reduction 
was slower, likely because of the MeCN co-solvent, but no macrocycle was observed. 
I also employed amino acids to displace H-AKTWA-MeNbz-Gly-NH2 (5.1.A) to 
determine whether the C terminal elongation with amino acids was efficient enough to 
modify unprotected peptides bearing nucleophilic side chains. Only glycine reacted 
quickly enough to outcompete macrolactam formation, affording 5.1.B as the major 





Table 5.1.1 Evaluation of inter- vs intramolecular attack using various nucleophiles. 
 
5.1.2 Selectivity for Cyclization-Prone Substrates and Evaluation of Other Nucleophilic 
Side Chains 
Peptides containing proline and glycine are generally more prone to 
macrocyclization.136 Peptides 5.1.E and 5.1.F were evaluated to determine whether more 
cyclization-prone substrates could be efficiently functionalized (Table 5.1.2). The 
proclivity of these peptides towards macrocyclization was validated by control reactions 
with MeOH/Hünig’s base and Hünig’s base alone (entries 2, 3, 5, and 6). Peptides 5.1.E 




















































a Unless noted, all reactions were performed on 20 mg crude peptide in 200 µL MeCN with 200 µL nucleophile at rt (24 ± 1 ºC), b Relative 
ratio of MS data, c Performed in 200 µL each MeCN, H2O, BuNH2, d 5 equiv of the Nuc•HCl salt was used and Hünig’s base was 
increased accordingly, e Performed on 60 mg crude peptide in 600 µL MeCN, f Performed in 100 µL THF and 200 µL MeCN using 5 equiv 











































































































50:47.5:2.5 ratio of butylamine/MeCN/H2O, excellent conversion to the butyl amide 
(5.1.E.2, 5.1.F.2) was observed for both peptides (entries 1 and 4). All remaining 
nucleophilic side chains were evaluated by replacing lysine with serine (5.1.G), cysteine 
(5.1.H), and tyrosine (5.1.I). In all cases, the butyl amide and the methyl ester could be 
accessed with no hydrolysis or macrocyclization. Omission of the exogenous nucleophile 
confirmed that these peptides form macrocycles during the short reaction (entries 9, 12, 
and 15). Although the intermolecular displacement to access C-terminally modified 
peptides was my initial target, these experiments demonstrated that this linker could be 
displaced with amino acid side chains. These preliminary investigations combined with 
my intermolecular single cysteine native chemical ligation gave rise to the synthesis of 
macrocyclic peptides entirely on resin. 
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Table 5.1.2 Selectivity for cyclization-prone substrates and evaluation of other 
nucleophilic side chains. 
 
5.2 On-Resin Macrolactamization Using an Intramolecular Native Chemical Ligation 
Approach 
 I recently established that on-resin displacement of the urea group proceeds with 
no epimerization of the C-terminal residue.167b As previously mentioned, I also determined 
that side-chain nucleophiles were effective in displacing an N-acyl urea (MeNbz) group 
to form head to side-chain macrocycles.167a Related methods were recently published 
using a benzotriazole (Bt) activation strategy.53,137 The Bt group appears to be more 
activating toward nucleophilic attack than the MeNbz group based on the reactivity 










aUnless noted, all reactions were performed on 5 mg crude peptide in 100 µL MeCN/H2O (95:5) with 100 µL nucleophile at rt 


























































































































would be selectively displaced by an N-terminal cysteine thiol in presence of fully 
unprotected peptides containing nucleophilic sidechain groups capable of head-to-
sidechain cyclization. I envisioned that I could capitalize on the pseudo-dilution effect to 
avoid intermolecular reactions and dilute reaction conditions.138,139 By performing the TFA 
cleavage on resin, I expected to reduce steric interactions from protecting groups and 
harness favorable conformational preferences induced by the primary amino acid 
sequence, while providing a product with good solubility properties. Finally, the self-
cleaving macrocyclization should simplify, if not avoid, purification of the final 
macrocycle.140  
 With these considerations in mind, I established the general approach outlined in 
Scheme 5.2. A dual linker strategy is employed which combined the hydroxymethyl 
benzoic acid (HMBA)47 linker and the N-methylated diaminobenzoyl (MeDbz) linker 
(5.2.A).74 This strategy facilitated reaction monitoring81,141 and could potentially allow for 
resin reuse. The target peptide is generated via solid-phase peptide synthesis (SPPS) via 
a fluorenyl-methoxycarbonyl (Fmoc) protection scheme.142,171 The N-acyl urea (MeNbz) 
was formed through activation of the MeDbz linker followed by on-resin side-chain 
protecting group removal which provided the resin-bound unprotected peptide 5.2.B. 
Upon neutralization or treatment with mild base, the thiol of the C-terminal cysteine 
residue displaced the MeNbz group, and subsequent S®N acyl transfer35,143 afforded the 




Scheme 5.2. Strategy for fully on-resin synthesis of peptide macrolactams. 
 
5.3 Scope of Solvent for On-Resin Macrocyclization 
The initial reaction screening process was performed with the substrate CFLFA–
MeNbz-G-HMBA bound to the polyethyleneglycol-based ChemMatrix resin (5.3.A, Table 
5.3).145 The cyclic O-acyl serine analog (SFLFA) of this peptide undergoes O ® N acyl 
transfer under organic conditions (piperidine/DMF), but suffers significant hydrolysis in 
pH 7.4 phosphate buffer.146 Thus, this substrate represented a viable, but not overly 
simplistic, starting point. I previously observed macrocyclization of appropriately located 
nucleophilic side chains including lysine, cysteine, and serine amino acids in the solution 
phase upon treatment with 10% Hünig’s base (DIEA) in MeCN.167b Application of these 
conditions resulted in no detectable conversion of peptide 5.3.A to the desired macrocycle 
(5.3.B), the hydrolyzed peptide (5.3.C, entry 1),147 or the corresponding thiolactone 
(5.3.D).148 Albericio and co-workers recently reported the cyclative cleavage of N-acylated 
N-terminal cysteine168a and b-amino-serine168b peptides using Hünig’s base in CH2Cl2. 
These conditions (entry 2) as well as DIEA/EtOAc (entry 3) also led to no conversion of 
peptide 5.3.B. Treatment with Hünig’s base in 2-methyltetrahydrofuran (2-MeTHF) led to 
trace formation of a mixture of cyclic peptide 5.3.B and thiolactone 5.3.D (entry 4). 
Similarly, trace thiolactone was observed in N-methylpyrrolidinone (NMP, entry 5).81 
Exposure of thiolactone 5.3.D to butylamine leads to rapid butyl amide formation, 
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For the industrial synthesis of macrocyclic peptides, it is ideal to avoid substances 
of very high concern (SVHC) as solvents.149 With this consideration in mind, I next 
considered a variety of solvents ranked as “green” and “amber” solvents, which have 
fewer environmental and health concerns than many traditional solvents.149b I observed 
good conversion (91%) to the desired cyclic lactam with no formation of 5.3.C or 5.3.D 
upon treatment with 10% Hünig’s base in 4-formylmorpholine (entry 6). The reactivity was 
further improved (>99% conversion) when the reaction was conducted in alternative 
amide-containing solvents such as N-butylpyrrolidinone (NBP, entry 7) and N,N-
dimethyldecanamide (entry 8). I observed complete conversion and excellent selectivity 
with NBP, which has been applied recently to green organic150 and peptide synthesis.149 
I also investigated 2,4,6-collidine, listed as a green solvent,149b and observed complete 
reactivity and selectivity for lactam formation in this reaction as well (entry 9).151  
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Table 5.3. Optimization of self-cleaving macrocyclization via Cys-mediated 
displacement of an N-acyl urea. 
 
 Finally, I investigated a variety of aqueous and mixed reaction conditions, which I 
envisioned would be ideal because lyophilization of the filtrate of the reaction could 
potentially lead directly to high purity products. To ensure solubility of the product 
macrocycles, I initially investigated a traditional native chemical ligation (NCL) buffer 
(Table 5.3, entry 10). I observed a mixture of the desired macrocycle (5.3.B), the C-
terminal MPAA ester (H-CFLFA-S(4-C6H4CH2COOH)), and the C-terminal guanidine 
adduct (H-CFLFA-NHC(NH)NH2).81 No hydrolysis (5.3.C) was observed and no starting 
material remained. In pH 7.2 phosphate buffer, the conversion was 69%, and lactam 
5.3.B remained physically trapped in the resin, requiring extensive rinsing with MeCN, 
































a All reactions were performed on 10 mg of resin using 250 µL of solvent, b 10% DIEA/Solvent, c Based on relative ratio of HPLC/MS 
data, ND= Not determined, d Observed cyclic thioester, conversion cannot be determined, e NCL buffer contains MPAA, TCEP•HCl, 
Guanidine•HCl, Na2HPO4 at pH 7.2, g 0.2 M Na2HPO4, f In addition to 5.3.B, C-terminal MPAA ester and guanidine adducts were 
















7 NBP >99 >99:<1:<1





12g (1:1) Na2HPO4:MeCN (6.5–7.2) >99 >99:<1:<1















11g,h Na2HPO4 (7.2)– 69 >99:<1:<1
















(entry 11). I next performed the cyclization in a mixture of phosphate buffer/MeCN, which 
was inspired by a recent report from Olsen and co-workers wherein thiodepsipeptides 
were synthesized via displacement of on-resin MeNbz by an internal cysteine in a mixture 
of aqueous phosphate buffer (0.2 M Na2HPO4, pH 6.8) and MeCN at 50 ºC.168c Treatment 
of a 1:1 mixture of phosphate buffer and MeCN at pH 7.2 resulted in excellent reactivity 
and selectivity (entry 12). I next confirmed that no detectable epimerization of the C-
terminal residue occurs during the cyclization by repeating these conditions using the C-
terminal D-Ala analog of peptide 5.3.B (5.5.G.2).81 The reaction is tolerant of a range of 
pH values, and lactam 5.3.B is the sole product at pH 6.5–7.2. 
 
Figure 5.3. RP-HPLC traces at 190 nm of epimerization determination for CLFLA cyclized 
in pH 7.2 Na2HPO4 buffer/MeCN (samples from Table 5.3, entry 12 (5.3.B, L-Ala) and 
Table 4, entry 7 (5.5.G.2, D-Ala)). 
 During the preparation of this work, a study from Olsen and co-workers applied 
their previously reported internal thiolactone conditions (0.2 M Na2HPO4 buffer – pH 6.8, 
MeCN, 50 ºC) to the synthesis of head-to-tail macrocyclic peptides.152 Their reported 
protocol is similar to my own with the exception of the reaction temperature and the post-
TFA cleavage rinse method (discussed below). Importantly, I do not observe dimer 
formation via undesired intermolecular disulfide formation for any of the conditions in 
entries 6-12 of Table 5.3. The presence of this impurity in the Olsen conditions adds the 










5.4 Non-Cysteine N-Terminal Macrocyclization 
 Following optimization of the cysteine-mediated cyclization, I sought to confirm the 
need for a thiol-containing residue in the N-terminal position using the optimal phosphate 
buffer/MeCN conditions. After MeDbz activation and removal of the N-terminal Boc group, 
each substrate (5.4.A.1-5.4.L.1) was subjected to a 1:1 v/v mixture of phosphate buffer 
(pH 7.2) and MeCN for 5 h (Table 5.4.1). Based on my previous studies of solution-phase 
side-chain macrolactamization and diversification167a of C-terminal MeNbz peptides, I 
expected that non-branched N-terminal primary amines would participate in 
macrocyclization reactions. However, the extent to which this pathway would compete 
with MeNbz hydrolysis remained unclear.167b N-Terminal glycine (5.4.A.1) reacted 
efficiently, with 84% conversion, and the corresponding macrolactam (5.4.B.1) was the 
sole product (entry 1). The more nucleophilic e-lysine peptide (5.4.B.2) proceeded less 
efficiently and formed mainly hydrolysis product 5.4.B.3 (entry 2).153 By contrast, in my 
previously reported solution-phase head-to-side-chain macrocyclization, treatment of 
unprotected peptides with 10% Hünig’s base in MeCN led to only 9% hydrolysis.167a 
Consistent with my expectations, AFLFA peptide 5.4.C.1 was almost unreactive (4% 
conversion), and the sole product was hydrolyzed peptide 5.4.C.3 (entry 3).168b 
Fortunately, Ala-containing macrocycles can be accessed by cysteine-mediated 
macrocyclization followed by reductive desulfurization.154 I previously observed good 
reactivity in C-terminal modification with primary alcohols such as MeOH and EtOH.167b 
Thus, I envisioned that the serine side-chain hydroxyl group might undergo 
macrolactonization followed by O to N acyl transfer.155 However, peptide 5.4.D.1 showed 
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no formation of lactam 5.4.D.2, instead proceeding with complete conversion to hydrolysis 
product 5.4.D.3 (entry 4).146 Because N-terminal D-amino acids can participate more 
efficiently in macrocyclization chemistry,130a I also evaluated D-amino acid analogs 
5.4.E.1 and 5.4.F.1. While the extent of MeNbz cleavage increased for D-alanine, D-
serine was less reactive. In both cases, the major product was hydrolysis (entries 5 and 
6).  
Table 5.4.1. Investigation of macrocyclization with non-N-terminal cysteine peptides in 
phosphate buffer/MeCN. 
 
 The same set of modifications were made to the sequence of the natural product 
mahafacyclin B (5.4.G).133 Cyclization with an N-terminal glycine nucleophile proceeded 
with excellent conversion (97%) but surprising levels of hydrolysis (~30%, Table 5.4.1, 
entry 7). Interestingly, e-lysine led to slower reactivity, presumably due to the increased 
degrees of freedom experienced by the lysine side chain, with reduced levels of 
hydrolysis (entry 8). The alanine and serine analogs were much more reactive in this 
peptide series, but again, hydrolysis was the major product for each (entries 9 and 10). 




3) Na2HPO4 (pH 7.2)











a All reactions were performed on 10 mg of resin using 500 µL of (1:1) 0.2 M Na2HPO4 buffer at pH 7.2/MeCN, b 
Based on relative ratio of HPLC/MS data.
GFLFA (5.4.A)
entrya sequenceamino acid (X) conversion (%)b
ratio































8 KFFGTFF (5.4.H) 61ε-Lys (K) 98:02
6 sFLFA (5.4.F)D-Ser (s) 85 04:96





Finally, the D-alanine and D-serine peptides demonstrated improved conversion with 
modest improvement in selectivity for macrocyclization (entries 11 and 12). Also, 
conversion improved significantly with modest improvement in macrolactam/hydrolysis 
ratio.  
 Previously, I found that 10% Hünig’s base in N-butylpyrrolidinone (NBP) also gave 
efficient conversion of linear peptide 5.3.A to lactam 5.3.B (Table 5.3). Thus, I selected 
a few representative entries where hydrolysis was observed from Table 5.4.1 and 
repeated the cyclization under NBP conditions. The results are summarized in Table 
5.4.2. Because of the unexpectedly large amount of hydrolysis observed in peptide 5.4.B, 
KFLFA, in phosphate buffer, I re-examined its reactivity using Hünig’s base in NBP (entry 
1). Improved conversion and better selectivity under these conditions was observed. 
Similarly, because the depsipeptide derived from SFLFA (5.4.D, entry 2) was known to 
be prone to hydrolysis in aqueous conditions,146 I evaluated it in DIEA/NBP, and I found 
that the serine side chain was not sufficiently reactive to induce depsipeptide formation. 
The level of hydrolysis experienced by several substrates suggested that the reaction 
might simply be too slow to out-compete hydrolysis in an aqueous environment. I selected 
representative peptides from the mahafacyclin series, which showed better reactivity 
overall than XFLFA, and subjected them to the DIEA/NBP conditions. Mahafacyclin 
(5.4.G) was cyclized with complete conversion, and no hydrolysis was observed. Serine 
analog 5.4.J remained recalcitrant to cyclization, with 23% conversion of MeNbz reacting 
to form mainly hydrolyzed peptide. D-Alanine peptide 5.4.K reacted with 79% conversion 
and formed a surprising amount of cyclic peptide for an a-substituted amine nucleophile. 
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As expected, better reactivity and selectivity was observed with N-terminal cysteine 
peptides. The increased nucleophilicity of thiols relative to alcohols and amines, 
particularly at neutral pH values, is crucial for effective macrocyclization. Fortunately, 
significant efforts to develop non-cysteine NCL variants have led to a variety of 
mercaptoamino acid derivatives, which can be employed for cyclization followed by 
desulfurization.36,144a,152,156 
Table 5.4.2. Reduced hydrolysis during macrocyclization of peptides with a non-cysteine 
N-terminal amino acid when performed in N-butylpyrrolidinone. 
 
5.5 Compatibility with Various C-Terminal Amino Acids 
 I next investigated the compatibility of representative C-terminal amino acids with 
cysteine-mediated cyclization under the pH 7.2 phosphate buffer/MeCN conditions. 
Substrates include unbranched, b-branched, basic, and acidic side chains and proline. 
Because alanine was the C-terminal residue in the parent substrate (CFLFA, Table 5.3, 
entry 12), I first evaluated the effect of omitting the side chain. For CFLFG (5.5.A.1) good 
selectivity favoring macrocyclization was retained; however, the reactivity decreased 
compared to the parent substrate (89% conversion, Table 5.5, entry 1). Isoleucine, a b-
branched amino acid, was similarly selective, forming only 5.5.B.2 in 78% conversion 
(entry 2). I next evaluated unprotected basic and acidic residues. Aspartic acid was prone 










a All reactions were performed on 10 mg of resin using 500 µL of solvent, b Based on relative ratio of HPLC/MS data.
entrya sequenceamino acid (X) conversion (%)b
ratio
2  :  3b
2 SFLFA (5.4.D) <1Ser (S) –
Boc peptide
5.4.B.2-5.4.K.2
4 SFFGTFF (5.4.J)Ser (S) 23 29:71




5 aFFGTFF (5.4.K)D-Ala (a) 79 73:27
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to peptide acid (5.5.C.3) formation in the phosphate buffer/MeCN conditions.81 I 
hypothesize that the aspartic acid side chain can cyclize onto the C terminus forming the 
reactive anhydride,157 which can be more susceptible to hydrolysis. To circumvent this 
issue, the reaction was conducted in 10% Hünig’s base in NBP for 5 h, resulting in 
complete conversion to desired macrocycle 5.5.C.2 (entry 3). The primary amine side 
chain of lysine did not interfere with the cyclization. Macrolactam 5.5.D.2 was formed with 
excellent reactivity and selectivity (entry 4). A C-terminal arginine residue was evaluated 
next because this amino is known to cyclize with activated C-termini.158 However, lactam 
5.5.E.2 was the sole observed product (entry 5), further highlighting the importance of the 
cysteine side chain in avoiding problematic side reactions. Next, I evaluated C-terminal 
proline, which is the most challenging C-terminal residue in NCL chemistry.159 The C-
terminal proline peptide CFLFP (5.5.F.1) was completely unreactive in Na2HPO4 (pH 
7.2)/MeCN for 5 h.81 Implementation of conditions designed for proline by Aucagne and 
co-workers did not alter this outcome.104 This lack of reactivity, while interesting, is not a 
significant limitation because proline is better placed in the middle of a sequence, where 
it can induce a turn in the peptide.160 I also observed slower reactivity when a D-alanine 
mutation was investigated at the C terminus compared to the parent substrate from Table 
5.3 (Table 5.5, entry 7). However, some lactam 5.5.G.2 was formed, and co-injection with 
lactam 5.3.B confirmed that no epimerization is observed under these conditions (see 
Figure 5.3).81  
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Table 5.5. Compatibility of various C-terminal amino acid residues with cyclization. 
 
5.6 Large Scale Optimization 
 When performing cyclizations on larger scales (>100 mg), I observed either 
exclusively hydrolysis or no reaction. I hypothesized that for the larger scale reactions, a 
sufficient amount of TFA remained embedded in the resin to change the pH of the 
subsequent cyclization reaction. Thus, I determined the pH of the resin after the TFA 
treatment followed by various rinsing protocols (Figure 5.6). For the reader’s 
convenience, the reference pH scale is included (Figure 5.6A) along with the pH of the 
Stockdill laboratory’s deionized water (Figure 5.6B) and the 0.2 M, pH 7.2 phosphate 
buffer (Figure 5.6C). The rinse procedure in Tables 5.3, 5.4.1, 5.4.2., and 5.5 involved 3 
rinses with CH2Cl2. After this rinse (Rinse Protocol A) was performed, I performed a single 
water rinse to test the pH and found the pH to be 0 (Figure 5.6D).81 For comparison, I 
also performed the rinse procedure reported by Olsen,152 again followed by a single water 
rinse. The pH was slightly increased to 1-2 (Figure 5.6E). I hypothesized that cyclization 
























a All reactions were performed on 10 mg of resin using 500 µL of solvent, all protecting groups are removed in the deprotection step 
using (95:2.5:2.5) TFA:TIPS:H2O, b 0.2 M Na2HPO4 buffer at pH 7.2, c Based on relative ratio of HPLC/ MS data, d Aspartimide was 
observed, e Heated at 50 ºC with Na2HPO4 at pH 5.8.
CFLFR (5.5.E.1)
6e CFLFP (5.5.F.1)











































7 CFLFa (5.5.G.1) 89 98:025– Na2HPO4/MeCND-Ala (a)
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deionized H2O, a pH range of 4-5 was observed (Figure 5.6F). Analysis of the rinses 
revealed that some hydrolysis of the peptide occurred during the H2O rinses. I envisioned 
that I could reach a higher pH more quickly using phosphate buffer (pH 7.2, Figure 5.6G). 
A pH of ~7 was reached after 5 rinses, with no observable hydrolysis detected in the 
rinses. Both resins from Figure 5.6F and 5.6G were then subjected to Na2HPO4 buffer 
(pH 7.2)/MeCN cyclization conditions. For the resin rinsed with water, I observed clean 
cyclization with no further hydrolysis. For the resin washed with buffer, I observed 
complete conversion, but both macrocyclized and hydrolyzed peptides were observed. I 
hypothesize that in both cases, the hydrolysis occurs during the rinse, but that the 
hydrolyzed peptide is more soluble in water/acetonitrile when the C-terminal acid is 
protonated. 
 
Figure 5.6. A) Reference pH images. B) Deionized water from the Stockdill lab (pH 6). C) 
0.2 M pH 7.2 Na2HPO4 buffer. D–G) Residual acid content of CFLFA–MeNbz-Gly-
ChemMatrix resin following TFA cleavage of the side-chain protecting groups and various 
rinsing protocols. D) First H2O rinse after performing rinse protocol A (3 x CH2Cl2; pH 0). 
E) First H2O rinse after rinsing with 3 x CH2Cl2 then 3 x DMF then CH2Cl2 (pH 1-2).  
F) After 20 rinses with DI water (pH 4-5). G) After 5 rinses with Na2HPO4 buffer (pH ~7). 
5.7 Synthesis of Challenging Substrates: Tetrapeptides 
 Having established guiding parameters for the composition of the N and C termini, 
as well as solving the resin pH problem, I turned my attention to the lengths of peptide 
accommodated by this chemistry. Tetracyclic and pentacyclic peptides are known to be 
challenging to cyclize.132 I had already observed excellent results in a pentacyclic system, 
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and thus turned my attention to the tetracyclic substrate CLFA. CLFA-MeDbz-G-HMBA-
ChemMatrix (5.7.A, Table 5.7.1, 100 mg) was rinsed with 10% Hünig’s base/NBP, and 
then the cyclization was performed in a fresh mixture of 10% Hünig’s base/NBP for 25 h 
(entry 1). Importantly, I observed complete conversion to the desired tetrapeptide lactam 
5.7.B with no hydrolysis. However, the NBP was cumbersome to remove by extraction, 
could not be lyophilized, and co-eluted with the desired peptide during purification (Figure 
5.7A). These conditions avoid hydrolysis and would be ideal for a side-chain anchored 
on-resin cyclization, where simple filtration of NBP would circumvent these challenges. 
Unfortunately, the difficulty of NBP removal from the product peptide ultimately renders 
its use impractical for a self-cleaving cyclization. Accordingly, I next performed the 
cyclization in Na2HPO4/MeCN after several H2O rinses were performed to bring the resin 
to pH 5-6 (Table 5.7.1, entry 2). While the cyclization was slower than the parent peptide 
CFLFA under the same conditions, requiring 8 h, I observed excellent reactivity and a 
clean crude trace (Figure 5.7B) in the formation of a challenging tetrapeptide. 
Lyophilization of the crude reaction mixture, resuspension of the peptide in MeOH/MeCN, 
and then re-lyophilization afforded the peptide with a crude yield of 39%. RP-HPLC 
purification led to isolation of the target tetrapeptide in 8% yield. It is noteworthy that the 
analogous ring contractive acyl transfer was prohibitive for O ® N acyl transfer in 
SLFA.146 I hypothesize that the longer C–S bond lengths facilitate the acyl transfer in the 
case of CLFA. Finally, I note that the residual acid discovered in Figure 5.6 plays a 
significant role in cyclization outcomes. Early in my studies, I performed rinsing protocol 
A (3 x CH2Cl2) on resin-bound 5.7.A (100 mg) and then immediately subjected it to 10% 
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Hünig’s base/NBP cyclization conditions (Table 5.7.1, entry 3). Minimal conversion was 
observed, with hydrolyzed peptide 5.7.C as the only observable product (Figure 5.7C). 
This result is of particular interest given the recent report by Olsen that tetrapeptides 
cannot be formed using their phosphate buffer conditions, which are similar to those in 
entry 2, where I observe clean cyclization with no hydrolysis or disulfide dimer 
formation.152 
Table 5.7.1. Synthesis of a tetrapeptide macrocycle, cyclo-CLFA, via various protocols. 
 
 
Figure 5.7. Crude RP-HPLC traces at 190 nm of CLFA cyclizations in Table 5.7.1. *The 
asterisked peak is not correlated with any peptide- or reagent-related mass spectrum.  
I next evaluated two additional tetrapeptides with my new rinse protocol (Table 
5.7.2). The C-terminal aspartic acid tetrapeptide132c macrocycle (5.7.F from 5.7.D) was 
isolated even though I previously was unable to cyclize a C-terminal aspartic acid peptide 
























a  Based on relative ratio of HPLC/MS data.
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A) From entry 1
B) From entry 2
C) From entry 3
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protocol C facilitated this reactivity (entry 2). However, I observed multiple peaks by 
PDA/MS corresponding to peptide 5.7.F, which means that macrocyclization at Asp is a 
limitation due to presumable aspartimide formation. I also performed the cyclization on 
peptide substrate CFPY161 (5.7.E, entry 3). However, I observed 9% head-to-tail dimer 
formation (5.7.G), which I had previously not observed. After 3 hours of agitation, I 
isolated a mixture of monomer and dimer in 61% crude yield with excellent HPLC crude 
purity. After subsequent silica gel chromatography, I isolated the cyclic monomer in 11% 
yield. 
Table 5.7.2. Synthesis of tetrapeptide macrocycles. 
 
5.8 Total Synthesis of Sunflower Trypsin Inhibitor-1 
 I next considered more lengthy peptides, such as the sunflower trypsin inhibitor 
(SFTI-1).134 Two SFTI-1 precursors 5.8.A and 5.8.B were synthesized, activated, and 
treated with global deprotection cocktail (TFA/TIPS/H2O). After removal of all protecting 
groups, the resins were rinsed with Rinse Protocol C, then treated with phosphate 
buffer/MeCN conditions. The peptides were cyclized to the reduced peptide 5.8.C and 















    rinse protocol C
3) Na2HPO4 (pH 7.2)/









a  Based on relative ratio of HPLC/MS data, b Based on loading prior to Boc-Cys(Trt)-OH coupling, c Contains mixure of 
monomer and dimer, d Five peaks corresponding to 432 m/z (5.7.F) are observed in the PDA/MS, we hypothesize this is a 
result of the aspartimide side reaction and dimer 5.7.G formation.
CLFA (5.7.A)



















































isolated in 4% yield from 5.8.A with excellent crude purity of 83%. The oxidized peptide 
5.8.D was isolated from 5.8.B with improved crude purity of 92%, which required no 
purification, isolating the peptide in 9% crude yield. I envisioned that the rapid cyclization 
of this transformation likely resulted from a thia-zip type mechanism,162 wherein the 
central cysteine reacted first due to its proximity to the activated C terminus, and the 
resulting thiolactone underwent trans-thiolactonization with the N-terminal cysteine 
followed by S to N acyl transfer. To probe this hypothesis, I synthesized an analog 
wherein the central cysteine was replaced with glycine, preventing internal 
thiolactonization. Consistent with my hypothesis, I observed that the glycine analog 
cyclized more slowly (3 h).81 This result is also suggestive that longer peptides will cyclize 
less efficiently in the absence of such an internal cysteine residue. 
Scheme 5.8. One-pot cyclization and oxidation of SFTI-1. 
 
5.9 Summary 
In summary, I have established several conditions under which the self-cleaving 
macrocyclization of fully deprotected N-acyl urea-linked peptides can be mediated by a 
free N-terminal cysteine. While traditional organic solvents fail to induce cyclization, 
several non-SVHC solvents as well as mixed buffer/acetonitrile conditions are effective. 
No epimerization is observed in phosphate buffer/MeCN conditions. An N-terminal Gly or 




3) Na2HPO4 (pH 7.2)















































branched primary amines. With the exception of proline, the reaction is tolerant of a wide 
variety of C-terminal residues. A highlight of the chemistry is that it can be performed on 
tetrapeptides to good effect using phosphate buffer/MeCN conditions, provided the resin 
is brought to a pH of 5-6 prior to cyclization. Additionally, the natural product sunflower 
trypsin inhibitor-1 (14 residues) was synthesized via this approach. Efforts to further 
investigate the utility of N-acyl urea activating groups for the advancement of peptide 
science are ongoing in the Stockdill laboratory. 
5.10 General Experimental Procedures 
5.10.1 Materials and Methods 
See Chapter Section 2.6 Materials and Methods under Section 2.6.1 General 
Experimental Procedures for Solid-Phase Peptide Synthesis, NMR, RP-HPLC-MS, and 
MeDbz Activation procedures.  
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Scheme 5.10.1. Calculating conversion of on-resin macrocyclization reactions.
 
On-Resin Trifluoroacetic Acid Deprotection: After MeDbz activation, 1-2 mL of 
(95:2.5:2.5) TFA/TIPS/H2O was added to the resin and agitated for 1 h (2 h for Arg(Pbf) 
containing sequences). After this time, the deprotection cocktail was removed and 
subsequently rinsed with CH2Cl2 (3 x 1 mL). 
Procedures for Resin Rinsing after TFA Treatment: 
Rinse Protocol A: After the TFA deprotection step was performed, the resin was rinsed 



























































































































1) Cyclization Reaction; Analytical Trace 1




cannot be used to 
determine conversion
3) HPLC Integration (if both cyclic peptide and peptide-NHBu are observed); conversions stated relative to SM (100% conversion = no 














was performed, the resin was rinsed with 0.2 M Na2HPO4 (pH 7.2) until the solution 
reached a pH of 7.2 (500 µL per rinse; 50 mg resin). Rinse Protocol C: After the TFA 
deprotection step was performed, the resin was rinsed with deionized H2O (pH ~6) until 
the solution reached a pH of 5-6 (1 mL per rinse; 100 mg resin). Rinse Protocol D: After 
the TFA deprotection step was performed, the resin was rinsed with 10% Hünig’s base/N-
butylpyrrolidinone (500 µL). 
General Procedure for Self-Cleaving Cyclization: After neutralization of the resin, 500 
µL-2 mL of (1:1) 0.2 M Na2HPO4 (pH 7.2)/MeCN was added to the resin and agitated at 
ambient temperature. Once the cyclization was complete, the reaction solution was 
collected and combined with additional MeCN resin rinses, frozen in LN2, and lyophilized 
to give a fluffy white solid. To avoid injecting large quantities of Na2HPO4 on the HPLC, 
the peptide was extracted with a mixture of MeOH/MeCN. The extraction solutions were 
combined and concentrated under reduced pressure, diluted with H2O/MeCN, frozen in 
LN2, and lyophilized to yield the crude peptide. The peptide was redissolved in H2O/MeCN 
and purified by semipreparative RP-HPLC. 
5.10.2 Experimental Procedures 
 
H-AKTWA-NHBu (5.1.B-NHBu). Table 5.1.1, entry 1: Crude peptide 5.1.A (20 mg) was 



















































ambient temperature for 30 min, followed by quenching with (1% TFA) 20% MeCN/H2O. 
The reaction was frozen and lyophilized. The solid was then dissolved in 20% MeCN/H2O 
and analyzed via RP-HPLC-MS. After 30 min, a ratio of >99:<1:<1 5.1.B/5.1.C/5.1.D was 
observed. 
 
H-AKTWA-NHBu (5.1.B-NHBu). Table 5.1.1, entry 2: Crude peptide 5.1.A (20 mg) was 
dissolved in 200 µL MeCN and subjected to 200 µL butylamine and 200 µL H2O. The 
reaction stirred at ambient temperature for 30 min, followed by quenching with (1% TFA) 
20% MeCN/H2O. The reaction was frozen and lyophilized. The solid was then dissolved 
in 20% MeCN/H2O and analyzed via RP-HPLC-MS. After 30 min, a ratio of 93:7:<1 
5.1.B/5.1.C/5.1.D was observed. 
 
H-AKTWA-NHCH2CCH (5.1.B-NHCH2CCH). Table 5.1.1, entry 3: Crude peptide 5.1.A 
(20 mg) was dissolved in 200 µL MeCN and subjected to 200 µL propargylamine. The 
reaction stirred at ambient temperature for 30 min, followed by quenching with (1% TFA) 





































































































in 20% MeCN/H2O and analyzed via RP-HPLC-MS. After 30 min, a ratio of >99:<1:<1 
5.1.B/5.1.C/5.1.D was observed. 
 
H-AKTWA-NHPh (5.1.B-NHPh). Table 5.1.1, entry 4: Crude peptide 5.1.A (20 mg) was 
dissolved in 200 µL MeCN and subjected to 200 µL aniline and 5 equiv DIEA. The reaction 
stirred at ambient temperature for 30 min, followed by quenching with (1% TFA) 20% 
MeCN/H2O. The reaction was frozen and lyophilized. The solid was then dissolved in 20% 
MeCN/H2O and analyzed via RP-HPLC-MS. After 30 min, a ratio of 8:<1:92 
5.1.B/5.1.C/5.1.D was observed. 
 
H-AKTWA-NHNH2 (5.1.B-NHNH2). Table 5.1.1, entry 5: Crude peptide 5.1.A (20 mg) 
was dissolved in 200 µL MeCN and subjected to 200 µL hydrazine. The reaction stirred 

























































































































MeCN/H2O. The reaction was frozen and lyophilized. The solid was then dissolved in 20% 
MeCN/H2O and analyzed via RP-HPLC-MS. After 30 min, a ratio of >99:<1:<1 
5.1.B/5.1.C/5.1.D was observed. 
 
H-AKTWA-NHOH (5.1.B-NHOH). Table 5.1.1, entry 6: Crude peptide 5.1.A (20 mg) was 
dissolved in 200 µL MeCN and subjected to 5 equiv hydroxylamine•HCl with 10 equiv 
DIEA. The reaction stirred at ambient temperature for 30 min, followed by quenching with 
(1% TFA) 20% MeCN/H2O. The reaction was frozen and lyophilized. The solid was then 
dissolved in 20% MeCN/H2O and analyzed via RP-HPLC-MS. After 30 min, a ratio of 
82:18:<1 5.1.B/5.1.C/5.1.D was observed. 
 
H-AKTWA-NMeOMe (5.1.B-NMeOMe). Table 5.1.1, entry 7: Crude peptide 5.1.A (20 
mg) was dissolved in 200 µL MeCN and subjected to 5 equiv hydroxylamine•HCl with 10 
equiv DIEA. The reaction stirred at ambient temperature for 30 min, followed by 


























































































































solid was then dissolved in 20% MeCN/H2O and analyzed via RP-HPLC-MS. After 30 
min, a ratio of <1:11:89 5.1.B/5.1.C/5.1.D was observed. 
 
H-AKTWA-OMe (5.1.B-OMe). Table 5.1.1, entry 8: Crude peptide 5.1.A (20 mg) was 
dissolved in 200 µL MeCN and subjected to 200 µL MeOH, followed by 5 equiv DIEA. 
The reaction stirred at ambient temperature for 30 min, followed by quenching with (1% 
TFA) 20% MeCN/H2O. The reaction was frozen and lyophilized. The solid was then 
dissolved in 20% MeCN/H2O and analyzed via RP-HPLC-MS. After 30 min, a ratio of 
42:<1:58 5.1.B/5.1.C/5.1.D was observed. 
 
cyclo-[AKTWA] (5.1.D). Table 5.1.1, entry 9: Crude peptide 5.1.A (20 mg) was 
dissolved in 200 µL MeCN and subjected to 10 equiv DIEA. The reaction stirred at 
ambient temperature for 30 min, followed by quenching with (1% TFA) 20% MeCN/H2O. 

















































































































and analyzed via RP-HPLC-MS. After 30 min, a ratio of <1:09:91 5.1.B/5.1.C/5.1.D was 
observed. 
 
cyclo-[AKTWA] (5.10.B). After isolation of the macrocycle from Table 5.1.1, entry 9, the 
head-to-tail macrocycle was synthetically made. The isolated macrocycle 5.1.D was 
spiked with the authentic head-to-tail macrocycle (5.10.B) and analyzed via RP-HPLC-
MS.  
 
H-AKTWA-b-amino alcohol (5.1.B-b-amino alcohol). Table 5.1.1, entry 10: Crude 
peptide 5.1.A (20 mg) was dissolved in 300 µL (1:2) THF/MeCN and subjected to 5 equiv 
NaBH4. The reaction stirred at ambient temperature for 30 min, followed by quenching 
with (1% TFA) 20% MeCN/H2O. The reaction was frozen and lyophilized. The solid was 
then dissolved in 20% MeCN/H2O and analyzed via RP-HPLC-MS. After 30 min, a ratio 


















2) HATU (2 equiv)
    DIPEA (4 equiv)


































































H-AKTWAG-OH (5.1.B-Gly-OH). Table 5.1.1, entry 11: H-Gly-OH (10 equiv) was 
weighed into a vial containing a stir bar. Peptide 5.1.A (20 mg, 25 µmol) was dissolved in 
300 µL of (2:1) MeCN/H2O and added to the amino acid. Then freshly distilled DIEA (11 
equiv) was added and allowed to stir at ambient temperature for 30 min. The reaction was 
quenched in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. After 30 min, a 
ratio of >99:<1:<1 5.1.B/5.1.C/5.1.D was observed. 
 
H-AKTWAA-OH (5.1.B-Ala-OH). Table 5.1.1, entry 12: H-Ala-OH (10 equiv) was 
weighed into a vial containing a stir bar. Peptide 5.1.A (20 mg, 25 µmol) was dissolved in 
300 µL of (2:1) MeCN/H2O and added to the amino acid. Then freshly distilled DIEA (11 



























































































































quenched in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. After 30 min, a 
ratio of <1:<1:>99 5.1.B/5.1.C/5.1.D was observed. 
 
H-AKTWAI-OH (5.1.B-Ile-OH). Table 5.1.1, entry 13: H-Ile-OH (10 equiv) was weighed 
into a vial containing a stir bar. Peptide 5.1.A (20 mg, 25 µmol) was dissolved in 300 µL 
of (2:1) MeCN/H2O and added to the amino acid. Then freshly distilled DIEA (11 equiv) 
was added and allowed to stir at ambient temperature for 30 min. The reaction was 
quenched in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. After 2 h, a ratio 












































































































































H-AKTWAP-OH (5.1.B-Pro-OH). Table 5.1.1, entry 14: H-Pro-OH (10 equiv) was 
weighed into a vial containing a stir bar. Peptide 5.1.A (20 mg, 25 µmol) was dissolved in 
300 µL of (2:1) MeCN/H2O and added to the amino acid. Then freshly distilled DIEA (11 
equiv) was added and allowed to stir at ambient temperature for 30 min. The reaction was 
quenched in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. After 6 h, a ratio 
of <1:<1:>99 5.1.B/5.1.C/5.1.D was observed. 
 
H-AKTPWA-NHBu (5.1.E.2-NHBu). Table 5.1.2, entry 1: Crude peptide 5.1.E.1 (5 mg) 
was dissolved in 100 µL (95:5) MeCN/H2O. Then 100 µL of butylamine was added the 
peptide solution and agitated for 30 min at ambient temperature, followed by quenching 
with (1% TFA) 20% MeCN/H2O. The reaction was immediately analyzed via RP-HPLC-
MS. After 30 min, a ratio of >99:<1:<1 5.1.E.2/5.1.E.3/5.1.E.4 was observed. 
 
H-AKTPWA-OMe (5.1.E.2-OMe). Table 5.1.2, entry 2: Crude peptide 5.1.E.1 (5 mg) was 




















































































































MeOH was added to the peptide solution and agitated for 30 min at ambient temperature, 
followed by quenching with (1% TFA) 20% MeCN/H2O. The reaction was immediately 
analyzed via RP-HPLC-MS. After 30 min, a ratio of 39:<1:61 5.1.E.2/5.1.E.3/5.1.E.4 was 
observed. 
 
cyclo-[AKTPWA] (5.1.E.4). Table 5.1.2, entry 3:  Crude peptide 5.1.E.1 (5 mg) was 
dissolved in 100 µL (95:5) MeCN/H2O. Then 11 equiv DIEA was added and agitated for 
30 min at ambient temperature, followed by quenching with (1% TFA) 20% MeCN/H2O. 
The reaction was immediately analyzed via RP-HPLC-MS. After 30 min, a ratio of 
<1:<1:>99 5.1.E.2/5.1.E.3/5.1.E.4 was observed. 
 
H-AKTGWA-NHBu (5.1.F.2-NHBu). Table 5.1.2, entry 4: Crude peptide 5.1.F.1 (5 
equiv) was dissolved in 100 µL (95:5) MeCN/H2O. Then 100 µL of butylamine was added 
to the peptide solution and agitated for 30 min at ambient temperature, followed by 
quenching with (1% TFA) 20% MeCN/H2O. The reaction was immediately analyzed via 






































































































H-AKTGWA-OMe (5.1.F.2-OMe). Table 5.1.2, entry 5: Crude peptide 5.1.F.1 (5 equiv) 
was dissolved in 100 µL (95:5) MeCN/H2O. Then a solution of 5 equiv DIEA and 100 µL 
of MeOH was added to the peptide solution and agitated for 30 min at ambient 
temperature, followed by quenching with (1% TFA) 20% MeCN/H2O. The reaction was 
immediately analyzed via RP-HPLC-MS. After 30 min, a ratio of 09:<1:88 
5.1.F.2/5.1.F.3/5.1.F.4 was observed. 
 
cyclo-[AKTGWA] (5.1.F.4). Table 5.1.2, entry 6: Crude peptide 5.1.F.1 (5 equiv) was 
dissolved in 100 µL (95:5) MeCN/H2O. Then 11 equiv DIEA was added and agitated for 
30 min at ambient temperature, followed by quenching with (1% TFA) 20% MeCN/H2O. 
The reaction was immediately analyzed via RP-HPLC-MS. After 30 min, a ratio of 





































































































H-ASTGWA-NHBu (5.1.G.2-NHBu). Table 5.1.2, entry 7: Crude peptide 5.1.G.1 (5 
equiv) was dissolved in 100 µL (95:5) MeCN/H2O. Then 100 µL of butylamine was added 
to the peptide solution and agitated for 30 min at ambient temperature, followed by 
quenching with (1% TFA) 20% MeCN/H2O. The reaction was immediately analyzed via 
RP-HPLC-MS. After 30 min, a ratio of >99:<1:<1 5.1.G.2/5.1.G.3/5.1.G.4 was observed. 
 
H-ASTGWA-OMe (5.1.G.2-OMe). Table 5.1.2, entry 8: Crude peptide 5.1.G.1 (5 equiv) 
was dissolved in 100 µL (95:5) MeCN/H2O. Then a solution of 5 equiv DIEA and 100 µL 
of MeOH was added to the peptide solution and agitated for 30 min at ambient 
temperature, followed by quenching with (1% TFA) 20% MeCN/H2O. The reaction was 
immediately analyzed via RP-HPLC-MS. After 30 min, a ratio of >99:<1:<1 







































































































cyclo-[ASTGWA] (5.1.G.4). Table 5.1.2, entry 9: Crude peptide 5.1.G.1 (5 equiv) was 
dissolved in 100 µL (95:5) MeCN/H2O. Then 11 equiv DIEA was added and agitated for 
30 min at ambient temperature, followed by quenching with (1% TFA) 20% MeCN/H2O. 
The reaction was immediately analyzed via RP-HPLC-MS. After 30 min, a ratio of 
<1:65:35 5.1.G.2/5.1.G.3/5.1.G.4 was observed. 
 
H-ACTGWA-NHBu (5.1.H.2-NHBu). Table 5.1.2, entry 10: Crude peptide 5.1.H.1 (5 
equiv) was dissolved in 100 µL (95:5) MeCN/H2O. Then 100 µL of butylamine was added 
to the peptide solution and agitated for 30 min at ambient temperature, followed by 
quenching with (1% TFA) 20% MeCN/H2O. The reaction was immediately analyzed via 




































































































H-ACTGWA-OMe (5.1.H.2-OMe). Table 5.1.2, entry 11: Crude peptide 5.1.H.1 (5 equiv) 
was dissolved in 100 µL (95:5) MeCN/H2O. Then a solution of 5 equiv DIEA and 100 µL 
of MeOH was added to the peptide solution and agitated for 30 min at ambient 
temperature, followed by quenching with (1% TFA) 20% MeCN/H2O. The reaction was 
immediately analyzed via RP-HPLC-MS. After 30 min, a ratio of >99:<1:<1 
5.1.H.2/5.1.H.3/5.1.H.4 was observed. 
 
cyclo-[ACTGWA] (5.1.H.4). Table 5.1.2, entry 12: Crude peptide 5.1.H.1 (5 equiv) was 
dissolved in 100 µL (95:5) MeCN/H2O. Then 11 equiv DIEA was added and agitated for 
30 min at ambient temperature, followed by quenching with (1% TFA) 20% MeCN/H2O. 
The reaction was immediately analyzed via RP-HPLC-MS. After 30 min, a ratio of 




































































































H-AYTGWA-NHBu (5.1.I.2-NHBu). Table 5.1.2, entry 13: Crude peptide 5.1.I.1 (5 equiv) 
was dissolved in 100 µL (95:5) MeCN/H2O. Then 100 µL of butylamine was added to the 
peptide solution and agitated for 30 min at ambient temperature, followed by quenching 
with (1% TFA) 20% MeCN/H2O. The reaction was immediately analyzed via RP-HPLC-
MS. After 30 min, a ratio of >99:<1:<1 5.1.I.2/5.1.I.3/5.1.I.4 was observed. 
 
H-AYTGWA-OMe (5.1.I.2-OMe). Table 5.1.2, entry 14: Crude peptide 5.1.I.1 (5 equiv) 
was dissolved in 100 µL (95:5) MeCN/H2O. Then a solution of 5 equiv DIEA and 100 µL 
of MeOH was added to the peptide solution and agitated for 30 min at ambient 
temperature, followed by quenching with (1% TFA) 20% MeCN/H2O. The reaction was 
immediately analyzed via RP-HPLC-MS. After 30 min, a ratio of >99:<1:<1 





































































































cyclo-[AYTGWA] (5.1.I.4). Table 5.1.2, entry 15: Crude peptide 5.1.I.1 (5 equiv) was 
dissolved in 100 µL (95:5) MeCN/H2O. Then 11 equiv DIEA was added and agitated for 
30 min at ambient temperature, followed by quenching with (1% TFA) 20% MeCN/H2O. 
The reaction was immediately analyzed via RP-HPLC-MS. After 30 min, a ratio of 
<1:19:81 5.1.I.2/5.1.I.3/5.1.I.4 was observed. 
 
 
Boc-C(Trt)FLFA-MeDbz-G-HMBA-TentaGel Resin (5.10.C). See the General 
Procedure for solid-phase peptide synthesis. TentaGel HMBA resin (200 mg, 0.2 mmol/g, 
0.04 mmol) was weighed into a 10-mL fritted SPPS vial and swelled in CH2Cl2 (2 mL) for 
15 min. The solvent was removed, and the resin underwent standard Fmoc-SPPS 


















































MeHN1) Fmoc-Gly-OH    HATU, DIPEA
    DMF
2) 20% Piperidine
3) Fmoc-MeDbz-OH
    HATU, DIPEA, DMF
1) 20% Piperidine
2) Fmoc-AA-OH
    HATU, DIPEA




























































and agitated MeCN with excess BuNH2 for 1.5 h. The solvent was removed, and directly 
analyzed via RP-HPLC-MS. 
Table 5.10.2. Macrocyclization on TentaGel Resin. 
 
 
Table 5.10.2, entry 1: Peptide 5.10.C (20 mg, 4 µmol) was weighed into a 2-mL reaction 
vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, the solvent was removed, 
and the resin was activated (see General Procedure). TFA/TIPS/H2O (95:2.5:2.5, 500 µL) 
was added to the resin and agitated for 30 min. The solvent was removed, and the resin 
was rinsed with CH2Cl2 (3 x). Then a 1:1 mixture of 0.2 M Na2HPO4 (pH 6.8) and MeCN 
(500 µL) was added to the resin. The reaction was heated to 50 ºC (µWave) for 2 h. The 



































– (1:1) Na2HPO4/MeCN (6.8)
(1:1) Na2HPO4/MeCN (7.2)–
50 <1:20
rt 6 51 <1:20
272
a All reactions were performed on 20 mg of resin using 200 µL of solvent, b Based on relative ratio of HPLC/MS 














    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 1:1 Na2HPO4 (0.2 M, pH 6.8)/







































Table 5.10.2, entry 2: Peptide 5.10.C (20 mg, 4 µmol) was weighed into a 2-mL reaction 
vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, the solvent was removed, 
and the resin was activated (see General Procedure). TFA/TIPS/H2O (95:2.5:2.5, 500 µL) 
was added to the resin and agitated for 30 min. The solvent was removed, and the resin 
was rinsed with CH2Cl2 (3 x). Then a 1:1 mixture of 0.2 M Na2HPO4 (pH 7.2) and MeCN 
(500 µL) was added to the resin. The reaction was agitated at ambient temperature for 6 
h. The solution was collected and directly analyzed via RP-HPLC-MS (51% conversion, 
<1:>99 of 5.3.B/5.3.C). 
 
Table 5.10.2, entry 3: Peptide 5.10.C (20 mg, 4 µmol) was weighed into a 2-mL reaction 
vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, the solvent was removed, 
and the resin was activated (see General Procedure). TFA/TIPS/H2O (95:2.5:2.5, 500 µL) 
was added to the resin and agitated for 30 min. The solvent was removed, and the resin 
5.10.C
1) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 1:1 Na2HPO4 (0.2 M, pH 7.2)/








































    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)






































was rinsed with CH2Cl2 (3 x). Then a mixture of 10% Hünig’s base in CH2Cl2 (500 µL) was 
added to the resin. The reaction was agitated at ambient temperature for 5 h. The solution 
was collected and directly analyzed via RP-HPLC-MS (>99% conversion, >99:<1 of 
5.3.B/5.3.C). 
 
Synthesis of cyclo[CFLFA] using standard in-solution intramolecular coupling. 
Fmoc-Ala TGT resin (60 mg, 0.046 mmol) was weighed into a 5-mL fritted reaction vessel. 
Linear, protected CFLFA peptide was synthesized using the General Procedure for 
SPPS. The peptide was cleaved from the resin using (1:1:3) TFE/AcOH/CH2Cl2 (2 mL for 
2 h). The solution was collected, reduced in volume using a constant stream of air, and 
the resulting residue was diluted with H2O, frozen in LN2, and lyophilized to yield the 
linear, protected peptide H-C(Trt)FLFA-OH (5.10.E, 7.2 mg, 19% crude yield from initial 
loading). Linear peptide (7.2 mg, 0.009 mmol) and HATU (1.2 equiv, 0.010 mmol) were 
dissolved in DMF (8.55 mL, 0.005 M). Then 3.6 equiv of DIEA was added to the reaction 
(0.005 mL, 0.031 mmol). The reaction was monitored my RP-HPLC-MS until the 
protected, cyclized peptide (5.3.B) was observed. Then an aliquot of the reaction was 
removed and immediately diluted with TFA/TIPS/H2O (95:2.5:2.5). This reaction was 
stirred at ambient temperature for 2 h. The solution was reduced in volume and the 
resulting residue was diluted with H2O and analyzed my RP-HPLC-MS (Figure A5-38). 
1) HATU (1.2 equiv)
    DIPEA (3.6 equiv)
    DMF (0.0005 M)
2) TFA/TIPS/H2O 






































    DIEA, DMF
3) TFE/AcOH/CH2Cl2 






Boc-C(Trt)FLFA-MeDbz-G-HMBA-ChemMatrix Resin (5.3.A). See the General 
Procedure for solid-phase peptide synthesis. AminoMethyl-ChemMatrix Resin (250 mg, 
0.56 mmol/g, 0.14 mmol) was weighed into a 10-mL fritted SPPS vial and swelled in 
CH2Cl2 (2 mL) for 15 min. The solvent was removed, and the resin underwent standard 
Fmoc-SPPS couplings and deprotections. To analyze the substrate, 10 mg of peptide 
was removed and agitated MeCN with excess BuNH2 for 1.5 h. The solvent was removed, 
and directly analyzed via RP-HPLC-MS. 
 
cyclo–[CFLFA] (5.3.B). Table 5.3, entry 1: Peptide 5.3.A (10 mg, 4 µmol) was weighed 
into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, the 
solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
O
FmocHN
MeHN 1) 20% Piperidine
2) Fmoc-AA-OH, HATU, DIPEA


























































    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)







































solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a mixture of 10% 
Hünig’s base in MeCN (500 µL) was added to the resin. The reaction was agitated at 
ambient temperature for 5 h. The solution was collected and directly analyzed via RP-
HPLC-MS (<1% conversion). 
 
cyclo–[CFLFA] (5.3.B). Table 5.3, entry 2: Peptide 5.3.A (10 mg, 4 µmol) was weighed 
into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, the 
solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a mixture of 10% 
Hünig’s base in CH2Cl2 (500 µL) was added to the resin. The reaction was agitated at 
ambient temperature for 5 h. The solution was collected and directly analyzed via RP-




    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)







































    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)






































cyclo–[CFLFA] (5.3.B). Table 5.3, entry 3: Peptide 5.3.A (10 mg, 4 µmol) was weighed 
into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, the 
solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a mixture of 10% 
Hünig’s base in EtOAc (500 µL) was added to the resin. The reaction was agitated at 
ambient temperature for 5 h. The solution was collected and directly analyzed via RP-
HPLC-MS (<1% conversion). 
 
cyclo–[CFLFA] (5.3.B). Table 5.3, entry 4: Peptide 5.3.A (10 mg, 4 µmol) was weighed 
into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, the 
solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a mixture of 10% 
Hünig’s base in 2-methyltetrahydrofuran (500 µL) was added to the resin. The reaction 
was agitated at ambient temperature for 5 h. The solution was collected and directly 
analyzed via RP-HPLC-MS. Although thiolactone and lactam are observed in the reaction 
5.3.A 5.3.B
1) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 10% DIEA/
     2-methyltetrahydrofuran 






































mixture, the conversion cannot be determined. When the cyclization mixture is combined 
with the butylamine cleavage, no cyclopeptide was observed. 
 
cyclo–[CFLFA] (5.3.B). Table 5.3, entry 5: Peptide 5.3.A (10 mg, 4 µmol) was weighed 
into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, the 
solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a mixture of 10% 
Hünig’s base in NMP (500 µL) was added to the resin. The reaction was agitated at 
ambient temperature for 5 h. The solution was collected and directly analyzed via RP-
HPLC-MS (trace conversion). **conversion cannot be determined  
 
cyclo–[CFLFA] (5.3.B). Table 5.3, entry 6: Peptide 5.3.A (10 mg, 4 µmol) was weighed 
into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, the 
5.3.A 5.3.B
1) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)







































    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 10% DIEA/
     4-formylmorpholine 






































solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a mixture of 10% 
Hünig’s base in 4-formylmorpholine (500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (91% conversion, >20:1 of 5.3.B:5.3.C). 
 
cyclo–[CFLFA] (5.3.B). Table 5.3, entry 7: Peptide 5.3.A (10 mg, 4 µmol) was weighed 
into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, the 
solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a mixture of 10% 
Hünig’s base in 1-butyl-2-pyrrolidinone (250 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (>99% conversion, >20:1 of 5.3.B/5.3.C). 
5.3.A 5.3.B
1) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 10% DIEA/
     1-butyl-2-pyrrolidinone







































cyclo–[CFLFA] (5.3.B). Table 5.3, entry 8: Peptide 5.3.A (10 mg, 4 µmol) was weighed 
into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, the 
solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a mixture of 10% 
Hünig’s base in N,N-dimethyldecanamide (250 µL) was added to the resin. The reaction 
was agitated at ambient temperature for 5 h. The solution was collected and directly 
analyzed via RP-HPLC-MS (>99% conversion, >20:1 of 5.3.B/5.3.C). 
 
cyclo–[CFLFA] (5.3.B). Table 5.3, entry 9: Peptide 5.3.A (10 mg, 4 µmol) was weighed 
into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, the 
solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
5.3.A 5.3.B
1) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 10% DIEA/
     N,N-dimethyldecanamide







































    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 10% DIEA/
     2,4,6-collidine






































solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a mixture of 10% 
Hünig’s base in 2,4,6-collidine (250 µL) was added to the resin. The reaction was agitated 
at ambient temperature for 5 h. The solution was collected and directly analyzed via RP-
HPLC-MS (>99% conversion, >20:1 of 5.3.B/5.3.C). 
 
cyclo–[CFLFA] (5.3.B). Table 5.3, entry 5.10.2: Peptide 5.3.A (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then 250 µL of 2,4,6-
collidine was added to the resin. The reaction was agitated at ambient temperature for 5 




    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 2,4,6-collidine







































    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) TCEP, Guanidine, MPAA






































cyclo–[CFLFA] (5.3.B). Table 5.3, entry 10: Peptide 5.3.A (10 mg, 4 µmol) was weighed 
into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, the 
solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then 500 µL of NCL 
buffer, which was made using a previously established procedure,163 was added to the 
resin. The reaction vessel was sealed and purged with Ar. The reaction was agitated at 
ambient temperature for 5 h under Ar. The solution was collected and directly analyzed 
via RP-HPLC-MS (>99% conversion, >99:1 of 5.3.B/5.3.C). 
 
cyclo–[CFLFA] (5.3.B). Table 5.3, entry 11: Peptide 5.3.A (10 mg, 4 µmol) was weighed 
into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, the 
solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then 250 µL of 0.2 M 
Na2HPO4 (pH 7.2) was added to the resin. The reaction was agitated at ambient 
temperature for 5 h. The solution was collected and directly analyzed via RP-HPLC-MS. 
No product was observed in the initial collection, but cyclized peptide was observed in the 
5.3.A 5.3.B
1) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)






































butylamine rinse, which indicates that MeCN is required to remove the peptide from the 
resin (69% conversion). 
 
cyclo–[CFLFA] (5.3.B). Table 5.3, entry 12a: Peptide 5.3.A (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a 1:1 mixture of 
0.2 M Na2HPO4 (pH 7.2) and MeCN (500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (>99% conversion, >99:<1 of 5.3.B/5.3.C). 
 
cyclo–[CFLFA] (5.3.B). Table 5.3, entry 12b: Peptide 5.3.A (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
5.3.A 5.3.B
1) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 0.2 M Na2HPO4 (pH 7.2)







































    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 0.2 M Na2HPO4 (pH 7)






































the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a 1:1 mixture of 
0.2 M Na2HPO4 (pH 7) and MeCN (500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (>99% conversion, >20:1 of 5.3.B/5.3.C). 
 
cyclo–[CFLFA] (5.3.B). Table 5.3, entry 12c: Peptide 5.3.A (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a 1:1 mixture of 
0.2 M Na2HPO4 (pH 6.8) and MeCN (500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (>99% conversion, >20:1 of 5.3.B/5.3.C). 
5.3.A 5.3.B
1) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 0.2 M Na2HPO4 (pH 6.8)







































cyclo–[CFLFA] (5.3.B). Table 5.3, entry 12d: Peptide 5.3.A (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a 1:1 mixture of 
0.2 M Na2HPO4 (pH 6.5) and MeCN (500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (>99% conversion, >99:<1 of 5.3.B/5.3.C). 
 
 
Boc-GFLFA-MeDbz-G-HMBA-ChemMatrix Resin (5.4.A.1). See the General 
Procedure for solid-phase peptide synthesis. AminoMethyl-ChemMatrix Resin (100 mg, 
0.56 mmol/g, 0.056 mmol) was weighed into a 10-mL fritted SPPS vial and swelled in 
5.3.A 5.3.B
1) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 0.2 M Na2HPO4 (pH 6.5)







































MeHN 1) 20% Piperidine
2) Fmoc-AA-OH, HATU, DIPEA



























































CH2Cl2 (2 mL) for 15 min. The solvent was removed, and the resin underwent standard 
Fmoc-SPPS couplings and deprotections. To analyze the substrate, 10 mg of peptide 
was removed and agitated MeCN with excess BuNH2 for 1.5 h. The solvent was removed, 
and directly analyzed via RP-HPLC-MS. 
 
 
Fmoc-K(Boc)FLFA-MeDbz-G-HMBA-ChemMatrix Resin (5.4.B.1). See the General 
Procedure for solid-phase peptide synthesis. AminoMethyl-ChemMatrix Resin (100 mg, 
0.56 mmol/g, 0.056 mmol) was weighed into a 10-mL fritted SPPS vial and swelled in 
CH2Cl2 (2 mL) for 15 min. The solvent was removed, and the resin underwent standard 
Fmoc-SPPS couplings and deprotections. To analyze the substrate, 10 mg of peptide 
was removed and agitated MeCN with excess BuNH2 for 1.5 h. The solvent was removed, 




MeHN 1) 20% Piperidine
2) Fmoc-AA-OH, HATU, DIPEA































































MeHN 1) 20% Piperidine
2) Fmoc-AA-OH, HATU, DIPEA

































Fmoc-AFLFA-MeDbz-G-HMBA-ChemMatrix Resin (5.4.C.1). See the General 
Procedure for solid-phase peptide synthesis. AminoMethyl-ChemMatrix Resin (250 mg, 
0.56 mmol/g, 0.14 mmol) was weighed into a 10-mL fritted SPPS vial and swelled in 
CH2Cl2 (2 mL) for 15 min. The solvent was removed, and the resin underwent standard 
Fmoc-SPPS couplings and deprotections. To analyze the substrate, 10 mg of peptide 
was removed and agitated MeCN with excess BuNH2 for 1.5 h. The solvent was removed, 
and directly analyzed via RP-HPLC-MS. 
 
 
Boc-S(tBu)FLFA-MeDbz-G-HMBA-ChemMatrix Resin (5.4.D.1). See the General 
Procedure for solid-phase peptide synthesis. AminoMethyl-ChemMatrix Resin (100 mg, 
0.56 mmol/g, 0.056 mmol) was weighed into a 10-mL fritted SPPS vial and swelled in 
CH2Cl2 (2 mL) for 15 min. The solvent was removed, and the resin underwent standard 






























MeHN 1) 20% Piperidine
2) Fmoc-AA-OH, HATU, DIPEA





























































was removed and agitated MeCN with excess BuNH2 for 1.5 h. The solvent was removed, 
and directly analyzed via RP-HPLC-MS. 
 
 
Boc-GFFGTFF-MeDbz-G-HMBA-ChemMatrix Resin (5.4.G.1). See the General 
Procedure for solid-phase peptide synthesis. AminoMethyl-ChemMatrix Resin (100 mg, 
0.56 mmol/g, 0.056 mmol) was weighed into a 10-mL fritted SPPS vial and swelled in 
CH2Cl2 (2 mL) for 15 min. The solvent was removed, and the resin underwent standard 
Fmoc-SPPS couplings and deprotections. To analyze the substrate, 10 mg of peptide 
was removed and agitated MeCN with excess BuNH2 for 1.5 h. The solvent was removed, 





MeHN 1) 20% Piperidine
2) Fmoc-AA-OH, HATU, DIPEA





















































































































































Fmoc-K(Boc)FFGTFF-MeDbz-G-HMBA-ChemMatrix Resin (5.4.H.1). See the General 
Procedure for solid-phase peptide synthesis. AminoMethyl-ChemMatrix Resin (100 mg, 
0.56 mmol/g, 0.056 mmol) was weighed into a 10-mL fritted SPPS vial and swelled in 
CH2Cl2 (2 mL) for 15 min. The solvent was removed, and the resin underwent standard 
Fmoc-SPPS couplings and deprotections. To analyze the substrate, 10 mg of peptide 
was removed and agitated MeCN with excess BuNH2 for 1.5 h. The solvent was removed, 
and directly analyzed via RP-HPLC-MS. 
 
 
Boc-AFFGTFF-MeDbz-G-HMBA-ChemMatrix Resin (5.4.I.1). See the General 
Procedure for solid-phase peptide synthesis. AminoMethyl-ChemMatrix Resin (100 mg, 
0.56 mmol/g, 0.056 mmol) was weighed into a 10-mL fritted SPPS vial and swelled in 
CH2Cl2 (2 mL) for 15 min. The solvent was removed, and the resin underwent standard 
Fmoc-SPPS couplings and deprotections. To analyze the substrate, 10 mg of peptide 
was removed and agitated MeCN with excess BuNH2 for 1.5 h. The solvent was removed, 















































































Boc-S(tBu)FFGTFF-MeDbz-G-HMBA-ChemMatrix Resin (5.4.J.1). See the General 
Procedure for solid-phase peptide synthesis. AminoMethyl-ChemMatrix Resin (100 mg, 
0.56 mmol/g, 0.056 mmol) was weighed into a 10-mL fritted SPPS vial and swelled in 
CH2Cl2 (2 mL) for 15 min. The solvent was removed, and the resin underwent standard 
Fmoc-SPPS couplings and deprotections. To analyze the substrate, 10 mg of peptide 
was removed and agitated MeCN with excess BuNH2 for 1.5 h. The solvent was removed, 
and directly analyzed via RP-HPLC-MS. 
 
Boc-aFFGTFF-MeDbz-G-HMBA-ChemMatrix Resin (5.4.K.1). See the General 

























































































































































0.56 mmol/g, 0.056 mmol) was weighed into a 10-mL fritted SPPS vial and swelled in 
CH2Cl2 (2 mL) for 15 min. The solvent was removed, and the resin underwent standard 
Fmoc-SPPS couplings and deprotections. To analyze the substrate, 10 mg of peptide 
was removed and agitated MeCN with excess BuNH2 for 1.5 h. The solvent was removed, 
and directly analyzed via RP-HPLC-MS. 
 
Boc-s(tBu)FFGTFF-MeDbz-G-HMBA-ChemMatrix Resin (5.4.L.1). See the General 
Procedure for solid-phase peptide synthesis. AminoMethyl-ChemMatrix Resin (100 mg, 
0.56 mmol/g, 0.056 mmol) was weighed into a 10-mL fritted SPPS vial and swelled in 
CH2Cl2 (2 mL) for 15 min. The solvent was removed, and the resin underwent standard 
Fmoc-SPPS couplings and deprotections. To analyze the substrate, 10 mg of peptide 
was removed and agitated in MeCN with excess BuNH2 for 1.5 h. The solvent was 















































































cyclo–[GFLFA] (5.4.A.2). Table 5.4.1, entry 1: Peptide 5.4.A.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a 1:1 mixture of 
0.2 M Na2HPO4 (pH 7.2) and MeCN (500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (84% conversion, >99:<1 of 5.4.A.2/5.4.A.3). 
 
cyclo–[KFLFA] (5.4.B.2). Table 5.4.1, entry 2: Peptide 5.4.B.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a 1:1 mixture of 
1) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 0.2 M Na2HPO4 (pH 7.2)/













































































2) Boc2O, DIPEA, DMF 
3) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
4) TFA/TIPS/H2O (95:2.5:2.5)
5) 0.2 M Na2HPO4 (pH 7.2)/
    MeCN, 5 h
H2N
 212 
0.2 M Na2HPO4 (pH 7.2) and MeCN (500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (23% conversion, 17:83 of 5.4.B.2/5.4.B.3). 
 
cyclo–[AFLFA] (5.4.C.2). Table 5.4.1, entry 3: Peptide 5.4.C.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a 1:1 mixture of 
0.2 M Na2HPO4 (pH 7.2) and MeCN (500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (4% conversion, <1:>99 of 5.4.C.2/5.4.C.3). 
 
cyclo–[SFLFA] (5.4.D.2). Table 5.4.1, entry 4: Peptide 5.4.D.1 (10 mg, 4 µmol) was 




2) Boc2O, DIPEA, DMF
3)4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
4) TFA/TIPS/H2O (95:2.5:2.5)
5) 0.2 M Na2HPO4 (pH 7.2)/





































    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 0.2 M Na2HPO4 (pH 7.2)/









































the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a 1:1 mixture of 
0.2 M Na2HPO4 (pH 7.2) and MeCN (500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (>99% conversion, 03:97 of 5.4.D.2/5.4.D.3). 
 
cyclo–[aFLFA] (5.4.E.2). Table 5.4.1, entry 5: Peptide 5.4.E.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a 1:1 mixture of 
0.2 M Na2HPO4 (pH 7.2) and MeCN (500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 




    then 1 M DIPEA/DMF
2) TFA:TIPS:H2O (95:2.5:2.5)
3) 0.2 M Na2HPO4 (pH 7.2)/






































cyclo–[sFLFA] (5.4.F.2). Table 5.4.1, entry 6: Peptide 5.4.F.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was agitated in 1 mL 20% piperidine/DMF for 15 
min. The solvent was removed, after this time and rinsed with CH2Cl2 (1 mL x 3). The 
resin was then agitated in a mixture of Boc anhydride (20 equiv), DIPEA (20 equiv), in 
DMF for 12 h. The resin was then rinsed with CH2Cl2 (1 mL x 3) and activated (see 
General Procedure). TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and 
agitated for 30 min. The solvent was removed, and the resin was rinsed with CH2Cl2 (3 
x). Then a 1:1 mixture of 0.2 M Na2HPO4 (pH 7.2) and MeCN (500 µL) was added to the 
resin. The reaction was agitated at ambient temperature for 5 h. The solution was 






2) Boc2O, DIPEA, DMF
3) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
4) TFA/TIPS/H2O (95:2.5:2.5)
5) 0.2 M Na2HPO4 (pH 7.2)/










































    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 0.2 M Na2HPO4 (pH 7.2)/













































cyclo–[GFFGTFF] (5.4.G.2). Table 5.4.1, entry 7: Peptide 5.4.G.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a mixture of 0.2 
M Na2HPO4 (pH 7.2)/MeCN (1:1, 500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (97% conversion, 71:29 of 5.4.G.2/5.4.G.3).  
 
cyclo–[KFFGTFF] (5.4.H.2). Table 5.4.1, entry 8: Peptide 5.4.H.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was agitated in 1 mL 20% piperidine/DMF for 15 
min. The solvent was removed and rinsed with CH2Cl2 (1 mL x 3). The resin was then 
agitated in a mixture of Boc anhydride (20 equiv), DIPEA (20 equiv), in DMF for 12 h. The 
resin was then rinsed with CH2Cl2 (1 mL x 3) and activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 





















































2) Boc2O, DIPEA, DMF 
3) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
4) TFA/TIPS/H2O (95:2.5:2.5)
5) 0.2 M Na2HPO4 (pH 7.2)/
    MeCN, 5 h
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of 0.2 M Na2HPO4 (pH 7.2) and MeCN (500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (61% conversion, 98:02 of 5.4.H.2/5.4.H.3).  
 
cyclo–[AFFGTFF] (5.4.I.2). Table 5.4.1, entry 9: Peptide 5.4.I.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a mixture of 0.2 
M Na2HPO4 (pH 7.2)/MeCN (1:1, 500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS. Exclusively hydrolyzed peptide was observed in the cyclization 
solution, however a minor amount of desired cyclic peptide was observed in the 


































    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 0.2 M Na2HPO4 (pH 7.2)/





















cyclo–[SFFGTFF] (5.4.J.2). Table 5.4.1, entry 10: Peptide 5.4.J.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a mixture of 0.2 
M Na2HPO4 (pH 7.2)/MeCN (1:1, 500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (37% conversion, 04:96 of 5.4.J.2/5.4.J.3).  
 
cyclo–[aFFGTFF] (5.4.K.2). Table 5.4.1, entry 11: Peptide 5.4.K.1 (10 mg, 4 µmol) was 


































    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 0.2 M Na2HPO4 (pH 7.2)/




















































    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 0.2 M Na2HPO4 (pH 7.2)/


















the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a mixture of 0.2 
M Na2HPO4 (pH 7.2)/MeCN (1:1, 500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (57% conversion, 03:97 of 5.4.K.2/5.4.K3).  
 
cyclo–[sFFGTFF] (5.4.L.2). Table 5.4.1, entry 12: Peptide 5.4.L.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a mixture of 0.2 
M Na2HPO4 (pH 7.2)/MeCN (1:1, 500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 


































    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 0.2 M Na2HPO4 (pH 7.2)/




















cyclo–[KFLFA] (5.4.B.2). Table 5.4.2, entry 1: Peptide 5.4.B.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a solution of 10% 
Hünig’s base in N-butyl-pyrrolidinone was added to the resin. The reaction was agitated 
at ambient temperature for 5 h. The solution was collected and directly analyzed via RP-
HPLC-MS (91% conversion, 95:05 of 5.4.B.2/5.4.B.3). 
 
cyclo–[SFLFA] (5.4.D.2). Table 5.4.2, entry 2: Peptide 5.4.D.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
1) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 10% DIPEA/N-butyl-pyrrolidinone












































    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 10% DIPEA/N-butyl-pyrrolidinone







































solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a solution of 10% 
Hünig’s base in N-butyl-pyrrolidinone was added to the resin. The reaction was agitated 
at ambient temperature for 5 h. The solution was collected and directly analyzed via RP-
HPLC-MS (<1% conversion). 
 
cyclo–[GFFGTFF] (5.4.G.2). Table 5.4.2, entry 3: Peptide 5.4.G.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a solution of 10% 
Hünig’s base in N-butyl-pyrrolidinone was added to the resin. The reaction was agitated 
at ambient temperature for 5 h. The solution was collected and directly analyzed via RP-
HPLC-MS (>99% conversion, >99:<1 of 5.4.G.2/5.4.G.3). Although 822 m/z appears in 
the MS, this elutes with 804 m/z which implies it is the [M + H2O]+ of cyclo[GFFGTFF]. 

























































cyclo–[SFFGTFF] (5.4.J.2). Table 5.4.2, entry 4: Peptide 5.4.J.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a solution of 10% 
Hünig’s base in N-butyl-pyrrolidinone was added to the resin. The reaction was agitated 
at ambient temperature for 5 h. The solution was collected and directly analyzed via RP-
HPLC-MS (23% conversion, 29:71 of 5.4.J.2/5.4.J.3). 
 
cyclo–[aFFGTFF] (5.4.K.2). Table 5.4.2, entry 5: Peptide 5.4.K.1 (10 mg, 4 µmol) was 










































































































the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a solution of 10% 
Hünig’s base in N-butyl-pyrrolidinone was added to the resin. The reaction was agitated 
at ambient temperature for 5 h. The solution was collected and directly analyzed via RP-
HPLC-MS (79% conversion, 73:27 of 5.4.K.2/5.4.K3). 
 
 
Boc-C(Trt)FLFG-MeDbz-G-HMBA-ChemMatrix Resin (5.5.A.1). See the General 
Procedure for solid-phase peptide synthesis. MeDbz-G-HMBA-ChemMatrix Resin (100 
mg, 0.56 mmol/g, 0.056 mmol) was weighed into a 10-mL fritted SPPS vial and swelled 
in CH2Cl2 (2 mL) for 15 min. The solvent was removed, and the resin underwent standard 
Fmoc-SPPS couplings and deprotections. To analyze the substrate, 10 mg of peptide 
was removed and agitated MeCN with excess BuNH2 for 1.5 h. The solvent was removed, 




MeHN 1) 20% Piperidine
2) Fmoc-AA-OH, HATU, DIPEA




























































MeHN 1) 20% Piperidine
2) Fmoc-AA-OH, HATU, DIPEA


































Boc-C(Trt)FLFI-MeDbz-G-HMBA-ChemMatrix Resin (5.5.B.1). See the General 
Procedure for solid-phase peptide synthesis. MeDbz-G-HMBA-ChemMatrix Resin (100 
mg, 0.56 mmol/g, 0.056 mmol) was weighed into a 10-mL fritted SPPS vial and swelled 
in CH2Cl2 (2 mL) for 15 min. The solvent was removed, and the resin underwent standard 
Fmoc-SPPS couplings and deprotections. To analyze the substrate, 10 mg of peptide 
was removed and agitated MeCN with excess BuNH2 for 1.5 h. The solvent was removed, 
and directly analyzed via RP-HPLC-MS. 
 
 
Boc-C(Trt)FLFD(OtBu)-MeDbz-G-HMBA-ChemMatrix Resin (5.5.C.1). See the 
General Procedure for solid-phase peptide synthesis. MeDbz-G-HMBA-ChemMatrix 
Resin (100 mg, 0.56 mmol/g, 0.056 mmol) was weighed into a 10-mL fritted SPPS vial 
and swelled in CH2Cl2 (2 mL) for 15 min. The solvent was removed, and the resin 




























MeHN 1) 20% Piperidine
2) Fmoc-AA-OH, HATU, DIPEA






























































10 mg of peptide was removed and agitated MeCN with excess BuNH2 for 1.5 h. The 
solvent was removed, and directly analyzed via RP-HPLC-MS. 
 
 
Boc-C(Trt)FLFK(Boc)-MeDbz-G-HMBA-ChemMatrix Resin (5.5.D.1). See the General 
Procedure for solid-phase peptide synthesis. MeDbz-G-HMBA-ChemMatrix Resin (100 
mg, 0.56 mmol/g, 0.056 mmol) was weighed into a 10-mL fritted SPPS vial and swelled 
in CH2Cl2 (2 mL) for 15 min. The solvent was removed, and the resin underwent standard 
Fmoc-SPPS couplings and deprotections. To analyze the substrate, 10 mg of peptide 
was removed and agitated MeCN with excess BuNH2 for 1.5 h. The solvent was removed, 





MeHN 1) 20% Piperidine
2) Fmoc-AA-OH, HATU, DIPEA





























































MeHN 1) 20% Piperidine
2) Fmoc-AA-OH, HATU, DIPEA





































































Boc-C(Trt)FLFR(Pbf)-MeDbz-G-HMBA-ChemMatrix Resin (5.5.E.1). See the General 
Procedure for solid-phase peptide synthesis. MeDbz-G-HMBA-ChemMatrix Resin (100 
mg, 0.56 mmol/g, 0.056 mmol) was weighed into a 10-mL fritted SPPS vial and swelled 
in CH2Cl2 (2 mL) for 15 min. The solvent was removed, and the resin underwent standard 
Fmoc-SPPS couplings and deprotections. To analyze the substrate, 10 mg of peptide 
was removed and agitated MeCN with excess BuNH2 for 1.5 h. The solvent was removed, 
and directly analyzed via RP-HPLC-MS. 
 
 
Boc-C(Trt)FLFP-MeDbz-G-HMBA-ChemMatrix Resin (5.5.F.1). See the General 
Procedure for solid-phase peptide synthesis. MeDbz-G-HMBA-ChemMatrix Resin (100 
mg, 0.56 mmol/g, 0.056 mmol) was weighed into a 10-mL fritted SPPS vial and swelled 
in CH2Cl2 (2 mL) for 15 min. The solvent was removed, and the resin underwent standard 
Fmoc-SPPS couplings and deprotections. To analyze the substrate, 10 mg of peptide 
was removed and agitated MeCN with excess BuNH2 for 1.5 h. The solvent was removed, 
and directly analyzed via RP-HPLC-MS. 
O
FmocHN
MeHN 1) 20% Piperidine
2) Fmoc-AA-OH, HATU, DIPEA




























































Boc-C(Trt)FLFa-MeDbz-G-HMBA-ChemMatrix Resin (5.5.G.1). See the General 
Procedure for solid-phase peptide synthesis. MeDbz-G-HMBA-ChemMatrix Resin (100 
mg, 0.56 mmol/g, 0.056 mmol) was weighed into a 10-mL fritted SPPS vial and swelled 
in CH2Cl2 (2 mL) for 15 min. The solvent was removed, and the resin underwent standard 
Fmoc-SPPS couplings and deprotections. To analyze the substrate, 10 mg of peptide 
was removed and agitated MeCN with excess BuNH2 for 1.5 h. The solvent was removed, 
and directly analyzed via RP-HPLC-MS. 
 
cyclo-[CFLFG] (5.5.A.2). Table 5.5, entry 1: Peptide 5.5.A.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 




























MeHN 1) 20% Piperidine
2) Fmoc-AA-OH, HATU, DIPEA


































    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 0.2 M Na2HPO4 (pH 7.2)/











































solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a 1:1 mixture of 
0.2 M Na2HPO4 (pH 7.2) and MeCN (500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (89% conversion, >99:<1 5.5.A.2/5.5.A.3). 
 
cyclo-[CFLFI] (5.5.B.2). Table 5.5, entry 2: Peptide 5.5.B.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a 1:1 mixture of 
0.2 M Na2HPO4 (pH 7.2) and MeCN (500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (78% conversion, >99:<1 5.5.B.2/5.5.B.3). 
 
1) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 0.2 M Na2HPO4 (pH 7.2)/











































    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 10% DIPEA/N-butyl-pyrrolidinone














































cyclo-[CFLFD] (5.5.C.2). Table 5.5, entry 3: Peptide 5.5.C.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a 1:1 mixture of 
0.2 M Na2HPO4 (pH 7.2) and MeCN (500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (>99% conversion, >99:<1 5.5.C.2/5.5.C.3).  
 
cyclo-[CFLFD] (5.5.C.2). Table 5.5, entry 5.10.2: Peptide 5.5.C.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a 1:1 mixture of 
0.2 M Na2HPO4 (pH 7.2) and MeCN (500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS. No peptide was observed. 
5.5.C.1 5.5.C.2
1) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 0.2 M Na2HPO4 (pH 7.2)/













































cyclo-[CFLFK] (5.5.D.2). Table 5.5, entry 4: Peptide 5.5.D.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a 1:1 mixture of 
0.2 M Na2HPO4 (pH 7.2) and MeCN (500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (>99% conversion, >99:<1 5.5.D.2/5.5.D.3). 
 
cyclo-[CFLFR] (5.5.E.2). Table 5.5, entry 5: Peptide 5.5.E.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
1) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 0.2 M Na2HPO4 (pH 7.2)/











































    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 0.2 M Na2HPO4 (pH 7.2)/




















































solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a 1:1 mixture of 
0.2 M Na2HPO4 (pH 7.2) and MeCN (500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (>99% conversion, >99:<1 5.5.E.2/5.5.E.3). 
 
cyclo-[CFLFP] (5.5.F.2). Table 5.5, entry 6: Peptide 5.5.F.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a 1:1 mixture of 
0.2 M Na2HPO4 (pH 7.2) and MeCN (500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS (<1% conversion). 
 
1) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 0.2 M Na2HPO4 (pH 5.8)/











































    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) 0.2 M Na2HPO4 (pH 7.2)/












































cyclo-[CFLFa] (5.5.G.2). Table 5.5, entry 7: Peptide 5.5.G.1 (10 mg, 4 µmol) was 
weighed into a 2-mL reaction vial and swelled in 500 µL CH2Cl2 for 30 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 30 min. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x). Then a 1:1 mixture of 
0.2 M Na2HPO4 (pH 7.2) and MeCN (500 µL) was added to the resin. The reaction was 
agitated at ambient temperature for 5 h. The solution was collected and directly analyzed 
via RP-HPLC-MS. This substrate was used for the epimerization essay (Figure A5-35). 
The reaction went to completion (>99% conversion) with a ratio of 98:2 of 5.5.G.2/5.5.G.3. 
 
Deprotected and activated peptide (50 mg, 0.028 mmol) was rinsed with H2O (500 µL 
each rinse) until a pH of ~4 was obtained.  Then 2 mL of (1:1) 0.2 M Na2HPO4 (pH 
7.2)/MeCN was added to the resin and agitated for 5 h.  The solution was collected, and 
the resin was rinsed with 1:1 MeCN/H2O to remove any remaining cyclic peptide. The pH 
was determined for each rinse. The rinse was also monitored by direct inject to determine 
any peptide loss in the form of hydrolysis. Hydrolysis was observed in water rinses. 
1) Rinse Protocol C
























Deprotected and activated peptide (50 mg, 0.028 mmol) was rinsed with 0.2 M Na2HPO4 
buffer at pH 7.2 (500 µL each rinse) until a pH of 7.2 was obtained.  Then 2 mL of (1:1) 
0.2 M Na2HPO4 (pH 7.2)/MeCN was added to the resin and agitated for 5 h.  The solution 
was collected, and the resin was rinsed with 1:1 MeCN/H2O to remove any remaining 
cyclic peptide. The pH was determined for each rinse. The rinse was also monitored by 
direct inject to determine any peptide loss in the form of hydrolysis. No hydrolysis was 
observed in phosphate buffer rinses. 
 
cyclo-[CLFA] (5.7.B). Table 5.7.1, entry 1: Peptide 5.7.A (100 mg, 0.034 mmol) was 
weighed into a 10-mL reaction vial and swelled in 2 mL CH2Cl2 for 20 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 2 h. The 
solvent was removed, and the resin was rinsed with 10% DIEA/NBP (500 µL, Rinse 
protocol D).  Then 2 mL of 10% Hünig’s base/NBP was added to the resin and agitated 
for 12 h at ambient temperature.  The solution was collected, and the resin was rinsed 
1) Rinse Protocol B






























































with MeCN to remove any remaining cyclic peptide. The washes were combined with the 
initial reaction mixture. The reaction mixture was directly analyzed via RP-HPLC-MS. 
Although CLFA-NHBu is observed in the butylamine cleavage trace, when combined with 
the reaction mixture for Trace 3, the two peaks elute at the same time implying that the 
butylamide mass is a adduct of the cyclized peptide 5.7.B (>99% conversion). 
 
cyclo-[CLFA] (5.7.B). Table 5.7.1, entry 2 and Table 5.7.2, entry 1: Peptide 5.7.A (100 
mg, 0.034 mmol) was weighed into a 10-mL reaction vial and swelled in 2 mL CH2Cl2 for 
20 min. After swelling, the solvent was removed, and the resin was activated (see General 
Procedure). TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 
2 h. The solvent was removed, and the resin was rinsed with H2O until a pH of ~4 was 
obtained (Rinse Protocol C).  Then 2 mL of (1:1) 0.2 M Na2HPO4 (pH 7.2)/MeCN was 
added to the resin and agitated for 12 h at ambient temperature.  The solvent was 
collected, and the resin was rinsed with 1:1 MeCN/H2O to remove any remaining cyclic 
peptide. The washes were combined with the initial reaction mixture. The liquid was 
diluted with H2O, frozen in LN2, and lyophilization to yield a fluffy white solid. The peptide 
was extracted from Na2HPO4 using a mixture of MeOH/MeCN. The extractions were 
combined and concentrated under reduced pressure. The resulting residue was diluted 
with H2O/MeCN, frozen in LN2, and lyophilized to yield the crude peptide (13.2 mg, 39% 
5.7.A 5.7.B
1) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
Rinse Protocol C
3) (1:1) Na2HPO4 pH 7.2/MeCN



































crude yield). The solid was re-dissolved in H2O/MeCN and purified by semi-preparative 
RP-HPLC (2.7 mg, 8% isolated yield).   
 
cyclo-[CLFA] (5.7.B). Table 5.7.1, entry 3: Peptide 5.7.A (100 mg, 0.034 mmol) was 
weighed into a 10-mL reaction vial and swelled in 2 mL CH2Cl2 for 20 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 2 h. The 
solvent was removed, and the resin was rinsed with CH2Cl2 (3 x, Rinse Protocol A).  Then 
2 mL of 10% Hünig’s base/NBP was added to the resin and agitated for 12 h at ambient 
temperature.  The solvent was collected, and the resin was rinsed with MeCN to remove 
any remaining cyclic peptide. The washes were combined with the initial reaction mixture. 
The reaction mixture was directly analyzed via RP-HPLC-MS.   
 
cyclo-[cRGD] (5.7.D). Table 5.7.2, entry 2: Peptide 5.7.D (100 mg, 0.0407 mmol) was 
weighed into a 10-mL reaction vial and swelled in 2 mL CH2Cl2 for 20 min. After swelling, 











































    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
Rinse Protocol C













































TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 2 h. The 
solvent was removed, and the resin was rinsed with H2O until a pH of ~4 was obtained.  
Then 2 mL of (1:1) 0.2 M Na2HPO4 (pH 7.2)/MeCN was added to the resin and agitated 
for 3 h.  The solution was collected, and the resin was rinsed with 1:1 MeCN/H2O to 
remove any remaining cyclic peptide. The washes were combined with the initial reaction 
mixture. The liquid was diluted with H2O, frozen in LN2, and lyophilization to yield a fluffy 
white solid. The peptide was directly subjected to a mixture of MeOH/MeCN, which 
solubilized the peptide and minimal phosphate salt. The mixture was sonicated, 
centrifuged, and decanted to separate off the phosphate salt pellet. This procedure was 
repeated until the peptide was no longer observed in the MeOH/MeCN solvent mixture 
by RP-HPLC. The solvent was then concentrated under reduced pressure, diluted with 
H2O/MeCN, frozen in LN2, and lyophilized to yield the crude peptide (10.1 mg, 58% crude 
yield, 41% crude purity).  
 
cyclo-[CFPY] (5.7.E). Table 5.7.2, entry 3: Peptide 5.7.E (100 mg, 0.0414 mmol) was 
weighed into a 10-mL reaction vial and swelled in 2 mL CH2Cl2 for 20 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 2 h. The 
5.7.E
1) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
Rinse Protocol C























































solvent was removed, and the resin was rinsed with H2O until a pH of ~4 was obtained.  
Then 2 mL of (1:1) 0.2 M Na2HPO4 (pH 7.2)/MeCN was added to the resin and agitated 
for 3 h.  The solution was collected, and the resin was rinsed with 1:1 MeCN/H2O to 
remove any remaining cyclic peptide. The washes were combined with the initial reaction 
mixture. The liquid was diluted with H2O, frozen in LN2, and lyophilization to yield a fluffy 
white solid. The peptide was directly subjected to a mixture of MeOH/MeCN, which 
solubilized the peptide and minimal phosphate salt. The mixture was sonicated, 
centrifuged, and decanted to separate off the phosphate salt pellet. This procedure was 
repeated until the peptide was no longer observed in the MeOH/MeCN solvent mixture 
by RP-HPLC. The solvent was then concentrated under reduced pressure, diluted with 
H2O/MeCN, frozen in LN2, and lyophilized to yield the crude peptide (12.9 mg, 61% crude 
yield, 9:1 5.7.F/5.7.G). To obtain a reasonable amount of peptide, the cyclization was 
repeated on 200 mg of 5.7.E (0.0458 mmol). The peptide was purified on silica gel with a 
mobile phase eluent of 9:1 CH2Cl2/MeOH to isolate the pure peptide 5.7.F in 11% yield 
(2.6 mg). 
 
Synthesis of head-to-tail dimer 5.7.G using standard in-solution intramolecular 
coupling. Fmoc-Tyr(tBu) TGT resin (200 mg, 0.21 mmol/g, 0.042 mmol) was weighed 

































using the General Procedure for SPPS. The peptide was cleaved from the resin using 
(1:1:3) TFE/AcOH/CH2Cl2 (2 mL for 2 h). The solution was collected, reduced in volume 
using a constant stream of air. The resulting resiude was diluted with H2O, frozen in LN2, 
and lyophilized to yield the linear, protected peptide H-C(Trt)FPY(tBu)C(Trt)FPY(tBu)-
OH. 
  
Linear peptide (5.3 mg, 0.003 mmol) and HATU (1.2 equiv, 0.004 mmol) were dissolved 
in MeCN (3.4 mL, 0.001 M). Then 3.6 equiv of DIEA was added to the reaction (0.002 
mL, 0.012 mmol). The reaction was monitored my RP-HPLC-MS until the protected, 
cyclized peptide was observed. **Residual acetic acid was present in the reaction 
mixture, which resulted in acetylation of the N-terminus. Then an aliquot of the reaction 
was removed and immediately diluted with TFA/TIPS/H2O (95:2.5:2.5). This reaction was 
stirred at ambient temperature for 2 h. The solvent was reduced in volume, diluted with 













































































Sunflower Trypsin Inhibitor-1 (5.8.D). Peptide 5.8.A (111.8 mg, 0.032 mmol) was 
weighed into a 10-mL reaction vial and swelled in 2 mL CH2Cl2 for 20 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 2 h. The 
solvent was removed, and the resin was rinsed with H2O until a pH of ~4 was obtained.  
Then 2 mL of (1:1) 0.2 M Na2HPO4 (pH 7.2)/MeCN was added to the resin and agitated 
for 23 h at ambient temperature.  The solution was collected, and the resin was rinsed 
with 1:1 MeCN/H2O to remove any remaining cyclic peptide. The washes were combined 
with the initial reaction mixture. The liquid was diluted with H2O, frozen in LN2, and 
lyophilization to yield a fluffy white solid. Incomplete removal of tBu and Pbf was observed 
as indicated by multiple peaks by HPLC. The crude peptide was agitated in 95:2.5:2.5 
TFA/TIPS/H2O for 2 h to remove the remaining protecting groups. The mixture was 
reduced in volume under a constant stream of air. The resulting residue was subjected to 
–20 ºC diethyl ether to precipitate the peptide. The slurry of peptide in diethyl ether was 
centrifuged, then the ether mixture was decanted to produce the crude peptide pellet. The 
1) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) (1:1) Na2HPO4 pH 7.2/MeCN

















































pellet was resuspended in 1:1 MeCN/H2O, frozen in LN2, and lyophilized. The peptide 
was directly subjected to a mixture of MeOH/MeCN, which solubilized the peptide and 
minimal phosphate salt. The mixture was sonicated, centrifuged, and decanted to 
separate off the phosphate salt pellet. This procedure was repeated until the peptide was 
no longer observed in the MeOH/MeCN solvent mixture by RP-HPLC. The solution was 
then concentrated under reduced pressure. The residue was diluted with H2O/MeCN, 
frozen in LN2, and lyophilized to yield the crude peptide (83% HPLC purity, 190 nm). The 




Sunflower Trypsin Inhibitor-1 (5.8.D). Peptide 5.8.B (100 mg, 0.0353 mmol) was 
weighed into a 10-mL reaction vial and swelled in 2 mL CH2Cl2 for 20 min. After swelling, 
the solvent was removed, and the resin was activated (see General Procedure). 
TFA/TIPS/H2O (95:2.5:2.5, 500 µL) was added to the resin and agitated for 2 h. The 
solvent was removed, and the resin was rinsed with H2O until a pH of ~4 was obtained.  
1) 4-nitrophenyl chloroformate
    then 1 M DIPEA/DMF
2) TFA/TIPS/H2O (95:2.5:2.5)
3) (1:1) Na2HPO4 pH 7.2/MeCN

















































Then 2 mL of (1:1) 0.2 M Na2HPO4 (pH 7.2)/MeCN was added to the resin and agitated 
for 13.5 h at ambient temperature.  The solution was collected, and the resin was rinsed 
with 1:1 MeCN/H2O to remove any remaining cyclic peptide. The washes were combined 
with the initial reaction mixture. The liquid was diluted with H2O, frozen in LN2, and 
lyophilization to yield a fluffy white solid. Incomplete removal of tBu and Pbf was observed 
as indicated by multiple peaks by HPLC. The crude peptide was agitated in 95:2.5:2.5 
TFA/TIPS/H2O for 2 h to remove the remaining protecting groups. The mixture was 
reduced in volume under a constant stream of air. The resulting residue was subjected to 
–20 ºC diethyl ether to precipitate the peptide. The slurry of peptide in diethyl ether was 
centrifuged, then the ether mixture was decanted to produce the crude peptide pellet. The 
pellet was resuspended in 1:1 MeCN/H2O, frozen in LN2, and lyophilized. The peptide 
was directly subjected to a mixture of MeOH/MeCN, which solubilized the peptide and 
minimal phosphate salt. The mixture was sonicated, centrifuged, and decanted to 
separate off the phosphate salt pellet. This procedure was repeated until the peptide was 
no longer observed in the MeOH/MeCN solvent mixture by RP-HPLC. The solution was 
then concentrated under reduced pressure. The residue was diluted with H2O/MeCN, 
frozen in LN2, and lyophilized to yield the crude peptide (4.6 mg, 9% crude yield, 92% 
HPLC purity, 190 nm). The peptide was not further purified due to excellent purity. 
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CHAPTER 6: A MILD CAPPING METHOD FOR SPPS ON THE N-METHYL 
DIAMINOBENZOYL LINKER: SYNTHESIS OF AN N-ACYL UREA APPENDED C. 
ELEGANS NEUROPEPTIDE 
This chapter was adapted with permission from Arbour, C. A.; Stockdill, J. L. Tetrahedron  
Lett. 2018, 59, 3903–3906 (reproduced by permission of Elsevier). 
6.1 Introduction 
As methods for the chemical synthesis of complex peptides and proteins continue 
to evolve, these approaches are becoming increasingly viable for large scale production 
of homogenous peptide and protein-based pharmaceutical agents.164 Toward this end, 
diaminobenzoyl (Dbz) linkers have gained traction in the synthetic community as versatile 
precursors for the synthesis of peptide thioesters74,165 for native chemical ligation 
(NCL),165,166 C-terminally modified peptides,167 and macrocyclic peptides168 via solid 
phase peptide synthesis (SPPS). Incomplete coupling reactions can lead to the formation 
of problematic deletion products that are difficult to separate from the desired peptide. 
Capping after an incomplete coupling via treatment with acetic anhydride and Hünig’s 
base169 prevents further elongation of these sequences (i.e., 6.1.A ® 6.1.B, Scheme 
6.1.1A) during Boc-170 or Fmoc-SPPS.171 The resulting peptides are both shorter than the 
target peptide and have a different charged state, changing their retention time and 
facilitating the purification of the desired target (6.1.E). I hypothesized that the unactivated 
N-methyl diaminobenzoyl (MeDbz) linker would be susceptible to acylation under these 
conditions (i.e., 6.1.F ® 6.1.G, Scheme 6.1.1B), resulting in low yields of the desired 
peptide from the resin. Herein, I establish the cumulative negative effect of performing 
capping reactions in presence of the MeDbz linker and present a mild, inexpensive 
protocol for the selective capping of the N terminus using benzoic acid, N,N'-
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dicyclohexylcarbodiimide (DCC), and Hünig’s base. I demonstrate the limitations of acetic 
anhydride capping and the effectiveness of benzoic acid capping in the context of the 
synthesis of a putative neuropeptide derived from the C. elegans neuropeptide-like 
protein precursor NLP-44.  
The diaminobenzoyl (Dbz) linker has become widely used in solid-phase peptide 
synthesis. However, a limitation of this linker is the formation of branched side-products 
(i.e., peptide growth on both aryl amines) during SPPS.165a-c Protection of one nitrogen 
atom by an Alloc group avoids branching and enables capping during peptide 
synthesis.165b However, Alloc-Dbz can decompose to the prematurely activated N-acyl 
urea (Nbz), leading to peptide loss via formation of C-terminal piperidinyl amide side 
products throughout the synthesis.172 Alternatively, capping can be performed in 
presence of a nitrobenzoyl analog, but a reduction step must be performed prior to 
activation of this linker.165c In 2015, a second-generation Dbz linker, N-
methyldiaminobenzoyl (MeDbz) was reported (6.1.F, Scheme 6.1.1B).165d The presence 
of an N-methyl group supresses the formation of branched products because of the 
increased steric hindrance of the secondary amine relative to the original primary amine. 
However, I hypothesized that with more reactive reagents, such as anhydrides, the 
secondary amine would be prone to acylation (i.e.; AcMeDbz, 6.1.G). The AcMeDbz 
moiety cannot be activated toward nucleophilic displacement, and so the target peptide 
(6.1.H) cannot be accessed following inadvertent linker acylation. I envisioned that 
employing milder carboxylic acid activation conditions would allow selective 
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functionalization of the N-terminal amine following incomplete coupling reactions without 
also acylating the linker. 
Scheme 6.1.1. A) Traditional acetic anhydride capping of unreacted N-terminal amines 
in solid-phase peptide synthesis. B) Failed MeDbz linker activation leads to peptide loss 
following capping. PG = t-butyoxycarbonyl (Boc) or fluorenylmethoxycarbonyl (Fmoc) 
 
6.2 Acetic Anhydride Acylation of MeDbz 
To confirm my hypothesis that the MeDbz linker is acylated under acetic anhydride 
capping conditions, I subjected a model tripeptide linked to the solid support via MeDbz-
Gly-Rink Amide to these conditions (6.2.A, Scheme 6.2). The protected tripeptide AWC, 
which I previously employed for C-terminal modification experiments,167b was treated with 
excess acetic anhydride and Hünig’s base169 in DMF for 30 min followed by the 
established MeDbz activation conditions and then removal from the solid-support.81 I 
observed a 10:90 ratio of AcMeDbz to MeNbz after a single capping step, confirming my 
hypothesis. I anticipated that the amount of AcMeDbz would increase with successive 



















































































Scheme 6.2. Evaluating the amount of acetylation of MeDbz with a single treatment of  
acetic anhydride on tripeptide, AWC. 
 
During the synthesis of the CAPA-PVK-1 consensus sequence 
(APHPSSALLVPYPRVG) of the C. elegans precursor peptide NLP-44,173,174 I 
experienced variable efficiency in the coupling of several residues. Often, double-
coupling175 did not significantly improve the outcome. Thus, I used this sequence as a 
testing ground to evaluate the cumulative effect of Ac2O capping. In Table 6.2.1, I 
selected five residues where variable coupling efficiency was observed, and I performed 
a capping reaction after each coupling. Starting from 300 mg of resin, peptide 6.2.E was 
synthesized, capping was performed, and then 10 mg of resin was removed, activated, 
and cleaved at the Gly-Rink Amide linkage. Analysis of the resulting crude peptide by 
analytical RP-HPLC revealed an 8:92 ratio of AcMeDbz-appended uncapped peptide 
(6.2.E.1) to desired MeNbz-appended uncapped peptide (6.2.E.2, entry 1).81,176 
Interestingly, no N-terminal capping products were observed. This protocol was repeated 
at each site indicated in Table 6.2.1. After coupling of the next Leu and Ac2O capping, I 
observed a ratio of 29:71 ratio of 6.2.F.1/6.2.F.2 (entry 2). Further elongation to peptide 
6.2.G and capping further increased the ratio to 35:65 6.2.G.1/6.2.G.2 (entry 3). 
Surprisingly, the next capping step did not alter the ratio of 6.2.H.1/6.2.H.2 (entry 4). 
AWCFmoc
AWCFmoc
    Boc Trt
1) Ac2O (50 equiv)
    DIEA (50 equiv)
    DMF, 30 min
2) activation
3) TFA/TIPS/H2O



































However, the final capping step after Pro(15) led to a ratio of 76:23 of AcMeDbz-peptide 
6.2.I.1 to desired MeNbz-appended peptide 6.2.I.2 (entry 5). From these experiments, it 
is evident that a significant and unacceptable loss of yield can occur when multiple 
capping steps are performed in presence of the MeDbz linker.  
Table 6.2.1. Increasing acylation of MeDbz linker with successive acetic anhydride 
capping steps in the synthesis of C. elegans CAPA-PVK-1. *Asterisk above the HPLC 
trace indicates capped peptide (AcMeDbz) peak. 
 
To avoid MeDbz acylation, I envisioned replacing the reactive acetic anhydride 
with an inexpensive commercially available carboxylic acid and a common activating 
agent such as DCC. I employed acids containing chromophores to facilitate detection of 
peptide deletion products via HPLC. Additionally, I expected that I would need to tune the 
sterics in the acid to achieve efficient reactivity at the N-terminal amine – where deletion 
had already occurred while avoiding acylation of the secondary amine. I found that the 
bulky diphenylacetic acid was too hindered to react efficiently with model peptide 6.2.J, 
affording only the N-terminally capped peptide 6.2.L in 20% conversion (Table 6.2.2, 
entry 1).81 Treatment with benzoic acid and DCC gave complete conversion of the N-







2) Ac2O, DIEA, DMF
3) activation
4) TFA/TIPS/H2O











































a All reactions were performed on 10 mg of resin, b Based on relative ratio of HPLC/MS 
data, c After capping was performed on 6.2.I, and subsequent Fmoc removal, the final 
















Ac-WC-AcMeDbz (6.2.K, entry 2). I also investigated a primary alkyl carboxylic acid, 
which was similarly effective (entry 3).  
Table 6.2.2. Mild N-terminal capping with various carboxylic acids. 
 
6.3 Synthesis of a C. elegans Neuropeptide 
To confirm the viability of this approach in a complex setting, I repeated the 
synthesis of the C. elegans CAPA-PVK-1 peptide. Starting from the MeDbz-bound resin 
(6.3.A), SPPS was performed with a capping step (benzoic acid, DCC, Hünig’s base) 
after each italicized residue (Scheme 6.3). A small portion of the resin (10 mg) was 
removed after each capping event, and the composition of peptides was analyzed. In 
contrast to the acetic anhydride capping performed in Table 6.2.1, no acylation of the 
MeDbz residue was detected following any of the capping steps.81 Following the coupling 
of the final amino acid, the MeDbz group was activated and the peptide was cleaved from 
the resin with concomitant side-chain protecting group removal. The resulting crude 
peptide was analyzed by RP-HPLC, and MeNbz-appended peptides 6.3.B and 6.3.C (3:2 
ratio) were the primary observed peptide products (Scheme 6.3). The crude mixture was 
1) 
 
   DCC (10 equiv)
   DIEA (20 equiv)
   DMF, 1.5 h 
2) activation
3) TFA:TIPS:H2O

























a All reactions were performed on 10 mg of resin, b  Capping was conducted in 1 




































readily purified to obtain pure peptide 6.3.D in 5% yield,177 where the maximum yield 
obtainable for the full sequence is 60%.  
When I attempted the SPPS of C. elegans CAPA-PVK-1 peptide without capping 
steps, I observed deletion products at all italicized residues. However, N-terminally 
benzoylated peptide 6.3.C was the only capping product detected in the synthesis in 
Scheme 6.3. Analysis of 10 mg resin after each benzoic acid capping event revealed that 
once Leu(8) was successfully capped, all remaining coupling reactions proceeded to 
completion. I hypothesize that because the effective loading of the resin was reduced 
from 0.5 mmol/g to 0.3 mmol/g after the first capping step, the remaining coupling 
reactions proceeded more efficiently. This loading is within the range of “low-loading” 
resins designed to facilitate difficult peptide syntheses.178  
Scheme 6.3. A) Synthesis of the C. elegans CAPA-PVK-1 peptide with benzoic acid 
capping, B) PDA (190 nm) data for crude peptide cleavage mixture, C) ESI-MS and PDA 
(254 nm) of pure peptide 6.3.D. 
  
6.4 Summary 
In summary, I have demonstrated the problematic proclivity of the MeDbz linker to 
undergo undesired acylation reactions, and I have developed a mild, inexpensive protocol 























1) Fmoc-SPPS with BzOH 
     capping after italicized 
     residues
2) activation
3) TFA/TIPS/H2O
    (95:2.5:2.5)
 248 
linker. I demonstrate that a single acetic anhydride capping event can reduce the amount 
of recoverable fully elongated peptide by approximately 10%, while 5 capping steps led 
to the loss of approximately 75% of the desired peptide. These values arise solely from 
prevented activation of the linker in the successfully elongated sequence, and thus will 
be multiplicative with yield losses caused by the intended N-terminal capping reaction. 
Because of the growing importance of the MeDbz/MeNbz linker strategy for a host of 
applications in SPPS, an understanding of the scope of the acetic anhydride reactivity 
problem, as well as a convenient strategy to avoid it, constitute critically needed 
information for the field of peptide synthesis. 
6.5 General Experimental Procedures 
6.5.1 Materials and Methods 
See Chapter Section 2.6 Materials and Methods under Section 2.6.1 General 
Experimental Procedures for Solid-Phase Peptide Synthesis, NMR, RP-HPLC-MS, and 
MeDbz Activation procedures. 
6.5.2 Experimental Procedures 
 
Peptide 6.2.A (10 mg, 3.5 µmol) was weighed into a 2-mL reaction vial and swelled in 
CH2Cl2 for 30 min. The solvent was removed, and a solution of acetic anhydride (50 equiv) 
and Hünig’s base (50 equiv) in DMF (1 mL) was added to the resin and agitated for 30 
min. After this time, the solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 
Exact Mass: 846.3
Molecular Weight: 847.0
1) Ac2O, DIPEA, DMF
2) 4-nitrophenyl 
    chloroformate, CH2Cl2 
    then 1 M DIPEA/DMF
3) TFA/TIPS/H2O
    (95:2.5:2.5)
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1 mL). A solution of 4-nitrophenyl chloroformate (5 equiv) in 500 µL CH2Cl2 was added to 
the resin and agitated for 1 h. After 1 h, The solvent was removed, and the resin was 
rinsed with CH2Cl2 (2 x 1 mL). Then 250 µL of a 1 M solution of Hünig’s base in DMF was 
added. This reaction was agitated for 30 min and removed, and the resulting resin was 
rinsed with CH2Cl2 (2 x 1 mL). The resin was immediately subjected to 1 mL 
TFA/TIPS/H2O (95:2.5:2.5) and agitated for 1 h. The solvent was removed and collected. 
The solvent was reduced in volume under a constant stream of air, then –20 ºC diethyl 
ether was added to the residue, the mixture was centrifuged, and the ether layer was 
decanted. The pellet was dissolved in 20% MeCN/H2O (1% TFA) and analyzed via RP-
HPLC-MS. 
 
Table 6.2.1, entry 1. Peptide 6.2.E-resin179 was subjected to a solution of acetic 
anhydride (50 equiv) and Hünig’s base (50 equiv) in DMF (1 mL) and agitated for 30 min. 
After this time, the solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). 
Peptide 6.2.E-resin (10 mg, 3.5 µmol) was removed and a solution of 4-nitrophenyl 
chloroformate (5 equiv) in 500 µL CH2Cl2 was added to the resin and agitated for 1 h. 
After 1 h, The solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). 
Then 250 µL of a 1 M solution of Hünig’s base in DMF was added. The reaction was 
agitated for 30 min and removed, and the resulting resin was rinsed with CH2Cl2 (2 x 1 
mL). The resin was immediately subjected to 1 mL TFA/TIPS/H2O (95:2.5:2.5) and 
1) Ac2O, DIPEA, DMF
2) 4-nitrophenyl 
     chloroformate
    CH2Cl2, 1 h
3) 1 M DIPEA/DMF
4) TFA/TIPS/H2O






























agitated for 1 h. The solvent was removed and collected. The solvent was reduced in 
volume under a constant stream of air, then –20 ºC diethyl ether was added to the residue, 
the mixture was centrifuged, and the ether layer was decanted. The pellet was dissolved 
in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. 
 
Table 6.2.1, entry 2. Peptide 6.2.F-resin was subjected to a solution of acetic anhydride 
(50 equiv) and Hünig’s base (50 equiv) in DMF (1 mL) and agitated for 30 min. After this 
time, the solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). 10 mg 
(3.5 µmol) of 6.2.F-resin was removed and a solution of 4-nitrophenyl chloroformate (5 
equiv) in 500 µL CH2Cl2 was added to the resin and agitated for 1 h. After 1 h, The solvent 
was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). Then 250 µL of a 1 M 
solution of Hünig’s base in DMF was added. This reaction was agitated for 30 min and 
removed, and the resulting resin was rinsed with CH2Cl2 (2 x 1 mL). The resin was 
immediately subjected to 1 mL TFA/TIPS/H2O (95:2.5:2.5) and agitated for 1 h. The 
solvent was removed and collected. The solvent was reduced in volume under a constant 
stream of air, then –20 ºC diethyl ether was added to the residue, the mixture was 
centrifuged, and the ether layer was decanted. The pellet was dissolved in 20% 
MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. 
 
1) Ac2O, DIPEA, DMF
2) 4-nitrophenyl 
     chloroformate
    CH2Cl2, 1 h































Table 6.2.1, entry 3. Peptide 6.2.G-resin was subjected to a solution of acetic anhydride 
(50 equiv) and Hünig’s base (50 equiv) in DMF (1 mL) and agitated for 30 min. After this 
time, the solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). 10 mg 
(3.5 µmol) of 6.2.G-resin was removed and a solution of 4-nitrophenyl chloroformate (5 
equiv) in 500 µL CH2Cl2 was added to the resin and agitated for 1 h. After 1 h, The solvent 
was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). Then 250 µL of a 1 M 
solution of Hünig’s base in DMF was added. This reaction was agitated for 30 min and 
removed, and the resulting resin was rinsed with CH2Cl2 (2 x 1 mL). The resin was 
immediately subjected to 1 mL TFA/TIPS/H2O (95:2.5:2.5) and agitated for 1 h. The 
solvent was removed and collected. The solvent was reduced in volume under a constant 
stream of air, then –20 ºC diethyl ether was added to the residue, the mixture was 
centrifuged, and the ether layer was decanted. The pellet was dissolved in 20% 
MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. 
 
1) Ac2O, DIPEA, DMF
2) 4-nitrophenyl 
     chloroformate
    CH2Cl2, 1 h





























1) Ac2O, DIPEA, DMF
2) 4-nitrophenyl 
     chloroformate
    CH2Cl2, 1 h
3) 1 M DIPEA/DMF
4) TFA/TIPS/H2O
































Table 6.2.1, entry 4. Peptide 6.2.H-resin was subjected to a solution of acetic anhydride 
(50 equiv) and Hünig’s base (50 equiv) in DMF (1 mL) and agitated for 30 min. After this 
time, the solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). Peptide 
6.2.H-resin (10 mg, 3.5 µmol) was removed and a solution of 4-nitrophenyl chloroformate 
(5 equiv) in 500 µL CH2Cl2 was added to the resin and agitated for 1 h. After 1 h, The 
solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). Then 250 µL of a 
1 M solution of Hünig’s base in DMF was added. This reaction was agitated for 30 min 
and removed, and the resulting resin was rinsed with CH2Cl2 (2 x 1 mL). The resin was 
immediately subjected to 1 mL TFA/TIPS/H2O (95:2.5:2.5) and agitated for 1 h. The 
solvent was removed and collected. The solvent was reduced in volume under a constant 
stream of air, then –20 ºC diethyl ether was added to the residue, the mixture was 
centrifuged, and the ether layer was decanted. The pellet was dissolved in 20% 
MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. 
 
Table 6.2.1, entry 5. Peptide 6.2.I-resin was subjected to a solution of acetic anhydride 
(50 equiv) and Hünig’s base (50 equiv) in DMF (1 mL) and agitated for 30 min. After this 
time, the solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). The 
Fmoc on the N-terminus was removed using 20% piperidine/DMF (1 mL) and agitated for 
+
1) Ac2O, DIPEA, DMF
2) 20% piperidine/DMF
3) Boc-Ala-OH, HATU, DIPEA
    DMF
4) 4-nitrophenyl chloroformate
    CH2Cl2, 1 h
5) 1 M DIPEA/DMF
6) TFA/TIPS/H2O































15 min. The solvent was removed and rinsed with DMF (2 x 1 mL). The free N-terminal 
amine was coupled with Boc-Ala-OH using standard HATU, Fmoc-SPPS conditions (See 
General Procedures). Peptide 6.2.I-resin (10 mg, 3.5 µmol) was removed and a solution 
of 4-nitrophenyl chloroformate (5 equiv) in 500 µL CH2Cl2 was added to the resin and 
agitated for 1 h. After 1 h, The solvent was removed, and the resin was rinsed with CH2Cl2 
(2 x 1 mL). Then 250 µL of a 1 M solution of Hünig’s base in DMF was added. This 
reaction was agitated for 30 min and removed, and the resulting resin was rinsed with 
CH2Cl2 (2 x 1 mL). The resin was immediately subjected to 1 mL TFA/TIPS/H2O 
(95:2.5:2.5) and agitated for 1 h. The solvent was removed and collected. The solvent 
was reduced in volume under a constant stream of air, then –20 ºC diethyl ether was 
added to the residue, the mixture was centrifuged, and the ether layer was decanted. The 
pellet was dissolved in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. 
 
Table 6.2.2, entry 1. Peptide Boc-6.2.A/6.2.J (10 mg, 3.5 µmol) was weighed into a 2-
mL reaction vial and swelled in CH2Cl2 for 30 min. The solvent was removed, and a 
solution of 2,2-diphenylacetic acid (10 equiv), DCC (10 equiv), and Hünig’s base (20 
equiv) in DMF (1 mL) was added to the resin and agitated for 1.5 h. After this time, the 
solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). A solution of 4-
nitrophenyl chloroformate (5 equiv) in 500 µL CH2Cl2 was added to the resin and agitated 
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mL). Then 250 µL of a 1 M solution of Hünig’s base in DMF was added. This reaction was 
agitated for 30 min and removed, and the resulting resin was rinsed with CH2Cl2 (2 x 1 
mL). The resin was immediately subjected to 1 mL TFA/TIPS/H2O (95:2.5:2.5) and 
agitated for 1 h. The solvent was removed and collected. The solvent was reduced in 
volume under a constant stream of air, then –20 ºC diethyl ether was added to the residue, 
the mixture was centrifuged, and the ether layer was decanted. The pellet was dissolved 
in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. 20% of capped peptide 
was observed. 
 
Table 6.2.2, entry 2. Peptide Boc-6.2.A/6.2.J (10 mg, 3.5 µmol) was weighed into a 2-
mL reaction vial and swelled in CH2Cl2 for 30 min. The solvent was removed, and a 
solution of benzoic acid (10 equiv), DCC (10 equiv), and Hünig’s base (20 equiv) in DMF 
(1 mL) was added to the resin and agitated for 1.5 h. After this time, the solvent was 
removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). A solution of 4-nitrophenyl 
chloroformate (5 equiv) in 500 µL CH2Cl2 was added to the resin and agitated for 1 h. 
After 1 h, The solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). 
Then 250 µL of a 1 M solution of Hünig’s base in DMF was added. This reaction was 
agitated for 30 min and removed, and the resulting resin was rinsed with CH2Cl2 (2 x 1 
mL). The resin was immediately subjected to 1 mL TFA/TIPS/H2O (95:2.5:2.5) and 
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volume under a constant stream of air, then –20 ºC diethyl ether was added to the residue, 
the mixture was centrifuged, and the ether layer was decanted. The pellet was dissolved 
in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. All of the free amine 6.2.J 
was converted to the capped peptide 6.2.L-COPh. 
 
Table 6.2.2, entry 3. Peptide Boc-6.2.A/6.2.J (10 mg, 3.5 µmol) was weighed into a 2-
mL reaction vial and swelled in CH2Cl2 for 30 min. The solvent was removed, and a 
solution of 5-hexynoic acid (10 equiv), DCC (10 equiv), and Hünig’s base (20 equiv) in 
DMF (1 mL) was added to the resin and agitated for 1.5 h. After this time, the solvent was 
removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). A solution of 4-nitrophenyl 
chloroformate (5 equiv) in 500 µL CH2Cl2 was added to the resin and agitated for 1 h. 
After 1 h, The solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). 
Then 250 µL of a 1 M solution of Hünig’s base in DMF was added. This reaction was 
agitated for 30 min and removed, and the resulting resin was rinsed with CH2Cl2 (2 x 1 
mL). The resin was immediately subjected to 1 mL TFA/TIPS/H2O (95:2.5:2.5) and 
agitated for 1 h. The solvent was removed and collected. The solvent was reduced in 
volume under a constant stream of air, then –20 ºC diethyl ether was added to the residue, 
the mixture was centrifuged, and the ether layer was decanted. The pellet was dissolved 
in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. All of the free amine 6.2.J 
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Peptide 6.2.E-resin was subjected to a solution of benzoic acid (10 equiv), DCC (10 
equiv), and Hünig’s base (20 equiv) in DMF (1 mL) and agitated for 1.5 h. After this time, 
the solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). Peptide 6.2.E-
resin (10 mg, 3.5 µmol) was weighed into a 2-mL reaction vial. A solution of 4-nitrophenyl 
chloroformate (5 equiv) in 500 µL CH2Cl2 was added to the resin and agitated for 1 h. 
After 1 h, The solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). 
Then 250 µL of a 1 M solution of Hünig’s base in DMF was added. This reaction was 
agitated for 30 min and removed, and the resulting resin was rinsed with CH2Cl2 (2 x 1 
mL). The resin was immediately subjected to 1 mL TFA/TIPS/H2O (95:2.5:2.5) and 
agitated for 1 h. The solvent was removed and collected. The mixture was reduced in 
volume under a constant stream of air, then –20 ºC diethyl ether was added to the residue, 
the mixture was centrifuged, and the ether layer was decanted. The pellet was dissolved 
in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. 
 
Peptide 6.2.F/6.2.E-resin was subjected to a solution of benzoic acid (10 equiv), DCC 
(10 equiv), and Hünig’s base (20 equiv) in DMF (1 mL) and agitated for 1.5 h. After this 
time, the solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). Peptide 
1) PhCO2H, DCC, DIPEA, DMF
2) 4-nitrophenyl chloroformate
    CH2Cl2, 1 h
3) 1 M DIPEA/DMF
4) TFA/TIPS/H2O
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6.2.F/6.2.E-resin (10 mg, 3.5 µmol) was weighed into a 2-mL reaction vial. A solution of 
4-nitrophenyl chloroformate (5 equiv) in 500 µL CH2Cl2 was added to the resin and 
agitated for 1 h. After 1 h, The solvent was removed, and the resin was rinsed with CH2Cl2 
(2 x 1 mL). Then 250 µL of a 1 M solution of Hünig’s base in DMF was added. This 
reaction was agitated for 30 min and removed, and the resulting resin was rinsed with 
CH2Cl2 (2 x 1 mL). The resin was immediately subjected to 1 mL TFA/TIPS/H2O 
(95:2.5:2.5) and agitated for 1 h. The solvent was removed and collected. The mixture 
was reduced in volume under a constant stream of air, then –20 ºC diethyl ether was 
added to the residue, the mixture was centrifuged, and the ether layer was decanted. The 
pellet was dissolved in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. 
 
Peptide 6.2.G-resin was subjected to a solution of benzoic acid (10 equiv), DCC (10 
equiv), and Hünig’s base (20 equiv) in DMF (1 mL) and agitated for 1.5 h. After this time, 
the solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). Peptide 6.2.G-
resin (10 mg, 3.5 µmol) was weighed into a 2-mL reaction vial. A solution of 4-nitrophenyl 
chloroformate (5 equiv) in 500 µL CH2Cl2 was added to the resin and agitated for 1 h. 
After 1 h, The solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). 
Then 250 µL of a 1 M solution of Hünig’s base in DMF was added. This reaction was 
1) PhCO2H, DCC, DIPEA, DMF
2) 4-nitrophenyl chloroformate
    CH2Cl2, 1 h
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4) TFA/TIPS/H2O



































agitated for 30 min and removed, and the resulting resin was rinsed with CH2Cl2 (2 x 1 
mL). The resin was immediately subjected to 1 mL TFA/TIPS/H2O (95:2.5:2.5) and 
agitated for 1 h. The solvent was removed and collected. The mixture was reduced in 
volume under a constant stream of air, then –20 ºC diethyl ether was added to the residue, 
the mixture was centrifuged, and the ether layer was decanted. The pellet was dissolved 
in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. 
 
Peptide 6.2.H-resin was subjected to a solution of benzoic acid (10 equiv), DCC (10 
equiv), and Hünig’s base (20 equiv) in DMF (1 mL) and agitated for 1.5 h. After this time, 
the solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). Peptide 6.2.H-
resin (10 mg, 3.5 µmol) was weighed into a 2-mL reaction vial. A solution of 4-nitrophenyl 
chloroformate (5 equiv) in 500 µL CH2Cl2 was added to the resin and agitated for 1 h. 
After 1 h, The solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). 
Then 250 µL of a 1 M solution of Hünig’s base in DMF was added. This reaction was 
agitated for 30 min and removed, and the resulting resin was rinsed with CH2Cl2 (2 x 1 
mL). The resin was immediately subjected to 1 mL TFA/TIPS/H2O (95:2.5:2.5) and 
agitated for 1 h. The solvent was removed and collected. The mixture was reduced in 
volume under a constant stream of air, then –20 ºC diethyl ether was added to the residue, 
+
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the mixture was centrifuged, and the ether layer was decanted. The pellet was dissolved 
in 20% MeCN/H2O (1% TFA) and analyzed via RP-HPLC-MS. 
 
Peptide 6.2.I-resin was subjected to a solution of benzoic acid (10 equiv), DCC (10 
equiv), and Hünig’s base (20 equiv) in DMF (1 mL) and agitated for 1.5 h. After this time, 
the solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 1 mL). The Fmoc on 
the N-terminus was removed using 20% piperidine/DMF (1 mL) and agitated for 15 min. 
The solvent was removed and rinsed with DMF (2 x 1 mL). The free N-terminal amine 
was coupled with Boc-Ala-OH using standard HATU, Fmoc-SPPS conditions (see 
General Procedures). Peptide 6.2.I-resin (10 mg, 3.5 µmol) was weighed into a 2-mL 
reaction vial. A solution of 4-nitrophenyl chloroformate (5 equiv) in 500 µL CH2Cl2 was 
added to the resin and agitated for 1 h. After 1 h, The solvent was removed, and the resin 
was rinsed with CH2Cl2 (2 x 1 mL). Then 250 µL of a 1 M solution of Hünig’s base in DMF 
was added. This reaction was agitated for 30 min and removed, and the resulting resin 
was rinsed with CH2Cl2 (2 x 1 mL). The resin was immediately subjected to 1 mL 
TFA/TIPS/H2O (95:2.5:2.5) and agitated for 1 h. The solvent was removed and collected. 
The mixture was reduced in volume under a constant stream of air, then –20 ºC diethyl 
ether was added to the residue, the mixture was centrifuged, and the ether layer was 
decanted. The pellet was dissolved in 20% MeCN/H2O (1% TFA) and analyzed via RP-
HPLC-MS. Based on the purity of the final peptide, SPPS optimization is still required. 
1) PhCO2H, DCC, DIPEA, DMF
2) 20% piperidine/DMF
3) Boc-Ala-OH, HATU
    DIPEA, DMF
4) 4-nitrophenyl chloroformate
    CH2Cl2, 1 h
5) 1 M DIPEA/DMF
6) TFA/TIPS/H2O




















Peptide 6.3.B-resin (61.9 mg, 0.031 mmol) was weighed into a 10-mL reaction vial and 
swelled in CH2Cl2 (1 mL) for 30 min. After The solvent was removed, a solution of 4-
nitrophenyl chloroformate (5 equiv) in 2 mL CH2Cl2 was added to the resin and agitated 
for 1 h. After 1 h, The solvent was removed, and the resin was rinsed with CH2Cl2 (2 x 1 
mL). Then 750 µL of a 1 M solution of Hünig’s base in DMF was added. This reaction was 
agitated for 30 min and removed, and the resulting resin was rinsed with CH2Cl2 (2 x 1 
mL). The resin was immediately subjected to 2 mL TFA/TIPS/H2O (95:2.5:2.5) and 
agitated for 1 h. The solvent was removed and collected. The resin was further rinsed 
with CH2Cl2 (2 x 1 mL) and combined. The mixture was reduced in volume under a 
constant stream of air, then –20 ºC diethyl ether was added to the residue, the mixture 
was centrifuged, and the ether layer was decanted. The pellet was dissolved in 20% 
MeCN/H2O (1% TFA), frozen in LN2 and lyophilized to yield the crude peptide mixture 
(25.8 mg, 44% crude yield). The crude peptide was re-dissolved in 20% MeCN/H2O (1% 
TFA) and purified via RP-HPLC-MS. The peptide was isolated in 5% yield (2.7 mg). This 













CHAPTER 7: SUMMARY AND OUTLOOK 
 The profound impact of the C-terminal moiety on peptide folding efficiency and 
secondary structure make C-terminally modified peptides excellent targets for peptide 
therapeutics. This minor change can impact thermodynamic peptide folding and enable 
access to different folded isomers. Similarly, the secondary structure of the peptide can 
be further manipulated to directly impact how the peptide interacts to a binding site, 
potentially making a peptide more or less potent. Throughout this thesis, I have described 
my synthetic work towards accessing these peptides, discussing the challenges that 
inherently accompany this chemistry. 
The mild activating properties of the activated N-methyl-diaminobenzoyl linker 
made for an excellent linker for C-terminal peptide manipulations. my initial work was 
exploring the scope of nucleophiles that could displace the activated linker (MeNbz), both 
on-resin and in-solution, to access protected and unprotected peptides, respectively. I 
moved next to displacement in solution, showing excellent reactivity for most 
nucleophiles. This work was performed on tripeptides initially, but to evaluate its broad 
applicability for peptides, I synthesized a larger peptide, one that contained nucleophilic 
side chains. I deemed it important to test these conditions on a larger substrate, because 
I hypothesized that the nucleophilicity of the side chains could outcompete the 
intermolecular displacement, resulting in undesired side reactions. Not surprisingly, this 
side reaction was the case for many nucleophiles.  
For my initial investigations, I evaluated C-terminal glycine to omit the possibility 
of epimerization. However, that was the major topic of discussion in the C-terminal 
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cysteine project. When this acidic amino acid is the C-terminal residue, it is prone to 
epimerization upon attachment and activation. I was able to minimize or eliminate this 
undesired product with some optimization. The development of epimerization-free C-
terminal modifications using a diaminobenzoyl linker has inspired other projects that are 
ongoing but, do to patent content, will be omitted from this chapter. 
Many projects have been conceived through the efforts of exploiting the 
diaminobenzoyl linker. The C-terminal modification project that used unprotected 
peptides, in-solution made for challenging chemistry due to the competition between 
intermolecular and intramolecular displacement of the MeDbz linker. Although it was 
important to investigate the propensity of specific sequences toward intramolecular 
macrocyclization, I acknowledge that this can be significantly cumbersome to handle 
when only interested in isolating the C-terminally modified peptide. I envision that this can 
be circumvented by isolating the fully protected peptide with the activated linker appended 
to the C terminus. To do so, I would need to modify the solid-support to accommodate 
this transformation. Ideally, the solid-support would need to be sensitive to non-acidic and 
non-nucleophilic cleavage conditions. A drawback to this approach would be peptide 
solubility because it will be fully protected. This work is currently in development in the 
Stockdill Laboratory. 
Lastly, I have been interested in access macrocyclic peptides using an on-resin 
native chemical ligation approach. To access these peptides with minimal hydrolysis, an 
N-terminal cysteine is incorporated and utilized in the macrocyclization step to 
outcompete water as a nucleophile. Currently ongoing in the Stockdill laboratory, N-
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methylated cysteine and homocysteine derivatives are being incorporated on the N 
terminus to evaluate their proclivity towards macrocyclization compared to traditional 
cysteine. I hypothesize that if I elongate the cysteine side chain, this could facilitate a 
faster macrocyclization for challenging macrocyclic peptides. Specifically, for more 
sterically hindered N-methylated amino acids and conformationally strained macrocycles, 
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Appendix A 
Appendix A.2: Spectrometric Data for Chapter 2 
Table 2.2.1. Spectrometric Data 
 
Figure A2.001. Analytical Column PDA of pure peptide at 254 nm for Table 2.2.1, entry 
1. Gradient: Isocratic 40% MeCN/H2O (0.1% formic acid) over 15 min. Retention time: 
2.68 min. 
 
Figure A2.002. Analytical Column PDA for determination of conversion via method A. 















Figure A2.003. Analytical Column PDA for determination of conversion via method B 
for Table 2.2.1, entry 2. Gradient: 20-40% MeCN/H2O (0.1% formic acid) over 30 min. 
 
Figure A2.004. Analytical Column PDA of pure peptide at 254 nm for Table 2.2.1, entry 















Figure A2.005. Analytical Column PDA for determination of conversion via method A 
for Table 2.2.1, entry 3. Gradient: 20-80% MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A2.006. Analytical Column PDA of pure peptide at 254 nm for Table 2.2.1, entry 













Figure A2.007. Analytical Column PDA for determination of conversion via method B 
for Table 2.2.1, entry 4. Gradient: 20-80% MeCN/H2O (0.1% formic acid) over 30 min. 
 
Figure A2.008. Analytical Column PDA of pure peptide at 254 nm for Table 2.2.1, entry 
















Figure A2.009. Analytical Column PDA for determination of conversion via method B 
for Table 2.2.1, entry 5. Gradient: 20-80% MeCN/H2O (0.1% formic acid) over 30 min. 
 
Figure A2.010. Analytical Column PDA of pure peptide at 254 nm for Table 2.2.1, entry 
















Figure A2.011. Analytical Column PDA for determination of conversion via method A for 
Table 2.2.1, entry 6. Gradient: 20-80% MeCN/H2O (0.1% formic acid) over 15 min. 
Table 2.2.2. Experimental Procedures and Spectrometric Data  
 
Figure A2.012. Analytical Column PDA of pure peptide at 254 nm for Table 2.2.2, entry 
























Figure A2.013. Analytical Column PDA of pure peptide at 254 nm Table 2.2.2, entry 1. 
Gradient: 40-95% MeCN/H2O (0.1% formic acid). Retention time: 14.01 min. 
  
Figure A2.014. Analytical Column PDA for determination of conversion via method A. 


























Figure A2.015. Analytical Column PDA after one round of silica gel chromatography for 
Table 2.2.2, entry 2. Gradient: 40-95% MeCN/H2O (0.1% formic acid). Retention time: 
4.39 min. 
 
Figure A2.016. Analytical Column PDA of pure peptide at 254 nm for Table 2.2.2, entry  























Figure A2.017. Analytical Column PDA for determination of conversion via method A 
for Table 2.2.2, entry 2. Gradient: 20-80% MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A2.018. Analytical Column PDA of pure peptide at 254 nm for Table 2.2.2, entry 


















Figure A2.019. Analytical Column PDA for determination of conversion via method A 
for Table 2.2.2, entry 3. Gradient: 20-80% MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A2.020. Analytical Column PDA of pure peptide at 254 nm for Table 2.2.2, entry 



















Figure A2.021. Analytical Column PDA for determination of conversion via method A 
for Table 2.2.2, entry 4. Gradient: 20-80% MeCN/H2O (0.1% formic acid) over 15 min. 
  
Figure A2.022. Analytical Column PDA of pure peptide at 254 nm for Table 2.2.2, entry 
















Figure A2.023. Analytical Column PDA for determination of conversion via method A 
for Table 2.2.2, entry 5. Gradient: 20-80% MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A2.024. Analytical Column PDA of pure peptide at 254 nm for Table 2.2.2, entry 














Figure A2.025. Analytical Column PDA for determination of conversion via method A 
Table 2.2.2, entry 6. Gradient: 20-80% MeCN/H2O (0.1% formic acid) over 15 min. 
Table 2.2.3. Experimental Procedures and Spectrometric Data 
 
Figure A2.026. Analytical Column PDA of pure peptide at 254 nm for Table 2.2.3, entry 

















Figure A2.027. Analytical Column PDA for determination of conversion via method A 
for Table 2.2.3, entry 1. Gradient: 20-80% MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A2.028. Analytical Column PDA for determination of conversion via method B 


























Figure A2.029. Analytical Column PDA for determination of conversion via method B 
for Table 2.2.3, entry 3. Gradient: 40-95(15 min)-95(1 min)% MeCN/H2O (0.1% formic 
acid) over 16 min. 
 
Figure A2.030. Analytical Column PDA of crude peptide at 254 nm for Table 2.2.3, entry 










































Figure A2.031. Analytical Column PDA for determination of conversion via method A 
for Table 2.2.3, entry 4. Gradient: 20-80% MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A2.032. Analytical Column PDA for determination of conversion via method B 


























Figure A2.033. Analytical Column PDA for determination of conversion via method B 
for Table 2.2.3, entry 6. Gradient: 40-95(15 min)-95(1 min)% MeCN/H2O (0.1% formic 











































Figure A2.034. Analytical Column PDA of crude 2.6.B at 254 nm. Gradient: 20-50% 
MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A2.035. Analytical Column PDA for determination of conversion via method A. 

















[M+H]+= 754 m/z 
 
[M+H-Trityl]+= 512 m/z 
 





Figure A2.036. Epimerization data of AWH-NH2, gradient: 20-50% MeCN/H2O (0.1% 
formic acid) over 15 min. *Trityl was removed for epimerization analysis 
 
 
Figure A2.037. Co-injection of both acid (2.2.D-OH) and amide (2.2.B-NH2) C-terminal 
peptides. Gradient of Analytical Column: 30-45% MeCN/H2O (0.1% formic acid) over 15 





















































Figure A2.038. Crude reaction mixture of 2.6.C using a gradient of 30-50% MeCN/H2O 
(0.1% formic acid) over 30 min. 
 
Figure A2.039. Crude reaction mixture of 2.6.D using a gradient of 30-50% MeCN/H2O 



















Scheme 2.4.1. Experimental Procedures and Spectrometric Data  
 
 
Figure A2.040. Analytical column of purified conopressin G. Gradient: 20-30% 
MeCN/H2O (0.1% formic acid) over 15 min. 
 
 
Figure A2.041. Analytical column of purified propargyl conopressin G. Gradient: 
Isocratic 30% MeCN/H2O (0.1% formic acid) over 15 min. 
(+) Scan (–) Scan 




Figure A2.042. Analytical column of purified methyl ester conopressin G. Gradient: 
Isocratic 30% MeCN/H2O (0.1% formic acid) over 15 min. 
 
 
Figure A2.043. Analytical column of pure 2.3.E. Gradient: 20-55% MeCN/H2O (0.1% 
formic acid) over 15 min, which resulted in broadening of the purified product peak. 
(+) Scan (–) Scan 








[M+2H]2+ = 525 
 










Figure A2.044. Analytical Column illustrating SPPS purity for GLP-1(7-36). Gradient: 





[M+2H]2+= 1863 m/z 
[M+3H]3+= 1243 m/z 
 [M+4H]4+= 932 m/z 
[M+5H]5+= 746 m/z 
[M-H]–= 1861 m/z 
 
PDA, 190 nm 
 
 











Figure A2.045. Analytical Column of crude native GLP-1(7-36). Gradient: 20-80% 







[M+2H]2+= 1649 m/z 
[M+3H]3+= 1100 m/z 
[M+4H]4+= 825 m/z 
[M+5H]5+= 660 m/z 
H-MeNbz-Gly 
PDA, 254 nm 
 
 





Figure A2.046. Analytical Column of purified native GLP-1(7-36). Gradient: 20-80% 
MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A2.047. Analytical Column PDA for determination of conversion via method A.  










PDA, 254 nm 
 
 




[(M+2H)/2]+= 1650 m/z 
[(M+3H)/3]+= 1100 m/z 
[(M+4H)/4]+–= 825 m/z 
[(M+5H)/5]+= 660 m/z 
[M-H]–= 1648 m/z 
 
 




Table 2.4.1. Spectrometric Data 
   
Figure A2.048. Table 2.4.1, entry 1. A) Co-injection and B) L-Ala, using a gradient of 
 20-40% MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A2.049. Analytical Column PDA for determination of conversion via method B 
for Table 2.4.1, entry 1. Gradient: 20-40% MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A2.050. Table 2.4.1, entry 2. Gradient of 20-40(10 min)-40% MeCN/H2O (0.1% 
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Figure A2.051. Analytical Column PDA for determination of conversion via method A 
for Table 2.4.1, entry 2. Gradient: 20-80% MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A2.052. Table 2.4.1, entry 3. Gradient of 20-40% MeCN/H2O (0.1% formic acid) 
over 15 min. 
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Figure A2.053. Analytical Column PDA for determination of conversion via method A 
for Table 2.4.1, entry 3. Gradient: 20-80% MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A2.054. Table 2.4.1, entry 4. Gradient of 20-80% MeCN/H2O (0.1% formic acid) 
over 15 min. 
 
    
 
 






















Figure A2.055. Analytical Column PDA for determination of conversion via method A 
for Table 2.4.1, entry 4. Gradient: 20-80% MeCN/H2O (0.1% formic acid) over 15 min. 














Table 2.4.2. Spectrometric Data 
 
 
   
Figure A2.056. Analytical Column PDA of crude 2.4.C. Gradient: 20-80% MeCN/H2O 
(0.1% formic acid) over 15 min. 
 
Figure A2.057. Reaction progress after 30 min of butylamine for Table 2.4.2, entry 1.  
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Figure A2.058. Reaction progress after 30 min of 3-azidopropylamine for Table 2.4.2, 
entry 2. Gradient: 20-45(12 min)- 95%(3 min)% MeCN/H2O (0.1% formic acid) over 15 
min. 
 
Figure A2.059. Reaction progress after 30 min of propargylamine for Table 2.4.2, entry 






























Figure A2.060. Reaction progress after 30 min of benzylamine for Table 2.4.2, entry 4. 
Gradient: 20-45(12 min)- 95%(3 min) MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A2.061. Reaction progress after 6 h of aniline and (5 equiv) DIEA for Table 2.4.2, 






























Figure A2.062. Reaction progress after 30 min of hydrazine for Table 2.4.2, entry 6. 
Gradient: 20-45(12 min)- 95%(3 min) MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A2.063. Reaction progress after 3 h of (5 equiv) hydroxylamine•HCl and (10 equiv) 
DIEA for Table 2.4.2, entry 7. Gradient: 20-45(12 min)-95%(3 min) MeCN/H2O (0.1% 
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Figure A2.064. Reaction progress after 6 h of Weinreb amine•HCl and DIEA for Table 
2.4.2, entry 8. Gradient: 20-45(12 min)- 95%(3 min) MeCN/H2O (0.1% formic acid) over  
15 min. 
 
Figure A2.065. Reaction progress after 30 min of MeOH and (5 equiv) DIEA for Table 



























Figure A2.066. Reaction progress after 5 h of EtOH and (5 equiv) DIEA for Table 2.4.2, 
entry 10. Gradient: 20-45(12 min)-95%(3 min) MeCN/H2O (0.1% formic acid) over 15 
min. 
 
Figure A2.067. Reaction progress after 30 min of BnOH and (5 equiv) DIEA for Table 
2.4.2, entry 11. Gradient: 20-45(12 min)-95%(3 min) MeCN/H2O (0.1% formic acid) 

























Figure A2.068. Reaction progress after 1 h of (10 equiv) PhOH and (5 equiv) DIEA for 
Table 2.4.2, entry 12. Gradient: 20-45(12 min)-95%(3 min) MeCN/H2O (0.1% formic 
acid) over 15 min. 
 
Figure A2.069. Reaction progress after 5 h of i-PrOH and (5 equiv) DIEA for Table 2.4.2, 

























Figure A2.070. Reaction progress after 30 min of 1 M NaOH (aq) for Table 2.4.2, entry 
14. Gradient: 20-45(12 min)-95%(3 min) MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A2.071. Reaction progress after 30 min of NaBH4 reduction for Table 2.4.2, entry 




























Scheme 2.4.2. Spectrometric Data  
 
Figure A2.072. Direct injection of crude TFE/AcOH/CH2Cl2 rinses of protected native 
GLP-1(7-36). 
 
Figure A2.073. Analytical Column PDA for determination of conversion via method A.  
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Figure A2.074. Analytical Column of crude Fmoc-GLP(7-36)-MeNbz-Gly-NH2. Gradient: 
20-80% MeCN/H2O (0.1% formic acid) over 15 min. 
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Figure A2.075. Analytical Column of crude GLP(7-36)-NHBu. Gradient: 20-80% 
MeCN/H2O (0.1% formic acid) over 15 min, Retention time: 7.68 min. 
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Figure A2.076. Analytical Column of GLP(7-36)-NHBu after one round of HPLC- 
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Appendix A.3: Spectrometric Data for Chapter 3 
 
Figure A3.01. A) Co-injection, B) D-Cys, C) L-Cys made from AWC-MeNbz-Gly-Rink, and 
D) L-Cys from AW-MeNbz-Gly-Rink, gradient: 20-40% MeCN/H2O + 0.1% formic acid 
over 15 min. The cysteine butylamide was used to displace AW-MeNbz-Gly-Rink to 
generate AWC-NHBu. This allowed us to confirm its enantiopurity. 
 
Figure A3.02. A) L-Cys, B) D-Cys, and C) Co-injection after SPPS, gradient: 40-95% 
MeCN/H2O + 0.1% formic acid over 15 min. *Note: The indicated peak in the above 
spectrum is a side product of Trp(Boc) in TFA.1 
 
Figure A3.03. A) L-Cys after 24 h, B) 4 h, C) 2 h, and D) co-injection, gradient: 40-95%  
MeCN/H2O + 0.1% formic acid over 15 min.  
                                                        
1 Franzén, H.; Grehn, L.; Ragnarsson, U. J. Chem. Soc., Chem. Commun. 1984, 0, 1699–1700. 
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Table 3.2: Spectrometric Data 
 
Figure A3.04. Analytical Column PDA of purified peptide at 190 nm for Table 3.2, entry 
1. Gradient: 40-95% MeCN/H2O (0.1% formic acid) over 15 min. Retention time: 8.77 
min. 
 
Figure A3.05. Analytical Column PDA for determination of conversion for Table 3.2, entry 
1. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min. 
 
Figure A3.06. Table 3.2, entry 1. A) D-Cys, B) L-Cys, and C) Co-injection, gradient: 40- 


















Figure A3.07. Table 3.2, entry 2. A) L-Cys, B) D-Cys, and C) Co-injection, gradient: 20- 
40% MeCN/H2O + 0.1% formic acid over 15 min. 
 
Figure A3.08. Analytical Column PDA for determination of conversion for Table 3.2,  
entry 2. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min. 
  
Figure A3.09. Table 3.2, entry 3. A) Co-injection and B) L-Cys, gradient: 20-40%  
MeCN/H2O + 0.1% formic acid over 15 min. 




















Figure A3.10. Analytical Column PDA for determination of conversion. Gradient: 20- 
80% MeCN/H2O + 0.1% formic acid over 15 min. 
 
Figure A3.11. Table 3.2, entry 4. A) Co-injection and B) L-Cys, gradient: 20-40% 
MeCN/H2O + 0.1% formic acid over 15 min. 
Co-Injection 















Figure A3.12. Analytical Column PDA for determination of conversion for Table 3.2, 
entry 4. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min. 
 
Figure A3.13. Table 3.2, entry 5. A) Co-injection and B) L-Cys, using a gradient of 20- 
40% MeCN/H2O + 0.1% formic acid over 15 min. 





















Figure A3.14. Analytical Column PDA for determination of conversion for Table 3.2,  
entry 5. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min. 
 
Figure A3.15. Table 3.2, entry 6. A) Co-injection, B) D-Cys, and C) L-Cys, using a 
gradient of 20-40% MeCN/H2O + 0.1% formic acid over 15 min. 

























Figure A3.16. Analytical Column PDA for determination of conversion for Table 3.2, 
entry 6. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min. 
 
Figure A3.17. Table 3.2, entry 7. A) Co-injection, B) D-Cys, and C) L-Cys, gradient of 
20-40% MeCN/H2O + 0.1% formic acid over 15 min. 
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Figure A3.18. Analytical Column PDA for determination of conversion for Table 3.2, 
entry 7. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min. 
 
Figure A3.19. Table 3.2, entry 8. A) L-Cys, B) D-Cys, and C) co-injection gradient of 20- 
45-95% MeCN/H2O + 0.1% formic acid over 15 min. 
    
 
 













Figure A3.20. Analytical Column PDA for determination of conversion for Table 3.2, 
entry 8. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min. 
  
Figure A3.21. Table 3.2, entry 9. A) Co-injection, B) L-Cys, using a gradient of 30% 
 MeCN/H2O + 0.1% formic acid over 15 min, PDA: 254 nm. 
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Figure A3.22. Analytical Column PDA for determination of conversion for Table 3.2,  
entry 9. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min. 
 
Figure A3.23. Table 3.2, entry 10. A) Co-injection, B) D-Cys, and C) L-Cys, gradient of 
30% MeCN/H2O + 0.1% formic acid over 15 min, PDA: 254 nm. 
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Figure A3.24. Analytical Column PDA for determination of conversion for Table 3.2, 
entry 10. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min. 
 
Figure A3.25. Table 3.2, entry 11. A) L-Cys and B) Co-injection, gradient of 20-40% 
MeCN/H2O + 0.1% formic acid over 15 min. 
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Figure A3.26. Analytical Column PDA for determination of conversion for Table 3.2, 
entry 10. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min. 
 
Figure A3.27. Table 3.2, entry 12. A) Co-injection, B) D-Cys, and C) L-Cys, gradient of  
20-40% MeCN/H2O over 15 min. 
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Figure A3.28. Analytical Column PDA for determination of conversion for Table 3.2, 
entry 12. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min. 
 
Figure A3.29. Table 3.2, entry 13. A) L-Cys after KOtBu treatment and B) L-Cys 
reference, using a gradient of 20-20(12 min)-95%(3 min) MeCN/H2O + 0.1% formic acid 
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Figure A3.30. Analytical Column PDA for determination of conversion for Table 3.2, 
entry 13. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min. 
 
Figure A3.31. Table 3.2, entry 14. Gradient of 20-20(12 min)-95%(3 min) MeCN:H2O + 
0.1% formic acid over 15 min. The L-Cys substrate has a delayed elution in the assay, 
but since no second peak is observed, no detectable epimerization was reported. 
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Figure A3.32. Analytical Column PDA for determination of conversion for Table 3.2, 
entry 14. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min. 
 
Figure A3.33. Table 3.2, entry 15. Gradient of 20-20(12 min)-95%(3 min) MeCN:H2O +  
0.1% formic acid over 15 min. 
        Co-Injection 
L-Cys, <1% epimerization 
 












Figure A3.34. Analytical Column PDA for determination of conversion for Table 3.2, 
entry 15. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min. 
 
Figure A3.35. Table 3.2, entry 16. A) Co-injection and B) L-Cys, Gradient of 20% 
MeCN/H2O + 0.1% formic acid over 15 min. 










PDA, 254 nm 
 
 
                    Co-Injection with D-Cys 




Figure A3.36. Analytical Column PDA for determination of conversion for Table 3.2,  
entry 16. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min. 
 
Figure A3.37. Table 3.2, entry A3-01. A) Co-injection and B) L-Cys, Gradient of 20% 
MeCN/H2O + 0.1% formic acid over 15 min. 
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Figure A3.38. Analytical Column PDA for determination of conversion for Table 3.2,  
entry 3.6.2. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min. 
Scheme 2. Spectrometric Data 
 
Figure A3.39. Analytical Column PDA of crude peptide 3.2.D, gradient of 5-30% 
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Figure A3.40. Analytical Column PDA of pure peptide 3.2.D, gradient of 5-40%  
MeCN/H2O + 0.1% formic acid over 15 min. 
 
  
Figure A3.41. Analytical Column PDA of crude peptide 3.2.E at 254 nm, gradient of 5- 
20% MeCN/H2O + 0.1% formic acid over 15 min. 
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Figure A3.42. Analytical Column PDA illustrating the final folding step of a-conotoxin  
ImI, gradient of 5-20% MeCN/H2O + 0.1% formic acid over 15 min. 
 
 
Figure A3.43. Analytical Column PDA of pure peptide 3.2.F, gradient of 5-20% 
MeCN/H2O + 0.1% formic acid over 15 min. Retention time: 13.84 min. 
    a-ImI 3.2.F 
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 a-ImI 3.2.F 
 





Figure A3.44. A) Analytical Column PDA of commercial a-conotoxin ImI at 254 nm, B) 
co-injection of synthetic (solution-phase folding) and commercial sample, gradient of 5- 
40% MeCN/H2O + 0.1% formic acid over 15 min.  
 
 
Figure A3.45. Analytical Column PDA of purified peptide 3.2.F at 254 nm, gradient of 5- 
40% MeCN/H2O + 0.1% formic acid over 15 min. Retention time: 9.08 min. 
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Figure A3.46. A) Analytical Column PDA of commercial a-conotoxin ImI at 254 nm, B) 
co-injection, C) synthetic sample, gradient of 5-40% MeCN/H2O + 0.1% formic acid over 
15 min. 
Table 3.3.1. Spectrometric Data  
 
Figure A3.47. Analytical Column PDA of crude peptide at 254 nm for Table 3.3.1, entry 
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Figure A3.48. Analytical Column PDA for determination of conversion for Table 3.3.1, 
entry 1. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min.  
 
Figure A3.49. Analytical Column PDA of crude peptide at 254 nm for Table 3.3.1, entry 




























Figure A3.50. Analytical Column PDA for determination of conversion for Table 3.3.1, 
entry 2. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min. 
 
Figure A3.51. Analytical Column PDA of crude peptide at 254 nm for Table 3.3.1, entry 

































Figure A3.52. Analytical Column PDA for determination of conversion for Table 3.3.1, 
entry 3. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min. 
 
 
Figure A3.53. Analytical Column PDA of crude peptide at 254 nm for Table 3.3.1, entry 



































Figure A3.054. Analytical Column PDA for determination of conversion for Table 3.3.1,  
entry 4. Gradient: 20-80% MeCN/H2O over 15 min.1 
Table 3.3.2. Spectrometric Data  
 
Figure A3.55. Reaction progress after 30 min of H-Cys-OH addition for Table 3.3.2, entry 


































Figure A3.56. Reaction progress after 30 min of H-Cys-OEt addition for Table 3.3.2, 
entry 2. Gradient: 20-45(12 min)-95(3 min)% MeCN/H2O + 0.1% formic acid over 15 
min. 
 
Figure A3.57. Table 3.3.2, entry 2. A) Co-injection, B) D-Cys, and C) L-Cys of in 
solution elongation of Cys-OEt, Gradient: 20-20(10 min)-45(5 min)% MeCN/H2O + 0.1% 


















Figure A3.58. Reaction progress after 30 min of H-Cys-NH2 addition for Table 3.3.2, 




Figure A3.59. Reaction progress after 30 min of H-Cys-NH2 addition, Gradient: 20-80% 















































Figure A3.60. A) Co-injection of authentic sample (made with traditional SPPS) and 
elongated product (3.3.D.1 from Table 3.3.2), B) C-terminal Cys-OH elongated product, 
AWAC-OH, gradient: 20-45(12 min)-95(3 min)% MeCN/H2O + 0.1% formic acid over 15 
min. 
Table 3.4. Spectrometric Data 
 
Figure A3.61. Reaction progress after 30 min of H-Cys-OH addition for Table 3.4, entry 








































Figure A3.62. Analytical Column PDA of crude peptide 3.4.2.C, gradient of 40-95-95% 
MeCN/H2O + 0.1% formic acid over 15 min. 
 
Figure A3.63. Analytical Column PDA for determination of conversion for Table 3.4, 






























Figure A3.64. Analytical Column PDA of crude peptide 3.4.2.C after 1 h for Table 3.4, 






















Figure A3.65. Analytical Column PDA of crude deprotected peptide 3.4.3.C for Table 
3.4, entry 4, gradient of 40-95-95% MeCN/H2O + 0.1% formic acid over 15 min. 
 
Figure A3.66. Analytical Column PDA for determination of conversion for Table 3.4, 
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Figure A3.067. Analytical Column PDA for determination of conversion for Table 3.4,  
entry 5. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min. 
 
Figure A3.68. Reaction progress after 30 min of H-Cys-OMe addition for Table 3.4, entry 
6. Gradient: 20-80% MeCN/H2O + 0.1% formic acid over 15 min, Retention time: 

























Scheme 3.5. Spectrometric Data 
 
 
Figure A3.69. Analytical Column PDA of pure peptide 3.5.B, gradient of 20-70% 
MeCN/H2O + 0.1% formic acid over 15 min. Retention time: 7.75 min. 
 
Figure A3.70. Analytical Column PDA for determination of conversion. Gradient: 20- 
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Figure A3.71. Analytical Column PDA of purified peptide at 190 nm. Gradient: 20-70% 
 + 0.1% formic acid MeCN/H2O. 
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Appendix A.4: Spectrometric Data for Chapter 4 
Table 4.2.1. Spectrometric Data 
 
Figure A4.01. Reaction progress after 30 min of H-Gly-OH addition for Table 4.2.1, 
entry 1. Gradient: 20-45(12 min)-95(3 min)% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.02. Reaction progress after 30 min of H-Ala-OH addition for Table 4.2.1, 























Figure A4.03. Reaction progress after 6 h of H-Pro-OH addition for Table 4.2.1, entry 3. 
Gradient: 20-45(12 min)-95(3 min)% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.04. Reaction progress after 1 h of H-Ile-OH addition for Table 4.2.1, entry 4. 


























Figure A4.05. Reaction progress after 30 min of H-Trp-OH addition for Table 4.2.1, 
entry 5. gradient: 20-45(12 min)-95(3 min)% MeCN/H2O (0.1% HCOOH) over 15 min. 
Table 4.3. Spectrometric Data 
 
Figure A4.06. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 1. 


























Figure A4.07. Analytical Column PDA for determination of conversion for Table 4.3, 
entry 1. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min.  
 
Figure A4.08. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 2. 




























Figure A4.09. Analytical Column PDA for determination of conversion for Table 4.3, 
entry 2. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.10. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 3. 



























Figure A4.11. Analytical Column PDA for determination of conversion for Table 4.3, 
entry 3. Gradient: 20-80% MeCN/H2O over 15 min (0.1% HCOOH).  
 
 
Figure A4.12. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 4. 
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Figure A4.13. Analytical Column PDA for determination of conversion for Table 4.3, 
entry 4. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.14. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 5. 

























Figure A4.15. Analytical Column PDA for determination of conversion for Table 4.3, 
entry 5. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.16. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 5 






























Figure A4.17. Analytical Column PDA for determination of conversion for Table 4.3, 
entry 5 (large scale). Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min.  
 
 
Figure A4.18. Analytical Column PDA of pure peptide for Table 4.3, entry 5 (large 
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Figure A4.19. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 6. 
Gradient: 40-95(10 min)-95(5 min)% MeCN/H2O (0.1% HCOOH). 
 
Figure A4.20. Analytical Column PDA for determination of conversion for Table 4.3, 
























Figure A4.21. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 7. 
Gradient: 40-95(10 min)-95(5 min)% MeCN/H2O (0.1% HCOOH). 
 
Figure A4.22. Analytical Column PDA for determination of conversion for Table 4.3, 





























Figure A4.23. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 8. 
Gradient: 40-95(10 min)-95(5 min)% MeCN/H2O (0.1% HCOOH). 
 
Figure A4.24. Analytical Column PDA for determination of conversion for Table 4.3, 
































Figure A4.25. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 
4.7.2. Gradient: 40-95(10 min)-95(5 min)% MeCN/H2O (0.1% HCOOH). 
 
Figure A4.26. Analytical Column PDA for determination of conversion for Table 4.3, 




























Figure A4.27. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 9. 
Gradient: 40-95(10 min)-95(5 min)% MeCN/H2O (0.1% HCOOH).  
 
Figure A4.28. Analytical Column PDA for determination of conversion for Table 4.3, 


























Figure A4.29. Analytical Column PDA of pure peptide for Table 4.3, entry 9, gradient of 
40-95(10 min)-95(5 min)% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.30. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 
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Figure A4.31. Analytical Column PDA for determination of conversion for Table 4.3, 
entry 10. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.32. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 


























Figure A4.33. Analytical Column PDA for determination of conversion for Table 4.3, 
entry 11. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.34. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 




























Figure A4.35. Analytical Column PDA for determination of conversion for Table 4.3, 
entry 12. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.36. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 





























Figure A4.37. Analytical Column PDA for determination of conversion for Table 4.3, 
entry 4.7.3. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.38. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 





























Figure A4.39. Analytical Column PDA for determination of conversion for Table 4.3, 
entry 13. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
 
Figure A4.40. Analytical Column PDA of pure peptide for Table 4.3, entry 13, gradient 











PDA, 254 nm 
 
 














Figure A4.41. Analytical Column PDA of mixed peptides for Table 4.3, entry 13, 
gradient of 40-95(10 min)-95(5 min)% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.42. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 








PDA, 254 nm 
 
 















Figure A4.43. Analytical Column PDA for determination of conversion for Table 4.3, 
entry 14. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.44. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 

























Figure A4.45. Analytical Column PDA for determination of conversion for Table 4.3, 
entry 15a. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.46. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 
































Figure A4.47. Analytical Column PDA of mixed peptide, gradient of 40-95(10 min)-95(5 
min)% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.48. Analytical Column PDA of pure peptide for Table 4.3, entry 15b. Gradient 























Figure A4.49. Analytical Column PDA for determination of conversion for Table 4.3, 
entry 15b. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.50. Analytical Column PDA of crude peptide at 254 nm for Table 4.3, entry 






























Figure A4.51. Analytical Column PDA for determination of conversion for Table 4.3, 
entry 16. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.52. Analytical Column PDA of crude peptide (1) at 254 nm for Table 4.3, 







       




















Figure A4.53. Analytical Column PDA of crude peptide (2) at 254 nm for Table 4.3, 
entry 17. Gradient: 40-95(10 min)-95(5 min)% MeCN/H2O (0.1% HCOOH). 
 
Figure A4.54. Analytical Column PDA for determination of conversion for Table 
























       




Table 4.4. Spectrometric Data 
 
Figure A4.55. Evaluation of C-terminal alanine epimerization with isoleucine for Table 
4.4, entry 1. A) L-Ala crude, B) D-Ala crude, and C) co-injection, gradient of 50% 
MeCN/H2O (0.1% HCOOH) over 15 min. For conversion see Figure A4.28 
 
Figure A4.56. Evaluation of C-terminal alanine epimerization with isoleucine for Table 
4.4, entry 2. A) D-Ala crude, B) co-injection, and C) L-Ala crude, gradient of 50% 


















Figure A4.57. Analytical Column PDA for determination of conversion for Table 4.4, 
entry 2. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.58. Evaluation of C-terminal alanine epimerization with isoleucine for Table 
4.4, entry 3. A) D-Ala crude, B) co-injection, and C) D-Ala crude, gradient of 20-40% 






















Figure A4.59. Analytical Column PDA for determination of conversion for Table 4.4, 
entry 3. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.60. Evaluation of C-terminal alanine epimerization with isoleucine for Table 
4.4, entry 4. A) L-Ala crude, B) D-Ala crude, and C) co-injection, gradient of 50% 

























Figure A4.61. Evaluation of C-terminal alanine epimerization with isoleucine for Table 
4.4, entry 5. A) L-Ala crude, B) D-Ala crude, and C) co-injection, gradient of 50% 
MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.62. Analytical Column PDA for determination of conversion for Table 4.4, 



























Figure A4.63. Evaluation of C-terminal alanine epimerization with isoleucine for Table 
4.4, entry 6. A) L-Ala crude, B) D-Ala crude, and C) co-injection, gradient of 50% 
MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.64. Analytical Column PDA for determination of conversion for Table 4.4, 





























Figure A4.65. Evaluation of C-terminal alanine epimerization with proline for Table 4.4, 
entry 7. A) L-Ala crude, B) D-Ala crude, and C) co-injection, gradient of 50% MeCN/H2O 
(0.1% HCOOH) over 15 min. For conversion see Figure A4.51 
 
Figure A4.66. Evaluation of C-terminal alanine epimerization with proline for Table 4.4, 
entry 8. A) D-Ala, B) co-injection, and C) L-Ala crude, gradient of 50% MeCN/H2O (0.1% 

















Table 4.5.1. Spectrometric Data 
 
Figure A4.67. Analytical Column PDA of crude peptide at 254 nm for Table 4.5.1, entry 
1. Gradient: 40-95(10 min)-95(5 min)% MeCN/H2O (0.1% HCOOH). 
 
Figure A4.68. Analytical Column PDA for determination of conversion for Table 4.5.1, 












PDA, 254 nm 
 
 
















Figure A4.69. Analytical Column PDA of crude peptide at 254 nm for Table 4.5.1, entry 
2. Gradient: 40-95(10 min)-95(5 min)% MeCN/H2O (0.1% HCOOH). 
 
Figure A4.70. Analytical Column PDA for determination of conversion for Table 4.5.1, 
entry 2. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 




























Figure A4.71. Analytical Column PDA of crude peptide at 254 nm for Table 4.5.1, entry 
3. Gradient: 80-95(10 min)-95(5 min)% MeCN/H2O (0.1% HCOOH). 
 
Figure A4.72. Analytical Column PDA for determination of conversion for Table 4.5.1, 
entry 3. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 




























Figure A4.73. Analytical Column PDA of crude peptide at 254 nm for Table 4.5.1, entry 
4. Gradient: 40-95(10 min)-95(5 min)% MeCN/H2O (0.1% HCOOH). 
 
Figure A4.74. Analytical Column PDA of purified mixed peptides for Table 4.5.1, entry 
4. Gradient of 40-95(10 min)-95(5 min)% MeCN/H2O (0.1% HCOOH) over 15 min. 


























Figure A4.75. Analytical Column PDA for determination of conversion for Table 4.5.1, 
entry 4. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
 
Figure A4.76. Analytical Column PDA of mixed peptides for Table 4.5.1, entry 5. 










PDA, 254 nm 
 
 














Figure A4.77. Analytical Column PDA for determination of conversion for Table 4.5.1, 
entry 5. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.78. Analytical Column PDA of crude reaction mixture for Table 4.5.1, entry 6. 




















4.5.G (iPrOH ester), [M+2H]2+ 





Figure A4.79. Analytical Column PDA of purified mixed peptides for Table 4.5.1, entry  
6. Gradient of 80-80(10 min)-95(5 min)% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.80. Analytical Column PDA of pure peptide for Table 4.5.1, entry 6. Gradient 























Figure A4.81. Analytical Column PDA for determination of conversion for Table 4.5.1, 
entry 6. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.82. Analytical Column PDA of crude reaction mixture for Table 4.5.1, entry 7. 
Gradient of 40-95(10 min)-95(5 min)% MeCN/H2O (0.1% HCOOH) over 15 min. 
 





















4.5.G (HFIP ester), [M+2H]2+ 





Figure A4.83. Analytical Column PDA for determination of conversion for Table 4.5.1, 
entry 7. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
 
Figure A4.84. Analytical Column PDA of mixed peptides for Table 4.5.1, entry 8. 








PDA, 214 nm 
 
 















Figure A4.85. Analytical Column PDA for determination of conversion for Table 4.5.1, 
entry 8. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
Table 4.5.2. Spectrometric Data 
 
Figure A4.86. Evaluation of C-terminal alanine epimerization with proline for Table 4.5.2, 
entry 1. A) D-Ala crude, B) co-injection, and C) L-Ala purified, gradient of 50% 
























Figure A4.87. Analytical Column PDA for determination of conversion for Table 4.5.2, 
entry 1. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.88. Evaluation of C-terminal alanine epimerization with proline for Table 
4.5.2, entry 2. A) D-Ala crude, B) co-injection, and C) L-Ala purified, gradient of 50% 






















Figure A4.89. Analytical Column PDA for determination of conversion for Table 4.5.2, 
entry 2. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.90. Evaluation of C-terminal alanine epimerization with proline for Table 
4.5.2, entry 3. A) D-Ala crude, B) co-injection, and C) L-Ala purified, gradient of 50% 






















Figure A4.91. Analytical Column PDA for determination of conversion for Table 4.5.2, 
entry 3. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.92. Evaluation of C-terminal alanine epimerization with proline for Table 
4.5.2, entry 4. A) D-Ala crude, B) co-injection, and C) L-Ala purified, gradient of 50% 






















Figure A4.93. Analytical Column PDA for determination of conversion for Table 4.5.2, 
entry 4. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
Table 4.5.3. Spectrometric Data 
 
Figure A4.94. Analytical Column PDA of crude reaction mixture for Table 4.5.3, entry 1. 






















4.5.M (HFIP ester), [M+2H]2+ 








Figure A4.95. Analytical Column PDA for determination of conversion for Table 4.5.3, 
entry 1. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
 
Figure A4.96. Analytical Column PDA of crude reaction mixture for Table 4.5.3, entry 2. 








4.5.M (HFIP ester), [M+2H]2+ 
PDA, 190 nm 
 
 



















Figure A4.97. Analytical Column PDA of purified peptide for Table 4.5.3, entry 2. 
Gradient of 80-80(10 min)-95(5 min)% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.98. Analytical Column PDA for determination of conversion for Table 4.5.3, 










PDA, 254 nm 
 
 












Figure A4.99. Analytical Column PDA of crude reaction mixture for Table 4.5.3, entry 2. 
Gradient of 80-80(10 min)-95(1 min)-95(4 min)% MeCN/H2O (0.1% HCOOH) over 15 
min. 
 
Figure A4.100. Analytical Column PDA of pure peptide for Table 4.5.3, entry 3. Gradient  








4.5.M (HFIP ester), [M+2H]2+ 
PDA, 190 nm 
 
 
Scan (+)   Scan (–) 















Figure A4.101. Analytical Column PDA for determination of conversion for Table 4.5.3, 
entry 3. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A4.102. Analytical Column PDA of crude reaction mixture for Table 4.5.3, entry 










PDA, 254 nm 
 
 







4.5.M (HFIP ester), [M+2H]2+ 









Figure A4.103. Analytical Column PDA for determination of conversion for Table 4.5.3, 

















Appendix A.5: Spectrometric Data for Chapter 5 
Table 5.1.1. Spectrometric Data 
 
Figure A5.01. Reaction progress after 30 min of butylamine for Table 5.1.1, entry 1. Gradient: 
20-45(12 min)-95%(3 min) MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A5.02. Reaction progress after 30 min of butylamine and H2O for Table 5.1.1, entry 2. 


































Figure A5.03. Reaction progress after 30 min of propargylamine for Table 5.1.1, entry 3. 
Gradient: 20-45(12 min)- 95%(3 min) MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A5.04. Reaction progress after 30 min of aniline and (5 equiv) DIEA for Table 5.1.1, 


































Figure A5.05. Reaction progress after 30 min of hydrazine for Table 5.1.1, entry 5. Gradient: 
20-45(12 min)- 95%(3 min) MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A5.06. Reaction progress after 30 min of (5 equiv) hydroxylamine and (10 equiv) DIEA 
for Table 5.1.1, entry 6. Gradient: 20-45(12 min)- 95%(3 min) MeCN/H2O (0.1% formic acid) 
































Figure A5.07. Reaction progress after 30 min of (5 equiv) MeNHOMe•HCl and (10 equiv)  
DIEA for Table 5.1.1, entry 6. Gradient: 20-45(12 min)- 95%(3 min) MeCN/H2O (0.1% formic 
acid) over 15 min. 
 
 
Figure A5.08. Reaction progress after 30 min of MeOH and DIEA for Table 5.1.1, entry 8.  
Gradient: 20-45(12 min)- 95%(3 min) MeCN/H2O (0.1% formic acid) over 15 min. 
 
 

































Figure A5.09. Reaction progress after 30 min of 10 equiv DIEA for Table 5.1.1, entry 9.  
Gradient: 20-45(12 min)-95%(3 min) MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A5.10. Co-injection of cyclo[AKTWA]. No head-to-tail peptide was observed in the 




























Figure A5.11. Reaction progress after 30 min of 5 equiv NaBH4 in (1:2) THF:MeCN for Table 
5.1.1, entry 10. Gradient: 20-45(12 min)- 95%(3 min) MeCN/H2O (0.1% formic acid) over 15 
min. 
 
Figure A5.12. Reaction progress after 30 min of H-Gly-OH addition for Table 5.1.1, entry 11. 

































Figure A5.13. Reaction progress after 30 min of H-Ala-OH addition for Table 5.1.1, entry 12. 
Gradient: 20-45(12 min)-95(3 min)% MeCN/H2O (0.1% HCOOH) over 15 min. 
 
Figure A5.14. Reaction progress after 2 h of H-Ile-OH addition for Table 5.1.1, entry 13.  























Figure A5.15. Reaction progress after 6 h of H-Pro-OH addition for Table 5.1.1, entry 14. 
Gradient: 20-45(12 min)-95(3 min)% MeCN/H2O (0.1% HCOOH) over 15 min. 
Table 5.1.2. Spectroscopic Data  
 
Figure A5.16. Reaction progress after 30 min of butylamine for Table 5.1.2, entry 1. Gradient: 

































Figure A5.17. Reaction progress after 30 min of DIEA/MeOH for Table 5.1.2, entry 2. 











PDA, 254 nm 
 
 





Figure A5.18. Reaction progress after 30 min of 11 equiv DIEA for Table 5.1.2, entry 3.  
Gradient: 20-45(12 min)- 95%(3 min) MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A5.19. Reaction progress after 30 min of butylamine for Table 5.1.2, entry 4. Gradient: 





















PDA, 254 nm 
 
 





Figure A5.20. Reaction progress after 30 min of DIEA/MeOH for Table 5.1.2, entry 5.  
Gradient: 20-45(12 min)-95%(3 min) MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A5.21. Reaction progress after 30 min of 11 equiv DIEA for Table 5.1.2, entry 6.  




















PDA, 254 nm 
 
 






Figure A5.22. Reaction progress after 30 min of butylamine for Table 5.1.2, entry 7. Gradient: 
15-45% MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A5.23. Reaction progress after 30 min of DIEA/MeOH for Table 5.1.2, entry 8. 
































Figure A5.24. Reaction progress after 30 min of 11 equiv DIEA for Table 5.1.2, entry 9.  
Gradient: 15-45% MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A5.25. Reaction progress after 30 min of butylamine for Table 5.1.2, entry 10. 
































Figure A5.26. Reaction progress after 30 min of DIEA/MeOH for Table 5.1.2, entry 11. 
Gradient: 15-45% MeCN/H2O (0.1% formic acid) over 15 min. 
 
 
Figure A5.27. Reaction progress after 30 min of DIEA/MeOH for Table 5.1.2, entry 12. 



























Figure A5.28. Reaction progress after 30 min of butylamine for Table 5.1.2, entry 13. 
Gradient: 15-45% MeCN/H2O (0.1% formic acid) over 15 min. 
 
Figure A5.29. Reaction progress after 30 min of DIEA/MeOH for Table 5.1.2, entry 14.  






























Figure A5.30. Reaction progress after 30 min of 11 equiv DIEA for Table 5.1.2, entry 15.  
Gradient: 15-45% MeCN/H2O (0.1% formic acid) over 15 min. 
 
 
Figure A5.31. Analytical trace of crude peptide 5.10.D cleaved with butylamine illustrating 
peptide purity. Gradient: 70-95-95% MeCN/H2O (0.1% HCOOH) over 15 min (C8 column). 
 
 




















Table 5.10.2. Spectroscopic Data. 
 
 
Figure A5.32. Analytical trace of crude reaction mixture (Trace 1) from Table 5.10.2, entry 1. 
Gradient: 5-100% MeCN/H2O (0.1% HCOOH) over 15 min (C8 column). 
 
Figure A5.33. Analytical trace determining reaction conversion (Trace 2) from Table 5.10.2, 










PDA, 254 nm 





Figure A5.34. Analytical trace of crude reaction mixture (Trace 1) from Table 5.10.2, entry 2. 
Gradient: 5-50% MeCN/H2O (0.1% HCOOH) over 15 min (C8 column). 
 
Figure A5.35. Analytical trace determining reaction conversion (Trace 2) from Table 5.10.2, 
entry 2. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C8 Column). 














Figure A5.36. Analytical trace of crude reaction mixture (Trace 1) for Table 5.10.2, entry 3. 
Gradient: 5-100% MeCN/H2O (0.1% HCOOH) over 15 min (C8 column). 
 
Figure A5.37. Analytical trace determining reaction conversion (Trace 2) for Table 5.10.2, 
entry 3. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C8 Column). 
 
Figure A5.38. Analytical trace of crude reaction mixture with an authentic sample of  
cyclo[CFLFA] to illustrate the S to N acyl transfer took place.  Gradient: 40-95% MeCN/H2O 








PDA, 190 nm 










Figure A5.39. Analytical trace of crude peptide cleaved with butylamine illustrating peptide 
purity. Gradient: 40-95-95% MeCN/H2O (0.1% HCOOH) over 15 min (C8 column). 
Table 5.3. Spectroscopic Data  
 
Figure A5.40. Analytical trace of crude reaction mixture (Trace 1) for Table 5.3, entry 1.  
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C8 column). No product was 
observed 
 
Figure A5.41. Analytical trace determining presence of peptide-NHBu in butylamine cleavage, 
confirming no reaction during cyclization step (Trace 2) for Table 5.3, entry 1. Gradient: 20- 
80% MeCN/H2O (0.1% HCOOH) over 15 min (C8 Column). 
Scan (+)      Scan (–) 
 














Figure A5.42. Analytical trace of crude reaction mixture (Trace 1) for Table 5.3, entry 2.  
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C8 column). No product was  
observed. 
 
Figure A5.43. Analytical trace determining reaction conversion (Trace 2) for Table 5.3, entry 
2. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C8 Column). 
 
Figure A5.44. Analytical trace of crude reaction mixture (Trace 1) for Table 5.3, entry 3. 










PDA, 254 nm 
cyclo[CFLFA] 
H-CFLFA-OH 





Figure A5.45. Analytical trace determining reaction conversion (Trace 2) for Table 5.3, entry 
3. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C8 Column). 
 
 
Figure A5.46. Analytical trace of crude reaction mixture (Trace 1) for Table 5.3, entry 4. 
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.47. Analytical trace determining reaction conversion (Trace 2) for Table 5.3, entry 
4. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 Column). 
H-CFLFA-NHBu 
 





PDA, 190 nm 
H-CFLFA-NHBu 
PDA, 254 nm 
Scan (+)        Scan (–) 





Figure A5.48. Analytical trace determining reaction conversion (Trace 3) for Table 5.3, entry 
4. Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 Column). 
 
Figure A5.49. Analytical trace of crude reaction mixture (Trace 1) for Table 5.3, entry 5.  
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C8 column). 
 
Figure A5.50. Analytical trace determining presence of peptide-NHBu in butylamine cleavage 
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PDA, 190 nm 





Figure A5.51. Analytical trace of crude reaction mixture (Trace 1) for Table 5.3, entry 6. 
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.52. Analytical trace determining reaction conversion (Trace 3) for Table 5.3, entry  









PDA, 190 nm 





Figure A5.53. Analytical trace of crude reaction mixture (Trace 1) for Table 5.3, entry 7. 
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.54. Analytical trace determining reaction conversion (Trace 2) for Table 5.3, entry 
7. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 Column). Peptide-NHBu 
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Figure A5.55. Analytical trace of crude reaction mixture (Trace 1) for Table 5.3, entry 8. 
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.56. Analytical trace determining reaction conversion (Trace 2) for Table 5.3, entry  





PDA, 190 nm 
H-CFLFA-NHBu 
PDA, 254 nm 







Figure A5.57. Analytical trace of crude reaction mixture (Trace 1) for Table 5.3, entry 9. 
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.58. Analytical trace determining reaction conversion (Trace 2) for Table 5.3, entry 
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Figure A5.59. Analytical trace of crude reaction mixture (Trace 1) for Table 5.3, entry 5.10.2A. 
Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.60. Analytical trace determining reaction conversion (Trace 3) for Table 5.3, entry 
5.10.2A. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 Column). 
 













Figure A5.61. Analytical trace of crude reaction mixture (Trace 1) for Table 5.3, entry 10. 
 Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.62. Analytical trace determining reaction conversion (Trace 2) for Table 5.3, entry  
10. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 Column). 
 
Figure A5.63. Analytical trace of crude reaction mixture (Trace 1) for Table 5.3, entry 11. 


















Figure A5.64. Analytical trace determining reaction conversion (Trace 3) for Table 5.3, entry 
11. Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 Column). 
 
 
Figure A5.65. Analytical trace of crude reaction mixture (Trace 1) for Table 5.3, entry 12a.  
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
cyclo[CFLFA] 
PDA, 190 nm 









Figure A5.66. Analytical trace determining reaction conversion (Trace 2) for Table 5.3, entry 
12a. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 Column). 
  
Figure A5.67. Epimerization assay. Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min 
(C18 Column). 
H-CFLFA-NHBu 
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Figure A5.68. Analytical trace of crude reaction mixture (Trace 1) for Table 5.3, entry 12b.  
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.69. Analytical trace of crude reaction mixture (Trace 3) for Table 5.3, entry 12b. 
Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 














Figure A5.70. Analytical trace of crude reaction mixture (Trace 1) for Table 5.3, entry 12c.  
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.71. Analytical trace of crude reaction mixture (Trace 3) for Table 5.3, entry 12c. 
Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 














Figure A5.72. Analytical trace of crude reaction mixture (Trace 1) for Table 5.3, entry 12d.  
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.73. Analytical trace of crude reaction mixture (Trace 3) for Table 5.3, entry 12d. 
Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 














Figure A5.74. Analytical trace of crude reaction mixture of 5.10.G. Gradient: 40-95% 
MeCN/H2O (0.1% HCOOH) over 15 min (C18 column).  
 
Figure A5.75. Analytical trace of crude reaction mixture of 5.10.H. Gradient: 40-95% 
MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
Scan (+)     Scan (–) 
 
Boc-GFLGA-MeDbz-G-NHBu 




PDA, 254 nm 





Figure A5.76. Analytical trace of crude reaction mixture of 5.10.I. Gradient: 40-95% 
MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
 
Figure A5.77. Analytical trace of crude reaction mixture for 5.10.J. Gradient: 70-95-95% 





PDA, 254 nm 
 
Scan (+)     Scan (–) 
Scan (+)     Scan (–) 
 
Boc-AFLGA-MeDbz-G-NHBu 






Figure A5.78. Analytical trace of crude reaction mixture for 5.10.K. Gradient: 70-95-95% 
MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.79. Analytical trace of crude reaction mixture for 5.10.L. Gradient: 40-95%  
MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Boc-GFFGT(tBu)FF-MeDbz-G-NHBu 
PDA, 220 nm 




PDA, 220 nm 






Figure A5.80. Analytical trace of crude reaction mixture for 5.10.M. Gradient: 70-95-95% 
MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
 
Figure A5.81. Analytical trace of crude reaction mixture for 5.10.N. Gradient: 70-95-95% 
MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Boc-AFFGT(tBu)FF-MeDbz-G-NHBu 
PDA, 254 nm 




PDA, 220 nm 





Figure A5.82. Analytical trace of crude reaction mixture for 5.10.O. Gradient: 70-95-95% 
MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.83. Analytical trace of crude reaction mixture for 5.10.P. Gradient: 70-95-95%  




PDA, 220 nm 
Scan (+)     Scan (–) 
 
Boc-aFFGT(tBu)FF-MeDbz-G-NHBu 
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Table 5.4.1. Spectroscopic Data 
 
 
Figure A5.84. Analytical trace of crude reaction mixture (Trace 1) for Table 5.4.1, entry 1. 
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.85. Analytical trace of crude reaction mixture (Trace 3) for Table 5.4.1, entry 1. 
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.86. Analytical trace of crude reaction mixture (Trace 1) for Table 5.4.1, entry 2. 
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Figure A5.87. Analytical trace butylamine cleavage establishing the reaction conversion (Trace 
3) for Table 5.4.1, entry 2. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 
column). 
 
Figure A5.88. Analytical trace of crude reaction mixture (Trace 1) for Table 5.4.1, entry 3.  
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column).  
 
Figure A5.89. Analytical trace both the crude reaction mixture and the butylamine cleavage to 
establish the reaction conversion (Trace 3) for Table 5.4.1, entry 3. Gradient: 20-80%  
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Figure A5.90. Analytical trace of crude reaction mixture (Trace 1) for Table 5.4.1, entry 4. 
 Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.91. Analytical trace of crude reaction mixture (Trace 3) for Table 5.4.1, entry 4. 






























Figure A5.92. Analytical trace of crude reaction mixture (Trace 1) for Table 5.4.1, entry 5. 
 Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.93. Analytical trace both the crude reaction mixture and the butylamine cleavage to 
 establish the reaction conversion (Trace 3) for Table 5.4.1, entry 5. Gradient: 20-80% 











































Figure A5.94. Analytical trace of crude reaction mixture (Trace 1) for Table 5.4.1, entry 6.  
Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.95. Analytical trace butylamine cleavage establishing the reaction conversion for 






































Figure A5.96. Analytical trace of crude reaction mixture (Trace 1) for Table 5.4.1, entry 7.  
Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.97. Analytical trace butylamine cleavage establishing the reaction conversion  



























Figure A5.98. Analytical trace of crude reaction mixture (Trace 1) for Table 5.4.1, entry 8. 
Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.99. Analytical trace butylamine cleavage establishing the reaction conversion 
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Figure A5.100. Analytical trace of crude reaction mixture (Trace 1) for Table 5.4.1, entry 9. 
Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.101. Analytical trace butylamine cleavage establishing the reaction conversion 
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Figure A5.102. Analytical trace of crude reaction mixture (Trace 1) for Table 5.4.1, entry 10.  
Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.103. Analytical trace butylamine cleavage establishing the reaction conversion 











PDA, 190 nm 





Figure A5.104. Analytical trace of crude reaction mixture (Trace 1) for Table 5.4.1, entry 11.  
Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.105. Analytical trace butylamine cleavage establishing the reaction conversion 


























Figure A5.106. Analytical trace of crude reaction mixture (Trace 1) for Table 5.4.1, entry 12. 
Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.107. Analytical trace butylamine cleavage establishing the reaction conversion 





















Table 5.4.2. Spectroscopic Data  
 
Figure A5.108. Analytical trace of crude reaction mixture (Trace 1) for Table 5.4.2, entry 1. 
Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.109. Analytical trace butylamine cleavage establishing the reaction conversion 
(Trace 3) for Table 5.4.2, entry 1. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min 
(C18 column). 
 
Figure A5.110. Analytical trace of crude reaction mixture (Trace 1) for Table 5.4.2, entry 2. 






















Figure A5.111. Analytical trace butylamine cleavage establishing the reaction conversion 
(Trace 2) for Table 5.4.2, entry 2. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min 
(C18 column). 
 
Figure A5.112. Analytical trace of crude reaction mixture (Trace 1) for Table 5.4.2, entry 3. 
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Figure A5.113. Analytical trace butylamine cleavage establishing the reaction conversion 




Figure A5.114. Analytical trace of crude reaction mixture (Trace 1) for Table 5.4.2, entry 4. 
Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.115. Analytical trace butylamine cleavage establishing the reaction conversion 
(Trace 3) for Table 5.4.2, entry 4. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min  
(C18 column). 























Figure A5.116. Analytical trace of crude reaction mixture (Trace 1) for Table 5.4.2, entry 5. 
Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.117. Analytical trace butylamine cleavage establishing the reaction conversion 























Figure A5.118. Analytical trace of the butylamine cleavage establishing SPPS purity for  
5.5.A.1. Gradient: 70-95-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
 
Figure A5.119. Analytical trace butylamine cleavage establishing SPPS purity for 5.5.B.1. 
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Figure A5.120. Analytical trace butylamine cleavage establishing SPPS purity for 5.5.C.1. 
 Gradient: 70-95-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.121. Analytical trace butylamine cleavage establishing SPPS purity for 5.5.D.1. 
Gradient: 70-95-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 




Scan (+)     Scan (–) 
PDA, 254 nm  
Boc-C(Trt)FLFK(Boc)-MeDbz-G-NHBu 
 





Figure A5.122. Analytical trace butylamine cleavage establishing SPPS purity for 5.5.E.1.  
Gradient: 70-95-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
 
Figure A5.123. Analytical trace butylamine cleavage establishing SPPS purity for 5.5.F.1. 
Gradient: 70-95-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
Scan (+)     Scan (–) 
 
 




Scan (+)     Scan (–) 
Boc-C(Trt)FLFP-MeDbz-G-NHBu 





Figure A5.124. Analytical trace butylamine cleavage establishing SPPS purity for 5.5.G.1. 
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). **Note: The peptide 
eluted in the wash (15-20 min) 
Table 5.5. Spectroscopic Data  
 
Figure A5.125. Analytical trace of crude reaction mixture (Trace 1) for Table 5.5, entry 1. 
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 




PDA, 254 nm 








Figure A5.126. Analytical trace both the crude reaction mixture and butylamine cleavage to 
establish reaction conversion (Trace 3) for Table 5.5, entry 1. Gradient: 40-95% MeCN/H2O 
(0.1% HCOOH) over 15 min (C18 column). 
 
 
Figure A5.127. Analytical trace of crude reaction mixture (Trace 1) for Table 5.5, entry 2. 
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
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Figure A5.128. Analytical trace both the crude reaction mixture and butylamine cleavage to  
establish reaction conversion (Trace 3) for Table 5.5, entry 2. Gradient: 40-95% MeCN/H2O 
(0.1% HCOOH) over 15 min (C18 column). 
 
 
Figure A5.129. Analytical trace of crude reaction mixture (Trace 1) for Table 5.5, entry 3. 
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
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Figure A5.130. Analytical trace butylamine cleavage establishing the reaction conversion 
(Trace 3) for Table 5.5, entry 3. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min 
(C18 column). 
 
Figure A5.131. Analytical trace of crude reaction mixture (Trace 1) for Table 5.5, entry 5.10.2. 
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
 
Figure A5.132. Analytical trace of crude reaction mixture (Trace 1) for Table 5.5, entry 4. 
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
Scan (+)     Scan (–) 
H-CFLFD-NHBu 
 














Figure A5.133. Analytical trace butylamine cleavage establishing the reaction conversion 




Figure A5.134. Analytical trace of crude reaction mixture (Trace 1) for Table 5.5, entry 5. 
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Figure A5.135. Analytical trace butylamine cleavage establishing the reaction conversion 
(Trace 2) for Table 5.5, entry 5. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min  
(C18 column). 
 
Figure A5.136. Analytical trace of crude reaction mixture (Trace 1) for Table 5.5, entry 6. 
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.137. Analytical trace butylamine cleavage establishing the reaction conversion 


















Figure A5.138. Analytical trace of crude reaction mixture (Trace 1) for Table 5.5, entry 7.  
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.139. Analytical trace butylamine cleavage establishing the reaction conversion 
(Trace 3) for Table 5.5, entry 7. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min 
(C18 column). The mass that corresponds to the acid-byproduct peptide elutes with the 
cyclo[CFLFa], which indicates that the mass is the [M + H2O]+ of the cyclic peptide. 
 
Figure A5.140. pH strips monitoring each rinse. A) pH after 5 H2O rinses after Rinse 
Protocol A, B) pH after 10 H2O rinses, C) pH after 20 H2O rinses.  
A) Rinse 5 B) Rinse 10 C) Rinse 20
cyclo[CFLFa] 
H-CFLFa-OH 
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Figure A5.141. Analytical trace of crude reaction mixture after 20 rinses of H2O (Trace 
1). Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.142. pH strips monitoring each rinse. A) pH of 0.2 M Na2HPO4 buffer (pH 
7.2) rinse after Rinse Protocol A, B) pH after 3 0.2 M Na2HPO4 buffer (pH 7.2) rinses.  
 
Figure A5.143. Analytical trace of crude reaction mixture after 3 rinses of Na2HPO4 
(Trace 1). Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 













Table 5.7.1 Spectroscopic Data 
 
Figure A5.144. Analytical trace of crude reaction mixture (Trace 1) for Table 5.7.1, entry 1.  
Gradient: 40-95% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.145. Analytical trace of butylamine cleavage (Trace 2) for Table 5.7.1, entry 1.  
Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column).  
 
Figure A5.146. Analytical trace butylamine cleavage establishing the reaction conversion 
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Figure A5.147. Analytical trace of crude reaction mixture (Trace 1) for Table 5.7.1, entry 2 and 
Table 5.7.2, entry 1. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
The mass that corresponds to the acid-byproduct peptide elutes with the cyclo[CLFA], which 
indicates that that mass is the [M + H2O]+ of the cyclic peptide. 
 
 
Figure A5.148. Analytical trace of purified cyclo[CLFA] for Table 5.7.1, entry 2 and Table 
5.7.2, entry 1. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.149. Analytical trace of the crude reaction mixture for Table 5.7.1, entry 3. Gradient: 
20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
cyclo[CLFA] [M+H]+ 





PDA, 190 nm 









Table 5.7.2 Spectroscopic Data 
 
 
Figure A5.150. Analytical trace of crude reaction mixture (Trace 1) for Table 5.7.2, entry 2. 
Gradient: 10-40% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.151. Analytical trace of the crude reaction mixture for Table 5.7.2, entry 2. Gradient:  
20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Scan (+)     Scan (–) 
H-cRGD-NHBu 
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Figure A5.152. Analytical trace of crude reaction mixture (Trace 1) for Table 5.7.2, entry 3.  
Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.153. Analytical trace of pure peptide for Table 5.7.2, entry 3. Gradient: 20-80% 
MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
cyclo[CFPY] 
H-CFPY-OH 
PDA, 190 nm 
Scan (+)     Scan (–) 
PDA, 190 nm 
 







Figure A5.154. Analytical trace of butylamine cleavage (Trace 2) for Table 5.7.2, entry 3.  
Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
  
Figure A5.155. Analytical trace of crude linear, protected peptide. Gradient: 70-95% 
MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.156. Analytical trace of crude cyclic, deprotected peptide. Gradient: 20-80% 
MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
H-CFPY-NHBu 
 
PDA, 254 nm 
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Figure A5.157. Analytical trace of crude cyclic, deprotected peptide. Gradient: 20-80% 
MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.158. MS trace set to 1021 m/z of A) Authentic head-to-tail peptide, B) and the crude 
reaction mixture from Table 5.7.2, entry 3. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 
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A) 
B) 
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Scheme 5.8. Spectroscopic Data 
 
Figure A5.159. Analytical trace of crude reaction mixture after 1 h of 5.8.A. Multiple peaks 
indicate incomplete oxidation. Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 
column). 
 
Figure A5.160. Analytical trace of butylamine cleavage after 1 h of 5.8.A cyclization. No starting 
material is observed representing complete cyclization to the macrolactam, but as indicated by 
the crude reaction mixture, the oxidation requires more time. Gradient: 20-80% MeCN/H2O 
(0.1% HCOOH) over 15 min (C18 column). 
reduced SFTI-1 [M+2H]2+ 
oxidized SFTI-1 [M+2H]2+ 
PDA, 190 nm 
SFTI-1-NHBu [M+2H]2+ 
SFTI-1-NHBu [M+3H]3+ 





Figure A5.161. Analytical trace of crude reaction mixture after 23 h from 5.8.A. Gradient: 20- 
80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.162. Analytical trace of pure SFTI-1 from 5.8.A. Gradient: 20-80% MeCN/H2O  
(0.1% HCOOH) over 15 min (C18 column). 
SFTI-1 [M+2H]2+ 
PDA, 190 nm 
Scan (+)     Scan (–) 
Scan (+)     Scan (–) 







Figure A5.163. Analytical trace of crude SFTI-1 from 5.8.B prior to second treatment of TFA. 
 Gradient: 20-80% MeCN/H2O (0.1% HCOOH) over 15 min (C18 column). 
 
Figure A5.164. Analytical trace of crude SFTI-1 from 5.8.B. Gradient: 20-80% MeCN/H2O 
(0.1% HCOOH) over 15 min (C18 column). 
 
SFTI-1 [M+2H]2+ 
PDA, 190 nm 
SFTI-1 [M+2H]2+ 
PDA, 190 nm 
Scan (+)     Scan (–) 
* 
* * * 
*SFTI-1+protecting groups 
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Appendix A.6: Spectrometric Data for Chapter 6 
Scheme 6.2. Spectrometric Data 
Figure A6.01. Analytical trace of acetic anhydride capped peptides from Scheme 6.2. 
Gradient: 20-80% MeCN/H2O (0.1% formic acid) over 15 min (C18 column). 
Scheme A6-01. Step-by-step schematic of acetic anhydride capping of CAPA-PVK-1 


























































































































Table 6.2.1. Spectroscopic Data 
 
Figure A6.02. Analytical trace of acetic anhydride capped peptides for Table 6.2.1, 
entry 1. Gradient: 40-95% MeCN/H2O (0.1% formic acid) over 15 min (C8 column). 
 
Figure A6.03. Analytical trace of acetic anhydride capped peptides for Table 6.2.1, 
entry 2. Gradient: 40-95% MeCN/H2O (0.1% formic acid) over 15 min (C8 column). 
Fmoc-LVPYPRVG-AcMeDbz-Gly 
Fmoc-LVPYPRVG-MeNbz-Gly 




































Figure A6.04. Analytical trace of acetic anhydride capped peptides for Table 6.2.1,  
entry 3. Gradient: 40-95% MeCN/H2O (0.1% formic acid) over 15 min (C8 column). 
 
 
Figure A6.05. Analytical trace of acetic anhydride capped peptides for Table 6.2.1, 
entry 4. Gradient: 40-95% MeCN/H2O (0.1% formic acid) over 15 min (C8 column). 
Fmoc-SSALLVPYPRVG-MeNbz-Gly 
Fmoc-SSALLVPYPRVG-AcMeDbz-Gly 


































Figure A6.06. Analytical trace of acetic anhydride capped peptides for Table 6.2.1,  
entry 5. Gradient: 40-95% MeCN/H2O (0.1% formic acid) over 15 min (C8 column). 
Table 6.2.2. Experimental and Spectroscopic Data  
 
 
Figure A6.07. Analytical trace of 2,2-diphenylacetic acid capped peptides for Table 6.2.2, 





PDA, 254 nm 
H-APHPSSALLVPYPRVG-AcMeDbz-Gly 
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Figure A6.08. Analytical trace of benzoic acid capped peptides for Table 6.2.2, entry 2. 
Gradient: 20-80% MeCN/H2O (0.1% formic acid) over 15 min (C8 column). 
 
Figure A6.09. Analytical trace of 5-hexynoic acid capped peptides. Gradient: 20-80% 













































Scheme 6.2. Experimental and Spectroscopic Data 
 
Figure A6.10. Crude analytical trace of benzoic acid capped peptide 6.5.A. Gradient: 
40-95% MeCN/H2O (0.1% formic acid) over 15 min (C8 column). 
 
 
Figure A6.11. Analytical trace of benzoic acid capped peptide 6.3.C. Gradient: 40-95% 
MeCN/H2O (0.1% formic acid) over 15 min (C8 column). 
Fmoc-LLVPYPRVG-MeNbz-Gly 
PhCO-LVPYPRVG-MeNbz-Gly 





















PDA, 254 nm 
 
Scan (+)     Scan (–) 
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Figure A6.12. Crude analytical trace of peptide 6.2.G.2 after benzoic acid capping.  
Gradient: 40-95% MeCN/H2O (0.1% formic acid) over 15 min (C8 column). 
 
Figure A6.13. Crude analytical trace of peptide 6.2.H.2 after benzoic acid capping.  
Gradient: 40-95% MeCN/H2O (0.1% formic acid) over 15 min (C8 column). 
Fmoc-SSALLVPYPRVG-MeNbz-Gly 
PhCO-SALLVPYPRVG-MeNbz-Gly 




PDA, 254 nm 
 
Scan (+)     Scan (–) 
Scan (+)     Scan (–) 
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Figure A6.14. Crude analytical trace of CAPA-PVK-1 peptide. Gradient: 20-80% 
MeCN/H2O (0.1% formic acid) over 15 min (C18 column). 
 
Figure A6.15. MS spectrum of CAPA-PVK-1 peptide.  
 
 Figure A6.16. Crude analytical trace of benzoic acid capped CAPA-PVK-1 peptide. 
 Gradient: 20-80% MeCN/H2O (0.1% formic acid) over 15 min (C18 column). 
  
Figure A6.17. Analytical trace of pure peptide 6.3.B. Gradient: 20-80% MeCN/H2O 























Figure A6.18. MS spectrum of benzoic acid capped CAPA-PVK-1 peptide.  
 
Figure A6.19. Illustrating the change in resin color after over-acylation of MeDbz. A)  
H-APHPSSALLVPYPRVG-MeDbz peptide capped with benzoic acid (MeDbz-appended 
peptides are typically a dark brown color.), B) Mixture of H-APHPSSALLVPYPRVG- 
MeDbz and H-APHPSSALLVPYPRVG-AcMeDbz peptides. 
A.  B.  
Scan (+)     Scan (–) 
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Appendix B                                 1H and 13C Spectra 
  
Figure B.01. 1H NMR (400 MHz, DMSO-d6) of compound 2.2.B-NH2. 
 














Figure B.03. 1H NMR (400 MHz, DMSO-d6) of compound 2.2.B-NH(CH2)3N3. 
  
















Figure B.05. 1H NMR (400 MHz, DMSO-d6) of compound 2.2.C-NH2. 
 














Figure B.07. 1H NMR (400 MHz, DMSO-d6) of compound 2.2.D-OMe. 
 














Figure B.09. 1H NMR (400 MHz, DMSO-d6) of compound Fmoc-2.2.D-OMe. 
 














Figure B.11. 1H NMR (499 MHz, Acetonitrile-d3) of compound 3.7.B. 
 
 









Figure B.13. 1H NMR (400 MHz, Chloroform-d) of compound 3.7.D. 
 








Figure B.15. 1H NMR (400 MHz, Methanol-d4) of compound 3.7.E. 
 
 









Figure B.17. 1H NMR (499 MHz, DMSO-d6) of compound 3.2.B.1-NH2. 
 
 















Figure B.19. 1H NMR (600 MHz, DMSO-d6) of compound 4.3.B-Gly. 
 
 
















Figure B.21. 1H NMR (499 MHz, DMSO-d6) of compound 4.3.B-Ile. 
 
 


















Figure B.23. 1H NMR (600 MHz, DMSO-d6) of compound 4.3.B-Ala. 
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ABSTRACT 
HARNESSING THE REACTIVITY OF THE N-METHYL DIAMINOBENZOYL LINKER 
TO ACCESS C-TERMINALLY MODIFIED AND MACROCYCLIC PEPTIDES 
by 
CHRISTINE A. ARBOUR 
May 2019 
Advisor: Dr. Jennifer L. Stockdill 
Major: Organic Chemistry 
Degree: Doctor of Philosophy 
This thesis describes the exploration of accessing C-terminally modified and 
macrocyclic peptides through N-acyl urea (MeNbz) displacement. Prior to this work, the 
diaminobenzoyl linker was used to access thioesters for native chemical ligation. Only 
solution-phase displacement of the N-acyl urea with thiol nucleophiles was previously 
reported.  
The N-Me-diaminobenzoyl (MeDbz) linker was initially used to access C-terminal 
glycine esters, amides, and acids from a single peptide substrate. This led to the total 
synthesis of Conopressin G and two analogs. The propensity of the C-terminal cysteine 
residue to undergo epimerization was investigated using this strategy. After optimization, 
C-terminal cysteine esters, amides, and acids were prepared with no detectible 
epimerization. This strategy was used toward the total synthesis of a-Conotoxin ImI. In 
addition, amino acids were used as nucleophiles to elongate the C terminus of the 
peptide, circumventing tedious solid-phase peptide syntheses. Lastly, an on-resin, self-
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cleaving macrocyclization strategy using an N-terminal cysteine was demonstrated to 
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